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Abstract 
Background 
Surrogate outcomes are measures of treatment effect that can be used to predict treatment effect 
on the true outcome of interest. Surrogates are valued as they can be used in place of true 
outcomes to reduce the length, size, or intrusiveness of a clinical trial. However, validation of 
surrogacy is a conceptually complicated area and much theoretical and practical statistical 
development has been conducted in recent years.  
Methods 
A systematic review was conducted to identify which surrogate evaluation approach was best 
suited to be extended to ordinal outcomes. I extended a foremost approach to the case where 
the surrogate, the true clinical outcome, or both are ordinal outcomes. This extension 
investigated surrogacy at both the trial and individual levels; trial level surrogacy was based on 
a two stage method. The extension was developed through large simulation studies and used to 
investigate whether deep venous thromboembolism (DVT) was a surrogate for the ongoing 
measure of death and disability the Oxford Handicap Scale (OHS), using data from the stroke 
trial CLOTS3. CLOTS3 was a large multi-centre randomised clinical trial which investigated 
whether intermittent pneumatic compression (IPC) applied to the legs reduced the occurrence 
of deep venous thromboembolism (DVT) in stroke clinical trial patients.  
Results 
The systematic review identified the information theory approach as the most intuitively and 
practically worthwhile approach to surrogacy evaluation. I extended this approach to: a binary 
surrogate and ordinal true outcome (the binary-ordinal setting); the ordinal-binary and the 
ordinal-ordinal settings. The simulation studies showed that the approach worked well in most 
scenarios tested. However, trial level surrogacy was impacted by loss of efficiency due to the 
use of the two stage method. Bias imposed at the trial level by separation of discrete outcomes 
was effectively dealt with using a penalised likelihood method. The information theory 
approach for ordinal outcomes identified no surrogate that would predict treatment effect of 
IPC on the true outcome OHS measured at six months in the stroke trial CLOTS3. 
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Lay Summary 
Imagine you have a serious illness with no known cure or treatment. Now suppose there is a 
drug that may help but no one will know if it can for three to five years, until big medical 
studies have been completed. Would this be good enough for you? 
Something similar happened during the HIV epidemic in the 1980s. Studying the effect of 
drugs on the HIV virus meant waiting for a slow and debilitating illness to progress to AIDs. 
Waiting such a long time for trials meant that more and more people suffered these serious 
outcomes because drugs could not be authorised speedily enough. Doctors started to consider 
approving drugs on the basis of treatment effects on earlier measures. They suggested that these 
earlier measures, surrogates, could be used to predict treatment effect on AIDs progression. 
Then clinical trials could be shortened and beneficial treatments could be prescribed as fast as 
possible. 
Making sure surrogates can predict treatment effect is not easy, as they can be influenced by 
many outside factors. Researchers decided that statistical tools for surrogacy evaluation were 
needed and I have investigated these in my work. 
There are many medical areas where illnesses are assessed using categories that are ordered 
from highest to lowest. These ordered categories do not always have the same increase in 
between categories. These kinds of measures are known as ordinal. For example, after a patient 
has an acute stroke the doctor might record a measure of the patient’s level of death and 
disability ranging from no symptoms, minor symptoms up to coma and death. This is known 
as the Oxford Handicap Scale. You will agree that the difference between no disability and 
minor symptoms and the difference between coma and death are not the same, but that there is 
in increase in severity as the scale moves up. Therefore, this is an example of an ordinal 
measure. 
In my work I changed the statistical tools I talked about above so that they could also 
investigate surrogates that are ordinal. I tested my new statistical tools to make sure that the y 
work in all kinds of settings and found that in general they worked well. Therefore, this work 
should let doctors working in medical areas where ordinal measures are used to investigate 
surrogates and hopefully reduce the length of trials on new drugs in these areas. 
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Chapter 1. Introduction 
Clinical trials can be lengthy, large and invasive for patients. As such they are 
expensive and have ethical implications. A substantial area of investigation has 
grown out of the desire to reduce the length and size of trials. These aspects of the 
trial will largely depend on the nature of the primary outcome of interest. For 
instance, whether the outcomes are rare or occur as a result of a lengthy disease 
process.  Sometimes ‘stand ins’ or surrogates are used in place of primary outcomes 
and can provide shorter or smaller trials. For example, if the surrogate occurs at a 
much earlier time point and can reliably predict the treatment effects on the true (or 
primary) outcome. In this thesis I adopt the surrogate definition of Temple (1999) 
who state that a surrogate is: 
 “…a laboratory measurement or physical sign that is used in therapeutic 
trials as a substitute for a clinically meaningful endpoint that is a direct measure of 
how a patient feels, functions or survives and is expected to predict the effect of the 
therapy”. 
Some researchers believe that a surrogate can inform on treatment actions on the true 
outcome, if there is a correlation between the surrogate and the true outcome. This 
has been shown not to be the case. Baker and Kramer (2003) showed that even where 
perfect correlation exists a surrogate cannot necessarily predict a treatment effect on 
the primary outcome. Wang et al. (2012) produced a thorough investigation of 
correlation approaches and showed how correlation metrics can have misleading 
results. They showed that a correlation approach without reference to treatment can 
be influenced by many different factors and is therefore not reliable. More 
sophisticated statistical approaches to surrogacy evaluation are required – many have 
been proposed.  
Ordinal outcomes have long been important measures in medical research, for 
example, the Oxford Handicap Scale (OHS) in stroke (Bamford et al., 1989). These 
measures are frequently used as primary outcomes in clinical trials. A surrogate 
outcome methodology that can deal with ordinal outcomes would allow surrogates to 
be legitimately investigated and adopted in these clinical areas. The current 
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methodology for surrogate evaluation of ordinal outcomes is limited; that which does 
exist requires development and refinement. 
In this thesis, I outline the work I conducted to extend the current foremost approach 
to surrogacy evaluation to the case of one or more ordinal outcomes.  
In order to achieve this, I conducted a systematic review of all the surrogate 
evaluation methodology since a previous review by Weir and Walley (2006). My 
review: investigated the current foremost approaches for surrogacy evaluation; 
investigated the understanding and perceptions of researchers in this area; and 
determined the best approach for extension to the case of ordinal outcomes.  
The three ordinal outcome settings I was interested in were the case of: a binary 
surrogate and ordinal true outcome (hereafter referred to as binary-ordinal); an 
ordinal surrogate and binary true outcome (ordinal-binary); and an ordinal surrogate 
and true outcome (ordinal-ordinal). I developed the methodology for these three 
settings. Then, I thoroughly investigated how the methodology worked in real life 
scenarios using simulation and case studies. 
I performed a thorough investigation of the best means of conducting the simulations 
in the surrogate context. My simulation incorporated a wide range of scenarios that 
might be expected to occur in real life settings. The simulations were complemented 
with case studies on the randomised clinical trial CLOTS3 (2013). In these case 
studies, relevant surrogacy clinical questions of interest were investigated and 
methodological issues were demonstrated. 
These simulation and case studies: determined the usefulness of the developed 
methodology; provided further information on the benefits of the chosen technique; 
and informed on issues relating to surrogacy evaluation in the context of ordinal 
outcomes. 
In what follows, the systematic review is discussed in Chapter 2. The methodology, 
simulation of the: binary-ordinal setting are discussed in Chapter 3 and Chapter 4; 
ordinal-binary setting in Chapter 5 and Chapter 6; and ordinal-ordinal setting in 
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Chapter 7 and Chapter 8. The case studies for all settings are presented in Chapter 9. 
Finally, I conclude in Chapter 10. 
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Chapter 2. Systematic review 
I aimed to update a previous systematic review by Weir and Walley (2006) on the 
theoretical statistical development of methods for validating surrogates. Molenberghs 
et al. (2004) and Burzykowski et al. (2005) summarised the early development of 
surrogacy evaluation. Lassere (2008) provided a useful overarching review of the 
evolution of the practice of using and appraising surrogates, including early 
statistical approaches to surrogate outcome evaluation. However, these papers do not 
discuss all relevant approaches to surrogacy evaluation. This review focuses on 
statistical methodology developments including the substantial advances that have 
occurred recently. It also highlights the fundamental differences in the current 
statistical evaluation frameworks and their advantages/disadvantages. This review 
will provide a thorough examination of the understanding and perceptions of 
investigators in this area of research. It will also provide an invaluable resource when 
attempting to fulfil the aim of extending the current methodologies to ordinal 
variables.  
The search process of this review was conducted in three parts. Firstly, before this 
PhD was undertaken a systematic literature search was conducted by Robert Lee 
(RL) from Jan 2003 to 16th of May 2011, after initial screening all papers were 
reviewed by both RL and Christopher Weir (CW) to determine which contributed to 
the methodology of surrogate endpoint evaluation. In part two, I updated the review 
from Jan 2011 to Feb 2013 following the same process as the first stage. I: searched 
the literature; conducted the initial screening; CW and I then reviewed the remaining 
papers to determine if they contributed to the methodology of surrogate outcome 
evaluation. In the third stage, an update of the review was conducted in September 
2015 covering the period January 2013 to 15th of September 2015 alongside an 
updated citation search. 
A search of the literature was conducted using MEDLINE and Web of Knowledge, 
papers were located using the search terms: 
Statist* AND (evaluat* or validat*) AND (surrogate OR biomarker) 
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After the papers were reviewed to determine which contributed to the methodology, 
a citation search was conducted on papers of specific interest (Buyse and 
Molenberghs, 1998), (Frangakis and Rubin, 2004), (Joffe and Greene, 2009) and 
(Alonso and Molenberghs, 2006). This was done via google scholar, MEDLINE and 
Web of Knowledge. These were then reviewed by one of HE, CW or RL to 
















Figure 2.1: Diagram of review process: incorporating all stages of the review 
Search of the literature discovered 
14,476 publications:  
 
Stage 1:  8,129 
Stage 2: 3,505 
Stage 3: 2,842 
A total of 14,540 papers were initially 
screened by HE or RL 
Two of HE, RL and 
CW reviewed these 
papers agreeing that 
111 contributed to the 
methodology 
Citation search located 64 papers 
After initial screening 250 remained: 
 
Stage one: 196 
Stage two: 38 
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Including all three parts of the review a total of 111 papers were deemed to have 
contributed to the statistical methodology of surrogacy evaluation. The full set of 
papers from Jan 2003 –Sep 2015 was thoroughly examined by me and the results of 
this work can be seen in sections 2.1 to 2.9. 
The structure of this chapter is as follows.  In section 2.1, I describe the seminal 
papers in this area. I move on to multi-trial approaches in section 2.2: the meta-
analytical and information theoretic approaches. Section 2.3 covers approaches 
dedicated to causal validity: principal stratification and direct and indirect effects. 
Section 2.4 describes a proposed division of approaches into two paradigms. Sections 
2.5 to 2.8 discuss interdisciplinary and miscellaneous approaches, surrogacy schemes 
(which establish broad evaluations of surrogacy worth) and practical issues. I 
conclude with a discussion in section 2.9.  
In the notation of this review: S and T represent the surrogate and true (primary) 
outcome respectively; Z represents treatment; i represents trials, where 𝑖 = 1, . . , 𝑁; j 
represents patients within a trial, where 𝑗 = 1, . . , 𝑛𝑖; 𝑁𝑇 = ∑ 𝑛𝑖
𝑘
𝑖  represents the total 
number of patients in all trials and U represents an unobserved confounding variable. 
Unless otherwise stated: causal validity approaches, in section 2.3, describe 
methodology based on binary surrogate and true outcomes; all other sections base 
their methodology on continuous outcomes. Finally, approaches other than those 
described in the multi-trial section, section 2.2, are based on single trials. 
2.1 Landmark and formative proposals 
2.1.1 Prentice 
Prentice (1989) first recognised the need for a statistical understanding of surrogacy. 
He defined a surrogate as a “response variable for which a test of the null hypothesis 
of no relationship to the treatment groups under comparison is also a valid test of the 
corresponding null hypothesis based on the true outcome”, as well as providing a set 
of operational criteria for time-to-event outcomes. The ‘main’ criterion of Prentice is: 
𝑓(𝑇|𝑆, 𝑍) = 𝑓(𝑇|𝑆)   (1) 
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Therefore, T conditional on S is independent of treatment regimen, in other words 
the surrogate fully describes the effect of treatment on the true outcome. Whilst this 
publication was ground-breaking in the field and inspired many subsequent 
developments the criteria have been criticised as being too stringent and of a poor 
formation for surrogacy evaluation (Freedman et al., 1992), (Fleming et al., 1994). 
2.1.2 Proportion of treatment effect explained (PTE) 
The main criterion of Prentice is used by Freedman et al. (1992) who developed the 
proportion of treatment effect explained (PTE) based on binary outcomes. 
PTE = 1 −
βS 
β 
       
(2) 
 
where βS and β are the estimates of the effects of Z regressed on T modelled with 
and without conditioning on S respectively. PTE quantifies the level of surrogacy 
and can be interpreted as the proportion of treatment effect on the true outcome that 
is explained by the surrogate. PTE=1 constitutes a perfect surrogate. However, PTE 
has been criticized as it does not always lie between 0 and 1, therefore it is not a true 
proportion. Furthermore, it requires that there is no interaction between the surrogate 
and treatment and encounters issues of imprecision (Weir and Walley, 2006). Several 
attempts have been made to redefine the PTE in a more meaningful form: Chen et al. 
(2003a) provided easily computed confidence intervals; Wang and Taylor (2002) 
proposed an alternative which requires fewer assumptions; Cowles (2002) based 
their PTE measure on a Bayesian and Huang and Huang (2010) on a counterfactuals 
approach (a hypothetical manipulation of the experiment, to ascertain the values 
patients would have experienced had they been on the alternative treatment to that 
allocated under randomisation).  
2.1.3 Relative effect and adjusted association (RE) 
Buyse and Molenberghs (1998) proposed another measure derived from the criteria 
of Prentice known as the relative effect .  
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Where α and 𝛽 are estimates the effect of S and T regressed on Z respectively. 
Relative effect enables prediction of the effect that treatment has upon the true 
outcome from the information gathered on the surrogate. The relative effect can be 
thought of as the slope of a regression of the effect of treatment on the true outcome 
against its effect on the surrogate. Hence relative effect is based on a regression that 
is assumed accurate based on one data point (the relative effect calculated from one 
trial only): this is a strong and untestable assumption.  
A further measure of surrogacy the adjusted association was proposed in the same 
paper. The adjusted association measures the association at the individual patient 
level between the true and surrogate outcome after adjustment for treatment. This 
paper was amended to correct for minor errors (Buyse et al., 2000a). 
2.2 Multi-trial approaches  
2.2.1 Accuracy and predictive power – Meta-analytical 
approach 
Following the criticism of RE, that predictive power and accuracy is limited when 
relying on only one data point, a measure calculated based on multiple REs from 
multiple trials was proposed by Buyse et al. (2000b). These authors evaluated 
surrogacy at two levels the individual trial level and the individual patient level; 
henceforward referred to as the trial level and individual level respectively.  
Buyse et al. (2000b) based their trial level measure of surrogacy on the linear 
regression of the treatment effects of S and T for each trial. If the same relationship 
between the treatment effects of S and T is seen across trials, S is a good surrogate. 
(It is also possible to use centres within a trial in place of separate trials if multiple 
trials are not available; hereafter for simplicity we use the word trial to cover either 
situation). This is measured via the coefficient of determination (R2) which captures 
the strength of the relationship between the treatment effects via the level of variation 
in the data that is explained by their linear regression. The modelling process for a 
random effects approach using a joint model is: 
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𝑆𝑖𝑗 = 𝜇𝑆 + 𝑚𝑆𝑖 + 𝛼𝑍𝑖𝑗 + 𝑎𝑖 𝑍𝑖𝑗 + 𝑆𝑖𝑗  (4) 
𝑇𝑖𝑗 = 𝜇𝑇 + 𝑚𝑇𝑖 + 𝛽𝑍𝑖𝑗 + 𝑏𝑖 𝑍𝑖𝑗 + 𝑇𝑖𝑗   
where (𝜇𝑠, 𝜇𝑇) and (α, β) are fixed intercepts and treatment effects respectively. 
(𝑚𝑆𝑖 , 𝑚𝑇𝑖 ) and (𝑎𝑖 , 𝑏𝑖 ) are random intercepts and treatment effects for the 𝑖
𝑡ℎ trial 
respectively. Error terms in (4) are jointly distributed, ( 𝑆𝑖𝑗, 𝑇𝑖𝑗 ) ~ N(0, ∑  ) and 
random effects, (𝑚𝑆𝑖 , 𝑚𝑇𝑖 , 𝑎𝑖 , 𝑏𝑖 )
T





(5)     
and 
𝐷 = (
𝑑𝑆𝑆 𝑑𝑆𝑇 𝑑𝑆𝑎 𝑑𝑆𝑏
 𝑑𝑇𝑇 𝑑𝑇𝑎 𝑑𝑇𝑏
  𝑑𝑎𝑎 𝑑𝑎𝑏




Buyse et al. (2000b) then proposed the use of the coefficient of determination as an 
expression of the validity of a surrogate at the trial level which they christened 𝑅trial
2 , 
see (7). The authors also proposed a measure of surrogacy at the individual level 
called 𝑅indiv
2  , see (8). This is the squared correlation between S and T after adjusting 
for treatment effect and trial. A potential surrogate is said to be perfect at the trial 
level if 𝑅trial
2 = 1 and at the individual level if 𝑅indiv



























As an alternative to the random effects approach described above, which can be 
computationally burdensome, a fixed effects approach can also be conducted using a 
two stage model. At stage one, the following joint model is fitted:  
𝑆𝑖𝑗 = 𝜇𝑆𝑖 + 𝛼𝑖 𝑍𝑖𝑗 + 𝑆𝑖𝑗  (9) 
𝑇𝑖𝑗 = 𝜇𝑇𝑖 + 𝛽𝑖 𝑍𝑖𝑗 + 𝑇𝑖𝑗  (10) 
where ( 𝑆𝑖𝑗, 𝑇𝑖𝑗 ) ~ N(0, ∑  ). At stage two, the intercept and treatment estimates of 
stage one are used as fixed explanatory variables against a response variable 
indicating which aspect of the model the estimates refer to. The errors of the stage 
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two model are equivalent to the random effects parameters in (4) again these are 
distributed (𝑚𝑆𝑖 , 𝑚𝑇𝑖 , 𝑎𝑖 ,𝑏𝑖 )
T
  ~ N(0, D). Hence all the components of the random 
effects approach can be calculated using a two stage fixed effects approach. 
2.2.2 Model fitting improvements– Meta-analytical approach 
Many authors have investigated the theoretical, practical and computational issues 
relating to the meta-analytical approach. For example, there was found to be a 
significant negative effect on the convergence of models if the number of trials or the 
between trial variability were small for the joint random effects approach (Buyse et 
al., 2000b). (Tibaldi et al., 2003) corroborate these findings and recommended using 
a fixed effects approach, since loss in statistical efficiency is only minor. They 
suggest that instead of the joint random and joint fixed effects models described in 
the previous section, (4) or (8) and (9) respectively, one could use the equivalent 
approaches with individual modelling of treatment on S and on T. At the second 
stage they suggest modelling: 
?̂?𝑖 = 𝜆0 + 𝜆1?̂?𝑆𝑖 + 𝜆2?̂?𝑖 + 𝑖 (11) 
Where ?̂?𝑖 are the estimated trial specific treatment effects of T, see (10), and  ?̂?𝑆𝑖  and 
?̂?𝑖 are the estimated trial specific intercepts and treatment effects of S respectively, 
see (9). An alternative measure of 𝑅trial
2  is then calculated from the coefficient of 
determination of (11). (Note: the use of individual models mean that ∑  and 
hence Rindiv
2  are not easily determined). Abrahantes et al. (2004) considered 
hierarchies within trials, for instance where individuals are modelled within centres 
within trials, and the influence of ignoring a hierarchical level. They concluded that, 
if the level of surrogacy was the same at trial and centre level a model which ignored 
a hierarchical level performed well. If the levels were different ignoring the trial 
level can lead to overestimation of the variability and biased estimates of the centre 
level association. However, trial and centre level results were similar if variation at 
the centre level was lower than that at the trial level which may justify the use of 
centre instead of trial in practice. Abrahantes et al. (2008) noted that the meta-
analytical approach has an enforced form and an implicit assumption that all the 
relationships are linear, and they suggested alternatives. They also suggested that 
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cross validation of the meta-analytical approach would prevent overly optimistic 
estimates. Further computational issues were investigated in Tilahun et al. (2007) in 
regard to the coding of treatment and ill conditioned matrices. 
2.2.3 Extensions to alternative settings- Meta-analytical 
approach 
We now focus on the extension of Buyse et al. (2000b) to the setting where the true 
or surrogate outcomes are time-to-event, binary, ordinal or repeated measures. 
Authors reformatted the models of the meta-analytical approach to fit the data types 
required, for example Cox models or generalised linear models, in order to extend 
the approach to alternative settings. In each setting it is possible to calculate 𝑅𝑡𝑟𝑖𝑎𝑙
2  
via the coefficient of determination exactly as in the continuous case; hence this 
process will not be re-described in the following sections. However, in order to 
calculate the correlation coefficients used to calculate 𝑅𝑖𝑛𝑑𝑖𝑣
2 , see (5) and (8), joint 
modelling is required and various complications arise when this is conducted in 
settings with non-continuous outcomes. Alternative measures of 𝑅𝑖𝑛𝑑𝑖𝑣
2   are therefore 
required and those proposed are described alongside other relevant methodology. 
Due to the non-uniform measurement of 𝑅𝑖𝑛𝑑𝑖𝑣
2  across settings Dai and Hughes 
(2012) proposed an alternative approach to the meta-analytical approach using 
estimating equations which is more readily extendable to other settings.  
2.2.3.1 Time-to-event 
Burzykowski et al. (2001) extended the meta-analytical approach for outcomes that 
are time-to-event variables. They proposed the use of a copula to model the joint 
survival function of (𝑆𝑖𝑗 , 𝑇𝑖𝑗 ) since other options are less flexible. In this setting, non-
linear relationships are more likely because the correlation across trials is assumed 
not to be consistent, making the use of the correlation coefficient for 𝑅𝑖𝑛𝑑𝑖𝑣
2  unviable. 
The authors therefore proposed the use of Kendall’s τ. After experiencing 
convergence problems with this approach, Renfro et al. (2012) substituted the second 
stage of modelling with a Bayesian alternative which they found avoided the 
undesirable assumptions of no measurement error and common baseline hazards 
across trials. As a further alternative, Tibaldi et al. (2004) suggested the use of the 
Plackett-Dale model (Plackett, 1965) for multivariate data, which can measure 
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dependence between two time-to-event outcomes and can be summarized via an odds 
ratio θ, Kendall’s τ or Spearman’s ρ. Burzykowski et al. (2003) considered the case 
where the surrogate is ordinal and the true outcome is a time-to-event variable.  They 
used the same approach as Tibaldi et al. (2004) except they modelled the surrogate 
outcome in (9) with a proportional odds model where ?̂?  is a latent continuous 
variable. 
An approach to adjusting for semi-competing risks, encountered in the meta 
analytical approach if S experiences dependent censoring via T, was described for 
the single trial measures in Ghosh (2008b) and Ghosh (2009) and extended for the 
meta-analytical approach in Ghosh et al. (2012a). They used the accelerated failure 
time model to account for and estimate dependent censoring, and dissociated the 
disease process and true outcome by investigating how the disease would have 
behaved had T not occured. They analysed S as a latent variable, which was then 
constrained to the region S≤T, called the region constraint, and made use of an 
artificial censoring technique to account for dependent censoring. There is some 
debate surrounding the authors use of the region constraint: Molenberghs (2012) 
described this approach as “elegant”. Berger et al. (2012) argued that region 
constraint does not describe reality and preferred a composite approach, 
incorporating the outcome and the censoring mechanism. Ghosh et al. (2012b) 
contended that the composite approach is not appropriate since the surrogate 
incorporates information on the true outcome.  
Other useful contributions were made by Abrahantes and Burzykowski (2010) who 
applied to time-to-event outcomes the simplified modelling techniques suggested in 
Tibaldi et al. (2003). However, these strategies were not found to be appropriate in 
this setting as considerable levels of bias occurred in the calculation of 𝑅𝑡𝑟𝑖𝑎𝑙
2 . This 
was thought to occur because their simplified approach ignored individual level 
association and ignoring a hierarchal level can bias results, as previously discussed 
(Abrahantes et al., 2004). Renfro et al. (2014) perform a comprehensive assessment 
of the bias due to using centres instead of trials for surrogacy assessment in a wide 
range of scenarios for time-to-event outcomes. They found the conclusions based on 
using centre would be similar to when trial had been used, however bias using centre 
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was larger in a number of scenarios. Shi et al. (2011) used a simulation study to 
compare conventional (non-joint model) and model based approaches (using joint 
models) at the trial level. They found that the conventional approaches have similar 
performance to model based approaches but with fewer computational difficulties.  
2.2.3.2 Binary and ordinal 
Molenberghs et al. (2001) extended the meta-analytical approach to the case where 
one outcome is binary and one continuous. They used a latent variable to represent 
the continuum underlying the dichotomized variable and applied a generalized linear 
model leading to an 𝑅indiv
2  of 𝜌2  calculated from the covariance matrix. Renard et al. 
(2002) used continuous latent variables represented by two observed binary surrogate 
and true outcomes. They then applied a multilevel probit model from which they 
identified parameters of interest using pseudo-likelihood techniques. In the case of 
ordinal outcomes, Alonso et al. (2002) investigated application of this methodology 
to psychiatry where surrogate and true outcomes could arguably be interchangeable.  
2.2.3.3 Repeated measures 
Alonso et al. (2003) proposed using time specific functions in (9) and (10) to take a 
repeated measurement surrogate and true outcome into account. They noted that the 
assumption in Buyse et al. (2000b), that the error variance covariance matrix ∑  in 
(5), is constant over all trials, is not appropriate in this setting. This is because 
repeated measures could differ between trials both in number and collection time. 
Therefore they suggested using the variance reduction factor (VRF), in place of 
𝑅𝑖𝑛𝑑𝑖𝑣
2 , to allow covariance structures to vary across trials. The VRF is calculated by 
summing, within each trial and then over all trials, the trace of the variance 
covariance matrix for repeated measurements on the true outcome and the true 
outcome given the surrogate. This was used to calculate the reduction in variance on 
the repeated measurements of the true outcome that can be attributed to incorporation 
of the surrogate. Alonso et al. (2004a) developed an individual level surrogacy 
evaluation technique based on a canonical correlation interpretation of the VRF. 
Canonical correlation identifies variables that explain shared variance through 
investigation of the variance covariance matrix of two different variables. The 
authors identified the measure 𝜃𝑝, related to the canonical correlations as a means of 
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evaluating surrogacy at the individual level for repeated measures, which can be 
thought of as the average of the canonical correlations over all trials. Though the 
authors pointed out that 𝜃𝑝 is symmetric and invariant for linear bijective 
transformations, it relies heavily on the normality assumption. As an alternative, 
(Alonso et al., 2006) introduced 𝑅∧
2 which is both symmetric and invariant and is also 
more readily extendable to non-normal settings. As with the VRF, a 𝑅∧
2 close to one 
indicates a good surrogate.  They then showed that 𝜃𝑝 can approximate 𝑅∧
2.  
Pryseley et al. (2010) proposed a means of calculating the optimum number of 
repeated measurements of the surrogate in terms of the cost, using a discrete true 
outcome. Weights are added to incorporate a researcher’s view of the importance of 
the cost of collecting repeated measurements versus increased precision in evaluation 
through collecting more repeated surrogate measures. 
Renard et al. (2003) investigated a repeated measures surrogate outcome for a time-
to-event true outcome. They used the simplified model (11) to calculate 𝑅𝑡𝑟𝑖𝑎𝑙
2  and 
the joint model using a latent Gaussian process for 𝑅𝑖𝑛𝑑𝑖𝑣
2 . Tilahun et al. (2009) 
investigated the case where one outcome is a repeated measure and the other is a 
cross sectional variable. The measures they propose are variations of the VRF and 𝑅∧
2 
with different results depending on which outcome is cross sectional. They found 
that their VRF alternative predicts the repeated measures sequence as a whole when 
the surrogate is cross sectional, whereas their 𝑅∧
2 predicts an ‘optimal linear 
combination’ of the repeated measures.  
2.2.4 Clinical interpretation– Surrogate threshold effect 
Another consideration in the meta-analytical approach is that there is no c ϵ [0,1] 
such that 𝑅𝑡𝑟𝑖𝑎𝑙
2 ≥ 𝑐  constitutes a good surrogate. Any such value would be 
completely arbitrary; therefore it is difficult to interpret the practical worth of any 
𝑅𝑡𝑟𝑖𝑎𝑙
2  value. The surrogate threshold effect (STE) based on the meta-analytical 
approach, was proposed by Burzykowski and Buyse (2006) to aid interpretation. The 
STE is defined as “the minimum value of a treatment effect on a surrogate outcome 
which the predicted effect on the true outcome would be significantly different from 
zero.” The larger the variance the larger the absolute value of STE, so the STE can 
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be thought of as a measure of the precision of the prediction of treatment effect on 
the true outcome. This is useful in practice as a large STE would indicate a large 
treatment effect on the surrogate is required before the true unknown treatment effect 
on the true outcome can be identified reliably from this data alone, suggesting a poor 
surrogate. Burzykowski and Buyse (2006) stated that a further benefit of STE is that 
it quantifies the loss of efficiency in estimating the treatment effect on the true 
outcome using the surrogate as opposed to the true outcome. One can then determine 
if this loss of efficiency is acceptable taking into account the corresponding reduction 
in trial duration. Johnson et al. (2009) assessed the STE in practice, using trial level 
data, and concluded that it is a straightforward promising measure of surrogacy. 
They noted that prediction intervals for the STE vary according to the size of a future 
trial being predicted, larger trials provide narrower confidence intervals.  
2.2.5 Unification – Likelihood Reduction Factor 
As seen in section 2.2.3 when the meta-analysis approach is extended to non-
continuous outcomes the interpretation of 𝑅𝑖𝑛𝑑𝑖𝑣
2  is incoherent across settings: 
measures take different forms and are sometimes assessed at a latent level. The 
likelihood reduction factor (LRF) is a quantification of individual level surrogacy 
that is applicable regardless of the type of outcome studied (Alonso et al., 2004b). 
This is based on the amount of information gained about the true outcome after 
accounting for the surrogate. These authors proposed the use of the generalised linear 
model versions of (10) and (12) for each trial i, for binary outcomes, which regress 
the true outcome on treatment with and without adjustment for the surrogate 
respectively: 
𝑇𝑖𝑗 = 𝜃0𝑖 + 𝜃1𝑖 𝑍𝑖𝑗 + 𝜃2𝑖 𝑆𝑖𝑗 + 𝑇|𝑆𝑖𝑗 
 (12) 
The difference in the amount of information on the true outcome gained from the 
surrogate is calculated via the difference in the log-likelihood between (10) and (12) 
which is formally expressed as  𝐺𝑖
2, for each trial i. 𝐿0 is always the log-likelihood 
for the unsaturated model, in this case (10), and 𝐿𝐿1 for the saturated model, (12), for 
trial i. 𝐺𝑖
2 = 2 ∗ (𝐿𝐿1 − 𝐿𝐿0). The LRF is then calculated: 
  Evaluation of surrogate outcomes 
Systematic review 17 












The authors stated that the LRF reduces to the 𝑅indiv
2  measure where outcomes are 
normally distributed.  
Qu and Case (2007) proposed an alternative measure: the proportion of information 
gain (PIG). Li and Qu (2010) investigated the PIG in relation to measurement error. 
Alonso et al. (2007) questioned the conceptual basis of PIG and listed several 
drawbacks. Miao et al. (2012) proposed non parametric versions of PIG and the LRF 
which do not assume a pre-specified form and performed better than the original 
versions under simulation study. Using Prentice’s main criterion the authors also 
proposed a safety measure which may help avoid potential type I errors. 
One criticism of the LRF is that, like PTE, it cannot account for the presence of an 
interaction between the surrogate and treatment in (12). A further critique, that it has 
no population level interpretation has been resolved through the development of an 
information theory approach. 
2.2.6 Population level interpretation- Information theory 
approach 
Information theory is chiefly concerned with the quantification of the level of 
uncertainty in a random variable. Entropy is a fundamental concept which is related 
to how readily (or with how much certainty) one can guess an observed value of a 
random variable. If an event is expected, then its occurrence does not provide as 
much information (has lower entropy) as if the converse were true. An extension of 
this concept proposed by Shannon and Weaver (1948) is a measure called entropy 
power (EP) which can be used to compare continuous random variables. 
A convenient aspect of information theory is that one can quantify the amount of 
uncertainty in a variable expected to be reduced if information about another variable 
is known. This is called the mutual information. In the case of surrogate outcomes, if 
the surrogate explains a lot of uncertainty surrounding the true outcome then the 
mutual information will calculate the corresponding reduction in its entropy. This 
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quantity can be considered as the information in T that is shared by S. Alonso and 







where 𝐸𝑃(𝑇) is the entropy power of T and 𝐸𝑃(𝑇|𝑆) is the entropy power of T given 
S. This can be thought of as the proportion of uncertainty in T at the individual level 
removed by adjusting for S. 𝑅ℎ
2 can also be mathematically linked to the mutual 
information. These concepts are in line with the aims of surrogate evaluation since 
surrogacy is concerned with increasing our knowledge about treatment effect on the 
true outcome through the use of the surrogate. Hence 𝑅ℎ
2 ≈ 1 indicates a good 
surrogate that removes almost all uncertainty in the true outcome. 𝑅ℎ
2 is consistent 
across different settings, providing a unified approach. Alonso and Molenberghs 
(2007) also proposed a version of 𝑅ℎ
2 applied at the trial level using the full 
hierarchical approach from Buyse and Molenberghs (1998). This they called the 𝑅ℎ𝑡
2 : 
𝑅ℎ𝑡





where 𝛼𝑖 and 𝛽𝑖 are the treatment effects on the surrogate and true outcome 
respectively. And can be interpreted as the proportion of uncertainty in the treatment 
effects on T removed by adjusting for treatment effects on S. 𝑅ℎ𝑡
2  can be shown to 
reduce to 𝑅trial
2  in the bivariate continuous setting.  
In order to account for heterogeneity among trials Alonso and Molenberghs (2007) 
proposed a meta-analytic 𝑅ℎ
2, where N  trials produce 𝑁𝑞  possible 𝑅ℎ𝑖
2 : 
                                   𝑅ℎ
2 = ∑ 𝛼𝑖 𝑅ℎ𝑖
2𝑁𝑞
𝑖=1
 where 𝜗𝑖 > 0 ∀ 𝑖 and ∑ 𝜗𝑖
𝑁𝑞
𝑖=1
= 1 (16) 
They note that the choice of 𝜗𝑖 represents an uncountable family of parameters. 
However they highlight that the LRF is a family member which supports unification 
through its common interpretation across settings and is a consistent estimator of 𝑅ℎ
2. 
This gives the LRF a connection to the population measure of surrogacy which was 
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previously unrecognised. The LRF is therefore a very useful and appropriate option 
for a multi-trial measure of 𝑅ℎ
2.  
Information theory provides a much needed unified approach. Alonso and 
Molenberghs (2008) noted additional advantages compared with the meta-analytical 
approach which include; narrower confidence intervals; joint models (which 
previously caused computational issues) are not used,  and latent variables (which 
hamper interpretation) are not required.  
2.2.7 Extensions to alternative settings- Information theory 
approach 
All extensions of information theory approach to different settings use the LRF to 
calculate 𝑅ℎ
2. As with the meta-analytical approach the models of the LRF, (10) and 
(12), are reformatted to fit particular data types. All published extension papers have 
been able to apply the LRF via (13) and derive 𝑅ℎ
2  in a format consistent with other 
settings.  
2.2.7.1 Time-to-event outcomes 
A time-to-event information theory approach published by Alonso and Molenberghs 
(2008)  suggested that, at the trial level, if trial specific treatment effects on S and T 
are linear then 𝑅ℎ
2=𝑅trial
2 , where 𝑅trial
2  is calculated according to Burzykowski et al. 
(2001), otherwise 𝑅ℎ
2 is the better measure of surrogacy. At the individual level, the 
authors fitted two survival models for (10) and (12) and then applied the LRF via 
(13). Pryseley et al. (2011) investigated information theory extensions to the case 
where censoring occurs, using the measures of O'Quigley and Flandre (2006). In the 
information theory setting Pryseley et al. (2011) named these measures LRF-a and 
𝑅XOQ
2 . LRF-a is weighted by ℎ𝑖, the number of deaths in each trial i, and partly 
accounts for the censoring mechanism. 𝑅XOQ
2  is a LRF measure using the Kaplan and 
Meier (1958) estimator, chosen because it consistently estimates the distribution 
function in the presence of censoring and is not impacted if censoring is independent 
(O'Quigley and Flandre, 2006). Pryseley et al. (2011) showed that in the information 
theory case the LRF-a did not account for censoring well but as long as the amount 
of semi-competing risks was not high 𝑅XOQ
2  was a good estimator of 𝑅h
2. 
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2.2.7.2 Binary outcomes 
Pryseley et al. (2007) extended the information theory approach for one binary and 
one continuous outcome. They used generalised linear models, in place of (10) and 
(12), to calculate the LRF. They found that in the cross sectional case the LRF 
reduces to 𝑅indiv
2 . Tilahun et al. (2008) compared information theory measures with 
the meta-analysis and simplified meta-analysis approaches advocated by Tibaldi et 
al. (2003) for the binary-binary case. They found the information theory approach 
superior, since it encountered fewer issues with model convergence and was easier to 
interpret (due to lack of latent variables). They also reported that simplification 
techniques worked well as long as data are available from many large trials. 
2.2.7.3 Repeated measures 
Alonso et al. (2006) included functions of time into the models used to determine the 
LRF for the repeated measures setting. Where both surrogate and true outcomes are 
repeated measures, the LRF is equivalent to 𝑅∧
2, see section 2.2.3.3. Where one is a 
repeated measure and the other a cross sectional variable, the LRF reduces to 𝑅indiv
2 .  
2.3 Causal evaluation     
2.3.1 Causal validity- Principal stratification 
Randomisation provides intervention groups that are on average balanced in terms of 
potential confounding variables; therefore, treatment can be reasonably assumed to 
be the only factor influencing outcome and a causal relationship can be inferred. 
However, if analysis is adjusted for variables measured after treatment allocation 
(variables that are not randomised) it becomes possible for comparison groups to be 
unbalanced in terms of possible confounding factors. In this case, any observed 
relationship between intervention and outcome may be due to the influence of the 
confounding factors and therefore outcome cannot be deemed to be caused by 
intervention. This is called ‘post-treatment selection bias’. This bias limits the ability 
of previously described approaches, in sections 2.1 and the individual level measures 
of section 2.2, to offer a causal interpretation of surrogacy, since surrogates are 
adjusted for in analysis of the true outcome and are measured post-randomisation. 
For a binary surrogate and time-to-event true outcome Frangakis and Rubin (2004) 
showed that since these approaches ignore the issues surrounding causality it is 
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possible to validate surrogates where treatment influences the true outcome without 
affecting the surrogate. They therefore proposed a causal surrogate evaluation 
approach via principal stratification. Nevertheless, trial level surrogacy under the 
meta-analytical and information theory approaches (section 2.2) does have a causal 
interpretation, since causal treatment effects on the true outcome are regressed on the 
treatment effects on the surrogate: hence the analysis of the true outcome is not 
affected by a post-treatment variable. 
As previously mentioned, in this and the following section, the methodology 
discussed is based on binary outcomes, unless otherwise stated. Consider a set of 
patients j=1,…,J; let  s(1), s(2), t(1) and t(2) be the binary surrogate and true 
outcomes for treatment Z, where Z= 1 or 2. In essence principal stratification centres 
on performing a within patient treatment comparison where every patient 
returns sj(1), sj(2), tj(1) and tj(2). Treatment effects on the true outcomes are 
assessed within basic principal strata which are based on the outcomes of the 
surrogate i.e. the ordered pair (sj(1), sj(2)) for each patient. The strata do not vary 
according to treatment hence there is no selection bias within stratum imposed by the 
surrogate. Furthermore, any treatment comparison within the strata is based on an 
identical set of patients and can be said to be causal.  
Frangakis and Rubin (2004) proposed a new definition of surrogacy where S is a 
principal surrogate in the case of a comparison between two treatments Z=1 and 2 if, 
for all fixed s, the comparison between ordered sets:  
{𝑇𝑗 (1): 𝑆𝑗 (1) = 𝑆𝑗 (2) = 𝑠} and {𝑇𝑗 (2): 𝑆𝑗 (1) = 𝑆𝑗(2) = 𝑠}  (17) 
results in equality. This definition says that S is a principal surrogate if causal effects 
of Z on T only occur in the strata where there are causal effects of Z on S. This is 
because, patients in (17) that have the same true outcome regardless of treatment 
only occur in the strata where patients have the same surrogate outcome regardless of 
treatment. It follows that causal treatment effects (where a patient has different 
outcomes for the two treatments) on the true outcome are restricted to strata that have 
causal treatment effects on the surrogate. 
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The authors suggested comparisons across ordered sets to quantify the level of 
surrogacy in practice. For example, when examining the set of patients where the 
treatment has a causal effect on the surrogate we consider the proportion of patients 
who also experience causal effects on the true outcome; this is the associative effect. 
Conversely the proportion with no treatment effect on the surrogate outcome based 
on the set where there is a causal effect on the true outcome is dissociative.  
2.3.1.1 Identification- Principal stratification 
Principal stratification requires both treatment outcomes to be known but generally 
only one is observed; in order to estimate unobserved outcomes a counterfactuals 
approach is adopted. Here, multiple imputation under the assumption of missing or 
incomplete data may be used to estimate missing responses. In this case, since only 
one of the treatment effects is observed, the counterfactual model is over 
parameterised; which leads to issues of identifiability. Additional assumptions are 
required to aid estimation (Rubin, 2004). Wolfson and Gilbert (2010) highlighted the 
difficulty of identifying all parameters and investigated a number of assumptions, 
some more stringent and testable than others, and their influence on the identifiability 
of principal surrogate measures. Considering the special case of vaccine trials, they 
found that estimating treatment effects on the true outcome within principal strata is 
possible but only in the case of certain conceivably improbable assumptions. They 
suggested a sensitivity analysis as a remedy but conceded that it may be more useful 
to focus on non-causal measures of surrogacy that are not restricted to principal strata 
to estimate treatment effects and that can be identified under less stringent 
assumptions. The strong assumption of monotonicity which might be true for most  
but not necessarily all patients is investigated by Li et al. (2011). This assumption 
states that if one treatment is better overall it is not possible for any patient on this 
treatment to fare worse than on placebo. They found that implementation of the 
monotonicity assumption could cause extreme bias if even a small number of 
patients’ outcomes violated the rule, which is likely in practice. On the other hand, 
relaxation of the assumption causes large loss of efficiency causing models to be 
unreliable. 
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2.3.1.2 Practical implementation- Principal stratification 
Regardless of these issues, there has been much work on developing the practical 
application of principal stratification.  Conlon et al. (2013) extended the approach in 
Frangakis and Rubin (2004) to the multivariate normal situation. Li et al. (2010) and 
Li et al. (2011), used a Bayesian imputation technique for the single and multi-trial 
setting respectively, proposed the common associative proportion, which is the 
proportion of patients that have causal treatment effects on both the surrogate and 
true outcome as opposed to the proportion that have causal effects on only one. Elliot 
et al. (2013) extend this approach to investigate a surrogate where there is missing 
data on the true outcome. The causal effect predictiveness (CEP) surface plot 
provides a quantification of principal surrogacy (Gilbert and Hudgens, 2006) & 
(Gilbert and Hudgens, 2008). The CEP incorporates a necessity requirement (ACN) 
based on the need for casual effects on the surrogate if witnessed on the true outcome 
and a sufficiency requirement (ACS) similar in spirit to the STE (see section 2.2.4). 
Functions of the CEP are used to summarise the magnitude of associative and 
dissociative proportions; the expected dissociative effect the proportion associative 
effect and the associative span. A further development in a similar vain to the CEP 
has also been presented for time-to-event clinical outcomes (Qin et al., 2008). Here a 
measure named predictive surrogacy informs a researcher of both the population 
level properties of necessity and sufficiency. Zigler and Belin  (2012) estimated the 
CEP surface using a Bayesian approach which suffers lower levels of bias through 
avoidance of untestable assumptions. Their approach incorporates prior information 
on observed and unobserved outcomes and in certain situations a sensitivity 
parameter that incorporates unobservable associations.  Huang and Gilbert (2011) 
developed a graphical aid the standardised total gain and summary measure total 
gain, to compare the worth of different composite surrogates. Finally, Gilbert et al. 
(2003) suggested that a sensitivity analysis may be required in the case of post 
treatment selection bias due to factors other than the surrogate. 
2.3.1.2.1 Augmented trial designs: adding practical implementation and 
identifiability 
Follmann (2006) investigated whether immune response variables had a causal role 
in the risk of outcome of interest. He suggested using augmented trial information to 
  Evaluation of surrogate outcomes 
Systematic review 24 
identify the value of a surrogate (immune response) that a person might have had, 
had they been randomised to the unobserved treatment (vaccine). He suggested two 
ways to achieve this, a baseline immunogenicity predictor and a closeout placebo 
vaccination approach.  
The baseline immunogenicity predictors approach uses a baseline variable that 
correlates highly with the immune response. Based on the baseline variable and 
observed outcomes they imputed the unobserved immune responses of patients on 
the placebo. 
The closeout placebo vaccination approach is based on providing the vaccine to the 
placebo group after the trial has completed and then observing their immune 
response. These post trial immune responses are then used as the unobserved 
immune responses of the placebo group for the original trial. This assumes that the 
timing of the application of the vaccine has no impact on outcome. In the context of 
vaccine trials these approaches aid identifiability and allow researchers to investigate 
whether immune response is causally related to risk of the outcome of interest 
(Follmann, 2006).  
Using the baseline immunogenicity predictor approach Gabriel and Gilbert (2014) 
proposed a time and surrogate dependent efficacy curve based on a Weibull model to 
assess principal surrogacy for time-to-event outcomes with right censoring. Gabriel 
et al. (2015) extend this approach to assess combinations of biomarkers as 
surrogates. Huang et al. (2013) used a pseudo score estimator to best utilise 
augmented data for the estimation of counterfactual results. Liu et al. (2014) 
suggested that a semiparametric likelihood or pseudo-likelihood (PL) approach is 
better than the pseudo score estimator and performed a simulation for comparison. 
They found that the semiparametric likelihood method is superior to pseudo score 
estimator since it does not require a model for missingness, but that the pseudo-
likelihood approach has a computational advantage over the semiparametric 
likelihood approach and pseudo score estimator.  
Miao et al. (2013) investigated these augmented trial approaches and showed how 
they aided identification. They also investigated whether misclassifying patients into 
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principal strata using augmented data would bias results of the absolute causal 
necessity (ACN) introduced in section 2.3.1.2. They found that in the case of 
“constant biomarkers” in vaccine trials, where placebo patients have no immune 
response, overall bias imposed by misclassification was small. For the case of 
“arbitrary” variability there was some bias witnessed, although knowledge of the 
behaviour of this bias may help interpretation of results.  
In light of these and previous developments Wolfson and Henn (2014) examined the 
principal surrogacy framework and highlighted conditions for partial or full 
identifiability of the ACN and ACS (described in section 2.3.1.2., which are based on 
principal strata).  
They find that: the stable unit treatment value assumption and ignorable treatment 
assignment do not provide much identifiability; the assumption that the surrogate is 
defined at the same time for all patients provides identifiability of some components 
of ACN and ACS; and the “constant biomarker” assumption for vaccine trials allows 
identifiability of one of the principal strata required to calculate ACN and ACS. The 
monotonic assumption can aid identification in some very particular circumstances.  
Overall, they show that the augmented trial design approach can allow for full 
identification of ACN and ACS. However, they do note that certain assumptions are 
only valid for particular trial types and are unlikely to hold for others. For instance, 
the constant biomarker and monotonic assumptions are more relevant for vaccine 
trials and in general will not be suitable. The same principle applies for the 
augmented trial designs. This thorough examination of identifiability shows that 
assessing surrogacy using PS can work under some very particular circumstances. 
However, for more general randomised trials identifiability of the principal 
stratification approach is still a very large and unresolved issue which hinders the 
assessment of surrogates in practice.  
2.3.1.3 Theoretical issues- Principal stratification 
Several authors Pearl (2011), Mealli and Mattei (2012), Pearl and Bareinboim  
(2011) and Joffe (2011) criticised the theoretical basis of principal stratification with 
respect to surrogacy suggesting analysis where treatment effects can only be assessed 
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in separate restricted strata may hinder and limit investigations. Furthermore, they 
claimed that the approach is not ideally framed to inspect the predictive ability or 
transportability (in this case, meaning the ability to transfer information learned in 
one trial to future trials) of a surrogate. Pearl and Bareinboim (2011) showed that 
since principal stratification is based on only one trial a principal surrogate may not 
be able to predict treatment effects in a new trial and a good predictor may not 
constitute a principal surrogate. They suggested a new causal conceptual approach 
for transportability based on graphical representations but this is of limited use since 
it cannot be applied in practice (Joffe, 2011). Gilbert et al. (2011) disputed these 
criticisms, outlining a case where research aims can be specifically addressed using 
principal stratification. They also suggested a measure investigated through 
sensitivity analysis or comparison of true and predicted results from multiple trials to 
tackle transportability. Furthermore, Baker (2006) and Baker (2008) proposed an 
average prediction error which assesses the average absolute difference between the 
predicted effect of Z on T, via the effect of Z on S, versus the true observed effect for 
each trial, and an approach based on hypothesis testing. Baker (2008) was amended 
in Baker (2009) to correct for minor errors. 
Chen et al. (2007) identified a paradox in principal stratification where causal 
treatment effects are seen on the surrogate and true outcome given the surrogate but 
not the true outcome; this may occur because an unobserved confounding variable, 
U, acts on both the surrogate and true outcomes. This situation is a matter of some 
concern in surrogate evaluation literature (Lauritzen, 2004). If this paradoxical 
situation cannot be identified it would result in the authorisation of treatments that 
have a negative impact on the true outcome of interest, with potentially fatal 
consequences.  
Principal stratification is susceptible to the so called surrogate paradox because it 
does not consider treatment directions. To avoid this issue the authors propose 
additional conditions based on treatment direction using the average causal effect 
(ACE). Ju and Geng (2010) showed that in certain situations the ACE can fail to 
detect the surrogate paradox, and hence they redefined the conditions in terms of a 
proposed distributional causal effect (DCE). Both approaches require knowledge of 
  Evaluation of surrogate outcomes 
Systematic review 27 
U which is unlikely in practice. Kuroki (2013) noted that neither the ACE or DCE 
gave a calculation of the size of the causal treatment effect on the true endpoint. 
They proposed the use of sharp bounds to derive ‘closed form formulas for upper and 
lower bounds on the causal effects of Z on Y [the true outcome]’. In other words, 
they set a range in which the casual effects must lie for a surrogate to be deemed 
valid.  Wu et al. (2011) suggested the ACE and DCE rely on the potentially invalid 
monotonicity assumption and do not account for equivalence relationships. They 
proposed conditions that a surrogate must meet in the counterfactual situation to 
satisfy the original criteria of Prentice, incorporating treatment directions. Gilbert et 
al. (2015) were also interested in PS, its connections to the surrogate paradox and the 
ideas of Prentice. Using the measures ACN and ACS of principal stratification they 
found no direct links to the criteria of Prentice or to the surrogate paradox. However, 
there was an implied relationship under certain conditions. 
2.3.1.4 Principal stratification: discussion 
In summary, principal stratification is a valuable approach to surrogate endpoint 
evaluation chiefly because it permits investigation of causal effects. As Wolfson and 
Gilbert (2010) stated “potential outcomes provide a natural way of formulating and 
answering important scientific questions that are difficult to answer without 
counterfactuals”. However, potential outcomes encountered serious issues: stringent 
assumptions affect the ability to estimate effectively, as a consequence of guarding 
against the alternative issue of non-identifiability. Identifiability has been found to be 
possible in some very particular circumstances but in the general case is still 
intractable. Additional issues surrounding transportability and the surrogate paradox 
do raise questions about the practical worth of such an approach. Although the issues 
of transportability and the surrogate paradox have been shown to be resolvable, such 
resolutions are currently not a central component of the principal stratification 
approach.  
Principal stratification is a promising approach to surrogacy evaluation, which may 
take a more prominent role in the future. However, given its limitations it is 
unsurprising that a well-established practical means of estimating surrogacy via 
principal stratification has yet to emerge.  
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2.3.2 Alternative causal approach - Direct and indirect effects 
Another causal surrogacy evaluation approach concerns the measurement of direct 
and indirect effects. Consider Figure 2.2 direct effects of the treatment are those that 
act only on the true outcome and not the surrogate. Indirect effects are those that act 
through the surrogate. Under a naïve model, as in Figure 2.2,A.)direct and indirect 
effects can be determined by empirical evidence observing the proportion of patients 
that had agreement in treatment effects between the true and surrogate outcomes 
(indirect effects) and the proportion where treatment only affects the true outcome 
(direct effects). However if one carries out a such a naïve analysis when more 
complex causal relationships exist the results may be biased (Emsley et al., 2010). 
Cox and Wermuth (2004) expored causal models that might occur in more detail, and 
recommend a sensitivity analysis in the case of unobserved confounding variables, 
see  Figure 2.2, B.). 
 
Figure 2.2: Direct and indirect effects of: A.) a naïve model B.) a model where a 
confounder U acts on S and T. 
Robins and Greenland (1992) investigated the means of identifying direct and 
indirect effects under a number of causal models. They used a potential outcomes 
approach under which all the possible outcomes that may have occurred had the 
treatment been different are investigated. A theoretical example showed that the 
typical means of measuring direct and indirect effects by adjusting for the surrogate 
may be biased because there is a striking difference in the true underlying 
relationships and the conclusions that can be drawn from the observable results. They 
went on to show that identifying direct and indirect effects is an intractable problem 
in a number of settings, even in the case of a cross over trial with no carry over. 
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However, when the surrogate outcome can be controlled, by some randomisation 
intervention or using information on additional confounding variables, direct and 
indirect effects can be identified via G-computation. 
Qu and Case (2006) used path analysis, in the case where multiple surrogate markers 
are being assessed, to determine the proportion of direct and indirect effects 
attributable to each of a collection of surrogate markers. Dibaj et al. (2010) 
highlighted some errors in the final models but Qu and Case (2010) pointed out that 
any direct and indirect effects calculated would be valid despite these. Ditlevsen et 
al. (2005a) investigate mediation variables (where a biological markers lies at least in 
part in the causal pathway from treatment to outcome), and used empirical evidence 
to calculate a measure based on the proportion of indirect effects which controls for 
potential confounders. Kaufman et al. (2005) criticised Ditlevsen et al. (2005a) for 
using a latent set up and for not adopting a causal approach. Ditlevsen et al. (2005b) 
further discuss this work in reference to MacKinnon et al. (2007). 
Taylor et al. (2005) showed that the alternative PTE measure, PE, of Wang and 
Taylor (2002) can be expressed in terms of direct and indirect effects. Using 
assumptions and constraints they found there are some relations, but no strong link, 
to measures from direct and indirect effects and principal stratification approaches. 
They concluded that PE is the only measure that can be estimated from the data and 
that, under untestable assumptions, it may have an ‘approximate causal 
interpretation’. 
2.4 Classification of approaches 
Joffe and Greene (2009) proposed classification of approaches under two paradigms: 
the causal effects and causal association paradigm. They considered the original  
definition of Prentice, the meta-analytical, principal stratification and the direct and 
indirect effects approaches. 
The causal effects paradigm (CE) requires the surrogate to lie in the causal pathway 
from treatment to the true outcome. This requirement is understandable and desirable 
but causes problems from a practical point of view. Measuring the association 
between Z, S and T is straightforward in the naïve scenario but not in a more 
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complicated situation where an unobserved confounder U influences S and T, see 
Figure 2.2, B.). In an investigation where U exists but is unaccounted for as there is 
an association of U→S and U→ T there would appear to be an association of Z→U 
therefore Z→T even if there is no direct effect present. Adjustment for the 
confounder U can be made via certain strong assumptions and where the surrogate 
can be manipulated, which is not generally practically feasible. Prentice and direct 
and indirect effects approaches fall under this paradigm. 
The causal association (CA) paradigm avoids this issue by not investigating the 
effect of the surrogate on the true outcome just the treatment effect on the surrogate 
and true outcome separately as in both the meta-analytical and the principal 
stratification approaches. There is no direct measurement of the relationship of the 
true outcome and surrogate calculated; therefore, issues related to modelling of the 
causal pathway are not relevant.  
The authors indicated that there are some connections between the two paradigms 
and situations in which models in each paradigm are related but interpretation of 
models and parameters are not the same.  They went on to state that the causal 
association paradigm is more useful in practice because it does not suffer issues of 
bias in the presence of confounding or interaction between variables. They also gave 
strong arguments for a multi-trial approach to surrogacy evaluation such as can be 
found in the meta-analytical and information theory approaches. However, they 
expressed regret that the current multi-trial approaches do not have a strong causal 
basis. 
2.4.1 Relationships within classifications of Joffe and Greene 
(2009) 
Alonso et al. (2014) investigated the relationship between the meta-analytical and the 
average causal necessity (ACN) of the principal surrogate approach. They assessed 
the conceptual setup of each approach in relation to the causal association framework 
of Joffe and Greene (2009). They quantify a causal association framework surrogate 
using the causal correlation of the potential treatment outcomes on S and T, they call 
this the individual causal association. They also investigated how the meta-analytical 
approach and ACN behaved under a range of scenarios with particular casual 
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relationships. They found that the ACN of principal stratification was very restrictive 
and suffered identifiability and transportability issues. Evaluation based on the meta-
analytical approach generally is also satisfied under a causal assessment. However, 
positive causal assessments based on one trial (current practice) can fail causal meta-
analytical assessments if heterogeneity between trials is high and causal effects are 
weak. 
2.4.2 Causally classified approaches and the surrogate 
paradox 
Vanderweele (2013) assessed the approaches classified in Joffe and Greene (2009) to 
see if they could identify paradoxical surrogates, see Table 2.1. Paradoxical 
surrogates occur when there is a positive treatment effect on the surrogate and a 
positive relationship between the surrogate and the true outcome but a negative 
treatment effect on the true outcome. As previously discussed (section 2.3.1.3), the 
occurrence of an unidentified paradoxical surrogate could have fatal consequences.  
Vanderweele (2013) suggested that surrogates may be paradoxical in three scenarios; 
first, where there was a direct effect of the treatment on the true outcome which by 
definition circumvents the surrogate; second, there was a confounding influence; or 
finally, treatment may affect the true outcome and the surrogate but not for the same 
individuals, this they call “transitivity”.  
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Joffe and Greene (2009) 
evaluation approach 
Can it identify the surrogate paradox? 
 Theoretically Practically 
PTE No No 




Principal stratification Yes – not as part of the original 
proposition but can be under 
additional proposals Chen et al. 





Yes – not set up to do so - but can 
be done under proposals of Elliot 
et al. (2014) 
Yes  
Table 2.1: Proposals of Joffe and Greene (2009) that can identify surrogate paradox 
The first of the approaches of Joffe and Greene (2009), the PTE, cannot recognise 
paradoxical surrogates. Theoretically, the direct and indirect effects approach can 
recognise them but identifiability issues mean this would be unfeasible in practice. 
Under conditions for “consistent” surrogates proposed by Chen et al. (2007) and Ju 
and Geng (2010) (see section 2.3.1.3) PS can theoretically identify the surrogate 
paradox but identifiability issues would again make this difficult in practice. The 
meta-analytical approach (and by extension the information theory approach) is not 
set up to identify the paradox however it could be used to do so.  
Elliot et al. (2014) took these ideas forward and proposed measures based on the 
meta-analytical approach methodology which assess the risk of the surrogate 
paradox. These calculate the probability of the surrogate paradox occurring given 
beneficial treatment effects on the surrogate, and the size of beneficial treatment 
effect on the surrogate needed to prohibit the occurrence of the surrogate paradox. 
2.5 Interdisciplinary approaches 
The following approaches to surrogacy evaluation use methods from a range of areas 
of statistical methodology.  
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Endogeneity concerns a dependent variable, in our case the surrogate, being 
correlated with the error term through an unobserved confounder variable U (as 
discussed in section 2.4). The issue of the unobserved confounder, U, can be resolved 
through the use of an instrumental variable which is correlated with the dependent 
variable and dependent on U but not part of the explanatory model. Ghosh et al. 
(2010) proposed the investigation of the following structural equation model for a 
single trial: 
𝑇 = 𝛼0 +  𝛼𝑆 + 𝑆  (18) 
where 𝛼0 and α are unknown intercept and treatment effect terms and 𝑆 is an error 
term with unknown distribution. Treatment, Z, is absent from (18) however in 
endogeneity it will contribute to the estimation of α if Z is an instrumental variable. 
To be instrumental it must fulfil three assumptions, one of which ties the concept of 
instrumentality to the evaluation of surrogacy and states that the effect of Z on T be 
fully explained by S (if Z is an instrumental variable it follows that S is a good 
surrogate for T.) They proposed a measure, related to the meta-analytical approach, 
and showed that it is causal under the instrumentality assumption on which it is 
strongly dependent. In the case where a mediation variable is controllable, Emsley et 
al. (2010) built two models and use endogeneity to aid identification. They assumed 
that a pre-randomisation covariate is instrumental to gain reliable estimates. 
However, this assumption has untestable components and relies on finding a suitable 
covariate. 
Several authors have considered surrogate evaluation from a missing data point of 
view. Some highlighted the usefulness of surrogates to estimate parameters where 
the true outcome is incomplete (Chen et al., 2003b) and (Chen et al., 2008). Benda 
and Gerlinger (2007) investigated the use of sperm count as a surrogate for a binary 
pregnancy true outcome. Surrogate data was missing in the initial trial but recorded 
pregnancy rates for sperm count intervals were available. They found that the more 
information in the initial trial the greater precision they had in estimates of the level 
of pregnancy in the trial of interest.  Korn et al. (2005a) and van Walraven et al. 
(2009) considered approaches where only trial level data is available, for multiple 
trials. The former focused on prediction of event rates between study groups which 
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are then used for comparison and the latter focused on trial level summaries that do 
not require individual level information. (Freedman, 2005) had some concerns about 
the approach in Korn et al. (2005a) which were further discussed in Korn et al. 
(2005b).  
For multiple trials and binary outcomes, Baker et al. (2012) investigated surrogacy 
using a formal assessment of a surrogate’s ability to predict treatment effect on the 
true outcome. They proposed a 95% prediction model incorporating an estimated 
random extrapolation error. Surrogates are assessed on the basis of a standard error 
multiplier; this compares the difference in the standard error calculated using the true 
outcome versus the standard error calculated using the prediction of true outcome 
based on the surrogate. A small standard error multiplier implies a good prediction 
model and therefore a useful surrogate. 
2.6 Miscellaneous  
Begg and Leung (2000) suggested there was a paradox in a Prentice based approach 
by Day and Duffy (1996). However, Baker et al. (2005) contested this assertion since 
contradictions exist in both authors calculations. MacKinnon et al. (2007) for 
mediation outcomes, proposed calculating  𝛽 − 𝛾𝑍 from the single trial version of 
models (10) and (12). If this measure equals zero, the mediator fully explains the true 
outcome.  Deslandes and Chevret (2007) proposed suitable joint models for two 
settings; first, repeated measures surrogates and time-to event true outcomes and 
second, multistate surrogates and a binary true outcomes. They then formally 
assessed surrogacy using a measure of PTE. 
Event free survival is a commonly used surrogate which a composite made up of 
some interim outcome, for instance relapse, and the true outcome. Ghosh (2008a) 
argued that in this case “a practical definition of surrogacy is one in which a 
composite outcome based on both the surrogate [interim outcome] and the true 
outcome yields the same result as the true outcome”. Based on this definition for 
time-to-event outcomes, the authors proposed an estimation of surrogacy using the 
correlation between treatment effects on the true outcome in relation to that on the 
composite outcome. 
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2.7  Surrogacy schemes 
Schemas for assessing levels of surrogacy have been suggested. Qin et al. (2007) and 
Gilbert et al. (2008) proposed a 3 level schema for biological measures focusing on 
vaccine studies. With increasing validity, a ‘correlate of risk’ is a biological measure 
that correlates with the primary outcome, this is easily verified. A ‘level one 
surrogate of protection’ is a correlate of risk whose response to vaccine can be used 
to predict the vaccine response on the true outcome and a ‘level two surrogate of 
protection’ is a level one surrogate of protection which can be used for prediction in 
different populations or treatments. The authors conceded that level two surrogates 
of protection are extremely difficult to assess. The authors proposed a means of 
evaluating surrogates under this schema, for time-to-event outcomes, but experienced 
computational issues with both a principal surrogate and a meta-analytical approach. 
Dunning (2008) suggested that the framework should identify surrogates that 
‘quantitatively predict the efficacy of the vaccine’ and proposed a means of doing so. 
Gilbert et al. (2009) argued that their approach already incorporated this.  
Lassere et al. (2007b), Lassere et al. (2007a) and Lassere (2008) proposed a system 
of validating surrogates for setting up a clinical trial. Their scheme is based on 
biological aspects, quality of data, practical issues and statistical evaluation. Hence it 
incorporates statistical and non-statistical aspects of surrogacy which are equally 
important. The proposed surrogate is scored between one and fifteen. Proposed 
surrogates with low scores are classified as biomarkers (disease centred variables of 
biological or pathological process) those with high scores as patient outcomes 
(variables that reflect how a patient feels functions or survives).  
2.8 General practical issues 
Sarkar and Qu (2007) investigated the impact of measurement error in surrogacy 
evaluation using a measure of the PTE called the excess relative odds , where the 
surrogate is continuous and the true outcome is binary. They found that in the 
presence of measurement error the excess relative odds are biased. In the case of 
binary outcomes, Kassai et al. (2005) suggested the diagnostic odds ratio , a measure 
of sensitivity and specificity, to quantify measurement error but provide no detailed 
approach for its use. 
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As previously discussed correlation is a poor indication of a surrogate’s worth. Baker 
and Kramer (2003) showed that, even where perfect correlation exists, a surrogate 
does not necessarily predict treatment effect on the true outcome. Wang et al. (2012) 
find that correlation can be influenced by many different factors and is therefore 
unsuitable for surrogate evaluation.  
A supposed advantage of the use of surrogates is the possibility of smaller clinical  
trials. Baker and Kramer (2012) investigated the extrapolation error for binary 
outcomes, see section 2.5, and suggested that small studies based on a surrogate 
could suffer serious problems. Kramer (2013) proposed the measure relative error 
(𝑅𝐸𝑀𝐼𝑋 ) which estimates the validity of an extrapolation assumption. They found 
that, under Prentice and principal stratification approaches, the 𝑅𝐸𝑀𝐼𝑋  is dependent 
on the size of the sample. They stated that a smaller surrogate clinical trial is more 
likely to give misleading results than a larger one. 
2.9 Discussion  
The use of adequate surrogates benefits patients, clinicians, researchers and 
pharmaceutical companies alike. Therefore, researchers have worked towards a 
satisfactory approach to surrogacy evaluation. This systematic review was conducted 
to investigate and consider the available statistical approaches for evaluating 
surrogates. 
I found that historic proposals, Prentice, PTE, relative effect and adjusted association 
provide useful and motivating conceptual ideas for evaluation. However, these have 
long since been deemed impractical and suffer serious bias due to adjusting for a 
surrogate which, as a post-randomisation variable, allows estimation of treatment 
effects on the true outcome to be influenced by confounders.  
The meta-analytical approach uses multiple trials to more accurately predict 
treatment effect on the true outcome. This has been superseded by the information 
theory approach which in addition offers unified interpretation across different types 
of outcome. Alternative approaches, the principal stratification and direct and 
indirect effects, are also prominent in the literature. A number of other avenues have 
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also been investigated showing that development in this area is by no means 
stagnating. 
I note that the main theoretical divergence in surrogacy evaluation approaches 
surrounds the need for causal validity. Principal stratification and direct and indirect 
effects approaches both provide this. Of the two, principal stratification has 
undergone the most development for applied use and has been suggested to be of 
more practical benefit (Joffe and Greene, 2009). I find that, though both these 
approaches are worthy and ambitious, they do not perform well upon practical 
application. Both take a counterfactuals approach and require assumptions to aid 
identifiability but cannot estimate effectively when the data do not follow the rigid 
framework imposed by these assumptions. Researchers may face various quandaries 
over balancing levels of bias, due to the use of invalid assumptions, and quality of 
estimation due to inability to identify parameters. In summary, principal stratification 
and direct and indirect effects are valuable and stimulating approaches to surrogate 
outcome evaluation, chiefly because they examine causal effects. However, they are 
both somewhat in their infancy in regard to practical developments and, thus far, no 
consistent and established approaches have gained prominence. 
I find, on balance, that the information theory approach is currently the preferred 
approach for assessing surrogacy. In comparison to its predecessor, the meta-
analytical approach, it provides a unified interpretation across settings, does not rely 
on interpretations at the latent level, and computational issues regarding the use of 
joint models are avoided. Both the meta-analytical and information theory 
approaches avoid the need to fully assess causal pathways at the trial level while still 
retaining a causal interpretation. This is because it assesses the relationship between 
treatment effect on the true outcome and treatment effect on the surrogate, rather 
than evaluating whether treatment acts on the true endpoint by acting on the 
surrogate. The latter approach provides a more thorough causal investigation but is 
less worthwhile overall as it leads to serious practical issues regarding multi -faceted 
treatment mechanisms and outside influences (Joffe and Greene, 2009). Despite 
these advantages, information theory provides no causal interpretation at the 
individual level. However, causality is not the main focus of information theory, 
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which assesses the value of the surrogate as a source of information. The multi trial 
aspect of both approaches provides the key advantage in that it “deals, albeit 
imperfectly, with transportability” (Joffe, 2011). In other words, if the same effect is 
seen across trials this provides evidence that this effect will also be present in a new 
trial assuming it is performed in the same population. This means it can inform on 
the ability of the surrogate to predict treatment effects on the true outcome which is a 
key aim of surrogacy evaluation and is not currently a central feature of the causal 
approaches (Pearl, 2011).  
Even though the information theory approach offers no causal interpretation at the 
individual level this negative is outweighed by its provision of a sophisticated 
approach to surrogacy evaluation that is straightforward to apply in practice, 
provides researchers with the pertinent information and has limited computational or 
interpretational issues. 
Finally, impressive as the surrogacy evaluation literature is, Prentice (1989) noted 
that surrogacy evaluation applies at most to treatments that act through the same 
mechanism of action. None of the methods presented in this chapter has proposed a 
solution to the evaluation of surrogates for different classes of treatments. 
This chapter has provided a comprehensive review of the statistical developments 
and current methodologies in the field of surrogate evaluation. The vast array and 
scope of the described publications demonstrate a continuing strong interest in 
developing valid surrogate evaluation approaches.
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Chapter 3. Extension of information theory for 
a binary surrogate and ordinal true outcome: 
Methodology 
As highlighted in the systematic review (Chapter 2), the most appealing approach to 
surrogacy evaluation from both a practical and theoretical perspective is the  
information theory approach. Practically speaking: it requires no stringent 
assumptions; suffers no serious computational difficulties; and provides a consistent 
approach across settings. From a theoretical perspective, it provides the pertinent 
information required and a causal interpretation at the trial level. Furthermore, it 
provides information on how well a surrogate is likely to perform as a predictor of 
treatment effect on the true outcome in a new trial. This is a fundamental aim of 
surrogacy and one which is not a principal feature of other well established approaches. 
Given the strong arguments in favour of the information theory approach I extended 
this methodology to the case where either the surrogate, the true outcome, or both are 
ordinal. Previous authors had suggested the means of doing this for the meta-analytical 
approach (Burzykowski et al., 2003) but none are currently available for the 
information theory approach. Hence, researchers in clinical areas where ordinal 
outcomes are used will be able to evaluate surrogacy.  
In this chapter I: outline the information theory approach in detail; show how this has 
been extended to the case of a binary surrogate and ordinal true outcome; present 
confidence intervals for information theory based measures; and outline my approach 
to avoiding bias where separation occurs. 
The notation of the following sections is as follows. Y and X represent two random 
variables, either discrete or continuous depending on the context. In the discrete 
context, Y and X have values 𝑘𝑏 , 𝑏 ∈ (1, … , 𝑚𝑦)  and  𝑘𝑑 , 𝑑 ∈ (1, … , 𝑚𝑥) and 
probabilities of occurrence of each value 𝑝𝑏  and 𝑝𝑑  respectively. I represent a putative 
surrogate as S, treatment as Z and the true outcome as T. In the multi trial context there 
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are i=1,2,…,N trials, and j=1,2,….,𝑛𝑖 patients per trial. 𝑁𝑇 = ∑ 𝑛𝑖𝑖 , the total number 
of patients in all trials. W is the number of categories in the ordinal true outcome. 
3.1 The meta-analytical approach: general truths 
The interpretation of individual level surrogacy under the meta-analytical approach 
was different across different types of outcome. The information theory approach was 
developed to resolve these inconsistency issues. The meta-analytical and information 
theory approaches are very closely linked and analogous in many respects. Therefore, 
a lot of the work in publications for the meta-analytical approach are relevant to that 
under the information theory approach. 
3.2 The information theory approach 
Information theory uses the central concept of entropy to measure the “information, 
choice and uncertainty” in a random variable (Shannon and Weaver, 1948). Entropy 
measures how uncertain one is about the outcome of individual draws from a Markov 
process. Taking the example of a coin toss, where a coin is heavily unfair towards one 
particular outcome, each new flip of the coin does not provide much information. Since 
one outcome is a great deal more likely than the other we already have a strong idea 
what the outcome will be. On the other hand, a balanced coin is much less easy to 
predict and therefore each outcome of the coin toss is providing more information and 
hence has higher entropy.  
Mathematically speaking, in the discrete case, entropy can be represented as 𝐻(𝑌) =
− ∑ 𝑝𝑏log (𝑝𝑏)𝑏 , where Y is a discrete random variable with values 𝑘1, 𝑘2 , … . , 𝑘𝑚𝑦  
and probabilities 𝑝1, 𝑝2 , … . , 𝑝𝑚𝑦  respectively (Shannon and Weaver, 1948). Entropy 
has a number of useful properties. For example, H=0 if and only if all but one 
probability takes the value zero (in other words, it has only one possible outcome), 
otherwise H is always positive. This can be demonstrated using the coin toss example: 
if the probability of a tail is one and a head is zero the new value of a toss will provide 
no information as we are 100% certain of the result. If a head has any probability larger 
than zero, a new toss will provide information and entropy will be larger than zero.  
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Through consideration of the case of the joint entropy of two random variables Y and 
X, where 𝑝𝑏,𝑑  is the joint probability of Y=b and X=d, 𝐻(𝑌, 𝑋) = − ∑ 𝑝𝑏,𝑑 log (𝑝𝑏,𝑑 )𝑏,𝑑  
and their conditional entropy 𝐻(𝑌|𝑋) = − ∑ 𝑝𝑏 |𝑑 log (𝑝𝑏|𝑑)𝑏𝑑  it can be shown 
that 𝐻(𝑌) ≥ 𝐻(𝑌|𝑋). This means that the entropy of Y is bigger or equal to the 
entropy of Y given X. Some intuitive conclusions follow from this: 𝐻(𝑌) = 𝐻(𝑌|𝑋) 
if and only if X and Y are independent, see Shannon and Weaver (1948); the 
uncertainty in Y is never increased by knowledge of X; and H(Y) is invariant by 
bijective transformations of Y. A full list and proofs of these and other properties of 
entropy can be found in Shannon and Weaver (1948). 
A concept of fundamental importance is called the mutual information. This is defined 
as 𝐼(𝑋, 𝑌) = 𝐻(𝑌) − 𝐻(𝑌|𝑋) and is interpreted as the amount of uncertainty in Y 
removed if X is known. These concepts are useful in surrogate evaluation as we are 
interested in the amount of information on T removed through the knowledge of S at 
the individual level. At the trial level we are interested in the amount of information 
of the treatment effects on T removed through the knowledge of treatment effects on 
S. 
Alonso and Molenberghs (2007) used these concepts and presented an information 
theory approach to surrogacy evaluation. Their approach was based on information 
theory concepts for continuous outcomes. Differential entropy was used to measure 
the entropy of continuous random variables. Assume Y is now a continuous random 
variable and 𝑓𝑦 is the corresponding density function, we define differential entropy as 
ℎ𝑑(𝑌) = − ∫ 𝑓𝑦(𝑦) log (𝑓𝑦(𝑦)) 𝑑𝑦. This holds most but not all of the properties of the 
discrete case.  Key differences are that ℎ𝑑 (𝑌) does change through transformations of 
Y and it can take negative values. Again, considering the case of two continuous 
variables X and Y and with joint density 𝑓𝑦𝑥 , the conditional differential entropy, 
ℎ𝑑(𝑌|𝑋),  and the mutual information,  𝐼(𝑋, 𝑌) = ℎ𝑑 (𝑌) − ℎ𝑑(𝑌|𝑋) , are defined in 
an analogous manner to the discrete case.  
The information theory measure of surrogacy was based on another more useful 
concept in the continuous setting, the entropy power, obtained by maximising the 
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differential entropy of a normally distributed continuous random variable is 𝐻(𝑌) =
1
2
log (2𝜋𝑒𝜎) meaning that 𝐸𝑃(𝑌) = 𝜎2. This suggests that for normally distributed 
variables information and variability are equivalent. However, in practice EP(Y) is 
larger than Var(Y) if the continuous variable is not normally distributed. 
3.3 Individual level surrogacy: information theory 
At the individual level Alonso and Molenberghs (2007) proposed an information 







Where, 𝐸𝑃(𝑇) is the entropy power of T and 𝐸𝑃(𝑇|𝑆) is the entropy power of T given 
S. This can be interpreted as the amount of uncertainty in the true outcome T removed 
when S is known. 𝑅ℎ
2 has useful properties including that: it is linked to the mutual 
information through 𝑅ℎ
2 = 1 − 𝑒2𝐼(𝑆,𝑇); 𝑅ℎ
2 is invariant by bijective transformations of 
S and T; for continuous variables there exists a deterministic relationship between S 
and T. Finally, 𝑅ℎ
2 = 0 if and only if T and S are independent, this result would suggest 
a poor surrogate that explains none of the uncertainty in T as you would expect if S 
and T were independent. 
Alonso and Molenberghs (2007) were keen to align the information theory approach 
to the meta-analytical approach by imposing a multi-trial framework. This was so that 
the information theory approach could tackle the issue of transportability and be used 
to predict the treatment effect on T in a new trial. However, in the multi-trial 
framework there were an uncountable number of options for the choice of summary 
parameter to be used to calculate surrogacy. 
In equation 3.2, if we have N trials we also have 𝑁𝑞 possible values of 𝑅ℎ𝑖
2 , the 𝑅ℎ
2 for 
the ith trial, since we can cluster trials depending on q different characteristics. Hence, 
there are many different choices for the parameter 𝜗𝑖 and an uncountable number of 
summary measures we could use to calculate 𝑅ℎ
2 in the multi-trial setting. 
  Evaluation of surrogate outcomes 
Methodology: Binary-ordinal setting 43 
𝑅ℎ




= 1 − ∑ 𝜗𝑖 𝑒




 𝜗𝑖 > 0 ∀ 𝑖,  ∑ 𝜗𝑖 = 1
𝑁𝑞 
𝑖=1
    
3.2 
 
Alonso and Molenberghs (2007) proposed a number of options but highlight the 
Likelihood Reduction Factor (LRF) as a good candidate to calculate 𝑅ℎ
2 in the multi-
trial setting. The LRF is particularly useful as it ranges in the unit interval and has a 
consistent interpretation across outcome types, for example the continuous, binary and 
time-to-event settings. As noted in section 2.2.5, the reason that the information theory 
approach was created was that its predecessor, the meta-analytical approach, does not 
provide a consistent interpretation at the individual level. 
In the following sections I introduce the LRF for continuous outcomes at the individual 
level and then show how this can be extended to the case of a binary surrogate and 
ordinal true outcome. 
3.3.1 Individual level: likelihood reduction factor 
The LRF was introduced as a means of evaluating surrogacy by Alonso et. al. (2006). 
Here I present the fixed effects LRF at the individual level, for the continuous -
continuous setting. The LRF is based on the amount of information gained about the 
true outcome after accounting for the surrogate. These authors proposed modelling 3.3 
and 3.4 for each trial i, these models regress the true outcome on treatment with and 
without adjustment for the surrogate respectively: 
𝑇𝑖𝑗 = 𝜇𝑖 + 𝛽𝑖 𝑍𝑖𝑗 + 𝑇𝑖𝑗 
 3.3 
𝑇𝑖𝑗 = 𝜃0𝑖 + 𝜃1𝑖 𝑍𝑖𝑗 + 𝜃2𝑖 𝑆𝑖𝑗 + 𝑖𝑗  3.4 
where: 𝜃0𝑖 and 𝜇𝑖 are intercept parameters with and without adjustment for the 
surrogate; 𝛽𝑖 is the treatment effect parameter for the true outcome; 𝜃1𝑖  and 𝜃2𝑖 are 
treatment and surrogate parameters for the model with adjustment for the surrogate. 
The difference in the amount of information on the true outcome gained from the 
surrogate is calculated via the difference in the log-likelihood between 3.3 and 3.4 
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which is formally expressed as 𝐺𝑖
2, for each trial i. 𝐿𝐿0 is always the log-likelihood for 
the unsaturated model, in this case 3.3, and 𝐿𝐿1 for the saturated model, 3.4, for trial 
i. 𝐺𝑖
2 = 2 ∗ (𝐿𝐿1 − 𝐿𝐿0). The LRF is then calculated: 
𝐿𝑅𝐹 = 𝑅ℎ











The authors stated that the LRF reduces to the 𝑅indiv
2  measure of the meta-analytical 
approach (see section 2.2.1) where outcomes are normally distributed. We will use the 
LRF to calculate the 𝑅ℎ
2 at the individual level for the binary-ordinal setting. 
3.3.2 Individual level: binary-ordinal 
At the individual level I applied the LRF in the binary-ordinal setting in the same 
manner as in the continuous case using (13) however this was based on the difference 
in 𝐺 
2 = 2 ∗ (𝐿𝐿1 − 𝐿𝐿0) of the following proportional odds models: 
𝑙𝑜𝑔𝑖𝑡(𝑃[𝑇𝑖𝑗 ≤ 𝑤]) = 𝜇𝑇𝑤𝑖
+ 𝛽𝑖 𝑍𝑖𝑗 3.6 
𝑙𝑜𝑔𝑖𝑡(𝑃[𝑇𝑖𝑗 ≤ 𝑤]) = 𝜃0𝑤𝑖
+𝜃1𝑖𝑍𝑖𝑗 + 𝜃2𝑖 𝑆𝑖𝑗 3.7 
Where, 𝑤 = 1, … . , 𝑊 − 1, and 𝑊 is the number of categories in the ordinal true 
outcome. 𝜇𝑇𝑤𝑖
 and 𝜃0𝑤𝑖
 are intercept parameters for each cut point of the ordinal true 
outcome for each trial, 𝛽𝑖 and 𝜃1𝑖  are treatment and 𝜃2𝑖  surrogate parameters. 
Again, the LRF is based on the difference in the amount of information gained on the 
true outcome with and without the surrogate for each trial.  
However, in the case of discrete outcomes and a family of conditional models the LRF 
is bounded above by a number strictly less than one. Consider the case of the 
calculation of information gain, 𝐺 
2, between an intercept only model and a saturated 
model with one additional variable. With log-likelihoods respectively of 𝐿𝐿0 and 𝐿𝐿1 
and 𝐺 
2 = 2(𝐿𝐿1 − 𝐿𝐿0). In the case of continuous responses, the probability of a 
specific value in the random variable is zero. However, in the discrete case all values 
of the response variable will have a non-negative probability hence Kent (1983) stated 
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that 𝐿𝐿0 ≤ 𝐿𝐿1 ≤ 0. Therefore, Kent (1983) further stated that for discrete response 
variables 𝐺 
2 ≤ −𝐿𝐿0. Meaning that 𝐺 
2 is less than or equal to the total amount of 
information in the response variable, as determined by the log-likelihood intercept only 
model of that variable.  
In the case of surrogacy evaluation in principle this response variable would be the 
true outcome T. And ideally, 𝐺 
2 ≤ −𝐿𝐿𝑇, where 𝐿𝐿𝑇 is the log-likelihood of the 
intercept only model, (𝑙𝑜𝑔𝑖𝑡(𝑃[𝑇𝑖𝑗 ≤ 𝑤]) = 𝜃3) and 𝐿𝐿𝑇 represents the total 
information present in T. 𝐺 
2 ≤ −𝐿𝐿𝑇 would be a desirable result since it would mean 
that it would be mathematically possible for the surrogate to explain all the information 
that is present in the true outcome. And, therefore, we could determine the amount of 
information in T that the surrogate explains. However, in the case of individual level 
surrogacy because both models are conditional on treatment it is not possible for the 
surrogate to explain all the information in T because 𝐺 
2 ≤ −𝐿𝐿𝑇 does not hold. 
Consider the two nested conditional models of the individual level, 3.6 and 3.7. These 
are nested conditional models as both are conditional on treatment, and 3.7 is the 
saturated model as it is also conditional on S. Let’s define the log-likelihoods of these 
conditional models as 𝐿𝐿𝑇|𝑍 and 𝐿𝐿𝑇|𝑍,𝑆 respectively. In this case 𝐺 
2 is bounded above 
by the information in the true outcome given the shared conditional variable, Z, rather 
than by the information in the true outcome alone. Mathematically this is 𝐺 
2 ≤ −𝐿𝐿𝑇|𝑍 
rather than 𝐺 
2 ≤ −𝐿𝐿𝑇, see Kent (1983). Therefore, at the individual level,  𝐺 
2 is 
bounded above by a value which is less than the full information in the true outcome. 
That is unless the conditional variable, Z, explains none of the variability. Since 𝑅ℎ
2 is 
based on the 𝐺 
2 this in turn means that 𝑅ℎ
2 is bounded above by a number less than 1, 
𝑅ℎ
2 ≤ 1 − 𝑒2𝐿𝐿𝑇|𝑆, as shown in Alonso and Molenberghs (2007).  
Hence, Alonso and Molenberghs (2007) proposed rescaling 𝑅ℎ
2 so that is composed in 
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They do this by rescaling 𝑅ℎ
2 using the information in T alone as calculated by 𝐿𝐿𝑇, 
see 1.8. Despite the rescaling the LRF has a consistent interpretation in this setting as 
well as that described previously. 
3.3.3 Individual level: modelling methods binary-ordinal 
For 𝑅ℎ
2 the LRF between the model with and without adjustment for the surrogate for 
each trial, see 3.3.2. However, an alternative procedure is to calculate only two models 
in total incorporating all trials. This can be done by using trial as a fixed effect variable 
in the model, as opposed to the two models 3.6 and 3.7 for each trial. Here: 
𝑙𝑜𝑔𝑖𝑡(𝑃[𝑇𝑖𝑗 ≤ 𝑤]) = 𝜇𝑇𝑤
0 +  𝜇𝑇𝑖 𝑡𝑟𝑖𝑎𝑙𝑖𝑗  + 𝛽𝑖 (𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑍𝑖𝑗 )  3.9 
         𝑙𝑜𝑔𝑖𝑡(𝑃[𝑇𝑖𝑗 ≤ 𝑤]) =  
𝜃0𝑤
0  +  𝜃0𝑖 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 + 𝜃1𝑖 (𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑍𝑖𝑗 ) +  𝜃2𝑖 (𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑆𝑖𝑗 ) 
3.10 
Where: 𝜇𝑇𝑤
0  and 𝜃0𝑤
0  are fixed intercepts for each of the W-1 cut points of the ordinal 
true outcome; 𝜇𝑇𝑖  and 𝜃0𝑖 are the trial specific shifts of the set of intercepts; 𝛽𝑖 and 𝜃1𝑖  
are treatment and 𝜃2𝑖  surrogate parameters for each trial i.  
This method would lead to an LRF based on the 𝐺 
2 of only 3.9 and 3.10. Rather than 
the 𝐺 𝑖
2  of 3.6 against 3.7 for each trial i which are then summed over all trials in the 
approach outlined in section 3.3.2. This two model only method was used to calculate 
individual level surrogacy in previous information theory publications in the binary-
binary setting (Tilahun et al., 2008) and binary-continuous setting (Pryseley et al., 
2007); according to their freely available software (I-Biostat, 2015). In this case, the 
LRF would be composed as in 3.11 as opposed to (13): 






The LRF in equation 3.11 for the individual level is only valid under the assumption  
that the “association between both variables is constant over trials” (Alonso et al., 
2004). This assumption may not hold in real life situations. Furthermore, practically 
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speaking, using this method in the ordinal setting, would lead to serious issues of over-
fitting because of the interaction term 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑆𝑖𝑗 in the second model (equation 3.10). 
Conversely, basing the LRF on (13) using separate models for each trial i is more in 
keeping with the multi-trial philosophy of the information theory approach; modelling 
issues are limited; and potentially invalid assumptions are not necessary. Hence, we 
will use separate models for each trial and apply the LRF using (13). 
3.4 Trial level surrogacy: information theory 
At the trial level we are interested in the treatment effects on the surrogate in relation 
to the treatment effects on the true outcome. In order to calculate this Alonso and 
Molenberghs (2007) proposed a two stage approach. At the first stage we obtain the 
treatment effects for each trial on the surrogate and true outcome, 𝛼𝑖 and 𝛽𝑖 
respectively. This is done by regressing the surrogate and true outcome on treatment 
in the models 3.12 and 3.13. First I present the models required for the continuous-
continuous case: 
𝑆𝑖𝑗 = 𝜇𝑆𝑖 + 𝛼𝑖 𝑍𝑖𝑗 + 𝑖𝑗 3.12 
𝑇𝑖𝑗 = 𝜇𝑇𝑖 + 𝛽𝑖 𝑍𝑖𝑗 + 𝑖𝑗 3.13 
Where 𝜇𝑆𝑖  and 𝜇𝑇𝑖  are intercept parameters and 𝛼𝑖  and 𝛽𝑖 are treatment effect estimates 
for S and T respectively for each trial i. Using the treatment effect estimates we 
calculate the information theory surrogacy measure 𝑅ℎ𝑡
2  through 3.14. 
𝑅ℎ𝑡
2 =




Where 𝐸𝑃(𝛽𝑖 ) is the entropy power of treatment effects on the true outcome and 
𝐸𝑃(𝛽𝑖|𝛼𝑖) is the entropy power of treatment effects on the true outcome given those 
on the surrogate. 𝑅ℎ𝑡
2  can be interpreted as the amount of uncertainty in the treatment 
effect on T removed through knowledge of the treatment effect on S. If 𝑅ℎ𝑡
2 ≈ 1 then 
the treatment effects on the surrogate explains a high level of the uncertainty in the 
treatment effects on the true outcome.  
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In the following sections I introduce the LRF for continuous outcomes at the trial level 
and then show how this can be extended to the case of a binary surrogate and ordinal 
true outcome. 
3.4.1 Trial level: likelihood reduction factor 
The LRF can be applied to calculate 𝑅ℎ𝑡
2  in the continuous-continuous case. In order 
to do this we model 3.12 and 3.13, the surrogate and true outcome regressed on the 
treatment respectively. These models provide treatment effect estimates for both S and 
T for each trial, these are represented by the parameters 𝛼𝑖 and 𝛽𝑖 respectively. At the 
second stage two further models are required: the null model (3.15) of treatment effects 
on the true outcome for each trial; and the treatment effects on the true outcome 
regressed on the intercepts and treatment effects of the surrogate for each trial  (3.16). 
𝛽?̂? = γ3 + 𝑖 3.15 
𝛽?̂? =  𝛾0 + 𝛾1𝜇𝑆?̂? + 𝛾2𝛼?̂? + 𝑖 , 3.16 
where, γ3 and 𝛾0 are the intercept parameters with and without adjustment for the 
surrogate, 𝛾1 and 𝛾2 are the parameters for the surrogate intercept and treatment effect 
estimates provided from stage one. The difference in the -2*log-likelihood between 
these two models can then be calculated and the LRF applied as in 3.17. 
𝐿𝑅𝐹 = 𝑅ℎ𝑡







3.4.2 Trial level: binary-ordinal 
In the binary-ordinal setting the only difference in the approach is in the models used 
at the first stage. Here a generalised linear model is fitted for the binary surrogate 
regressed on treatment, in 3.18. A proportional odds model is fitted for the ordinal true 
outcome regressed on treatment, in 3.19. This is done to estimate the treatment effects 
 𝛽𝑖  and 𝛼𝑖 . 
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𝑙𝑜𝑔𝑖𝑡[𝑃(𝑆𝑖𝑗 = 1)] = 𝜇𝑆𝑖 + 𝛼𝑖 𝑍𝑖𝑗 3.18 
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇𝑖𝑗 ≤ 𝑤)] = 𝜇𝑇𝑤𝑖
+ 𝛽𝑖 𝑍𝑖𝑗 3.19 
Where, 𝑤 = 1, … . , 𝑊 − 1, and W is the number of categories in the ordinal true 
outcome, 𝜇𝑇𝑤𝑖
is the set of intercept parameters for each W-1 cut point of the ordinal 
true outcome and all other parameters are the same as the continuous case. The second 
stage models 3.15 and 3.16 can be fitted in the same manner as in the continuous 
setting using the parameters of 3.18 and 3.19, and the LRF applied as in 3.17. The LRF 
gives consistent results at the trial level for both the continuous setting and the binary-
ordinal setting. 
3.4.3 Trial level: modelling methods 
The calculation of 3.12 and 3.13 can be done in one of two ways in order to gain 
estimates of 𝛽𝑖 and 𝛼𝑖. First, as described above, by modelling the surrogate/true 
outcome regressed on the treatment separately for each trial, see equations 3.18 and 
3.19. Or secondly, by using two models only, regressing surrogate or true outcome on 
the terms 𝑡𝑟𝑖𝑎𝑙𝑖𝑗  and the interaction 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑍𝑖𝑗, in a similar manner to that discussed 
for individual level surrogacy (see section 3.3.3). Either method will return the 
required parameter estimates 𝛽𝑖, 𝜇𝑆𝑖  and 𝛼𝑖 for each trial and since the latter method is 
less laborious this will be used hereafter. 
3.4.4 Trial level: discussion 
3.4.4.1 Weighting by trial size 
Given that the 𝑅ℎ𝑡
2  is calculated in two stages the LRF is based only on one 𝐺 
2. This 
leads to an issue at the trial level since the two stage approach does not adequately take 
into account the differences between trials. The only way to achieve this is to use the 
full bivariate meta-analytical approach. However, as discussed in section 2.2.2 this is 
extremely computationally burdensome even in the continuous-continuous setting. 
(The computational issue was the reason for the development of the two stage 
approach.) As a partial remedy to this problem in the two stage approach, in the context 
of the meta-analytical approach Tibaldi et al. (2003a) suggested adjusting the analysis 
  Evaluation of surrogate outcomes 
Methodology: Binary-ordinal setting 50 
to account for trial size. This could be an equally valid technique in the information 
theory setting.  
It is important to take account of trial size in the analysis as smaller trials will have 
less ability to estimate treatment effects accurately. These treatment effect estimates 
are used at the second stage of the analysis, see 3.15 and 3.16. If the models at the 
second stage of modelling are unweighted then these smaller trial’s treatment estimates 
will contribute just as much to the model as larger trial’s estimates, which are likely to 
be more precise. Weighting by trial size should enable the model to put more emphasis 
on estimates that are more reliable.  
In order to achieve this at the second stage of modelling a weighting term can be added 
to the linear models, 3.15 and 3.16, based on the exact trial size, therefore trials that 
are larger contribute more to the model. Weighting can be applied to linear models in 
R using the weight term in the function lm. The weight term tells the model to 
conduct weighted least squares which in this case minimises ∑ 𝑤𝑒𝑖𝑔ℎ𝑡𝑖 ∗ 𝑒
2
𝑖  where 
𝑤𝑒𝑖𝑔ℎ𝑡𝑖 is the set weights for each trial i, R core team (2016). If 𝑤𝑒𝑖𝑔ℎ𝑡𝑖  in this case 
is set to the exact size of the trial i then each trials contribution at the second stage is 
weighted according to the size of the trial with larger trials contributing more to the 
analysis.  
3.4.4.2 Connections to meta-analytical approach 
It is interesting to note that the information theory trial level surrogacy is based on the 
same model at the second stage, equation 3.16, as that used under the simplification of 
Tibaldi et al. (2003b) at the second stage of the meta-analytical approach (see section 
2.2.1). Tibaldi et al. (2003b) uses the coefficient of determination of this model as the 
measure of surrogacy rather than information gain but the two approaches should give 
identical results in practice. This is an example of the close links between the 
information theory and meta-analytical approaches. It also demonstrates why it can be 
reasonable to compare the theory and simulation results from publications under the 
meta-analytical approach to the ones from information theory. 
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3.5 Confidence intervals: binary-ordinal 
Confidence intervals are calculated based on 𝐺  
2, of the LRF see section 3.3.1, and 
therefore on the log-likelihoods of two models. Though the models might differ 
between settings, i.e. generalized linear or proportional odds models, the form of the 
variable utilised 𝐺  
2 is the same. Therefore, there are no differences at all between 
settings in how the confidence intervals are calculated or in their assumptions. The one 
exception is in the rescaling of intervals for discrete outcomes at the individual level, 
which will be discussed in 3.5.2, however this has no impact on the interpretation of 
the confidence intervals or their assumptions.  
Therefore, confidence intervals give consistent interpretations between settings in 
much the same way as the LRF, which is advantageous as consistency was the main 
driving force for the development of the information theory approach. 
The LRF of Alonso and Molenberghs (2007) was based on the ideas of Kent (1983) 
who utilised the non-central 𝜒 
2 distribution in order to provide confidence intervals 
for the information gain 𝐺 
2. Kent (1983) proposed different intervals for small and 
large information gain. A distinction between large and small was not provided but 
apparently the asymptotics for the small confidence intervals are ‘more useful’ , 
therefore, I used these intervals. 
The central 𝜒 
2 distribution is usually referred to simply as the 𝜒 
2 distribution. We can 
think of the central 𝜒 
2 distribution as based on the null hypothesis. In this case the null 
hypothesis, H0: 𝐺2 = 0, is that the two models used to calculate the LRF have the 
same log-likelihood, with the alternative hypothesis H1: 𝐺2 ≠ 0. 𝐺2 is the gain in 
information calculated using the -2*log-likelihood ratio test between two models. The 
non-central 𝜒 
2 distribution represents all the possible distributions under the 
alternative hypothesis, H1: 𝐺2 ≠ 0, where there are deviations from the null, 𝐺2 = 0. 
To be clear, a hypothesis test at this point is not being administered, the non-central 
𝜒 
2 distribution can just be conceptualised under this terminology. Two important 
components of the confidence intervals proposed by Kent (1983) are defined in the 
following: 
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𝑃[𝜒𝑝
2(𝛾𝑝:𝛼(𝐺
2)) ≥ 𝐺2] = 𝛼 and 𝑃[𝜒𝑝
2(𝛿𝑝:𝛼(𝐺
2)) ≤ 𝐺2] = 𝛼 3.20 
Where 𝛾𝑝:𝛼 and 𝛿𝑝:𝛼 are draws from the non-central 𝜒 
2 distribution where an 
information gain of 𝐺2 is observed. These parameters are based on the significance 
level α. Here p represents the degrees of freedom, this is equal to the number of 
additional parameters in the fuller model. At the individual level, model 3.7 
incorporates the binary surrogate in addition to the parameters of 3.6 which is one 
additional degree of freedom, hence p=1. The equalities in 3.20 return the value of the 
𝜒 
2 distribution where the probability of observing values at or larger/lower than 𝐺 
2 
equal α. In other words, in the case of a 95% confidence interval, these are the 2.5th 
and 97.5th percentiles of the non-central 𝜒 
2 distribution that deviates from the null 
hypothesis of no difference by 𝐺 
2. This is unless: 
𝑃[𝜒𝑝
2(0) ≥ 𝐺2] > 𝛼 then 𝛾𝑝:𝛼(𝐺
2) = 0  3.21 
𝜒𝑝
2(0) is the central 𝜒 
2 distribution or 𝜒 
2 under the null hypothesis, H0: 𝐺2 = 0. We 
wish to determine the probability of 𝐺 
2or one more extreme occurring under the null 
hypotheses. In other words conduct a significance test under the null hypothesis of 
𝐺 
2=0. If the p-value is larger than α we cannot reject the null hypothesis that there is 
no information gain and the lower limit of the confidence interval is set to equal zero.  
This makes sense intuitively because if the confidence interval contains zero we cannot 
reject the null hypothesis that there is no difference. 
Kent (1983) suggest a (1-alpha)% confidence interval for an estimate of 𝐺2calculated 










Here 𝑛𝑘 is the number of observations the models are based on. Suppose we have ?̂? 
which is the maximum likelihood estimate under the parameter space Θ1of the larger 
model. The log-likelihood ratio test is applied. Then μ is equal to one if ‘the true 
density function belongs to {𝑓(𝑥; 𝑦; 𝜃|𝜃𝜖Θ1}’ Bergman and Holmquist (2012). This 
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means that we assume that one combination of variables constitutes the correct model 
in equation 3.7 in the individual level case or 3.16 at the trial level. Since we must 
compose our models the way described in order to investigate surrogacy this is a valid 









where 𝛾1:𝛼/2(𝐺 2̂) and 𝛿1:𝛼/2(𝐺 2̂) were calculated as described above. In order to 
provide confidence intervals for the LRF as opposed to the 𝐺 
2, Kent (1983) proposed 
that they should be converted to: 
[1 − 𝑒𝑥𝑝 (−
𝛾1:𝛼/2(𝐺 2̂)
𝑛𝑘





3.5.1 Confidence intervals: trial level 
At the trial level the confidence intervals could be applied by calculating the bounds 
of the interval according to 3.24, where 𝑛𝑘 = 𝑁𝑇 the total number of patients for all 
trials.  
3.5.2 Confidence intervals: individual level 
Confidence intervals for 𝑅ℎ
2  at the individual level have multiple 𝐺𝑖  
2 values, for each 
trial i, therefore converting the intervals to those for the LRF was more complicated. I 
decided to follow the setup of the LRF of Alonso et al. (2006) for 𝑅ℎ





















The confidence intervals at the individual level also require adjustment in the same 
manner as 𝑅ℎ
2 since they are bounded above by a number less than one, see section 
3.3.2. 
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3.6 Separation: binary-ordinal 
In the case of categorical variables, separation and quasi-complete separation can 
occur: in these instances, maximum likelihood estimates are not unique. In this section 
I discuss: how complete and quasi-complete separation occurs both in the binary and 
ordinal case; how this affects the calculation of 𝑅ℎ𝑡
2 ; and discuss a solution to this issue.  
3.6.1 Separation: binary 
Consider the case of two binary variables, as in the calculation of 𝑅ℎ𝑡
2  at the first stage 
of modelling where a binary surrogate is regressed on a binary treatment variable for 
a certain trial (see 3.18). Complete and quasi-complete separation is related to the 
occurrence of zero cells in a cross-tabulation of these two variables. 
The occurrence of no separation is shown in Table 3.1. 
 Treatment Placebo 
Surrogate     Y  
                      N 
A≠0 B≠0 
C≠0 D≠0 
Table 3.1: No separation when comparing binary outcomes, no zero cells. 
Complete separation occurs when a binary variable X can perfectly predict Y as 
represented in Table 3.2: 
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 Treatment Placebo 
   Surrogate    Y  







Table 3.2 Complete separation of two binary variables 
In comparison the more common issue of quasi-complete separation occurs if any of 





Table 3.3: An example of quasi-complete separation of two binary variables 
In both complete and quasi-complete separation the maximum likelihood is bounded 
above by a number less than zero however it has no maximum (Allison, 2008). A 
graphical representation of this can be seen in Figure 3, which is an increasing function 
but has no maximum. 
There is no maximum because of the way in which the maximum likelihood of the 
parameter of interest is calculated. In the case of two binary variables this is as follows: 
?̂? = ln (
𝐴 ∗ 𝐷
𝐵 ∗ 𝐶 
) 
3.26 
Here we can see that if any or more than one of A, B, C or D equal zero issues occur. 
If a zero occurs on the denominator then ?̂?=∞ which is undefined, if a zero occurs on 
the numerator then ?̂?=ln(0) which is also undefined (Allison, 2008). 
 Treatment Placebo 
Surrogate     Y  
                      N 
0 B≠0 
C≠0 0 
 Treatment Placebo 
Surrogate     Y  
                      N 
A≠0 B≠0 
C≠0 0 
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Figure 3: Hypothetical example of the log-likelihood of a parameter which suffers 
separation 
3.6.2 Separation: ordinal 
At the first stage of calculating 𝑅ℎ𝑡
2  in the binary-ordinal setting an ordinal true 
outcome is regressed on a binary treatment variable for a certain trial (see 3.18). An 
ordinal outcome against a binary treatment indicator can also suffer separation. This 
has the same consequences on the calculation of 𝑅ℎ𝑡
2  as in the binary case. The 
description of separation for ordinal variables I present will refer back to the case of 
two binary variables. In the following tables any character in a cell of a table represents 
a number greater than zero and hence is not a zero cell. 
Here I present the definition of separation for ordinal outcomes as given by Agresti 
(2014). However, he labelled all possible occurrences of separation in the ordinal case 
as quasi-complete separation. 
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Imagine you collapse the categories of an ordinal variable into a binary variable at 
each possible threshold. For each collapse, if one or more of the cells in the two by 
two crosstab is zero then quasi-complete separation exists (Agresti, 2014). 
In the example in Table 3.4, if you dichotomise the seven point scale into binary groups 
at any threshold of the scale the resultant crosstabs contain zero cells, and would look 
like Table 3.3. This is an example of quasi-complete separation since at each ordinal 
threshold separation occurs.  
1 2 3 4 5 6 7 
















0 0 0 0 0 
Table 3.4 quasi-complete separation example for ordinal variable 
However if 𝐵2≠0 and you were to dichotomise at one you get Table 3.1. In this case, 
since dichotomisation at at least one cut point gives no separation in the binary case 
there is no quasi-complete separation. 
Another way in which the ordinal variable may have quasi-complete separation is if 
there “exists a pair of rows for which all observations on one row never fall above any 
observation in the other row” (Agresti, 2014). 
In Table 3.5 we see an example of this situation where none of the values of the 
categories recorded in row one are higher than any recorded in in row two, even though 
some values are the same. In other words, there is no overlap of at least two categories 
between rows. This type of separation equates closely to complete separation in the 
binary case and will be referred to as such for ordinal outcomes in the remainder of 
this thesis. 
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1 2 3 4 5 6 7 

























Table 3.5: quasi-complete separation example for ordinal variable 
3.6.3 Impact of separation on surrogate evaluation 
Now I will discuss how separation affects surrogacy evaluation. I start by describing 
the way that functions for proportional odds or generalised linear models behave in R, 
SAS and other statistical programs when separation occurs.  
According to Allison (2008) the typical scenario is that the model will try to converge 
but the occurrence of zeros will prevent this since there is no unique-maximum 
likelihood of the affected parameters. The model will go through several iterations 
attempting to converge. Upon each iteration the affected parameter estimate will 
increase and this will continue until a fixed iteration limit is exceeded. At this point 
the affected parameter estimate will typically be very large and its standard error may 
be extremely large. Statistical software generally tends to be poor at reporting this 
issue through error messages. 
In the case of surrogate evaluation at the trial level we use a two stage approach. At 
the first stage two binary (S|Z) or an ordinal and a binary variable (T|Z) are regressed 
on one another (equations 3.18 and 3.19) for each trial. This is with the aim of returning 
treatment effect estimates on the binary surrogate and ordinal true outcome, however 
if separation occurs for a particular trial these estimates may be very large. Then at the 
second level treatment effects for each trial are modelled on one another (equation 
3.16), where separation exists there will be outlying points in the regression. The LRF 
will then be based on the log–likelihood of a model with potentially highly influential 
outliers. Overall, the work I have conducted suggests that this leads to underestimation 
of 𝑅ℎ𝑡
2 , data not shown. 𝑅ℎ𝑡
2  estimation will therefore be very unreliable in the presence 
of separation. 
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3.6.4 Solution to separation issues 
There are various solutions to the issue of separation suggested by Allison (2008). 
These include: deleting problematic variables; combining categories; reporting only 
the likelihood ratio statistics; using exact logistic regression; using penalized 
maximum likelihood or Bayesian estimation.  
I could not remove any of the variables and still meet my aims, and I could not report 
only the likelihood ratio statistics as the surrogate evaluation requires parameter 
estimates. I could have combined categories but this would have potentially led to loss 
of information. A Bayesian approach has not been developed for the information 
theory approach and therefore development of this to overcome separation would have 
been too involved. Furthermore, Allison (2004) found that generally speaking 
uninformative priors led to convergence problems. Of the remaining options penalised 
maximum likelihood was cited as being the best for parameter estimation (Heinze and 
Schemper, 2002).  
The penalized likelihood technique of Firth (1993) was originally introduced to reduce 
small sample bias in maximum likelihood estimates but has been found to be useful in 
dealing with separation (Heinze and Schemper, 2002). Firth (1993) found that bias 
occurred in estimates through trying to derive the score function. The score function 
is the first derivative of the log-likelihood which is used to obtain maximum likelihood 
estimates if the function is concave. However, since the score function is unbiased and 
in the case of separation it is not concave (i.e. has no maxima) problems arise in 
calculating maximum likelihood estimates. Firth (1993) suggested adding a bias-term 
to the score function to resolve this.  
Heinze and Schemper (2002) applied the technique of Firth (1993) to deal with 
instances of separation. The bias-term they applied to the score function was based on 
the information matrix of the parameter that was affected by separation. The influence 
of the bias term is asymptotically negligible. Firth (1993) showed that using a score 
function incorporating the bias-term leads to removal of the overall bias in parameter 
estimation. Heinze and Schemper (2002) assessed this technique and showed that it 
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was “an ideal solution to separation” as it produces finite parameter estimates that are 
superior overall to those from alternative methods. 
Given that separation causes severe bias in results of surrogacy evaluation I applied 
the “ideal solution” of Firth (1993) to resolve this issue for the information theory 
approach in the binary-ordinal setting at the trial level. 
3.6.5 Separation: final considerations  
There are some final comments on separation to cover: 
 In R there are commands logistf and pordlogist that can be used to 
apply Firth’s approach to both the binary and ordinal cases. There are some 
bugs in the program for the ordinal case which will be discussed in further 
detail in the next chapter.  
 If a correction of separation is not used, the trials where separation occurs 
would need to be removed from analysis to avoid the bias previously 
mentioned. This may lead to large loss of information where trials are set to be 
small and separation is more likely.  
 Firth’s approach works best for small samples and in order to calculate the Firth 
corrected estimate of 𝑅ℎ𝑡
2  two models for each separate trial will need to be run 
as opposed to a full model incorporating all trials. As discussed in section 3.4.3 
this will return the same estimates as full models but will be more laborious. 
 Finally, I should note that, in the case of complete or quasi-complete 
separation, parameter estimates but not likelihood estimates are affected, hence 
individual level surrogacy which does not rely on parameter estimation can be 
estimated without using this alternative method. 
3.7 Conclusions: binary-ordinal 
I have extended one of the foremost approaches to surrogacy evaluation to the case of 
a binary surrogate and ordinal true outcome. Information theory can be applied in the 
multi-trial setting via the LRF. I have provided formulae for applying the LRF at both 
the trial and individual levels in the binary-ordinal setting and specific modelling 
approaches that are most appropriate in either case.  
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At the individual level I adopted a multi-trial LRF approach so that differences 
between trials can be taken into account, this has not been addressed in previous 
literature. A multi-trial LRF is not possible at the trial level since a two stage approach 
is necessary. The fact that 𝑅ℎ𝑡
2  cannot account for differences between trials has been 
identified as an issue by Tibaldi et al. (2003b) who suggested adjusting for trial size as 
a partial remedy. 
I have provided confidence intervals for both the trial and individual levels. 
Confidence intervals for the individual level offer an improvement on those previously 
published. I have also adopted the penalized likelihood technique of Firth (1993) as a 
novel technique for dealing with the common issue of the occurrence of separation in 
the information theory approach for discrete outcomes. 
This work will help researchers assess surrogacy in areas of research where ordinal 
outcomes are primary outcomes of interest. 
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Chapter 4. Simulation study: for a binary 
surrogate and ordinal true outcome 
In the previous chapter I outlined how the information theory approach to surrogate 
evaluation has been extended to the case of a binary surrogate and ordinal true 
outcome. It was important that this extension was well investigated through 
simulation study and case study to determine how well it works. This chapter will 
outline the approaches and results of the simulation study that I have performed in 
order to achieve this.  
This chapter outlines: the simulation study process (the models required to set it up 
and practicalities of doing so) in Section 4.1.1; the results of the simulation at the 
individual and trial level, sections 4.2.1 and 4.2.2; and finally give my conclusions. 
As in previous chapters: S denotes a surrogate; T a true outcome; Z was treatment; 
i=1,..,N trials and j=1,..,𝑛𝑖 patients per trial. 
4.1.1 Simulation study: set up  
The simulation study determines how well the information theory surrogate 
evaluation approach in the binary-ordinal setting performs under a variety of 
different scenarios.  
In the simulation study continuous variables for S and T were first simulated, these 
were dichotomised or split into categories to represent a binary S and an ordinal T, as 
in Pryseley et al. (2007). Pryseley et al. (2007) highlighted that 𝑅ℎ
2 represents 
surrogacy for the latent unobserved continuous surrogate and true outcomes. This 
means that surrogacy is established in the continuous underlying setting. 
Categorisation of the variables leads to lower strengths of surrogacy in the observed 
discrete setting. However, at the trial level the “relationship between the treatment 
effects on the latent-continuous and observed-binary surrogate endpoints was linear”, 
Pryseley et al. (2007). Hence, the value of 𝑅ℎ𝑡
2  is valid on both scales and the value 
of 𝑅ℎ𝑡
2  should theoretically be the same in the underlying and observed settings.  
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It was valid to simulate continuous outcomes which were then categorised due to the 
precedent set in other publications. Furthermore, categorised continuous variables are 
true to life, since treatment measures often represent underlying unknown continua. 
This will be discussed in more detail in Section 4.1.3.3.1. 
In order to determine the best way of setting up the simulation study I investigated 
previous methods used for surrogate evaluation of non-causal approaches, i.e. not 
principal stratification (see section 2.3).  
In this section I:  
 draw conclusions on the best simulation method in the binary-ordinal case, 
section 4.1.1.4;  
 outline the models required to implement this, section 4.1.2;  
 and discuss some practicalities: 
o general practicalities, section 4.1.3.1;  
o theoretical and coding practicalities, section 4.1.3.2;  
o and finally some more in-depth considerations, see section 4.1.3.3. 
4.1.1.1 Set up: previous methods 
Simulation methods not considered were those under direct and indirect effects or 
principal stratification. These methods simulate counterfactual results and 
relationships which are not necessary for the information theoretic approach. Hence, 
these approaches were not suitable. There are two simulation methods so far 
published in the surrogate evaluation literature for non-counterfactual approaches. I 
in this section I discuss the set-up of each alongside criticisms and outline how these 
can be implemented. 
4.1.1.2 Previous methods: simulation method one 
The first method to setting up a simulation study found in the surrogate evaluation 
literature was a well-established one by Burzykowski et al. (2005) which was 
duplicated in a number of publications by the same group of authors. These authors 
created simulation studies where the true values of 𝑅ℎ
2  and 𝑅ℎ𝑡
2   were known. The 
amount of variation at individual and trial level, trial size and number of trials were 
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varied to see if this influenced the ability of their method to estimate the correct 
surrogacy strength.  
The model seen in equation 4.1 is based on the meta-analytical approach, see section 
2.2.1. The parameters of the model are given set values to enable simulation.  
𝑆𝑖𝑗 = 0.50 + 𝑚𝑆𝑖 + (0.05 + 𝛼𝑖 )𝑍𝑖𝑗 + 𝑆𝑖𝑗 , 
𝑇𝑖𝑗 = 0.45 + 𝑚𝑇𝑖 + (0.03 + 𝛽𝑖 )𝑍𝑖𝑗 + 𝑇𝑖𝑗 , 
(𝑚𝑆𝑖 , 𝑚𝑇𝑖 , 𝛼𝑖 , 𝛽𝑖) ~ N(0,D)  , ( 𝑆𝑖𝑗 , 𝑇𝑖𝑗 )  ~ N(0, ∑  ), 
 𝐷 = 𝛿𝐶
2 (
1 0.85 0 0
 0.85 1 0 0
 0  0 1 𝜌
 0 0  𝜌 1
) 𝜌2 = 0.90, 
     






This is a joint mixed effects model of S and T regressed on treatment, with individual 
errors distributed N(0, ∑  ), and random intercepts and random treatment effects for 
trial distributed N(0,D). Here, 𝛿2 was set to either 0.1 or 3 and 𝛿𝐶
2 to 0.1 or 10 these 
denote the within trial and between trial variability respectively Burzykowski et al. 
(2005). 
In the simulation the fixed effects coefficients of the meta-analytical model, in 
equation 4.1, were given proposed values, the fixed intercepts were 0.50 and 0.45 
and fixed treatment effects 0.05 and 0.03. The covariance parameters of the error 
terms and the jointly distributed random effects were selected in matrices ∑  and D in 
order to create certain strengths of surrogacy. When the covariation of the random 
treatment effects of S and T was 𝜌2=0.90 in D surrogacy at the trial level was 0.90. 
Surrogacy can readily be set to some other value via this component of D. Surrogacy 
at the individual level was set via the covariation of S and T in ∑  which in this 
example was 0.80. Each random variable in the joint model can be simulated using 
multivariate normal distributions based on the covariance matrices ∑  and D. Putting 
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all of these components together using the above formulae means continuous values 
for S and T can be simulated for each patient. In our case the continuous S and T 
could then be categorised to create a binary surrogate and ordinal true outcome.  
The true values of 𝑅ℎ
2  and 𝑅ℎ𝑡
2  can be set with precision using this simulation 
method. This allows assessment of the amount of bias in estimates for each scenario. 
The meta-analytical approach was the predecessor to the information theory 
approach and analogous in many respects. It is a highly valued approach to surrogacy 
evaluation in its own right and in the continuous setting has few drawbacks. 
Therefore, it is valid to simulate surrogacy using the models of the meta-analytical 
approach for use in assessing the measures of the information theory approach. 
4.1.1.3 Previous methods: simulation method two 
The second simulation method considered, proposed by Lassere et al. (2007a), was 
conceptually appealing and compared various surrogate evaluation approaches to 
determine the best. They set up their simulation to infer certain treatment 
relationships between the surrogate and true outcome. They then overlaid a 
corresponding correlation between the surrogate and true outcome at the individual 
level. In surrogacy evaluation it is important to take treatment effects into account as 
reliance on a correlation between surrogate and true outcome without reference to 
treatment is insufficient. Therefore, any measure that validates a surrogate based on 
correlation regardless of the treatment effect relationships between S and T is a poor 
means of determining surrogacy. This simulation approach would highlight those 
surrogacy evaluation approaches that fail in this regard. 
However, a detailed description of the method of the simulation was not provided in 
the Lassere et al. (2007a) paper. Therefore, a formal description of the method 
cannot be provided and only generalities can be discussed. 
This simulation method investigated various magnitudes of correlation of S and T 
combined with different strengths of treatment effect agreement between S and T. 
The true strength of surrogacy was determined by the treatment effect relationships. 
So that in some situations the surrogacy message from the correlations did not agree 
  Evaluation of surrogate outcomes 
Simulation: Binary-ordinal setting 67 
with true strength of surrogacy. A good surrogacy measure was one that could 
determine the true strength of surrogacy and not rely on the magnitude of correlation. 
The scenarios proposed by Lassere et al. (2007a) were: 
 Strong positive correlation between S and T at the individual level. 
 Weak positive correlation between S and T at the individual level. 
 No correlation between S and T at the individual level. 
Within each of these there were the additional four scenarios of: 
 Treatment effect (Z) on T and not on S. 
 Treatment effect on S and not on T. 
 No treatment effects. 
 Or treatment effects on both. 
Trying to emulate this approach raised several issues and led to two main arguments 
against its use: 
1. The Lassere et al. (2007a) method does not specify the exact value of 𝑅ℎ
2 and 
𝑅ℎ𝑡
2 . Unlike Lassere et al. (2007a) my simulation was intended to only 
investigate one approach to surrogacy evaluation which would provide no 
reference point for comparison. Scenarios where there were “Treatment 
effects on both” represent the case of a strong surrogate. But what strength of 
surrogacy does this represent, say 0.70 or 0.90? And if our surrogate 
evaluation measures returned a value of 0.68 would this be a bias of 0.02 or 
0.22? Therefore, this simulation method was not adequately framed to 
determine the degree of precision of our surrogate evaluation measure.  
2. There are severe difficulties in modelling this situation given the complicated 
nature of the relationships under investigation. 
4.1.1.4 Previous methods: conclusions 
Attempting implementation of the Lassere et al. (2007a) method highlights certain 
practical and conceptual difficulties. The most striking being the inability of the 
method to tell how biased a surrogacy evaluation method is compared to the real 
strength of surrogacy. Since this was an integral part of what I wished to achieve I 
adopted the structural set up of Burzykowski et al. (2005). However I was persuaded 
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to incorporate some aspects of the concepts of the Lassere et al. (2007a) method by 
providing a wider investigation of the influence of different and conflicting strengths 
of surrogacy at the individual and trial levels.  
The main aims of the simulation study were therefore to investigate the impact on 𝑅ℎ
2 
and 𝑅ℎ𝑡
2  of:  
 higher and lower values of the true strength surrogacy in 𝑅ℎ
2 and 𝑅ℎ𝑡
2 ;  
 strength of surrogacy disagreeing between the trial and individual levels;  
 non-proportional odds in the ordinal true outcome;  
 and varying the number of trials and the number of patients per trial. 
4.1.2 Set up: binary-ordinal setting 
First I will describe the scenarios investigated in the simulation, the exact working or 
set-up of these scenarios is described in what follows or in section 4.1.3. Then I will 
describe the mathematical models that are used to simulate the data. Each component 
of the model is simulated or set and then 𝑆𝑖𝑗 and 𝑇𝑖𝑗 calculated on the basis of these 
as normally distributed variables that are then categorised as described in 4.1.3. 
Finally, when all the parameters have been discussed a model with the set parameter 
values is given. 
The scenarios investigated in the simulation for the binary-ordinal setting are shown 
in Table 4.1. The number and size of trials were chosen to correspond to the previous 
work of Burzykowski et al. (2005). Strengths of surrogacy were set to be high or low 
or disagree in strength at trial and individual levels, this will be discussed further 
below. Assessment of the impact of non-proportional odds was also conducted in the 
simulation. The set-up of the non-proportional odds setting will be discussed further 
in 4.1.3. I will now outline the simulation mathematically. 
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Factor varied under 
simulation study  
Levels of factor  
  
Number of trials  5, 10, 20 or 30  
Number of patients per trial  
Small trial size  
Large trial size  
 
10, 20, 40 or 60  
100, 150, 200 or 300  
True surrogacy strength  𝑅ℎ
2=0.64 or 0.30 and 
𝑅ℎ𝑡
2 =0.90 or 0.30 




both strong or both weak 
 
𝑅ℎ




2= 0.30 & 𝑅ℎ𝑡
2 =0.30 
 Disagree  
one weak one strong 
 
𝑅ℎ




2= 0.30 & 𝑅ℎ𝑡
2 =0.90 
Trial level: 






Non proportional odds 
  
Table 4.1: Scenarios investigated in this binary-ordinal simulation 
I based my simulation on the model seen in equation 4.2, to produce variables 𝑍𝑖𝑗, 
𝑆𝑖𝑗 and 𝑇𝑖𝑗 , this was advocated by Burzykowski et al. (2005). The model in  4.2 is a 
joint mixed effects model of 𝑆𝑖𝑗 and 𝑇𝑖𝑗 regressed on treatment, with individual 
errors distributed N(0, ∑  ), and random intercepts and random treatment effects for 
trial distributed N(0,D). The parameters of the model 𝜇𝑆, 𝜇𝑡, a, b, 𝜌
2, 𝜓2 ,𝛿2and 𝛿𝑐
2 
which will be discussed below are given set values to enable simulation.  
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𝑆𝑖𝑗 = 𝜇𝑆 + 𝑚𝑆𝑖 + (𝑎 + 𝛼𝑖 )𝑍𝑖𝑗 + 𝑆𝑖𝑗 , 
𝑇𝑖𝑗 = 𝜇𝑇 + 𝑚𝑇𝑖 + (𝑏 + 𝛽𝑖 )𝑍𝑖𝑗 + 𝑇𝑖𝑗 , 
(𝑚𝑆𝑖 , 𝑚𝑇𝑖 , 𝛼𝑖 , 𝛽𝑖) ~ N(0,D)  , ( 𝑆𝑖𝑗 , 𝑇𝑖𝑗 )  ~ N(0, ∑  ), 
 𝐷 = 𝛿𝐶
2 (
1 075 0 0
 0.75 1 0 0
 0  0 1 𝜌
 0 0  𝜌 1
) 𝜌2 = 0.90, 
     







𝜇𝑆, 𝜇𝑡, a, b, 𝛿
2and 𝛿𝑐
2  are set to correspond to the simulation of Burzykowski et al. 
(2005), Tilahun et al. (2008b) and Pryseley et al. (2007). The fixed intercepts, 𝑚𝑆𝑖  
and 𝑚𝑇𝑖  of equation 4.2, were set to 0.50 and 0.45 respectively, and the fixed 
treatment effects, , a and b of equation 4.2, to 0.05 and 0.03. 𝛿2 denotes the trial level 
variability and 𝛿𝐶
2 the individual level variability these were both set to 3, see 
Burzykowski et al. (2005).  
The components of the covariance matrices were set to infer certain strengths of 
surrogacy with 𝜌2  setting trial level surrogacy and 𝜓2 individual level surrogacy, and 
correspond to the scenarios in Table 4.1. To simulate weak surrogacy at respective 
levels I set 𝜌2  =𝜓2=0.30, and for strong surrogacy at respective levels I set 𝜌2  =0.90 
and 𝜓2=0.64. As can be seen in Table 4.1 different combinations of these strengths 
of surrogacy are investigated in this simulation.  
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The values of the fixed trial intercepts and treatment effects differ to those of 
Burzykowski et al. (2005) only in scale. The selected values were identical to those 
adopted by this group of authors when they published simulation studies for 
information theory measures of surrogacy (Tilahun et al., 2008b) and (Pryseley et al., 
2007). When 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 our results will be roughly comparable to these 
publications. The only difference will be in the choice of lower co-variation in the 
random intercepts (0.75 instead of 0.85), see variance covariance matrix D in 
equation 4.2. This value was chosen to be more in keeping with all values of 𝑅ℎ𝑡
2  in 
my simulation scenarios, which was also done by Abrahantes et al. (2004). This did 
not change the strength of surrogacy but 0.75 was closer to the other component, 𝜌 in 
D, when surrogacy was weak, 𝜌 =0.55 (i.e.  𝜌2 = 𝑅ℎ
2 = 0.30 ), and in using this term 
the components of D were not too different to each other which may be more 
realistic to real life scenarios. For the simulation set up with a summary of all of 
these chosen parameter values see Table 4.3. 
𝑆𝑖𝑗 = 0.50 + 𝑚𝑆𝑖 + (0.05 + 𝛼𝑖 )𝑍𝑖𝑗 + 𝑆𝑖𝑗 , 
𝑇𝑖𝑗 = 0.45 + 𝑚𝑇𝑖 + (0.03 + 𝛽𝑖 )𝑍𝑖𝑗 + 𝑇𝑖𝑗 , 
(𝑚𝑆𝑖 , 𝑚𝑇𝑖 , 𝛼𝑖 , 𝛽𝑖) ~ N(0,D)  , ( 𝑆𝑖𝑗 , 𝑇𝑖𝑗 )  ~ N(0, ∑  ), 
 𝐷 = 3 (
1 075 0 0
 0.75 1 0 0
 0  0 1 𝜌
 0 0  𝜌 1
) , 𝜌2 = Rht
2 = 0.90 or 0.30, 
     
∑ = 3 (
1 𝜓
𝜓 1
) , 𝜓2 = 𝑅ℎ
2 = 0.64 𝑜𝑟 0.30 
4.3 
The models described above can be easily implemented, although several practical 
aspects of performing this simulation study have to be discussed. 
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4.1.3 Set up binary-ordinal: practicalities 
In this section I outline and justify the setup of this simulation study. I start with 
general practical considerations and then move on to theoretical and coding issues. I 
finish by outlining some more involved issues. 
4.1.3.1 Practicalities: general 
 A starting seed was selected and the full code used to run the simulation was 
saved and backed up.  
 All datasets simulated represent one iteration of a scenario and contain a set 
number of trials of a given size. Each trial dataset was stored as an RDS file. 
The variables within each dataset were; the continuous true and surrogate 
outcomes, the binary surrogate and ordinal true outcomes, the number of 
trials and treatment group. 
 For each dataset simulated a surrogate analysis was performed. The surrogate 
analysis results for every dataset simulated with a record of the occurrence of 
any modelling issues was recorded. 
 There were 250 simulated datasets created for each scenario. The median 
value of  𝑅ℎ
2 and 𝑅ℎ𝑡
2  will be reported in line with Pryseley et al. (2007). This 
was appropriate for our results as some distributions of simulated 𝑅ℎ
2 and 𝑅ℎ𝑡
2  
values were skewed especially where the true value was high. The median 𝑅 
2 
value for a certain scenario served as a measure of the bias present in our 
results. In addition, I present the interquartile ranges (IQRs) of the 250 𝑅ℎ
2 
and 𝑅ℎ𝑡
2  for each scenario. I give the IQRs as one value of the length of the 
interquartile range rather than the upper and lower bounds to simplify tables 
and ease comparisons across scenarios where comparisons of the degree of 
precision in estimation need to be assessed. These ranges will give an 
indication of the degree of precision of these estimates under each condition. 
Finally, the coverage and median upper and lower bounds of the confidence 
intervals will be presented. The coverage of the CIs, at the trial level, is 
calculated as the % of intervals in a particular scenario that include the true 
value of surrogacy as set by the simulation. However, this will be based on 
the empirical asymptotic truth at the individual level, as will be discussed 
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further in section 4.1.3.3.3.1. The confidence intervals were calculated using 
the noncentral 𝜒2 distribution as discussed in section 3.5. Presenting these 
statistics will inform on how well these intervals performed in the simulation 
study. 
 Burton et al. (2006) recommend recording and appropriately dealing with the 
occurrence of errors in simulation studies. I recorded convergence issues 
using the R command tryCatch(). This function allows warning and error 
messages to be reported without breaking the loop. If the models failed for 
any reason this was recorded.  
4.1.3.2 Practicalities: theoretical and coding 
 I set the amount of between and within trial variation to the same value, 𝛿2= 
𝛿𝐶
2=3 (see Equation4.2). This was appropriate as Abrahantes et al. (2004) 
showed that bias was lower when variation was at least as large at the lower 
hierarchical level than at the higher one. Every publication by this group of 
authors since Abrahantes et al. (2004) has used 𝛿2= 𝛿𝐶
2=3. 
 An investigation of simulation studies with a three level hierarchy, individual 
patients, centres and trials, have been investigated in Burzykowski et al. 
(2005). For this study I was only interested in two levels, individual patients 
and centres within a trial. This was because these two levels of the hierarchy 
corresponded to the case study presented in the next chapter. 
 The work of Tilahun et al. (2007) suggested that coding treatment group in 
the simulation study (1,-1) was better than (0,1). The latter meant that the 
variance of one treatment arm was likely to be less than that in the other 
which would only be relevant in very particular studies.  
In my study coding the treatment (1, -1) led to strong instances of separation 
of treatment groups within trials. Often, perfect separation would occur and 
patients on treatment 1 would all have an outcome but no patients on -1 
would, even for very large trial sizes. This seemed like an unrealistic 
scenario. As previously discussed, the occurrence of separation led to serious 
estimation bias, see section 3.6. Furthermore, it seemed unsound to let the 
coding of treatment influence results when it was not specified as part of the 
simulation model. Hence, a binary treatment variable was coded (0.5,-0.5) for 
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simulation purposes. Under this coding the number of separation issues was 
greatly reduced. This coding was still in keeping with the proposals of 
Tilahun et al. (2007) as it still allows for equal variance in both treatment 
arms. 
 In order to create a binary surrogate outcome, the simulated continuous 
surrogate was dichotomised at the mean. This was in keeping with previous 
publications in information theory and the meta-analytical approach (Tilahun 
et al., 2008b), (Pryseley et al., 2007) and (Burzykowski et al., 2005). 
 I simulated a seven category true outcome to match the Oxford Handicap 
Scale, (Van Swieten et al., 1988), used in the case study. This will be 
discussed in the next chapter.  
 Continuous simulated true outcome variables were created based on a set 
treatment relationship using linear models. To create ordinal outcomes with 
proportional odds the continuous variables were categorised using six evenly 
spaced cut off points. The cut off points were determined according to the 
quantiles of the true outcome variable, see column 1, Table 4.2. Since the 
continuous variables are linear and cut points are the same across treatment 
groups the same relationship between the two groups should be retained 
within each resultant category. Hence, the odds should be proportional across 
categories of the ordinal variable.  
o The cut points of the ordinal variable were chosen to be equally 
spaced to make sure that no one category was more likely to suffer 
missing data than another. I anticipate no issues of generalizability of 
the findings of this scenario to proportional odds scenarios were this is 
not the case. 
o An illustrative simulation was run to see the true simulated odds ratios 
for a particular scenario. This simulation was run 1000 times for the 
case of 30 trials and 300 patients, and strong surrogacy at both levels, 
to provide an example of these values. The odds ratios at each cut 
point were calculated for each simulated ordinal true outcome and the 
median odds ratios are shown in Table 4.2. As can be seen the odds 
ratios for the proportions odds setting are very similar for each cut 
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point, hence we can conclude that in this simulation the proportional 
odds scenario holds true to its name. 
 Column 1: 
Proportional odds 
Column 2: 
Non proportional odds 

















       
1 ≤ 0.143 0.143 0.9714 ≤ 0.25 0.25 0.4900 
2 0.143-0.286 0.143 0.9774 0.25-0.286 0.036 0.9806 
3 0.286-0.429 0.143 0.9776 0.286-0.429 0.143 0.9767 
4 0.429-0.571 0.143 0.9731 0.429-0.571 0.143 0.9845 
5 0.571-0.714 0.143 0.9838 0.571-0.714 0.143 0.9827 
6 0.714-0.857 0.143 0.9714 0.714-0.857 0.143 0.9749 
7 ≥ 0.857 0.143 - ≥ 0.857 0.143 - 
       
Table 4.2: Categorisation of continuous true outcome into ordinal true outcome. 
Simulated odd ratios were based on 1000 runs of the study set up with 30 trials, 300 
patients, and strong surrogacy at both levels, the median odds ratios over all 
simulated cases are given for each cut point. 
o It was important in the case of simulating non-proportional odds 
variables that the treatment relationships of the underlying continuous 
outcomes were not altered via categorisation. Therefore, for the non-
proportional odds scenario one treatment was categorised according to 
equal quartile cut-points, as in column 1 Table 4.2. The divergent 
treatment group was also categorized based on these equal cut points 
except for two categories. Category one of the divergent treatment 
group incorporated a much larger amount of quantiles, the first 0.25 
quantiles, meaning category 2 had much fewer quantiles, 0.036 
quantiles (see Table 4.2). In the divergent treatment group, the odds in 
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relation to the other treatment group are not the same as each other or 
to the other categories on the scale. Hence, the odds are not 
proportional. The remaining categories retain the treatment 
relationships set by the simulation and have proportional odds in 
relation to each other. Refer again to the median odds ratios taken 
from the simulation of true ordinal outcomes in Table 4.2, this time 
for the case of non-proportional odds. We see that the odds ratios are 
very similar for all but the first cut of the ordinal true outcome. Here 
the odds ratio is 0.49 as opposed to approximately 0.98 for the other 
cut points. Therefore, this shows that as anticipated the odds ratios in 
the simulation are proportional for all but one cut point of the ordinal 
true outcome. Hence, an ordinal true outcome with non-proportional 
odds was simulated without fundamentally changing the treatment 
relationships simulated at the underlying continuous-continuous 
setting.  
o This simulation method was adapted from the simulation study of 
ordinal outcomes of McHugh et al. (2010b). In that study it was 
hypothesised that a treatment only benefited one category of the 
simulated ordinal outcome, affecting the resultant proportional odds 
assumption. In keeping with this work I hypothesized that, in addition 
to the treatment relationship simulated in the underlying continuous 
setting, the treatment resulted in some patients who would otherwise 
have had a category two outcome to have a category one outcome.  
4.1.3.3 Practicalities: in-depth issues 
Several additional avenues of investigation were identified after further reading and 
investigation of preliminary results. These were: how to deal with issues of loss of 
information; a technique for dealing with separation of treatment groups; and finally 
the choose of R commands to be used in the simulation. 
4.1.3.3.1 Loss of information 
I first simulated a continuous surrogate and a continuous true outcome, these were 
then dichotomised or categorised into binary and ordinal outcomes. Tilahun et al. 
(2008b) and Pryseley et al. (2007) investigated surrogacy in the binary-binary and 
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binary-continuous settings respectively. They demonstrated that dichotomisation or 
categorisation of continuous outcomes leads to estimates of 𝑅ℎ
2 that are much 
reduced compared with the surrogacy strength set at the latent continuous setting.  
4.1.3.3.2 Loss of information: Simulation rationale 
Dichotomised or categorised surrogates are less informative than continuous 
surrogates because they provide less information. However categorised versions of 
continuous outcomes are present in real life scenarios and are likely to suffer the 
same issue, Tilahun et al. (2008a). The ordinal measure Oxford Handicap Scale 
(OHS) is a reliable seven category measure of death and disability. This measure has 
less inter-observer variability than might be present in a measure of death and 
disability say on a 100-point scale. However, the true underlying amount of disability 
is likely to be on a more finely graded scale than the OHS. If it were possible to 
reliably measure the true amount of disability on a continuous scale this would be 
much more informative than the OHS. In the absence of a reliable continuous 
measure, OHS is a good approximation of this underlying continuum. Therefore, 
simulating continuous variables that are then categorised is a good way of providing 
data that represents this real life scenario. 
4.1.3.3.3 Loss of information: theoretical impact 
The selected strength of 𝑅ℎ
2 in the simulation represents the underlying latent 
continuous variables but the 𝑅ℎ
2 value of the observed binary and ordinal variables 
was unknown. Several publications investigated the bias imposed by dichotomising 
and categorising variables, (Taylor and Yu, 2002, Cochran, 1968, Bollen and Barb, 
1981, Krieg, 1999). Cox (1957) showed that the maximum amount of information 
retained when a dichotomisation occurred was 63.7%. This retention of information 
increased as the number of groups created via categorisation increased. The amount 
of information retained for the largest categorisation reported of six groups was 
94.20%: my ordinal variable has seven groups.  
It would be useful to be able to determine the true strength of surrogacy in the 
observed binary-ordinal case where this was set to a certain strength at the 
underlying continua. It was possible to investigate the impact on surrogacy of 
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dichotomising continuous outcomes under the meta-analytical approach but not 
under the information theory approach. Also, it was not possible to do this for ordinal 
outcomes under either framework: we therefore do not know the true surrogacy 
strength in the observed binary-ordinal setting. 
I have shown that the estimates of 𝑅ℎ
2 in this simulation study in the observed binary-
ordinal setting will be substantially lower than in the underlying latent setting. I have 
therefore included a third scenario in the simulation study, where 𝑅ℎ
2=1 in the latent 
continuous setting. This was done to establish what the ceiling effect was for 𝑅ℎ
2 in 
the binary-ordinal setting. The results of this scenario will be discussed later, section 
4.2.1.5. 
4.1.3.3.3.1 Coverage of confidence intervals 
Given that the true value of 𝑅ℎ
2 is not known in order to calculate the coverage of the 
confidence intervals the large scale approximation of 𝑅ℎ
2 as determined by the 
simulation for each scenario will be used instead. 
4.1.3.3.4 Separation 
The large bias imposed through the occurrence of complete and quasi-complete 
separation was discussed in section 3.6. In this case, separation occurred in 
regression analysis when zero cells were present in trial cross-tabulations of 
treatment and surrogate or treatment and true outcome.  
4.1.3.3.4.1 Separation at the individual level 
In section 3.6.3 I discussed how treatment effect estimates can be severely biased in 
the presence of separation. Treatment effect estimates are crucial for calculating trial 
level surrogacy. It was also noted that this issue does not impact individual level 
surrogacy, as this does not rely on treatment effect estimation. It only uses log-
likelihood statistics which are not affected. However, there is one instance of the 
presence of zeros which does impact on the individual level surrogacy. If patients in 
a certain trial, regardless of treatment, do not have any surrogate outcomes or all 
have surrogate outcomes the models failed, since the surrogate variable was 
effectively only returning one value. Hence the first model of true outcome regressed 
on treatment worked, but adding the surrogate as an explanatory variable in the 
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second model led to model failure. If you recall I was interested in the amount of 
information on the true outcome that was provided by the surrogate and calculated 
this by using the -2*log-likelihood difference between the two models described 
(with and without adjustment for the surrogate), see section 3.3.2. If the second 
model does not converge the log-likelihood could not be calculated for this model. 
There were two ways I could have dealt with this issue. One was to remove all the 
trials where separation of this kind occurred (occurrence can be as high as 17% of 
trials). Secondly, since the surrogate does not provide any information on the true 
outcome effectively the log likelihood of the second model can be thought of as just 
as informative as the first. In other words, the surrogate provides no additional 
information on the true outcome. I believed the former technique was inappropriate 
as it was throwing out information on trials where the surrogate was uninformative 
and therefore may lead to inflated estimates.  
The results of both techniques showed that indeed this was the case (data not shown). 
Where instances of this pattern of zeros were prevalent the results showed that the 
trial removal technique led to overestimation compared to the alternative technique 
where estimation was very good. Therefore, where no surrogate outcome was 
recorded for a particular trial in the analysis the difference in the log-likelihood 
between the two models with and without adjustment for the surrogate was recorded 
as zero.  
4.1.3.3.4.2 Separation at the trial level 
As previously mentioned, separation has the most severe impact on trial level 
surrogacy where stage one estimation was badly impacted by separation. These 
estimates were regressed at the second stage of modelling and could result in 
influential outlying points, see section 3.6.3. To deal with issues of separation I 
proposed the use of the penalised likelihood technique of Firth, see section 3.6.4. 
This technique allowed trials where separation occurred to be retained in the analysis 
and provided sensible treatment effect estimates. In the simulation, the penalized 
likelihood technique results will be compared to a trial removal technique where 
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trials where separation occurs were removed from analysis (resulting in loss of 
information).  
There are two points that need to be discussed in relation to separation in terms of the 
setup of this simulation study. Firstly, the method of implementing the technique of 
Firth in R will be discussed in Section 4.1.3.3.5. Secondly, there was an issue in 
calculating 𝑅ℎ𝑡
2  under the trial removal technique if a large number of trials with 
separation in a particular simulated dataset were removed from analysis.  
Scenarios where there were only ten patients per trials suffered to a much larger 
extent from issues of separation at the trial level compared to other scenarios. 
However, the high instances of separation in these smaller trial size scenarios meant 
that often less than three trials were available within one scenario for the calculation 
of 𝑅ℎ𝑡
2 . This was the case regardless of the number of trials. I set the analysis so that 
at least three trials had to be available for a particular simulated scenario. This was 
done, because second stage models were based on the treatment effect estimates for 
each trial, and these models do not converge with less than three data points. This 
meant that simulated datasets where less than three trials were available would not 
have results returned for 𝑅ℎ𝑡
2 . The simulation ran until 250 simulated datasets were 
created for each scenario where results were possible. The number of failures were 
recorded. 
 
Figure 4.1: R output for second stage trial level models with only three trials 
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Furthermore, where there were only three trials at the second stage of modelling the 
calculation of  𝑅ℎ𝑡
2  was complicated due to an issue with lack of degrees of freedom. 
The output from such a situation can be seen in Figure 4.1. Such a model returns a 
log-likelihood of infinity and hence a 𝑅ℎ𝑡
2  of 1; an erroneous result. Where there was 
an issue with degrees of freedom the calculation of 𝑅ℎ𝑡
2  was not performed. 
4.1.3.3.5 Modelling in R 
In this section I briefly describe the logic behind the R functions chosen to perform 
generalised linear and cumulative logit link regression for the binary surrogate and 
ordinal true outcome respectively. I will also discuss the penalised likelihood 
functions needed in the binary-ordinal setting to deal with instances of separation. 
Cumulative logit link proportional odds models were used to analyse the ordinal true 
outcome as a response variable in the models required at both the trial and individual 
levels. Alternative link functions were not considered.  
The R functions lrm from the package RMS and the polr from the package MASS 
both have a proportional odds set up. lrm was based on equation 7.6 and polr 
takes a latent variable method described in section 7.2.3 of Agresti (2014). 
Thompson (2009) provided an R manual to accompany Agresti (2002) which has 
been endorsed by Agresti (2012). Thompson (2009) recommend the use of lrm and 
polr as being transparent and easily fitted cumulative logit models. The lrm 
function was used to calculate 𝑅ℎ
2 at the individual level and polr for 𝑅ℎ𝑡
2  at the trial 
level.  
For models with the binary true outcome as a response variable the usual generalised 
linear model command glm was used, for generalised linear models. Second stage 
models were modelled using the command lm, for ordinary linear regression. 
4.1.3.3.5.1 Modelling the penalized likelihood technique 
To deal with issues of separation I suggested using the penalised likelihood 
technique of Firth (1993), see section 3.6.4. For generalised linear models a 
command in R called logistf from the package of the same name can deal with 
separation. This package was based on the work of Heinze and Schemper (2002) and 
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Firth (1993). logistf performs better where datasets are small and uncomplicated 
by hierarchies. Therefore, single models for each trial within a dataset were 
computed as opposed to a full model incorporating all trials (see 3.4.3). This single 
model method returned the treatment effect estimates of each trial as required. Where 
separation does not occur the treatment effect estimates that were required were 
calculated using the glm command, otherwise the logistf command was applied.  
There is also a command available which provides a penalized likelihood approach 
for cumulative logit link models called pordlogist from the package 
OrdinalLogisticBioplot (Hern'andez, 2013). This command uses a simpler penalized 
likelihood technique in line with Firth (1998) based on Le Cessie and Van 
Houwelingen (1992). This is an auxiliary command as part of the 
OrdinalLogisticBioplot package. This command has some bugs. Where zero cells 
were present in both treatment arms, i.e. an empty category, in a certain trial the 
command failed. On the advice of Vicente Villardón (2015), one of the authors of the 
package, I recoded the ordinal variable to ignore zero categories which resolved this 
issue. In the ordinal models used the odds were considered as proportional between 
categories meaning that the removal of zero categories should not change results. 
The polr function was used to estimate treatment effects for trials where separation 
does not occur and pordlogist when it did. Using both logistf and 
pordlogist means that all trials were retained in the simulation study despite the 
presence of separation and so the bias imposed by this issue was removed. 
4.1.4 Set up: Conclusions 
I have investigated historic simulation studies in the surrogate evaluation context and 
concluded that a method based on a joint mixed model was best for my purposes. 
This method permits the exact strength of surrogacy to be set (at the individual level 
this is only at the underlying continuum) to allow the degree of bias and variability in 
results to be assessed.  
The simulation will investigate surrogacy: for varying numbers and sizes of trials; for 
non-proportional odds; and when surrogacy strength differs at the trial and individual 
levels. A ceiling effect for the individual level will be investigated by simulating a 
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perfect surrogacy scenario. A solution for separation in the trial level models will be 
investigated using a penalized likelihood technique and compared to a trial removal 
technique.  
4.2 Simulation study: Results 
For a full description of the scenarios investigated see Table 4.1 and section 4.1.4. 
The summary results given are: the median 𝑅 
2 for a given scenario; the variation of 
𝑅 
2; and the median upper and lower bounds of all of the confidence intervals 
calculated for each 𝑅 
2 for a particular setting. The tables in the remainder of this 
chapter show results for a subset of the trial sizes investigated. Unless otherwise 
stated, results for scenarios not included in the tables were consistent with those 
shown. Full tables for every setting are provided in Appendix A.  
Some of the results show conflicting biases especially at the trial level. Therefore, the 
results can be difficult to interpret. To aid this Table 4.3, for reference, outlines the 
relevant issues and what scenarios they affect and also in which section they are 
described.  
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 Issue Scenarios 
affected 
Reason Discussed in 
section(s): 









All scenarios Loss of information 















estimation due to 
categorisation and 











Model fitting issues 
 
4.2.2.2.5 
Separation All scenarios Zero cells in trial 
crosstabs 
resolved through use 




     
Table 4.3: Issues present in results of simulation study 
I will first discuss the results for individual level surrogacy 𝑅ℎ
2 in section 4.2.1  and 
then those for trial level surrogacy 𝑅ℎ𝑡
2  in section 4.2.2. 
4.2.1 Results: individual level surrogacy 
In this section, I describe:  
 the scenario where surrogacy was set to be strong at both the trial and 
individual levels;  
 where this was weak at both levels;  
 where the strength of surrogacy differs at trial and individual levels;  
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 the behaviour of 𝑅ℎ
2 under deviations from the proportional odds assumption;  
 the ceiling investigation results;  
 and finally compare the results to those of previous publications. 
 
4.2.1.1 Individual level surrogacy R2h: strong surrogacy 
Here surrogacy was set to be strong at both levels, 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90, in the 
underlying continuous setting. Due to loss of information the observed results for the 
binary-ordinal setting were expected to be lower than in the underlying continuum. 
As can be seen in Table 4.4 surrogacy strength for the observed binary-ordinal 
setting was much lower than that set in the underlying continuous setting 
(𝑅ℎ𝑡
2 =0.64). As trial sizes increased the value of 𝑅ℎ
2 converged to around 0.29, 
suggesting that this approximates the true surrogacy strength for the observed binary-
ordinal setting. Small number and sizes of trials scenarios also return results 
consistent with 0.29. 
The IQRs of 𝑅ℎ
2 were fairly narrow for small numbers and sizes of trials but this 
decreased further as the size and number of trials increased. The coverage of nearly 
all scenarios was 100% indicating that the intervals are conservative (the only 
exceptions were for smaller numbers of trials with larger trial sizes). However, the 
median confidence intervals had sensible ranges. The width of these median intervals 
decreased with an increase in the size of trials, with good precision for larger trial 
sizes. However, increases in the number of trials had little impact on the intervals. 
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Number 




𝟐  IQR 𝑹𝒉





CI upper  
 
       
5 10 0.347 0.154 100% 0.046 0.757 
5 60 0.305 0.086 100% 0.126 0.519 
5 100 0.300 0.063 99% 0.155 0.465 
5 300 0.304 0.058 96% 0.213 0.401 
       
10 10 0.337 0.107 100% 0.046 0.742 
10 60 0.293 0.063 100% 0.121 0.499 
10 100 0.302 0.056 100% 0.156 0.467 
10 300 0.294 0.040 99% 0.207 0.389 
       
20 10 0.342 0.072 100% 0.046 0.743 
20 60 0.297 0.039 100% 0.121 0.501 
20 100 0.293 0.036 100% 0.151 0.455 
20 300 0.292 0.031 100% 0.205 0.386 
       
30 10 0.340 0.071 100% 0.047 0.739 
30 60 0.295 0.033 100% 0.121 0.500 
30 100 0.294 0.027 100% 0.151 0.454 
30 300 0.293 0.025 100% 0.206 0.387 
       
Table 4.4: Simulation study: Median R2h estimates based on 250 simulations for each 
scenario, where true values set to: R2h =0.64 and R2ht=0.90.  
4.2.1.2 Individual level surrogacy R2h: weak surrogacy 
The findings for strong surrogacy were mirrored when surrogacy was set to be weak 
at both the trial and individual level; 𝑅ℎ𝑡
2 =𝑅ℎ
2 =0.30. The expected strength of 
surrogacy in the unobserved latent setting was 0.30 however the estimated value of 
𝑅ℎ
2 for the observed binary surrogate converges to around 0.13, see Table 4.5. 
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Number 




𝟐  IQR 𝑹𝒉
𝟐  % cover 
CIs 
lower 
95% CI  
 upper 
95% CI  
        
5 10 0.216 0.142 100% 0.013 0.659 
5 60 0.147 0.056 100% 0.030 0.336 
5 100 0.135 0.043 100% 0.038 0.282 
5 300 0.135 0.033 99% 0.070 0.216 
       
10 10 0.211 0.101 100% 0.018 0.648 
10 60 0.141 0.037 100% 0.029 0.327 
10 100 0.136 0.032 100% 0.041 0.281 
10 300 0.134 0.023 100% 0.070 0.214 
       
20 10 0.212 0.070 100% 0.018 0.645 
20 60 0.139 0.029 100% 0.030 0.325 
20 100 0.136 0.021 100% 0.041 0.279 
20 300 0.131 0.017 100% 0.068 0.210 
       
30 10 0.209 0.050 100% 0.018 0.645 
30 60 0.140 0.022 100% 0.030 0.328 
30 100 0.136 0.019 100% 0.040 0.279 
30 300 0.131 0.011 100% 0.068 0.210 
       
Table 4.5: Simulation study: Median R2h estimates based on 250 simulations for each 
scenario, where true values set to: R2h =0.30 and R2ht =0.30.  
4.2.1.3 Individual level surrogacy R2h: differing strengths of surrogacy 
I now discuss the impact of differing strengths of surrogacy at the trial and individual 
levels on individual level surrogacy estimation.  
In Table 4.6 the values of 𝑅ℎ
2 when they were set to 0.64 were similar whether 
𝑅ℎ𝑡
2 =0.90 or 𝑅ℎ𝑡
2 =0.30. Even though results where surrogacy strengths differ were 
consistently lower, this bias was always small. This suggests that there was little bias 
imposed on 𝑅ℎ
2 where surrogacy strengths disagreed. The same direction and degree 
of bias was also observed where 𝑅ℎ
2=0.30 and trial level was set to be strong, see 
Appendix A Table A.5.  
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Surrogacy strong both 
levels 
Surrogacy strong 𝑹𝒉




















        
5 10 0.34
7 
0.154 100% 0.336 0.172 100% 
5 60 0.30
5 
0.086 100% 0.302 0.078 100% 
5 100 0.30
0 
0.063 99% 0.304 0.064 99% 
5 300 0.30
4 
0.058 96% 0.301 0.056 97% 
        
10 10 0.33
7 
0.107 100% 0.330 0.106 100% 
10 60 0.29
3 
0.063 100% 0.300 0.058 100% 
10 100 0.30
2 
0.056 100% 0.294 0.052 100% 
10 300 0.29
4 
0.040 99% 0.298 0.046 99% 
        
20 10 0.34
2 
0.072 100% 0.327 0.082 100% 
20 60 0.29
7 
0.039 100% 0.292 0.033 100% 
20 100 0.29
3 
0.036 100% 0.291 0.039 100% 
20 300 0.29
2 
0.031 100% 0.291 0.033 100% 
        
30 10 0.34
0 
0.071 100% 0.327 0.073 100% 
30 60 0.29
5 
0.033 100% 0.290 0.031 100% 
30 100 0.29
4 
0.027 100% 0.290 0.031 100% 
30 300 0.29
3 
0.025 100% 0.288 0.025 100% 
        
Table 4.6: Simulation study: Median R2h estimates based on 250 simulations for each 
scenario, where true values set to: R2h =0.64 and R2ht =0.90 or 0.30.  
The coverages were comparable across settings with most returning 100% coverage. 
The IQRs of 𝑅ℎ
2 in the simulations were also consistent in either scenario. 
4.2.1.4 Individual level surrogacy R2h: non-proportional odds 
As can be seen in Table 4.7, when we compare proportional odds against non-
proportional odds there was little difference in 𝑅ℎ
2 estimates. Non-proportional odds 
results were generally lower but within approximately 0.01 of the proportional odds 
scenario regardless of the size or number of trials.  
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Number 
of  trials 
Trial 
size 




=0.64            
IQR 𝑅ℎ




=0.64            
IQR 𝑅ℎ
2 % cover 
CIs  
        
5 10 0.347 0.154 100% 0.344 0.160 100% 
5 60 0.305 0.086 100% 0.310 0.087 99% 
5 100 0.300 0.063 99% 0.308 0.063 100% 
5 300 0.304 0.058 96% 0.302 0.058 95% 
        
10 10 0.337 0.107 100% 0.322 0.114 100% 
10 60 0.293 0.063 100% 0.295 0.051 100% 
10 100 0.302 0.056 100% 0.296 0.051 100% 
10 300 0.294 0.040 99% 0.288 0.050 100% 
        
20 10 0.342 0.072 100% 0.333 0.078 100% 
20 60 0.297 0.039 100% 0.294 0.038 100% 
20 100 0.293 0.036 100% 0.294 0.033 100% 
20 300 0.292 0.031 100% 0.292 0.031 100% 
        
30 10 0.340 0.071 100% 0.330 0.066 100% 
30 60 0.295 0.033 100% 0.292 0.036 100% 
30 100 0.294 0.027 100% 0.290 0.030 100% 
30 300 0.293 0.025 100% 0.288 0.021 100% 
        
Table 4.7: Simulation study: Median R2h estimates based on 250 simulations for each 
scenario, where true values set to: R2h =0.64 and R2ht =0.90. Comparing results for 
proportional odds and non-proportional odds.  
The coverage and IQRs of the proportional odds and non-proportional odds estimates 
were comparable between scenarios. 
4.2.1.5 Individual level surrogacy R2h: ceiling affect 
The results of the simulation study presented for 𝑅ℎ
2  show the impact of loss of 
information that occurs when a binary surrogate and ordinal true outcome represent 
underlying continua. The values of 𝑅ℎ
2 returned in these settings were just less than 
half that set in the continuous setting for both 𝑅ℎ
2=0.64 and 𝑅ℎ
2=0.30. I investigated 
the simulation scenario where 𝑅ℎ
2=1 at the underlying continuum (perfect surrogacy 
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at the individual level) to see if there was an upper-bound on how useful a binary 
surrogate can be for an ordinal true outcome. 
Number 




𝟐  IQR 𝑹𝒉







       
5 10 0.521 0.174 100% 0.109 0.856 
5 60 0.531 0.155 93% 0.332 0.714 
5 100 0.516 0.156 86% 0.368 0.648 
5 300 0.490 0.155 53% 0.413 0.566 
       
10 10 0.500 0.113 100% 0.108 0.840 
10 60 0.502 0.098 99% 0.315 0.672 
10 100 0.504 0.097 93% 0.358 0.634 
10 300 0.488 0.106 70% 0.410 0.566 
       
20 10 0.493 0.086 100% 0.107 0.836 
20 60 0.501 0.068 100% 0.312 0.669 
20 100 0.491 0.066 98% 0.351 0.624 
20 300 0.489 0.066 88% 0.409 0.568 
       
30 10 0.484 0.071 100% 0.105 0.823 
30 60 0.493 0.055 100% 0.310 0.664 
30 100 0.491 0.056 100% 0.351 0.621 
30 300 0.479 0.051 96% 0.401 0.554 
       
Table 4.8: Simulation study: Median R2h estimates based on 250 simulations for each 
scenario, where true values set to: R2h =1 and R2ht =0.90.. 
The estimates for 𝑅ℎ
2=1 seemed to converge on approximately 0.48 as trial sizes 
increased, and to a lesser extent as the number of trials increased, see Table 4.8. This 
suggested that the most useful a binary surrogate for an ordinal true outcome can be, 
at the individual level, had a ceiling of around 0.48. 
As the number of patients increase the coverage is increasingly poor, except where 
there are a large number of trials. The IQRs are much larger in this setting than in 
previous settings suggesting that the 𝑅ℎ
2 values between simulations vary a lot. Also, 
the confidence intervals decrease in size as the number of patients increase (see the 
median bounds). Where the IQRs are large and the intervals decrease it is much more 
likely that the interval will not contain the large sample approximation of 𝑅ℎ
2 which 
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explains why the coverage decreases. Overall in the case of ‘perfect’ surrogacy the 
intervals do not appear to work well, however, this is a very particular scenario that 
is unlikely to occur in practice. Other settings do not have such large IQRs and are 
unlikely to suffer the same issue to the same degree. 
4.2.1.6 Individual level surrogacy R2h: comparison to other 
methodology 
No publications on information theory surrogacy evaluation for ordinal surrogates 
were available in the literature. However, it was possible to compare my results to 
the published findings in the binary-binary and binary-continuous settings. 
4.2.1.6.1 Comparison to the binary-binary setting 
In the binary-binary setting, (Tilahun et al., 2008a), results converge to 
approximately 0.21 compared to 0.29 in the binary-ordinal case when 𝑅ℎ
2=0.64 and 
𝑅ℎ𝑡
2 =0.90 at the underlying continua. This suggest that an ordinal true outcome is 
more desirable when investigating surrogacy than with a binary true outcome. This is 
logical given the additional loss of information in the binary-binary setting. 
However, there is another possible explanation for the difference. The information 
theory results in the binary-binary setting were produced using the LRF based on one 
full model for all trials as opposed to the summation of the LRF for separate models 
for each trial (see section 3.4.3). Tilahun et al., 2008a used a full model method 
according to the freely available software released with this publication (I-Biostat, 
2015). Therefore, only one statistic of the amount of information gained about the 
true outcome (one LRF calculation) after adjustment for the surrogate was used 
rather than a summation of this statistic across individual trials. Therefore, they 
relied heavily on the assumption that association between the surrogate and true 
outcome was constant over trials. This could also be an explanation for the 
differences seen in 𝑅ℎ
2 results between the binary-binary setting and my results for 
the binary-ordinal setting. 
4.2.1.6.2 Comparison to the binary-continuous setting 
In the binary-continuous setting values of 𝑅ℎ
2 converged to approximately 0.16, 
Pryseley et al. (2007), compared to 0.29 in the binary-ordinal setting when 𝑅ℎ
2=0.64 
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and 𝑅ℎ𝑡
2 =0.90 at the underlying continua. This was again much lower than in the 
binary-ordinal simulation results. This is contrary to expectation since the binary-
continuous setting suffers less loss of information than the binary-ordinal setting. 
4.2.1.6.3 Comparison conclusions 
Using these comparisons, I could suggest that the results of the binary-ordinal setting 
showed that a binary surrogate for an ordinal true outcome was more informative 
than other discrete outcome settings. However, it was equally likely that the use of a 
multi-trial method for individual level surrogacy in this case was the reason for the 
improvements in these results. Suggesting that a multi-trial method is superior to the 
methods used in the binary-binary and binary-continuous publications. 
4.2.1.7 Individual level surrogacy R2h: Conclusions  
The results of this simulation study suggest that the loss of information imposed by 
dichotomising a continuous surrogate and categorising an ordinal true outcome was 
substantial. A binary surrogate for an ordinal true outcome appears to be half as 
informative as their continuous counterparts. It would be interesting to see if any 
improvement on this ceiling would be possible with an ordinal surrogate as opposed 
to a binary one, as this would provide more information (this will be discussed in 
6.2.1.6). However, it should be noted that an ordinal surrogate is not always better 
than a binary surrogate if the binary representation more naturally describes the 
status of the measure it is representing (Burzykowski et al., 2005). 
Median 𝑅ℎ
2 estimates were fairly consistent regardless of the size or number of trials. 
Although, an increase in trial size slightly improved estimation of 𝑅ℎ
2 . Differing 
strengths of surrogacy at the trial and individual level and the presence of non-
proportional odds had little impact on 𝑅ℎ
2 estimates. Research has shown that the 
proportional odds model is capable of handling divergences from the proportional 
odds assumption well (McHugh et al., 2010a). This may explain why individual level 
surrogacy assessment performed well regardless of the presence of non-proportional 
odds. 
The confidence intervals had 100% coverage in nearly all scenarios, that are likely to 
occur in practice, suggesting that these are conservative. The median 95% bounds 
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suggested that the intervals do not cover the whole parameter space and are relatively 
narrow in some scenarios suggesting that they are useful to some degree.  
In the case of “perfect” surrogacy, see section 4.2.1.5, the intervals do not work well 
– however this is a very particular case that is unlikely to occur in practice and other 
scenarios do not suffer the same issues to the same degree.   
The coverage at the individual level was based on the large scale approximation, 
rather than the true value of 𝑅ℎ
2, therefore, these were not ideally formatted, see 
4.1.3.3.3. However, the overall impression from the coverage results is that these 
intervals are too conservative in the general case and alternatives should be 
considered. 
4.2.2 Results: trial level surrogacy 
In this section I describe: 
 the scenario where surrogacy was strong at both the trial and individual 
levels;  
 where surrogacy was weak at both levels;  
 where the strength of surrogacy disagrees at the trial and individual levels; 
 where non-proportional odds were present;  
 and finally, compare the penalised likelihood to the trial removal technique 
for dealing with separation.  
4.2.2.1 Trial level surrogacy R2ht: strong surrogacy 
Consider Table 4.9, the results for trial level surrogacy when surrogacy was set to be 
strong at both levels (𝑅ℎ𝑡
2  simulated to be 0.90) are presented. 
Table 4.9 shows that there was overestimation where there were five trials and 
moderate to large trial sizes but as the number of trials increased the median 𝑅ℎ𝑡
2  
displayed greater underestimation. This was worse for smaller trial sizes. On the 
whole, the coverage of the confidence intervals improved as the number and size of 
trials increased – with approximately 95% coverage for larger numbers of patients 
per trial. However, in the case of small numbers of patients per trial and larger trial 
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numbers the coverage is poor, this is likely because of the relatively large amount of 
bias in 𝑹𝒉𝒕
𝟐  results in these scenarios rather than issues with the intervals themselves.  
Number 




𝟐  IQR 𝑹𝒉𝒕






CI upper  
 
       
5 10 0.781 0.367 82% 0.120 0.988 
5 60 0.923 0.146 93% 0.408 0.998 
5 100 0.924 0.135 92% 0.411 0.998 
5 300 0.949 0.111 93% 0.513 0.999 
       
10 10 0.616 0.304 68% 0.121 0.922 
10 60 0.838 0.153 84% 0.412 0.979 
10 100 0.862 0.132 91% 0.462 0.984 
10 300 0.900 0.090 95% 0.553 0.990 
       
20 10 0.571 0.203 45% 0.207 0.843 
20 60 0.803 0.120 76% 0.503 0.947 
20 100 0.831 0.098 86% 0.552 0.957 
20 300 0.870 0.082 95% 0.625 0.969 
       
30 10 0.549 0.169 21% 0.249 0.791 
30 60 0.798 0.100 69% 0.560 0.928 
30 100 0.829 0.092 83% 0.611 0.942 
30 300 0.865 0.065 94% 0.672 0.957 
       
Table 4.9: Simulation study: Median R2ht estimates based on 250 simulations for 
each scenario, in the binary-ordinal setting where true values set to: R2h =0.64 and 
R2ht =0.90. 
The size of the IQRs of 𝑅ℎ𝑡
2  were larger than that experienced at the individual level 
in the same scenario (see section 4.2.1.1). Given that the two stage trial level 
surrogacy approach was used, second stage models were based on a sample of size 
equal to the number of trials. Conversely, a one stage approach (as used at the 
individual level) would have been based on the number of trials multiplied by the 
size of the trials. Therefore, the larger ranges in the distributions is unsurprising 
given that trial level surrogacy was based on two stages. For instance, in the scenario 
of 30 trials and 300 patients the IQR in 𝑅 
2 results at the individual level was 0.025as 
opposed to 0.065  at the trial level. 
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4.2.2.1.1 Comparison to continuous-continuous setting: strong surrogacy 
Theoretically, at the trial level, the results for the binary-ordinal setting and the 
setting where a continuous surrogate and continuous true outcome (continuous-
continuous setting) were modelled, should be the same. We can compare binary-
ordinal results to those for the continuous-continuous setting. In the continuous 
setting there was also overestimation when there were only five trials, see Table 
4.10. However, the underestimation seen in the binary-ordinal setting for ten or 
above trials was not present in the continuous-continuous setting. Where there were 
30 trials and 300 patients the median 𝑅ℎ𝑡
2  was 0.865 in the binary-ordinal setting and 
0.902 in the continuous setting. Large underestimation can also be seen for smaller 
trial sizes and number of trials in the binary-ordinal setting. This underestimation 
was not as pronounced in the continuous-continuous setting.  
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2   IQR 𝑅ℎ𝑡
2   𝑅ℎ𝑡
2   IQR 𝑅ℎ𝑡
2  
      
5 10 0.781 0.367 0.931 0.165 
5 60 0.923 0.146 0.950 0.103 
5 100 0.924 0.135 0.953 0.095 
5 300 0.949 0.111 0.959 0.069 
      
10 10 0.616 0.304 0.840 0.137 
10 60 0.838 0.153 0.909 0.096 
10 100 0.862 0.132 0.916 0.072 
10 300 0.900 0.090 0.919 0.068 
      
20 10 0.571 0.203 0.835 0.100 
20 60 0.803 0.120 0.900 0.065 
20 100 0.831 0.098 0.902 0.054 
20 300 0.870 0.082 0.910 0.058 
      
30 10 0.549 0.169 0.826 0.078 
30 60 0.798 0.100 0.895 0.053 
30 100 0.829 0.092 0.900 0.050 
30 300 0.865 0.065 0.902 0.054 
      
Table 4.10: Simulation study: Median R2ht estimates based on 250 simulations for 
each scenario, in binary-ordinal and continuous-continuous setting where true 
values set to:  R2h =0.64 and R2ht =0.90. 
4.2.2.1.2 Underestimation R2ht: strong surrogacy 
Given that the continuous setting does not suffer such large issues of bias it seemed 
that this was at least partially driven by the discrete nature of the outcomes in the 
binary-ordinal setting. 
The two stage nature of the information theory approach at the trial level and 
categorisation of outcomes led to inefficiencies in estimation. Recall that at the first 
stage of modelling 𝑅ℎ𝑡
2  treatment effects were estimated for each trial for both the 
surrogate and the true outcome. These estimates were then regressed in the models at 
the second stage to calculate the 𝑅ℎ𝑡
2 . This two stage approach was introduced as an 
alternative to the computationally burdensome full joint mixed model of the meta-
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analytical approach (see section 2.2.1). The two stage approach was effectively: 
taking a large computational problem; partitioning it into smaller components; 
solving for each component; and combining the results of these to give an overall 
answer. 
Molenberghs et al. (2011) investigated the impact of a similar method on statistical 
efficiency and found that when the number of partitions was large compared to the 
size of the partitions, inefficiency occurs. Partitions in this case were trials. In Table 
4.10 as the number of trials increased and sizes decreased the bias worsened which 
was in keeping with the results of Molenberghs et al. (2011). 
On top of the inefficiency due to the two stage approach, binary or ordinal outcomes 
are less efficient at providing parameter estimation than continuous outcomes. In our 
case the response variables of the stage one models have been dichotomised or 
categorised to create binary and ordinal response outcomes. (In either case the 
discrete variables were regressed on treatment to estimate treatment effects for each 
trial.) Taylor et al. (2006) and Taylor and Yu (2002) showed that where regression 
variables were categorisations of continuous variables inefficiency occurs in 
estimation. This inefficiency is much worse for binary outcomes as opposed to 
categorical outcomes. This result suggested that the dichotomisation of the binary 
surrogate contributed more to the inefficient results than the categorisation of the 
ordinal true outcome. 
In summary, the bias in results was due to inefficiency imposed by a two stage 
approach compounded by the use of binary and ordinal outcomes. This was 
substantiated by the larger IQRs in the 𝑅ℎ𝑡
2  results than for 𝑅ℎ
2 (where a one stage 
approach was used). This result was also true in the continuous-continuous setting, 
data not shown. Furthermore, the IQRs of 𝑅ℎ𝑡
2  in the continuous-continuous setting 
were narrower than in the binary-ordinal setting, see Table 4.10.  
Consider Table 4.11, I present additional settings where each trial has tenfold more 
patients (3000 patients) than the highest scenario currently considered. The median 
𝑅ℎ𝑡
2  results were much closer to the true strength of surrogacy in these scenarios and 
the widths of the IQRs were closer to that in the continuous setting. Therefore, the 
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2   IQR 𝑅ℎ𝑡
2   
    
5 3000 0.959 0.079 
10 3000 0.902 0.078 
20 3000 0.896 0.062 
30 3000 0.890 0.057 
    
Table 4.11: Additional simulation scenarios: Median R2ht estimates based on 250 
simulations for each scenario, where R2h =0.64 and R2ht=0.90 and trial size was 
3000. 
4.2.2.1.3 Overestimation R2ht: strong surrogacy 
There was some evidence of overestimation in Table 4.10 for small numbers of trials. 
This issue was referenced in row three of Table 4.3 and the reason for this bias will 
be full explained in section 4.2.2.2.5 in reference to weak surrogacy strengths where 
this issue is more pronounced. However, the overestimation occurs in the case of 
strong surrogacy for small numbers of trials for the same reason. 
4.2.2.2 Trial level surrogacy R2ht: weak surrogacy 
Here I discuss the case where surrogacy is weak at both levels, 𝑅ℎ
2 = 𝑅ℎ𝑡
2 =0.30, I 
expect the trial level results to be in the region of 0.30. 
The results of this section were more complex than others therefore, I will: first, 
describe the results; compare them to the underlying continuous-continuous setting; 
discuss them in relation to the two conflicting biases; and then conclude. 
4.2.2.2.1 Results R2ht: weak surrogacy 
Consider Table 4.12, when surrogacy was weak there was extremely large 
overestimation where trial numbers were small which worsened as the size increased. 
As the number of trials increased estimation improved where trial sizes were large 
but then displayed underestimation where trial sizes were small.  
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Number 




𝟐  IQR 𝑹𝒉𝒕





CI upper  
        
5 10 0.561 0.539 74% 0.011 0.959 
5 60 0.596 0.485 76% 0.016 0.965 
5 100 0.670 0.491 71% 0.038 0.976 
5 300 0.658 0.473 79% 0.033 0.974 
       
10 10 0.327 0.326 76% 0.005 0.790 
10 60 0.440 0.366 91% 0.023 0.852 
10 100 0.431 0.360 95% 0.020 0.847 
10 300 0.401 0.385 95% 0.014 0.832 
       
20 10 0.238 0.227 92% 0.009 0.602 
20 60 0.324 0.299 95% 0.035 0.678 
20 100 0.329 0.202 97% 0.037 0.682 
20 300 0.333 0.224 96% 0.039 0.685 
       
30 10 0.211 0.171 97% 0.017 0.510 
30 60 0.283 0.176 88% 0.047 0.583 
30 100 0.303 0.154 92% 0.057 0.601 
30 300 0.313 0.164 94% 0.063 0.610 
       
Table 4.12: Simulation study: median R2ht estimates based on 250 simulations for 
each scenario, in the binary-ordinal setting where true values set to: R2h =0.30 and 
R2ht=0.30. 
The size of the IQRs of 𝑅ℎ𝑡
2  were  large compared to where surrogacy was set to be 
strong, see Table 4.9. The IQRs decreased as the number of trials increased but 
remains much larger in relation to strong surrogacy strength scenarios. For instance, 
in the information-rich scenario of 30 trials and 300 patients the IQR when surrogacy 
was strong was 0.065 as opposed to 0.164 where surrogacy was set to be weak. The 
coverage improved as the number of trials increased, but was quite poor for small 
numbers of trials, this was again likely due to the increased bias in the 𝑅ℎ𝑡
2  results.  
4.2.2.2.2 Comparison to continuous-continuous setting: weak surrogacy 
In order to understand these results it was necessary again to compare them to those 
for the continuous-continuous setting. 
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In Table 4.13 the pattern of overestimation seen in the binary-ordinal setting was 










2  IQR 𝑅ℎ𝑡
2  𝑅ℎ𝑡
2  IQR 𝑅ℎ𝑡
2  
      
5 10 0.561 0.539 0.600 0.453 
5 60 0.596 0.485 0.659 0.399 
5 100 0.670 0.491 0.676 0.539 
5 300 0.658 0.473 0.683 0.440 
      
10 10 0.327 0.326 0.438 0.298 
10 60 0.440 0.366 0.446 0.347 
10 100 0.431 0.360 0.402 0.376 
10 300 0.401 0.385 0.429 0.324 
      
20 10 0.238 0.227 0.349 0.212 
20 60 0.324 0.299 0.353 0.199 
20 100 0.329 0.202 0.327 0.213 
20 300 0.333 0.224 0.355 0.222 
      
30 10 0.211 0.171 0.326 0.172 
30 60 0.283 0.176 0.329 0.179 
30 100 0.303 0.154 0.358 0.210 
30 300 0.313 0.164 0.336 0.204 
      
Table 4.13: Median R2ht estimates based on 250 simulations for each scenario, in 
continuous-continuous setting where true values set to: R2h =0.30 and R2ht =0.30. 
In both settings there was large overestimation as the number of trials decreased. The 
median 𝑅ℎ𝑡
2  result was as high as 0.658 for five trials and 300 patients against a true 
value of 0.30. A result of 0.658 would represent the case of a moderately good 
surrogate, which could lead to a false conclusion of a valid surrogate. The 
continuous-continuous setting showed overestimation for every scenario. 
4.2.2.2.3 Comment R2ht: weak surrogacy 
Before I go on to discuss the reason for this overestimation, note that compared to 
the continuous-continuous setting the binary-ordinal results were again showing 
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lower results as the number of trials increased. This was still present in larger trial 
sizes but was a more serious issue for smaller trial sizes. Therefore, the binary-
ordinal setting results seemed to be more accurate only because they were suffering 
two opposing forms of bias (see rows two and three of Table 4.3). 
4.2.2.2.4 Underestimation R2ht: weak surrogacy 
The reason for the underestimation in the binary-ordinal setting was again due to the 
inefficiency imposed by the use of a binary surrogate and ordinal true outcome 
instead of continuous outcomes, as described in section 4.2.2.1.2. Again, if we add 
an extra scenario to our simulation where the largest number of patients was 
increased tenfold (3000 patients) we find that the results in the binary-ordinal setting 
more closely resemble those for the larger trial sizes of the continuous-continuous 
setting (see Table 4.14). Given that a larger sample size returns more comparable 
results to the continuous setting, it was fair to conclude that this underestimation was 
caused by the inefficiency of the binary and ordinal outcomes. 
 Binary-ordinal 
Number 








2   
    
5 3000 0.591 0.428 
10 3000 0.491 0.300 
20 3000 0.360 0.245 
30 3000 0.326 0.191 
    
Table 4.14: Additional simulation scenarios: Median R2ht estimates based on 250 
simulations for each scenario, where R2h= R2ht=0.30 and trial size was 3000 
4.2.2.2.5 Overestimation 𝑅ℎ𝑡
2 : weak surrogacy 
I now discuss the reasons for overestimation in the binary-ordinal and continuous-
continuous settings.  
The information theory approach at the trial level was effectively based on the 
coefficient of determination (𝑅 
2 ) of the second stage models. In this case, the 
coefficient of determination is a measure of the ability of the surrogate treatment 
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effect estimates to predict those for the true outcome. Better predictive ability 
corresponds to a higher estimate of the strength of surrogacy.  
We can see graphically in Figure 4.2 an artificial example assembled using the 
simulation code. First, let us consider the case where there are 30 trials. Here, where 
surrogacy is strong (𝑅ℎ𝑡
2 = 0.90) treatment effect estimates are very close to the 
regression line. Conversely, the residuals are larger for the case of lower surrogacy 
and 30 trials, and the points are more widely scattered, i.e. have poor predictive 
ability. If we select only five of these points, to represent the situation where there 
were five trials, for strong surrogacy the regression is still representative of that for a 
larger number of trials, i.e. the residuals are small. 
The surrogacy estimates are 𝑅ℎ𝑡
2̂ = 0.757 for both five and 30 trials, where we are 
expecting results of 0.90.  
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Figure 4.2: Regressions of treatment effect estimates on the true outcome regressed 
on the surrogate for: five/thirty trials and high surrogacy (top left and right resp.); 
five/thirty trials and weak surrogacy (bottom left and right respectively) 
However, when surrogacy was weak, since there was much more variability in the 
treatment effect estimates for the five selected trials, these do not provide good 
estimation. The regression based on the five selected trials was not representative of 
that obtained for thirty trials. In these models the true relationship is not fitted and 
the model instead fits too closely to these inadequate data (in this case because there 
were too few data points). Hence, there were smaller residuals than in the 30 trials 
case and the model appeared to have higher predictive ability/surrogacy. This was 
simply due to the fact that there were fewer points and is an example of overfitting. 
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Where there were 30 points (30 trials), overfitting does not occur and estimates 
closer to the true value of surrogacy were obtained. Here, 𝑅ℎ𝑡
2̂ =0.638 for five trials 
and 𝑅ℎ𝑡
2̂ =0.156 for thirty trials where we were expecting results of 0.30. This 
example highlights why it is difficult to estimate surrogacy effectively when there 
are lower strengths of surrogacy and small numbers of trials. 
4.2.2.2.6 Conclusion R2ht: weak surrogacy 
Due to the nature of the information theory, when there is weak surrogacy, 
overfitting for small numbers of trials leads to inflated estimation. This explains the 
overestimation witnessed in results for small numbers of trials, the much wider IQRs 
in 𝑅ℎ𝑡
2  and worse coverage of confidence intervals. The results in Table 4.13 show 
that overestimation was present even in the case of 30 trials. 
I have also found that, in keeping with the results of strong surrogacy, the binary-
ordinal setting displays underestimation compared to the continuous-continuous 
setting due to the inefficiency of discrete variables as opposed to continuous 
variables. 
4.2.2.3 Trial level surrogacy R2ht: differing strengths of surrogacy 
In Table 4.15 we can compare the results where surrogacy was strong at both levels 
to the case where surrogacy was strong at the trial level but weak at the individual 
level. Generally, having different strengths of surrogacy at both levels does not affect 
estimation of 𝑅ℎ𝑡
2 . However, as the number of trials increased, if trial sizes were 
small, there was greater underestimation for disagreement in surrogacy strengths. 
In the converse case, where surrogacy was weak at the trial level and strong at the 
individual level, we also see an impact on the results where surrogacy disagrees. 
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Number 
of  trials 
Trial 
size 





2   







2   






        
5 10 0.781 0.367 82% 0.753 0.325 85% 
5 60 0.923 0.146 93% 0.902 0.174 88% 
5 100 0.924 0.135 92% 0.913 0.154 93% 
5 300 0.949 0.111 93% 0.947 0.101 92% 
        
10 10 0.616 0.304 68% 0.531 0.320 74% 
10 60 0.838 0.153 84% 0.826 0.159 88% 
10 100 0.862 0.132 91% 0.852 0.148 85% 
10 300 0.900 0.090 95% 0.896 0.085 96% 
        
20 10 0.571 0.203 45% 0.451 0.226 38% 
20 60 0.803 0.120 76% 0.774 0.136 71% 
20 100 0.831 0.098 86% 0.817 0.104 83% 
20 300 0.870 0.082 95% 0.861 0.081 94% 
        
30 10 0.549 0.169 21% 0.447 0.194 17% 
30 60 0.798 0.100 69% 0.757 0.103 55% 
30 100 0.829 0.092 83% 0.798 0.088 79% 
30 300 0.865 0.065 94% 0.857 0.066 92% 
        
Table 4.15: Simulation study: Median R2ht estimates based on 250 simulations for 
each scenario, where true values set to: R2ht =0.90 and R2h =0.64 or 0.30.  
4.2.2.4 Trial level surrogacy R2ht: non-proportional odds 
I will now discuss the results where the odds of the ordinal true outcome were not 
proportional. The binary-ordinal results for the non-proportional odds scenario were 
similar to the proportional odds scenario, see Table 4.16.  
This suggests that the presence of deviations from the proportional odds assumption 
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Number 
of  trials 
Trial 
size 
Proportional Non proportional 
 
  𝑅ℎ𝑡
2   
=0.90            
IQR 
𝑅ℎ𝑡





2   
=0.90             
IQR 
𝑅ℎ𝑡




        
5 10 0.781 0.367 82% 0.791 0.311 86% 
5 60 0.923 0.146 93% 0.916 0.152 88% 
5 100 0.924 0.135 92% 0.920 0.124 91% 
5 300 0.949 0.111 93% 0.945 0.114 93% 
        
10 10 0.616 0.304 68% 0.595 0.304 72% 
10 60 0.838 0.153 84% 0.837 0.133 86% 
10 100 0.862 0.132 91% 0.858 0.129 89% 
10 300 0.900 0.090 95% 0.881 0.123 93% 
        
20 10 0.571 0.203 45% 0.533 0.221 41% 
20 60 0.803 0.120 76% 0.808 0.120 79% 
20 100 0.831 0.098 86% 0.827 0.101 79% 
20 300 0.870 0.082 95% 0.858 0.080 94% 
        
30 10 0.549 0.169 21% 0.525 0.164 21% 
30 60 0.798 0.100 69% 0.788 0.098 64% 
30 100 0.829 0.092 83% 0.833 0.077 81% 
30 300 0.865 0.065 94% 0.858 0.080 94% 
        
Table 4.16: Simulation study: Median R2ht estimates based on 250 simulations for 
each scenario, where true values set to: R2ht =0.90 and R2h =0.64. Comparing results 
for proportional odds and non-proportional odds. 
4.2.2.5 Trial level surrogacy R2ht: dealing with separation 
Recall that we discussed issues of separation in section 3.6 and how this impacts 
surrogacy estimation. We also discussed how this was dealt with in the simulation in 
section 4.1.3.3. For an overview of this issue see row four of Table 4.3. 
4.2.2.5.1 Occurrence of separation: trial level 
The separation for binary outcomes in the simulation ranged from 2.5% to 79.8%. 
The average was 23.4%. Separation in the ordinal case was recorded independently 
for complete and quasi-complete separation. The amount of ordinal complete 
separation ranged from 0% to 28.6% with an average of 4.5%. Quasi-complete 
separation for ordinal outcomes ranged from 0% to 23.3% with an average of 3.2%. 
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Hence, under this random simulation process, separation occurred frequently and 
needed to be addressed. 
4.2.2.5.2 Comparison of penalized likelihood and trial removal technique: 
separation at the trial level 
Two techniques were taken to deal with the issues of separation. The first was to 
apply a penalized likelihood technique which allows trials with separation to be 
retained in analysis. The second technique was to remove trials where separation 
occurs which led to loss of information. 
In Table 4.17 the penalized likelihood technique was compared to the removal of 
trials technique. Focusing, firstly, on the case of 20 and 30 trials the estimates of 
surrogacy for smaller trial sizes were much better using the penalized likelihood 
technique. In the trial removal technique these estimates were extremely poor where 
there were only ten patients per trial.  
The results for lower numbers of trials (five or ten trial scenarios) also send the same 
message, although this is less obvious at first. When we consider the median 𝑅ℎ𝑡
2 , the 
results appear to be better or similar for the trial removal technique where trial sizes 
were small. However, in the case of as few as ten patients per trial, it was likely that 
separation occurred very frequently. In the case of fewer than three trials being 
available for the analysis for the removal trial technique the simulation was set to 
return a null value (see section 4.1.3.2). The simulation was run until 250 results 
were obtained for both the penalized likelihood and removal technique i.e. 250 
datasets were simulated where three or more trials were available. 
In the five trials of ten patients scenario, 90.3% of datasets had less than three trials 
available for analysis and therefore null results were returned for the trial removal 
technique. In the ten trials and ten patients per trial scenario 46.1% of simulated 
datasets returned a null value, see Table 4.17. Where simulations were not rejected, 
for having only three or fewer trials, generally a lot fewer than the stated number of 
trials were available for analysis. I found that as the number of trials removed 
increased so too did the value of 𝑅ℎ𝑡
2  using the trial removal technique. This was due 
to the overestimation outlined in row three of Table 4.3 and discussed in section 
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4.2.2.2.5. Therefore, where there were small numbers of trials 𝑅ℎ𝑡
2  estimates for the 
trial removal technique were artificially high due to bias and were not a result of 
more effective estimation compared to the penalized likelihood technique. 
Number 






Trial removal technique 
  𝑅ℎ𝑡
2   





2   








        
5 10 0.781 0.367 0.803 0.464 90.3% 4 
5 60 0.923 0.147 0.930 0.159 14.4% 5 
5 100 0.924 0.135 0.934 0.136 7.1% 5 
5 300 0.949 0.111 0.948 0.114 0.8% 5 
        
10 10 0.616 0.304 0.633 0.546 46.1% 5 
10 60 0.838 0.153 0.833 0.263 0.0% 9 
10 100 0.862 0.132 0.847 0.161 0.0% 9 
10 300 0.900 0.090 0.895 0.101 0.0% 10 
        
20 10 0.571 0.203 0.411 0.420 2.7% 7 
20 60 0.803 0.120 0.793 0.191 0.0% 17 
20 100 0.831 0.098 0.826 0.146 0.0% 18 
20 300 0.870 0.082 0.871 0.080 0.0% 19 
        
30 10 0.549 0.169 0.278 0.383 0.4% 11 
30 60 0.798 0.100 0.783 0.162 0.0% 25 
30 100 0.829 0.092 0.823 0.103 0.0% 27 
30 300 0.865 0.065 0.866 0.066 0.0% 29 
        
Table 4.17: Simulation study: Median R2ht estimates based on 250 simulations for 
each scenario, where true values set to: R2ht =0.90 and R2h =0.64. Comparing 
penalized likelihood technique against trial removal technique (trial removal 
technique results include the % of time the calculation of R2ht was not possible and 
the median number of trials available for analysis when it was). 
This finding was supported by the fact that the IQRs for the penalised likelihood 
technique were narrower than the trial removal technique. 
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As the number of patients increased the benefits of the penalized likelihood 
technique were less evident in the median 𝑅ℎ𝑡
2  results. However, for these scenarios 
the penalized technique had narrower IQRs of 𝑅ℎ𝑡
2 . Meaning that in general results 
for the penalized likelihood technique were more precise. This was because the 
penalized likelihood technique was based on the full dataset in each case, whereas 
the trial removal technique will often be based on a much reduced dataset due to the 
removal of trials data where separation occurs. Often fewer than half of the trials 
were retained in analysis (see Table 4.17). This represents a huge loss of information 
when the trial removal technique was implemented. Even where there were large 
numbers of patients per trial the median number of trials retained in the removal 
technique was generally lower than that simulated, see Table 4.17.  
In comparison the penalized likelihood allows the retention of all trials in the 
analysis and does not suffer loss of information. The only time trials are removed 
from analysis for the penalized likelihood approach is when failure in the pordlogist 
model occurs for the ordinal outcome, however this only happened 0.5% of the time. 
Hence, I concluded that the penalized likelihood technique was far superior to a trial 
removal technique as it provides better estimation and does not suffer loss of 
information. This valuable methodological advancement has solved a problematic 
issue in discrete information theory surrogacy evaluation. 
4.2.2.6 Trial level surrogacy R2ht: comparison to other methodology 
4.2.2.6.1 Weak surrogacy: comparison 
I have highlighted the issue of overestimation in the information theory approach 
where there were small numbers of trials which mostly impacts lower strengths of 
surrogacy. Only one previous publication assesses lower strengths of surrogacy 
Burzykowski et al.(2005). This publication used the meta-analytical as opposed to 
the information theory approach but the results should be comparable to ours since 
these two approaches are very similar. In Burzykowski et al.(2005) surrogacy was set 
to be 0.50 at the trial level for continuous outcomes. The summary 𝑅 
2 estimates were 
in the region of 0.54 when results of 0.50 were expected. This simulation was based 
on 25 trials with 50 plus patients in each trial. This was a similar amount of 
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overestimation to that which was observed in my study for the continuous-
continuous setting, see Table 4.10 for 30 trials. Therefore, these results go some way 
to corroborating my findings. 
4.2.2.6.2 Discrete outcome information theory approaches 
There have been two previous papers on information theory surrogacy evaluation for 
discrete outcomes. One paper discussed the continuous-binary setting, (Pryseley et 
al., 2007) and one the binary-binary setting, (Tilahun et al., 2008b). Both settings 
showed much worse underestimation than in the binary-ordinal setting when the true 
value was 0.90 (see Table 4.3). For 30 trials and 300 patients and strong surrogacy, 
the median 𝑅ℎ𝑡
2  value was 0.75 in the binary-continuous setting and 0.764 in the 
binary-binary setting, as opposed to 0.865 in my binary-ordinal setting.  
I believe this was because these authors have not taken account of the issue of 
separation. The code available for these publications on the authors website gives no 
indication of adjustment for or removal of separation occurrences (I-Biostat, 2015). 
Furthermore, when problematic separation trials were not removed from my analysis 
the bias in results was similar to that reported in these publications. Hence, I attribute 
their observed bias in the binary-binary and binary-continuous settings to the 
unresolved problem of separation. The serious bias in these publications 
demonstrates the advantage of the development of the penalized likelihood technique 
to deal with issues of separation. 
4.2.2.7 Trial level surrogacy R2ht: conclusions 
In conclusion, trial level surrogacy though not theoretically affected by the 
categorisation of continuous outcomes was impacted practically speaking due to 
inefficiencies in estimation imposed through the use of a two stage approach. This 
led to underestimation as the number of trials increased and trial sizes decreased. It 
also led to wider IQRs. 
When the number of trials was small the regressions were based on only a few data 
points (treatment effect estimates for each trial). This led to overfitting in stage two 
models and the surrogate falsely appeared to have a strong predictive/surrogate 
potential. Ten or more trial scenarios led to less inflated estimation. 
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When there was no bias in 𝑅ℎ𝑡
2  results the confidence intervals showed good 
coverage, especially for larger trial sizes and numbers of patients per trial.  
I have also demonstrated the huge advantage of using a penalized likelihood 
technique to deal with the occurrence of separation in discrete outcomes for 
surrogacy evaluation; as opposed to a trial removal technique or ignoring the issue 
altogether. Separation was found to occur frequently under simulation and to greatly 
bias the results in previous publications (Pryseley et al., 2007) and (Tilahun et al., 
2008b). 
Results for differing surrogacy strengths at the trial and individual levels showed that 
there was some bias in results for small trial sizes which worsened as the number of 
trials increased. There was little effect on results where non-proportional odds were 
present. 
4.2.3 Results: conclusions 
I have shown that the loss of information that impacted 𝑅ℎ
2 in the observed binary-
ordinal setting was substantial. Where a binary surrogate and an ordinal true outcome 
were present the estimates of 𝑅ℎ
2 in the observed setting were just less than half as 
informative as those set at the underlying continua. The presence of discordant 
strength of surrogacy at the trial and individual levels and non-proportional odds 
have little impact on the estimation of 𝑅ℎ
2. 
Considering previous publications for discrete outcomes, it appeared that binary 
surrogates for ordinal true outcomes are more informative than other discrete 
scenarios. The alternative explanation was that using a method based on the amount 
of information gained for each trial separately is superior to methods that calculate 
the amount of information gained for all trials as a whole. 
The confidence intervals at the individual level are conservative, perhaps bootstrap 
intervals would be more appropriate. 
Three issues were identified at the trial level: underestimation; overestimation and 
separation. These can be considered as issues relating to the two stage nature of the 
information theory approach. Underestimation and separation were due to or resulted 
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in difficulties in estimation in stage one models, the former because of inefficiencies 
and the latter due to modelling issues. Overestimation was due to overfitting in stage 
two models. 
Simulation demonstrated a high frequency of separation and showed the need for a 
solution to this problem in surrogate evaluation methodology. The use of a penalized 
likelihood technique resolved the issue of separation, this has not previously been 
considered in the surrogate literature. The simulation and comparisons to previous 
published research have shown that techniques that ignore or remove trials that suffer 
separation were greatly inferior to the penalized likelihood technique. The penalized 
likelihood technique returns sensible results without suffering loss of information. 
4.3 Simulation study: conclusions 
I set up a simulation study to investigate the ability of the information theory 
approach in the binary-ordinal setting to estimate surrogacy. I have carefully 
investigated the literature in considering the set-up of the simulation study then 
effectively demonstrated the worth of the information theory methodology in various 
scenarios.  
This simulation study has identified issues and interesting aspects of information 
theory that have been previously unknown. Where possible, methodological 
resolutions to this issues have been demonstrated. Overall, extending the information 
theory approach to the binary-ordinal setting has proved to be a useful addition to the 
collection of settings already developed.
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Chapter 5. Extension of information theory to 
the case of an ordinal surrogate and binary 
true outcome: Methodology  
In this Chapter I outline how the information theory approach can be extended to the 
case of an ordinal surrogate and binary true outcome. I: re-introduce the information 
theory approach for continuous outcomes; show how this can be extended to the 
ordinal-binary setting at the individual and trial level; and briefly discuss the 
application of the penalized likelihood method in the ordinal-binary setting.  
As in previous chapters I represent a putative surrogate as S, treatment as Z and the 
true outcome as T. In the multi trial context there are i=1,2,…,N trials, and 
j=1,2,….,𝑛𝑖 patients per trial. 𝑁𝑇 = ∑ 𝑛𝑖𝑖 , the total number of patients in all trials. 
Here the ordinal surrogate has V ordered categories. 
5.1 The information theory approach: a re-
introduction 
Information theory involves the study of the amount of information or uncertainty in 
a random variable. Entropy is a key concept and informs on the amount of 
uncertainty in a draw from a random variable, i.e. if one outcome is much more 
likely then we are fairly certain what the result of the draw will be. Another useful 
concept in information theory is that of the mutual information, which calculates the 
amount of uncertainty in one variable that can be accounted for by another, see 
section 3.2 for more details. 
Alonso and Molenberghs (2007) proposed using these concepts among others to 
calculate the amount of uncertainty in the true outcome (treatment effects on T) 
accounted for by the surrogate (treatment effects on S) at the individual (trial) level. 
This was an intuitive proposal since surrogacy investigations require knowledge of 
the amount of information on the true outcome explained by the surrogate. The 
measures proposed were 𝑅ℎ
2 for the individual level and 𝑅ℎ𝑡
2  at the trial level, see 
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section 3.2. Alonso and Molenberghs (2007) suggested the use of the likelihood 
reduction factor (LRF) to estimate 𝑅ℎ
2 and 𝑅ℎ𝑡
2  in the multi trial setting as it provides 
a consistent interpretation across settings and ranges in the unit interval. An 𝑅2=0 
represents a surrogate of no value and 𝑅2=1 the perfect surrogate. 
In the following sections I re-introduce the LRF and show how it can be used to 
calculate 𝑅ℎ
2 and 𝑅ℎ𝑡
2 . I then show how the LRF can be applied to the case of an 
ordinal surrogate and binary true outcome. 
5.2 Individual level surrogacy: LRF reintroduction 
Consider the continuous-continuous setting at the individual level. The LRF is based 
on the amount of information gained about the true outcome after accounting for the 
surrogate. Alonso et al. (2006) proposed using two models for continuous outcomes 
for each trial i: 
𝑇𝑖𝑗 = 𝜇𝑖 + 𝛽𝑖 𝑍𝑖𝑗 + 𝑇𝑖𝑗 
 5.1 
𝑇𝑖𝑗 = 𝜃0𝑖 + 𝜃1𝑖 𝑍𝑖𝑗 + 𝜃2𝑖 𝑆𝑖𝑗 + 𝑇|𝑆𝑖𝑗 ,
 5.2 
where: 𝜃0𝑖 and 𝜇𝑖 are intercept parameters with and without adjustment for the 
surrogate; 𝛽𝑖 is the treatment effect parameter for true outcome without adjustment 
for the surrogate; 𝜃1𝑖  and 𝜃2𝑖  are treatment and surrogate parameters for the model 
which adjusts for the surrogate. The difference in the amount of information on the 
true outcome gained from the surrogate is calculated via the difference in the log-
likelihood between 5.1 and 5.2, which is formally expressed as 𝐺𝑖
2, for each trial i. 𝐿0 
is always the log-likelihood for the unsaturated model, in this case 5.1, and 𝐿𝐿1 for 
the saturated model, 5.2, for trial i. 𝐺𝑖
2 = 2 ∗ (𝐿𝐿1 − 𝐿𝐿0). The LRF is then 
calculated: 
𝐿𝑅𝐹 = 𝑅ℎ












2 can be interpreted as the amount of uncertainty in T that that can be explained by 
knowledge of S, for more details see section 3.3.1. 
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5.2.1 Individual level: ordinal-binary  
This methodology is extended to the case of an ordinal surrogate and binary true 
outcome. I replaced the models of 5.1 and 5.2 with two generalised linear models, for 
each trial i, as the response variable is the binary true outcome.  
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇𝑖𝑗 = 1)] = 𝜇𝑖 + 𝛽𝑖 𝑍𝑖𝑗 5.4 
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇𝑖𝑗 = 1)] = 𝜃0𝑖 + 𝜃1𝑖 𝑍𝑖𝑗 + 𝜃2𝑖 𝑆𝑖𝑗 , 5.5 
where the parameters in these models are directly comparable to those in the 
continuous setting above. In the case of discrete true outcomes the individual level 
was bounded above by a number less than one and had to be rescaled (Alonso and 
Molenberghs, 2007). This was done in exactly the same manner as the binary-ordinal 
setting, see section 3.3.2. 
5.2.1.1 Modelling the ordinal surrogate explanatory variable 
In this case the surrogate variable in 5.5 was ordinal. This could be modelled using 
one of two methods.  
The first option was to model the ordinal variable as a quantitative variable, 
assuming that the underlying scale was continuous. This would be under the 
assumption that the observed ordinal variable was linearly related to an underlying 
continuum which was in turn linearly related, in this case through the logit link, to 
the response variable (Winship and Mare, 1984). This assumption is equivalent to the 
proportional odds assumption for the ordinal response variable of the binary-ordinal 
setting. 
The alternative method was to model the ordinal variable as a factor using dummy 
variables. If there were seven categories in the ordinal outcome then six dummy 
variables were produced, each against a constrained reference category. This set up 
ignored the natural ordering of the ordinal variable and was un-parsimonious.  
When the methods are compared there appears to be more draw backs to the dummy 
variable option. The fact that it ignored the ordering of the ordinal variable would 
lead to loss of information and its un-parsimonious nature may cause a lack of 
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degrees of freedom in the case of small trial sizes. Therefore, I modelled the ordinal 
explanatory variable as an interval scale variable and assumed that it was linearly 
related to the underlying continuum.  
5.3 Trial level surrogacy: LRF reintroduction 
In order to apply the LRF at the trial level a two stage approach is required. Again I 
first describe the case where continuous outcomes are used. At the first stage, two 
linear models for each trial i are required: 
𝑆𝑖𝑗 = 𝜇𝑆𝑖 + 𝛼𝑖 𝑍𝑖𝑗 + 𝑖𝑗 5.6 
𝑇𝑖𝑗 = 𝜇𝑇𝑖 + 𝛽𝑖 𝑍𝑖𝑗 + 𝑖𝑗 5.7 
An alternative way to achieve this is by using two models which incorporate all 
trials: 
𝑆𝑖𝑗 = 𝜇𝑆𝑖 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 + 𝛼𝑖 (𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑍𝑖𝑗 ) + 𝑖𝑗 5.8 
𝑇𝑖𝑗 = 𝜇𝑇𝑖 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 + 𝛽𝑖 (𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑍𝑖𝑗 ) + 𝑖𝑗 5.9 
In either case we return two variables, 𝛼𝑖 and  𝛽𝑖, of the treatment effect estimates on 
the surrogate and true outcome respectively for each trial i. 𝜇𝑇𝑖  and 𝜇𝑆𝑖  are the 
intercepts for each trial i of the true outcome surrogate regressed on treatment 
respectively. At the second stage two further models are required: the intercept only 
model, 3.15; and treatment effect estimates of true outcome regressed on intercept 
and treatment effects of the surrogate for each trial i, 3.16. 
?̂?𝑖 = γ3 + 𝑖 5.10 
?̂?𝑖  = 𝛾0 + 𝛾1 ?̂?𝑆𝑖 + 𝛾2?̂?𝑖 + 𝑖 , 5.11 
where 𝛾0 and 𝛾3 are intercept parameters with and without adjustment for the 
surrogate; and 𝛾1 and 𝛾2 are the parameters for the surrogate intercept and treatment 
estimate variables. The difference in the 2*log-likelihood between these two models 
can then be calculated and the LRF applied as in 3.17.  
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𝐿𝑅𝐹 = 𝑅ℎ𝑡







The LRF is rescaled since it was found to be bounded above by a number less than 
one in the discrete case (Alonso and Molenberghs, 2007) this was done in exactly the 
same manner as the binary-ordinal setting, see section 3.3.2. 
5.3.1 Trial level: ordinal-binary 
In the ordinal-binary setting, the same procedure is followed as that for continuous 
outcomes. At the first stage of modelling, since we have an ordinal surrogate and a 
binary true outcome as response variables, a proportional odds model and a 
generalized linear model are required. These can again be used to calculate treatment 
effect estimates. Here I followed the approach used in the binary-ordinal setting and 
used full models incorporating all trials, in a similar manner to 5.8 and 5.9. 
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑆𝑖𝑗 ≤ 𝑣)] = 𝜇𝑆𝑣
0 + 𝜇𝑆𝑖 𝑡𝑟𝑖𝑎𝑙𝑗 + 𝛼𝑖 (𝑍𝑖𝑗 ∗ 𝑡𝑟𝑖𝑎𝑙𝑗 ) 5.13 
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇𝑖𝑗)] = 𝜇𝑇𝑖 𝑡𝑟𝑖𝑎𝑙𝑗 + 𝛽𝑖 (𝑍𝑖𝑗 ∗ 𝑡𝑟𝑖𝑎𝑙𝑗 ) 5.14 
Here, 1.14 is a proportional odds model, where, 𝑣 = 1, … , 𝑉 − 1, and 𝑉 is the 
number of categories in the ordinal surrogate. In this case 𝜇𝑆𝑣
0  are the assumed fixed 
intercept cut points relating to the ordinal variable and 𝜇𝑆𝑖  are trial specific shifts of 
the set of intercepts (Burzykowski et al., 2004). 𝜇𝑆𝑉
0  and 𝜇𝑆𝑖  are the natural parameter 
estimates one would receive from the model under the assumption of proportional 
odds for all the explanatory variables. All other parameters are the same as those 
produced in the continuous-continuous setting. 
At the second stage of modelling, models 3.15 and 3.16 can be fitted. Then the LRF 
can be calculated (using 3.17) in a similar way as for the continuous-continuous case 
(using 𝜇𝑆𝑖 , 𝛼𝑖 and 𝛽𝑖). Here, the trial specific shift of the set of intercepts, 𝜇𝑆𝑖 , can be 
used as a measure of the variability of the intercepts over trials, as advocated by 
Burzykowski et al. (2004) in the meta-analytical setting. 
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5.4 Confidence intervals: ordinal-binary  
Confidence intervals for trial and individual level surrogacy in the ordinal-binary 
setting can be applied in exactly the same manner as the binary-ordinal setting, see 
section 3.5. 
5.5 Separation: ordinal-binary 
A solution to the issue of separation is to use the penalized likelihood technique of 
Firth (1993). To see more details of this method and the issues of separation see 
section 3.6. 
The penalized likelihood technique can be applied in the ordinal-binary setting in 
much the same manner as in the binary-ordinal setting (section 3.6.4). The only 
difference is that in the ordinal-binary setting calculation of intercept variables is 
complicated. The publically available penalized likelihood technique software for 
ordinal outcomes cannot currently deal with large datasets that have hierarchical 
structures. Since this is the case, the penalized technique requires using separate 
models of surrogate and true outcome regressed on treatment for each trial i, as in 
5.15 and 5.16.   
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑆𝑖𝑗 ≤ 𝑣)] = 𝜇𝑆𝑣𝑖
 +𝛼𝑖 𝑍𝑖𝑗 5.15 
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇𝑖𝑗 = 1)] = 𝜇𝑇𝑖 + 𝛽𝑖 𝑍𝑖𝑗 , 5.16 
where, 𝑣 = 1, … , 𝑉 − 1. 
These separate models are equivalent to 5.6 and 5.7 in the continuous-continuous 
setting. In this case, the proportional odds model of the separate models (5.15) would 
return a separate intercept parameter for each cut-point of the ordinal outcome 
variable for each trial, 𝜇𝑆𝑣𝑖
 . All other parameters are equivalent to those in the 
models of the continuous setting (5.6 and 5.7). The use of such a set of variables is 
also suggested by Burzykowski et al. (2004) in the meta-analytical context. In the 
information theory context, the second stage model 3.16 can be replaced with the 
following model, using all the surrogate intercept variables of 5.15. 
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?̂?𝑖  = 𝜌0 + 𝜌1 ?̂?𝑆1𝑖
+ 𝜌2?̂?𝑆2𝑖
+ ⋯ + 𝜌𝑉 −1?̂?𝑆𝑉−1𝑖
+ 𝜌𝑆?̂?𝑖 + 𝑖 5.17 
Here, ?̂?𝑆1𝑖
 , … , ?̂?𝑆𝑉−1𝑖
 are the intercept estimates for each cut point modelled along 
with a treatment effects estimate variable, ?̂?𝑖. 𝜌0 , 𝜌1,.. , 𝜌𝑉−1, 𝜌𝑆  are their 
corresponding parameter estimates respectively.  
However, when there are only a few trials this model would lead to overfitting. In the 
case of only five trials, an ordinal variable with three categories and two cut-points 
leads to a model based on 5.17 with three explanatory variables; two intercept 
variables, ?̂?𝑆1𝑖
  and ?̂?𝑆2𝑖
 , and treatment, ?̂?𝑖. This model would be based on five 
observations (the treatment estimates for the five trials) and result in issues of lack of 
degrees of freedom.  
One way to resolve this would be to calculate the mean intercept value for each trial 
over all cut-points. This would provide one estimate of the intercept for each trial, 
𝜇̅𝑆𝑉𝑖
 ̂ . Then stage two models of trial level surrogacy would become: 
?̂?𝑖 = γ3 + 𝑖 5.18 
?̂?𝑖  = 𝛾0 + 𝛾1𝜇̅𝑆𝑉𝑖
 ̂ + 𝛾2?̂?𝑖 + 𝑖 , 5.19 
where parameters are defined in the same manner as in the continuous case, see 
equations 3.15 and 3.16. The LRF could be applied to these models using 3.17 in the 
same manner as in the continuous-continuous case.  
5.6 Conclusions: ordinal-binary 
I have extended the information theory approach to the case of an ordinal surrogate 
and binary true outcome.  
In addition to the theory discussed in the binary-ordinal setting, this has included: a 
discussion of the best way to model an ordinal surrogate explanatory variable for the 
models at the individual level; using a trial specific shift variable for calculating 
intercept estimates for use in trial level surrogacy; and a mean intercept variable to 
  Evaluation of surrogate outcomes 
Methodology: Ordinal-binary setting 120 
do the same when separation occurs as the trial specific shift variable cannot be 
produced.  
The trial specific shift method is more in keeping with the method used in other 
settings to represent intercept variations across trials than the mean intercept method. 
However, the mean intercept method was expected to return comparable results.
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Chapter 6. Simulation study: for an ordinal 
surrogate and binary true outcome 
In the previous chapter I discussed how the information theoretic measures 𝑅ℎ
2 and 
𝑅ℎ𝑡
2  for surrogate evaluation can be extended to the case of an ordinal surrogate and 
binary true outcome. In this chapter, I present a simulation study conducted to 
investigate the behaviour of these measures in the ordinal-binary setting under 
various scenarios. 
I outline the setup of the simulation study, various practical considerations and 
present simulation results for both 𝑅ℎ
2 and 𝑅ℎ𝑡
2 . 
As in previous chapters: S denotes a surrogate; T a true outcome; Z treatment; with 
i=1,..,N trials and j=1,..,𝑛𝑖 patients per trial. 
6.1 Simulation study: set up 
In the binary-ordinal setting I investigated approaches used in simulation studies for 
surrogate evaluation, see section 4.1.1.1. I concluded that the one presented by 
Burzykowski et al. (2005) would be best for my purposes. I adopted this set up for 
the simulation in the ordinal-binary setting.  
First, a continuous S and T were simulated using a joint mixed model. Then these 
variables were categorised into an ordinal S and a binary T in the same manner as in 
the binary-ordinal setting only on the opposite outcomes. This will be further 
discussed in section 6.1.1. 
The models used to simulate the study in the ordinal-binary setting were exactly the 
same as in the binary-ordinal setting. For details, see section 4.1.2. 
The scenarios investigated in the simulation for the binary-ordinal setting are shown 
in Table 6.1. These included: 
 varying the number and size of trials;  
 varying the strength of surrogacy at the trial and individual levels;  
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 differing the strength of surrogacy at the trial and individual levels;  
 examining both proportional and non-proportional odds in the ordinal 
surrogate outcome at the trial level;  
 and examining linear and non-linear relationships in outcomes at the 
individual level.  
The investigation of the assumptions (proportional odds and linear relationship) 
tested in the ordinal-binary setting were slightly different to those in the binary-
ordinal setting. These scenarios will be discussed in section 6.1.2. 
Factor varied under 
simulation study  
Levels of factor  
  
Number of trials  5, 10, 20 or 30  
Number of patients per trial  
 
Small trial size  
Large trial size  
 
 
10, 20, 40 or 60  
100, 150, 200 or 300  
True surrogacy strength  𝑅ℎ
2=1, 0.64 or 0.30 and 
𝑅ℎ𝑡
2 =0.90 or 0.30 







both strong or both weak 
 
𝑅ℎ




2= 0.30 & 𝑅ℎ𝑡
2 =0.30 
 Disagree  
one weak one strong 
 
𝑅ℎ




2= 0.30 & 𝑅ℎ𝑡
2 =0.90 
Trial level: 














Table 6.1: Scenarios investigated in the binary-ordinal simulation. 
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In each scenario 250 simulations were conducted. The median 𝑅2 values from the 
250 simulations for each scenario are presented in the results section. This is to give 
some idea of the bias in the 𝑅2 estimates. The variance of 𝑅2 estimates in the 250 
simulations are also presented to assess precision. In each scenario, the median lower 
and upper confidence bounds were determined, over the 250 individual confidence 
intervals for each simulated dataset. These give an indication of how well the 
confidence intervals perform under each scenario.  
The practical set-up of the simulation was the same as the binary-ordinal setting in 
terms of the coding, saving and reported output, see section 4.1.3.3. A few aspects of 
the simulation differed in the ordinal-binary to the binary-ordinal setting or should be 
reintroduced. These are discussed below. 
6.1.1 Loss of information 
6.1.1.1 Loss of information: individual level 
As in the binary-ordinal setting, the ordinal-binary setting was impacted by loss of 
information. This occurred because the simulated continuous S and T were 
categorised into discrete variables. This scenario was reflective of real life where 
discrete variables may represent underlying continua and therefore this setup was 
appropriate (see section 4.1.3.1 for more information).  
As in the binary-ordinal setting we cannot determine the true strength of surrogacy in 
the observed ordinal-binary setting where this was set to a certain strength at the 
underlying continuous setting. See section 4.1.3.3.1 for more information. 
To determine the ceiling in the ordinal-binary setting a third scenario was added to 
the simulation. Setting surrogacy to be ‘perfect’ (i.e. 𝑅ℎ
2 = 1) in the underlying 
continuous-continuous setting enabled me to determine empirically the highest value 
a surrogate could possibly take in the observed ordinal-binary setting. 
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6.1.1.2 Loss of information: trial level 
Loss of information impacted trial level surrogacy in the binary-ordinal setting 
despite the fact that theoretically this should not occur, see section 4.2.2.1 for a 
discussion of this topic. 
Theoretically, the two stage nature of the approach effectively split a large 
computationally difficult problem into separate components which were then solved 
individually. The solutions to each component were brought together to give an 
overall result for the whole problem. The splitting of the problem combined with loss 
of information due to categorisation has been shown to lead to loss of efficiency, 
(Molenberghs et al., 2011), (Taylor and Yu, 2002) and (Taylor et al., 2006). 
Theoretically, this loss of efficiency worsens as the number of components (trials) 
the problem is split into increases. This loss of efficiency should theoretically 
improve if the corresponding size of the components is large, the reasoning for this 
was thoroughly explained in section 4.2.2.1.2. 
6.1.2 Assumptions 
6.1.2.1 Proportional odds assumption: trial level 
At the first stage of trial level surrogacy evaluation, a proportional odds model for 
the ordinal surrogate was applied, see section 5.3.1. Therefore, it was appropriate to 
assess whether deviations from the proportional odds assumption of the ordinal 
surrogate impacted results. 
In the simulation study proportional odds were simulated in exactly the same manner 
as in the binary-ordinal setting, see section 4.1.3. As in the binary-ordinal setting, 
diversions from the proportional odds assumption were investigated by differing the 
categorisation of treatment groups. One treatment group had ordinal cut points based 
on the proportional odds scenario, see Table 6.2 column one. The other treatment 
group followed this rule for five of the categories but deviated for two, where one 
group was based on a much larger range of quantiles than the other, see Table 6.2 
column two. This was based on the setup of the simulation for the binary-ordinal 
setting, see section 4.1.3.2. 
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To investigate the median simulated true surrogate proportional and non-proportional 
odds ratios at each cut point of the ordinal surrogate see Table 6.3, this simulation 
was conducted in the same was as for the true outcome in the binary-ordinal setting 
see section 4.1.3.2. These simulated median odds ratios demonstrate that in the 
proportional odds setting the odds are indeed proportional at each cut point of the 
ordinal surrogate, and in the non-proportional odds setting the odds are proportional 
at all but one of the cut point as anticipated. 
 Column 1 
Treatment group one 
Column 2 






in quantiles  
Quantiles continuous Difference in 
quantiles 
     
1 ≤0.143 0.143 ≤0.25 0.25 
2 0.143-0.286 0.143 0.25-0.286 0.036 
3 0.286-0.429 0.143 0.286-0.429 0.143 
4 0.429-0.571 0.143 0.429-0.571 0.143 
5 0.571-0.714 0.143 0.571-0.714 0.143 
6 0.714-0.857 0.143 0.714-0.857 0.143 
7 ≥0.857 0.143 ≥0.857 0.143 
     
Table 6.2: Set up of non-proportional odds scenario. 






   
1  0.9749 0.4926 
2  0.9637  0.9892 
3  0.9635  0.9776 
4  0.9652  0.9767 
5  0.9700  0.9785 
6  0.9574 0.9749 
   
Table 6.3: Simulated odds were based on 1000 runs of the study set up with 30 trials, 
300 patients, and strong surrogacy at both levels, the median odds ratios over all 
simulated cases are given for each cut point. 
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6.1.2.2 Proportional odds assumption: individual level 
In the ordinal-binary setting at the individual level, the models for assessing 
surrogacy were based on generalised linear models for the binary response variable 
true outcome, see section 5.2.1. Unlike in the binary-ordinal setting, no proportional 
odds models were used, therefore it was not necessary to investigate the non-
proportional odds assumption for individual level surrogacy.  
6.1.2.3 Linear relationship assumption: individual level 
As discussed in section 5.2.1.1, one of the models of individual level surrogacy 
incorporated the ordinal surrogate as a quantitative explanatory variable. This is 
under the assumption that the observed ordinal variable is linearly related to an 
underlying continuum which is linearly related, in this case through the logit link, to 
the response variable (Winship and Mare, 1984). This is the equivalent assumption to 
the proportional odds assumption for an ordinal explanatory variable. Therefore, I 
used the non-proportional coding to test this assumption: a justification of this 
statement follows. 
In the simulation, a simulated continuous S was linearly related to the continuous T 
(the response variable). However, if S was categorised using the setup for the non-
proportional scenario, two of the categories of the ordinal S would not be linearly 
related to the simulated continuous S. Therefore, this assumption would be invalid. 
Hence, I used the coding of the non-proportional odds scenario to investigate the 
linear relationship assumption imposed on models at the individual level. 
6.1.3 Trial level: separation 
Separation is a common occurrence for discrete outcomes and under the information 
theory approach leads to severe bias at the trial level, see section 3.6. Two techniques 
were compared to assess the best for dealing with separation: 1) the penalized 
likelihood technique; and 2) the technique which removed trials where separation 
occurred from analysis. 
The calculation of the trial specific intercept values for use in stage two models is 
more complicated in the ordinal-binary compared to the binary-ordinal setting. This 
  Evaluation of surrogate outcomes 
Simulation: Ordinal-binary setting 127 
is because of the measures returned from models based on ordinal response variables 
(in this case the surrogate), see section 5.3.1. In the case of the penalized likelihood 
technique a ‘mean intercept’ method was adopted. The trial removal technique uses a 
‘trial specific shift’ method, this method is more in keeping with the approach used 
in the binary-ordinal setting. Comparison of the penalized likelihood and trial 
removal techniques served as an indicator of how well the intercept methods worked. 
6.1.4 Set up: conclusions 
The setup of the simulation in the ordinal-binary setting has been outlined. This was 
similar to that of the binary-ordinal setting. Except that the proportional odds 
assumption was not applied at the individual level and the equivalent linear 
relationship assumption was required. Additionally, calculation of intercept variables 
was more complicated in the ordinal-binary setting; results were examined to identify 
if any issues arose as a result of this. 
6.2 Simulation study: results  
In this section results of the simulation study for the individual level and then the 
trial level surrogacy is presented. Various issues and biases in the results are outlined 
in Table 6.4. 
Issues of loss of information (at the individual level), underestimation and separation 
(at the trial level) highlighted in rows one, two and four of Table 6.4, respectively 
have been discussed earlier in this Chapter, see sections 4.1.3.3.1, 4.2.2.1.2 and 
4.2.2.2.1. The problem of overestimation, also shown in row three of this table, was 
discussed for the binary-ordinal setting in section 4.2.2.2. Issues described in Table 
6.4 are present in the results of the ordinal-binary setting and will be discussed 
further in the sections indicated in Table 6.4. Some of these issues conflict with each 
other making description of results complicated. Therefore, this table should be 
considered to aid understanding. 
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 Issue Scenarios affected Reason Discussed in 
section(s): 





lower than true 
value 






























Separation All scenarios Zero cells in 
trial crosstabs 
Resolved 





     
Table 6.4: Issues present in simulation study results. 
Preliminary findings prompted the secondary investigations of interest on: 
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 the ceiling in 𝑅ℎ
2;  
 and the benefit of the penalized likelihood technique for 𝑅ℎ𝑡
2  when separation 
occurs. 
The following summary results are given: the median 𝑅 
2 for a given scenario; the 
IQRs of 𝑅 
2 the 100% coverage of the confidence intervals and their median upper 
and lower bounds for each scenario. The tables in the remainder of this chapter show 
results for a subsection of the trial sizes investigated. Unless otherwise stated, results 
for scenarios not included in tables were consistent with those shown. Full tables for 
every setting are provided in Appendix B.  
6.2.1  Results: individual level surrogacy 
Results for the individual level surrogacy are described in this section. I describe the 
following scenarios:  
 where surrogacy was set to be strong at both trial and individual level; 
 where this was weak;  
 where the strength of surrogacy differed at trial and individual levels;  
 where there were deviations from the linear relationship assumption. 
I also present the results of the ceiling investigation and compare these to the binary-
ordinal setting. 
6.2.1.1 Individual level surrogacy R2h: strong surrogacy 
Surrogacy was set to be strong at both levels, 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90, in the 
underlying continuous setting. As previously mentioned, see section 6.1.1.1, loss of 
information means that the observed results for the ordinal-binary setting were 
expected to be lower than in the underlying continuum. 
The results in Table 6.5 show that as the number and sizes of trials increased the 
value of surrogacy in the observed ordinal-binary setting converged to around 0.39. 
The impact of trial size was greater than that off number of trials, however all values 
returned were close to 0.39. The IQRs of  𝑅ℎ
2 were much narrower as the number and 
size of trials increased. The coverage of the confidence intervals was 100% in nearly 
all scenarios. The median confidence intervals covered nearly the whole parameter 
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𝟐  IQR  
𝑹𝒉






CI upper  
 
       
5 10 0.452 0.177 100% 0.051 0.999 
5 60 0.410 0.106 100% 0.168 0.687 
5 100 0.414 0.096 100% 0.214 0.631 
5 300 0.405 0.068 98% 0.287 0.531 
       
10 10 0.446 0.140 100% 0.054 0.989 
10 60 0.399 0.076 100% 0.164 0.674 
10 100 0.395 0.058 100% 0.204 0.610 
10 300 0.397 0.054 100% 0.279 0.522 
       
20 10 0.420 0.104 100% 0.049 0.964 
20 60 0.396 0.058 100% 0.165 0.667 
20 100 0.393 0.045 100% 0.205 0.607 
20 300 0.393 0.037 100% 0.277 0.517 
       
30 10 0.424 0.074 100% 0.051 0.964 
30 60 0.397 0.040 100% 0.163 0.669 
30 100 0.393 0.033 100% 0.203 0.605 
30 300 0.389 0.033 100% 0.273 0.513 
       
Table 6.5: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2 =0.64 and 𝑅ℎ𝑡
2  =0.90. 
6.2.1.2 Individual level surrogacy R2h: weak surrogacy 
The findings for strong surrogacy were mirrored in the case of weak surrogacy, 
where surrogacy was set to 𝑅ℎ
2 =0.30 and 𝑅ℎ𝑡
2 =0.30 in the underlying continuous 
setting. 
The results in Table 6.6 show that as the number and size of trials increased the value 
of surrogacy in the observed ordinal-binary setting converged to about 0.17. The 
impact of trial sizes was much greater than that off the number of trials. In the case 
of small trial sizes, estimates were as large as 0.282.   
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𝟐  IQR  
𝑹𝒉






CI upper  
        
5 10 0.296 0.184 100% 0.017 0.868 
5 60 0.195 0.069 100% 0.040 0.445 
5 100 0.182 0.055 100% 0.054 0.375 
5 300 0.181 0.038 100% 0.095 0.287 
       
10 10 0.266 0.115 100% 0.019 0.851 
10 60 0.187 0.048 100% 0.038 0.434 
10 100 0.180 0.039 100% 0.054 0.368 
10 300 0.173 0.030 100% 0.090 0.278 
       
20 10 0.279 0.081 100% 0.023 0.855 
20 60 0.182 0.030 100% 0.038 0.429 
20 100 0.177 0.033 100% 0.053 0.362 
20 300 0.175 0.019 100% 0.092 0.280 
       
30 10 0.280 0.067 100% 0.022 0.854 
30 60 0.184 0.026 100% 0.039 0.428 
30 100 0.179 0.024 100% 0.054 0.366 
30 300 0.172 0.017 100% 0.089 0.275 
       
Table 6.6: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2 =0.30 and 𝑅ℎ𝑡
2  =0.30. 
6.2.1.3 Individual level surrogacy R2h: differing strengths of surrogacy 
The results of 𝑅ℎ
2 for discordant strengths of surrogacy were much the same as those 
for agreement in surrogacy strength, see Table 6.7. Those for discordant strengths 
were marginally lower than for agreement. The coverages and the IQRs were much 
the same. 
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5 10 0.452 0.177 100% 0.443 0.206 100% 
5 60 0.410 0.106 100% 0.415 0.088 100% 
5 100 0.414 0.096 100% 0.409 0.089 100% 
5 300 0.405 0.068 98% 0.403 0.073 96% 
        
10 10 0.446 0.140 100% 0.433 0.138 100% 
10 60 0.399 0.076 100% 0.405 0.072 100% 
10 100 0.395 0.058 100% 0.397 0.056 100% 
10 300 0.397 0.054 100% 0.388 0.055 100% 
        
20 10 0.420 0.104 100% 0.429 0.087 100% 
20 60 0.396 0.058 100% 0.400 0.044 100% 
20 100 0.393 0.045 100% 0.389 0.047 100% 
20 300 0.393 0.037 100% 0.389 0.038 100% 
        
30 10 0.424 0.074 100% 0.425 0.079 100% 
30 60 0.397 0.040 100% 0.395 0.042 100% 
30 100 0.393 0.033 100% 0.393 0.034 100% 
30 300 0.389 0.033 100% 0.384 0.031 100% 
        
Table 6.7: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2 =0.64 and 𝑅ℎ𝑡
2  =0.90 or 0.30. 
6.2.1.4 Individual level surrogacy R2h: linear relationship assumption 
There was very little impact of the divergence from the linear relationship 
assumption on estimates of surrogacy at the individual level, see Table 6.8. The 
results where the linearity assumption was not valid were uniformly slightly lower 
than those where the assumption held, regardless of the number or size of trials. 
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5 10 0.452 0.177 100% 0.449 0.204 100% 
5 60 0.410 0.106 100% 0.416 0.097 100% 
5 100 0.414 0.096 100% 0.406 0.081 100% 
5 300 0.405 0.068 98% 0.399 0.070 97% 
        
10 10 0.446 0.140 100% 0.437 0.158 100% 
10 60 0.399 0.076 100% 0.398 0.067 100% 
10 100 0.395 0.058 100% 0.403 0.060 100% 
10 300 0.397 0.054 100% 0.391 0.048 100% 
        
20 10 0.420 0.104 100% 0.414 0.102 100% 
20 60 0.396 0.058 100% 0.392 0.052 100% 
20 100 0.393 0.045 100% 0.390 0.044 100% 
20 300 0.393 0.037 100% 0.383 0.043 100% 
        
30 10 0.424 0.074 100% 0.423 0.076 100% 
30 60 0.397 0.040 100% 0.393 0.038 100% 
30 100 0.393 0.033 100% 0.386 0.036 100% 
30 300 0.389 0.033 100% 0.382 0.028 100% 
        
Table 6.8: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2 =0.64 and 𝑅ℎ𝑡
2  =0.90.. Comparing results for 
non-linear relationship scenario. 
6.2.1.5 Individual level surrogacy R2h: ceiling effect 
The results showed that the strength of individual level surrogacy in the ordinal-
binary setting compared to the underlying continuum was much lower due to loss of 
information. I investigated 𝑅ℎ
2 results in the observed ordinal-binary setting when the 
strength of surrogacy was ‘perfect’ at the individual level in the underlying 
continuous setting. This was done to see if there was a ceiling on surrogacy strength 
in the ordinal-binary setting. 
As can be seen in Table 6.9 the value of surrogacy of the observed ordinal surrogate 
converges to around 0.70 as numbers and sizes of trials increases. In the case of 
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perfect surrogacy at the underlying continuum, this suggests that the strongest an 






𝟐  IQR  
𝑹𝒉







       
5 10 0.620 0.220 100% 0.107 1 
5 60 0.733 0.140 97% 0.461 0.969 
5 100 0.726 0.136 96% 0.516 0.916 
5 300 0.733 0.135 75% 0.611 0.847 
       
10 10 0.615 0.133 100% 0.113 1 
10 60 0.723 0.098 100% 0.460 0.955 
10 100 0.718 0.088 99% 0.510 0.904 
10 300 0.717 0.096 90% 0.596 0.828 
       
20 10 0.603 0.093 100% 0.108 1 
20 60 0.704 0.066 100% 0.441 0.937 
20 100 0.707 0.071 100% 0.502 0.891 
20 300 0.707 0.071 100% 0.586 0.819 
       
30 10 0.595 0.078 100% 0.107 1 
30 60 0.697 0.053 100% 0.436 0.932 
30 100 0.701 0.049 100% 0.496 0.887 
30 300 0.704 0.054 100% 0.587 0.816 
       
Table 6.9 Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2=1 and 𝑅ℎ𝑡
2 =0.90. 
As in the binary-ordinal setting the confidence intervals for the case of ‘perfect’ 
surrogacy seem to be behaving differently to previous scenarios, see section 4.2.1.5. 
As in the binary-ordinal setting the scenario of ‘perfect’ surrogacy presented here is a 
very particular case of surrogacy that is unlikely to be seen in practice. 
6.2.1.6 Individual level surrogacy R2h: comparison to binary-ordinal 
setting 
Since one outcome was dichotomised and one categorised in both the binary-ordinal 
and ordinal-binary settings one might have expected to see similar ceiling results. 
However, the ceiling in the ordinal-binary setting was much higher, around 0.70, 
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than in the binary-ordinal setting, around 0.47. Observed results for all strengths of 
surrogacy at the individual level were lower for the binary-ordinal setting. 
Surrogacy reflects the amount of information on the true outcome that can be 
provided by the surrogate. Therefore, it makes sense that, the amount of information 
retained in the surrogate was most pertinent to the level of the ceiling. The ceiling 
was lowest when the surrogate was binary (i.e. where more information was removed 
from the underlying continuum compared to an ordinal outcome). This is regardless 
of the fact that the ordinal-binary setting had a binary true outcome.  
6.2.1.7 Individual level surrogacy R2h: conclusions  
𝑅ℎ
2 estimates converged to around 0.39 when this was set to 0.64 at the underlying 
continuum, and 0.17 where this was set to 0.30 at the underlying continuum. Smaller 
trials gave larger 𝑅ℎ
2 estimates and wider IQRs. The number of trials had limited 
impact. Differing strengths of surrogacy at trial and individual levels and non-
adherence to the linear relationship assumption had little impact on 𝑅ℎ
2 estimation.  
The coverages of the confidence intervals were 100% in nearly all scenarios, that are 
likely to be seen in practice, suggesting these are conservative. Although, the median 
confidence interval results suggest the intervals were sensible and by no means 
covered the whole parameter space. 
The median 𝑅ℎ
2 value converged to about 0.70 where surrogacy was set to one in the 
underlying continuous-continuous setting. This corresponds to a large loss of 
information. This ceiling effect was much higher than that observed in the binary-
ordinal setting.  
6.2.2 Results: trial level surrogacy 
In this setting I describe the results at the trial level: 
 where surrogacy was strong at both the trial and individual levels;  
 where surrogacy was weak at both levels;  
 where the strength of surrogacy disagreed at trial and individual levels;  
 where non-proportional odds of the ordinal surrogate were present.  
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 Finally, I compare the penalised likelihood technique to deal with separation 
to the technique where trials with separation were removed from analysis.  
 
The underestimation and overestimation issues presented in Table 6.4 affected the 
results at the trial level.  
6.2.2.1 Trial level surrogacy R2ht: strong surrogacy 
In Table 6.10, the results for trial level surrogacy when surrogacy was strong at both 
trial and individual levels and 𝑅ℎ𝑡






𝟐  IQR  
𝑹𝒉𝒕






CI upper  
 
       
5 10 0.760 0.376 92% 0.097 0.986 
5 60 0.907 0.165 95% 0.358 0.997 
5 100 0.923 0.172 94% 0.408 0.998 
5 300 0.944 0.116 93% 0.489 0.999 
       
10 10 0.588 0.324 55% 0.097 0.913 
10 60 0.823 0.188 92% 0.385 0.976 
10 100 0.860 0.143 93% 0.457 0.983 
10 300 0.888 0.104 98% 0.523 0.988 
       
20 10 0.487 0.204 14% 0.133 0.793 
20 60 0.771 0.142 75% 0.452 0.935 
20 100 0.820 0.111 89% 0.531 0.953 
20 300 0.862 0.077 97% 0.610 0.967 
       
30 10 0.480 0.197 3% 0.184 0.744 
30 60 0.760 0.103 61% 0.503 0.910 
30 100 0.798 0.081 80% 0.560 0.928 
30 300 0.854 0.071 96% 0.653 0.952 
       
Table 6.10: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, in the binary-ordinal setting where true values set to: 𝑅ℎ
2 =0.64 and 
𝑅ℎ𝑡
2  =0.90. 
Estimation improved as the size of trials increased. Results showed overestimation 
for data sets containing five trials. However, as the number of trials increased they 
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began to show underestimation. This was worst for the largest trial scenario of 30 
trials; for example, the median 𝑅ℎ𝑡
2 =0.859for 300 patients (0.90 was expected). The 
IQRs of 𝑅ℎ𝑡
2  and coverage of confidence intervals improved as size and numbers of 
trials increased. However, the coverage was very poor for smaller numbers of 
patients per trial which worsened as the number of trials increased, this was probably 
due to the relative bias in 𝑅ℎ𝑡
2 results for these scenarios. 
6.2.2.1.1 Strong surrogacy: comparison to continuous-continuous setting 
In Table 6.11, the results of strong surrogacy for the ordinal-binary scenario 
compared to the underlying continuous-continuous setting are presented. The 
underestimation witnessed in the ordinal-binary setting was not present at the 
underlying continuum when larger numbers of patients per trial were available 
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2   IQR 𝑅ℎ𝑡
2  𝑅ℎ𝑡
2   IQR 𝑅ℎ𝑡
2  
      
5 10 0.760 0.376 0.931 0.165 
5 60 0.907 0.165 0.950 0.103 
5 100 0.923 0.172 0.953 0.095 
5 300 0.944 0.116 0.959 0.069 
      
10 10 0.588 0.324 0.840 0.137 




0.860 0.143 0.916 0.072 
10 300 0.888 0.104 0.919 0.068 
      
20 10 0.487 0.204 0.835 0.100 
20 60 0.771 0.142 0.900 0.065 
20 100 0.820 0.111 0.902 0.054 
20 300 0.862 0.077 0.910 0.058 
      
30 10 0.480 0.197 0.826 0.078 
30 60 0.760 0.103 0.895 0.053 
30 100 0.798 0.081 0.900 0.050 
30 300 0.854 0.071 0.902 0.054 
      
Table 6.11: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, in binary-ordinal and continuous-continuous setting where true 
values set to:  𝑅ℎ
2 =0.64 and 𝑅ℎ𝑡
2  =0.90. 
6.2.2.1.2 Underestimation R2ht: strong surrogacy 
I outlined that categorising S and T into binary and ordinal outcomes led to loss of 
efficiency in calculating results at the trial level in section 6.1.1.2.   
Proof of this theory of inefficiency was obtained by considering an additional 
scenario in the simulation study. Consider Table 6.12, 3000 patient scenarios for 
each trial size are presented. These results are much closer to the true strength of 
surrogacy and indicate that it was indeed inefficiency that caused the underestimation 
in results. 
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2   IQR 
𝑅ℎ𝑡
2  
    
5 3000 0.956 0.071 
10 3000 0.920 0.050 
20 3000 0.891 0.035 
30 3000 0.883 0.024 
    
Table 6.12 Additional simulation scenarios: Median 𝑅ℎ𝑡
2  estimates based on 250 
simulations for each scenario, where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 and trial size was 3000. 
6.2.2.1.3 Overestimation R2ht: strong surrogacy 
There was some evidence of overestimation in Table 6.10 for small number of trials. 
This issue was referenced in row three of Table 6.4 and will be discussed in section 
6.2.2.2.2. 
6.2.2.2 Trial level surrogacy R2ht: weak surrogacy 
Here I discuss the case where surrogacy was weak at both levels, 𝑅ℎ
2 = 𝑅ℎ𝑡
2 =0.30. 
The results showed that as the number of trials decreased, overestimation worsened, 
see Table 6.13. Where there were five trials and 300 patients’, trial level surrogacy 
was 0.663, indicating a moderately good surrogate in contrast to the true strength of 
surrogacy of 0.30. The IQRs were wider than the strong surrogacy scenario, for 
comparison see Table 6.11, but still showed improvement as the number and size of 
trials increased. Confidence intervals showed better coverage as the number of trials 
increased but did not differ greatly by increased trial size. 
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𝟐   IQR 𝑹𝒉𝒕





CI upper  
 
       
5 10 0.619 0.431 84% 0.021 0.968 
5 60 0.596 0.503 80% 0.016 0.965 
5 100 0.672 0.506 83% 0.038 0.976 
5 300 0.666 0.391 80% 0.036 0.975 
       
10 10 0.285 0.350 96% 0.000 0.763 
10 60 0.385 0.353 98% 0.011 0.823 
10 100 0.399 0.357 95% 0.013 0.831 
10 300 0.424 0.326 97% 0.019 0.844 
       
20 10 0.225 0.232 94% 0.007 0.589 
20 60 0.314 0.198 96% 0.030 0.669 
20 100 0.324 0.271 98% 0.035 0.678 
20 300 0.284 0.249 96% 0.020 0.644 
       
30 10 0.196 0.155 90% 0.012 0.495 
30 60 0.285 0.173 95% 0.048 0.584 
30 100 0.297 0.199 98% 0.054 0.596 
30 300 0.321 0.190 96% 0.068 0.618 
       
Table 6.13: Simulation study: median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, in the binary-ordinal setting where true values set to: 𝑅ℎ
2 =0.30 and 
𝑅ℎ𝑡
2  =0.30. 
6.2.2.2.1 Comparison to underlying continuous-continuous setting: weak 
surrogacy 
Results for the ordinal-binary setting were compared to the underlying continuous-
continuous setting, shown in Table 6.14. The pattern of overestimation was 
consistent at both the observed ordinal-binary and underlying continuous-continuous 
settings. Results in the continuous-continuous setting showed overestimation in 
every setting. However, results for the ordinal-binary setting were consistently lower 
than the underlying continuous-continuous setting, the difference being greater for 
smaller trial sizes. 
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2  IQR 𝑅ℎ𝑡
2  𝑅ℎ𝑡
2  IQR 𝑅ℎ𝑡
2  
      
5 10 0.619 0.431 0.600 0.453 
5 60 0.596 0.503 0.659 0.399 
5 100 0.672 0.506 0.676 0.539 
5 300 0.666 0.391 0.683 0.440 
      
10 10 0.285 0.350 0.438 0.298 
10 60 0.385 0.353 0.446 0.347 
10 100 0.399 0.357 0.402 0.376 
10 300 0.424 0.326 0.429 0.324 
      
20 10 0.225 0.232 0.349 0.212 
20 60 0.314 0.198 0.353 0.199 
20 100 0.324 0.271 0.327 0.213 
20 300 0.284 0.249 0.355 0.222 
      
30 10 0.196 0.155 0.326 0.172 
30 60 0.285 0.173 0.329 0.179 
30 100 0.297 0.199 0.358 0.210 
30 300 0.321 0.190 0.336 0.204 
      
Table 6.14: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for each scenario, in 
continuous-continuous setting where true values set to: 𝑅ℎ
2 =0.30 and 𝑅ℎ𝑡
2  =0.30. 
6.2.2.2.2 Overestimation R2ht: weak surrogacy 
The overestimation witnessed in both the observed ordinal-binary and underlying 
continuous-continuous settings occurred because of overfitting in second stage 
models where the number of trials was small. The reason for this was thoroughly 
discussed in the binary-ordinal setting in section 4.2.2.2.1.  
6.2.2.2.3 Underestimation R2ht: weak surrogacy 
There was also evidence of underestimation when surrogacy was weak. Notice that 
the results in the ordinal-binary setting were consistently lower than in the 
underlying continuous-continuous setting. This was more noticeable as the size of 
trials decreased. The reason for this was again because of inefficiency due to loss of 
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information and a two stage approach as described in section 6.2.2.1 also see Table 
6.4. 
6.2.2.3 Trial level surrogacy R2ht: differing strengths of surrogacy 
𝑅ℎ𝑡
2  estimation was little affected where there was strong surrogacy at the trial level 
but weak surrogacy at the individual level compared to where this was strong at both 
levels, see Table 6.15. The estimates were lower for the discordant strengths scenario 
when there were few patients per trial. Confidence interval coverages were also 
poorer. Similar discrepant results were found when surrogacy was strong at the 
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5 10 0.760 0.376 92% 0.703 0.335 89% 
5 60 0.907 0.165 95% 0.895 0.187 94% 
5 100 0.923 0.172 94% 0.920 0.171 98% 
5 300 0.944 0.116 93% 0.947 0.112 95% 
        
10 10 0.588 0.324 55% 0.504 0.367 44% 
10 60 0.823 0.188 92% 0.789 0.195 86% 
10 100 0.860 0.143 93% 0.837 0.154 94% 
10 300 0.888 0.104 98% 0.881 0.101 98% 
        
20 10 0.487 0.204 14% 0.436 0.235 4% 
20 60 0.771 0.142 75% 0.746 0.129 71% 
20 100 0.820 0.111 89% 0.790 0.126 85% 
20 300 0.862 0.077 97% 0.864 0.084 95% 
        
30 10 0.480 0.197 3% 0.388 0.221 1% 
30 60 0.760 0.103 61% 0.725 0.118 46% 
30 100 0.798 0.081 80% 0.790 0.102 72% 
30 300 0.854 0.071 96% 0.851 0.079 92% 
        
Table 6.15: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, where true values set to: 𝑅ℎ𝑡
2  =0.90 and 𝑅ℎ
2 =0.64 or 0.30. 
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6.2.2.4 Trial level surrogacy R2ht: non-proportional odds 
Slight differences in the estimates of surrogacy at the trial level were observed due to 
the divergence from the proportional odds assumption, see Table 6.16. 𝑅ℎ𝑡
2  estimates 
were marginally lower when the odds were not proportional and trial sizes were large 
and marginally larger where trial sizes were small, however these differences were 
minor. The results did not vary according to the number of trials and the coverage of 





Proportional Non proportional 
 
  𝑅ℎ𝑡
2   
=0.90            
IQR 𝑅ℎ𝑡
2  % cover 
CIs 
𝑅ℎ𝑡
2   
=0.90             
IQR 𝑅ℎ𝑡
2  % cover 
CIs 
        
5 10 0.760 0.376 92% 0.758 0.401 85% 
5 60 0.907 0.165 95% 0.905 0.185 94% 
5 100 0.923 0.172 94% 0.925 0.149 96% 
5 300 0.944 0.116 93% 0.931 0.111 96% 
        
10 10 0.588 0.324 55% 0.562 0.299 52% 
10 60 0.823 0.188 92% 0.808 0.202 90% 
10 100 0.860 0.143 93% 0.828 0.150 94% 
10 300 0.888 0.104 98% 0.885 0.099 99% 
        
20 10 0.487 0.204 14% 0.505 0.196 11% 
20 60 0.771 0.142 75% 0.756 0.156 70% 
20 100 0.820 0.111 89% 0.805 0.131 83% 
20 300 0.862 0.077 97% 0.859 0.088 96% 
        
30 10 0.480 0.197 3% 0.495 0.195 2% 
30 60 0.760 0.103 61% 0.756 0.112 56% 
30 100 0.798 0.081 80% 0.797 0.097 76% 
30 300 0.854 0.071 96% 0.852 0.074 91% 
        
Table 6.16: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, where true values set to: 𝑅ℎ𝑡
2  =0.90 and 𝑅ℎ
2 =0.64. Comparing results 
for proportional odds and non-proportional odds. 
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6.2.2.5 Trial level surrogacy R2ht: dealing with separation 
6.2.2.5.1 Occurrence of separation: trial level 
The percentage of separations across scenarios for binary outcomes in the simulation 
ranged from 3.2% to 79.9%. The average was 23.4%. Separation in the ordinal case 
was recorded separately for complete and quasi-complete separation. Ordinal 
complete separation ranged from 0% to 14.4% with an average of 3.4%. Quasi-
complete separation ranged from 0% to 21.9% with an average of 1.8%. Hence, 
separation occurred frequently under a random simulation process in the ordinal-
binary setting and led to bias in 𝑅ℎ𝑡
2  which needed to be resolved. 
6.2.2.5.2 Comparison of penalized likelihood and trial removal techniques: 
separation trial level 
Two techniques were applied to deal with separation: the penalized likelihood 
technique and the trial removal technique (here trials where separation occurred were 
removed from analysis), see section 4.1.3.3.4. 
In Table 6.17 the penalized likelihood technique was compared to the removal of 
trials technique for strong surrogacy at both levels. The results were roughly 
comparable across settings with the exception of small trial sizes where separation 
occurs most frequently. Comparison of these two sets of results was not 
straightforward because of the impact of removing different numbers of trials within 
a particular scenario in the trial removal technique.  
Comparing the techniques for ten patients per trial, estimation was better for larger 
numbers of trials for the penalised technique and better for the trial removal 
technique for small numbers of trials. However, this does not take into account the 
fact that up to 92% of the simulations were rejected under the removal technique 
because less than three trials were available for analysis. Furthermore, when 
simulations were not rejected often a lot fewer than the stated number of trials were 
available for analysis. I found that as the number of trials removed increased so too 
did the value of 𝑅ℎ𝑡
2  in the removal technique. This was due to overestimation 
because of overfitting which occurs when there are only a few trials, outlined in 
Table 6.4 and section 6.1.1.2. Therefore, 𝑅ℎ𝑡
2  estimates for the trial removal 
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technique were artificially high where there were small numbers of trials and were 









Trial removal technique 
  𝑅ℎ𝑡
2   
=0.90            
IQR 𝑅ℎ𝑡
2  𝑅ℎ𝑡
2   
=0.90            
IQR 𝑅ℎ𝑡




        
5 10 0.760 0.376 0.823 0.423 92.0% 4 
5 60 0.907 0.165 0.916 0.167 13.5% 5 
5 100 0.923 0.172 0.925 0.150 4.9% 5 
5 300 0.944 0.116 0.946 0.127 0.4% 5 
        
10 10 0.588 0.324 0.674 0.496 48.7% 5 
10 60 0.823 0.188 0.829 0.245 0.0% 9 
10 100 0.860 0.143 0.859 0.169 0.0% 9 
10 300 0.888 0.104 0.898 0.109 0.0% 10 
        
20 10 0.487 0.204 0.431 0.519 7.7% 7 
20 60 0.771 0.142 0.780 0.215 0.0% 17 
20 100 0.820 0.111 0.835 0.113 0.0% 18 
20 300 0.862 0.077 0.878 0.084 0.0% 19 
        
30 10 0.480 0.197 0.284 0.414 0.8% 10 
30 60 0.760 0.103 0.791 0.129 0.0% 26 
30 100 0.798 0.081 0.826 0.101 0.0% 27 
30 300 0.854 0.071 0.865 0.061 0.0% 29 
        
Table 6.17: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, where true values set to: 𝑅ℎ𝑡
2  =0.90 and 𝑅ℎ
2 =0.64. Comparing 
penalized likelihood technique against trial removal technique (trial removal 
technique results include the % of time the calculation of 𝑅ℎ𝑡
2  was not possible and 
the median number of trials available for analysis when it was). 
This finding was supported by the fact that the IQRs for the penalised likelihood 
technique were much narrower than the trial removal technique. The penalised 
likelihood technique gave consistent estimation regardless of the number of 
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occurrences of separation. The penalized likelihood technique was far superior to a 
trial removal technique in terms of estimation, occurrence of modelling errors and 
information retention. It is a useful addition to the information theory approach in the 
ordinal-binary setting. 
6.2.2.5.3 Comparison of penalized likelihood and trial removal techniques: 
intercept calculation 
In order to calculate surrogate intercept variables for second stage models the: 
penalized likelihood technique used a mean intercept method; and the trial removal 
technique used a trial specific shift method. The results for the penalized likelihood 
and trial removal techniques were much the same for larger trial sizes where the 
occurrences of separation were not as frequent. This suggested that the means of 
calculating the surrogate intercept variable in either case had not imposed bias in 
results and were fit for purpose. 
6.2.2.6 Trial level surrogacy R2ht: comparison to binary-ordinal setting 
Comparisons of trial level surrogacy between the ordinal-binary and binary-ordinal 
settings showed very few differences.  
There was slightly greater underestimation via the penalised likelihood technique for 
small trial sizes in the ordinal-binary setting, see Table 6.17 and Table 4.17. 
However, this difference in underestimation in techniques was only minor. 
6.2.3 Trial level surrogacy R2ht: conclusions  
The results in the ordinal-binary setting showed that trial level surrogacy worked 
well in general. Coverage of the confidence intervals were good when there was little 
bias in R2ht results.  
However, three issues affected results: underestimation; overestimation; and 
separation. These issues were all related to the models of the two stages of the 
information theory approach. Underestimation and bias imposed by separation 
affected estimation in stage one models. Underestimation because of inefficiency and 
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separation due to modelling issues. Overestimation occurred because of overfitting in 
second stage models for small numbers of trials. 
Underestimation worsened as the number of trials increased and sizes decreased. 
Overestimation largely affected weak surrogacy scenarios which worsened as trial 
sizes decreased. There was underestimation for small trial sizes and when surrogacy 
strengths differed at the trial and individual levels and slight differences in results 
where the ordinal surrogate was not proportional.  
Finally, the penalised likelihood technique for dealing with separation was shown to 
be extremely adept at avoiding bias and loss of information. A mean intercept 
method used for the penalized technique was adequate for estimation purposes and 
incurred no bias compared to that used for the trial removal technique.  
The fact that the binary-ordinal and ordinal-binary setting results were broadly 
comparable was not surprising, given that both settings had one dichotomised binary 
and one categorised ordinal variable. 
6.3 Simulation study: conclusions 
I ran a simulation study to investigate how well the information theory approach in 
the ordinal-binary setting estimated surrogacy under a variety of scenarios. Loss of 
information impacted estimation of surrogacy in the observed ordinal-binary setting 
at the individual level, with a ceiling of around 0.70. Estimation improved as trial 
sizes increased and, to a lesser extent, as the number of trials increased. Loss of 
information in the ordinal-binary setting was not as bad as in the binary-ordinal 
setting. Seemingly, this is because it is more important to retain information in the 
surrogate than in the true outcome. Confidence intervals at the individual level were 
conservative. 
At the trial level, overall estimation of surrogacy was good. However, issues 
occurred in each of the two stages of the approach which impacted results: 
underestimation, overestimation and separation. Overall, a penalized likelihood 
technique for dealing with issues of separation in discrete outcomes was far superior 
to a trial removal technique.  
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These findings suggest that the information theory approach in the ordinal-binary 
setting provide a generally effective extension to the surrogacy evaluation 
framework. The addition of a penalized likelihood technique for dealing with issues 
of separation is especially worthwhile. 
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Chapter 7. Extension of information theory to 
the case of an ordinal surrogate and true 
outcome: Methodology  
In this Chapter I outline how the information theory approach can be extended to the 
case of an ordinal surrogate and ordinal true outcome (the ordinal-ordinal setting). 
The extension to the ordinal-ordinal setting incorporates components of the previous 
two settings. Hence, I will only briefly introduce the information theory approach 
and how this is extended to the ordinal-ordinal setting. I will refer back to the 
previous settings to justify the methods adopted. 
As in previous chapters I represent a putative surrogate as S, treatment as Z and the 
true outcome as T. In the multi trial context there are I=1,2,…,N trials, and 
j=1,2,….,𝑛𝑖 patients per trial. 𝑁𝑇 = ∑ 𝑛𝑖𝑖  is the total number of patients in all trials. 
The ordinal surrogate and true outcomes have 𝑉 and 𝑊 ordered categories 
respectively. 
Alonso and Molenberghs (2007) suggested the use of the LRF to estimate trial and 
individual level surrogacy in the multi trial setting under the information theory 
approach. As in the previous settings I used the LRF to calculate surrogacy. 
In the following sections I will remind the reader how the LRF can be used to 
calculate 𝑅ℎ
2 and 𝑅ℎ𝑡
2  in the continuous-continuous setting. I will then show how the 
LRF can be applied in the case of an ordinal surrogate and ordinal true outcome. 
7.1 Individual level surrogacy: LRF reintroduction 
The LRF is based on the amount of information gained about the true outcome after 
accounting for the surrogate. Alonso et al. (2006) proposed two models, for each trial 
i, for continuous outcomes S and T: 
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𝑇𝑖𝑗 = 𝜇𝑖 + 𝛽𝑖 𝑍𝑖𝑗 + 𝑇𝑖𝑗 
 7.1 
𝑇𝑖𝑗 = 𝜃0𝑖 + 𝜃1𝑖 𝑍𝑖𝑗 + 𝜃2𝑖 𝑆𝑖𝑗 + 𝑇|𝑆𝑖𝑗 ,  7.2 
where: 𝜃0𝑖 and 𝜇𝑖 are intercept parameters with and without adjustment for the 
surrogate; 𝛽𝑖 is the treatment effect parameter for the true outcome; 𝜃1𝑖  and 𝜃2𝑖 are 
treatment and surrogate parameters for the model with adjustment for the surrogate. 
The difference in the amount of information on the true outcome gained from the 
surrogate is calculated via the log-likelihood ratio test between 5.1 and 5.2 which is 
formally expressed as 𝐺𝑖
2, for each trial i. 𝐿0 is always the log-likelihood for the 
unsaturated model, in this case 5.1, and 𝐿𝐿1 for the saturated model, 5.2, for trial i. 
𝐺𝑖
2 = 2 ∗ (𝐿𝐿1 − 𝐿𝐿0). The LRF is then calculated: 
𝐿𝑅𝐹 = 𝑅ℎ












2 can be interpreted as the amount of uncertainty in T that can be explained by 
knowledge of S, for more details see section 3.3.1. 
1.1.1 Individual level: ordinal-ordinal  
In the case of an ordinal surrogate and ordinal true outcome, I replaced the models of 
5.1 and 5.2 with two proportional odds models, for each trial i, for ordinal S and T:  
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇𝑖𝑗 ≤ 𝑤)] = 𝜇𝑤𝑖 + 𝛽𝑖 𝑍𝑖𝑗 7.4 
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇𝑖𝑗 ≤ 𝑤)] = 𝜃𝑤𝑖 + 𝜃1𝑖 𝑍𝑖𝑗 + 𝜃2𝑖 𝑆𝑖𝑗 7.5 
Where: 𝑤 = 1, … . , 𝑊 − 1; W is the number of categories in the ordinal true 
outcome; and 𝜇𝑤𝑖  and 𝜃𝑤𝑖  are the W-1 intercepts for the cut points of the ordinal true 
outcome, all other parameters are the same as in the continuous-continuous setting. 
As in the ordinal-binary setting, section 5.2.1.1, the ordinal surrogate was modelled 
as a quantitative explanatory variable.  
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In the case of discrete true outcomes the information theoretic measure at the 
individual level was bounded above by a number less than one and had to be rescaled 
(Alonso and Molenberghs, 2007), this was done in exactly the same manner as in the 
binary-ordinal setting, see section 3.3.2. 
1.2 Trial level surrogacy: LRF reintroduced 
In order to apply the LRF at the trial level a two stage approach is required. Again I 
first describe the case where continuous outcomes are used. At the first stage two 
models which incorporate all trials are used: 
𝑆𝑖𝑗 = 𝜇𝑆𝑖 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 + 𝛼𝑖 (𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑍𝑖𝑗 ) + 𝑖𝑗 7.6 
𝑇𝑖𝑗 = 𝜇𝑇𝑖 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 + 𝛽𝑖 (𝑡𝑟𝑖𝑎𝑙𝑖𝑗 ∗ 𝑍𝑖𝑗 ) + 𝑖𝑗 7.7 
Here: ?̂?𝑖 and ?̂?𝑖 contain the trial specific treatment effect estimates on the surrogate 
and true outcome respectively; and 𝜇𝑆𝑖  and 𝜇𝑇𝑖  are the trial specific intercepts for the 
surrogate and true outcome respectively. 
At the second stage two further models are required, the intercept only model, 3.15, 
and trial specific treatment effect estimates of true outcome regressed on trial 
specific intercept and treatment effects of the surrogate, 3.16: 
?̂?𝑖 = γ3 + 𝑖 7.8 
?̂?𝑖  = 𝛾0 + 𝛾1 ?̂?𝑆𝑖 + 𝛾2?̂?𝑖 + 𝑖 , 7.9 
where: 𝛾0 and 𝛾3 are intercept parameters with and without adjustment for the 
surrogate; 𝛾1 and 𝛾2 are the parameters for the surrogate intercept and treatment 
estimate variables. The difference in the -2*log-likelihood between these two 
models, G2, can then be calculated and the LRF applied as in 3.17.  
𝐿𝑅𝐹 = 𝑅ℎ𝑡
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1.2.1 Trial level: ordinal-ordinal  
In the ordinal-ordinal setting the same procedure for applying the LRF at the trial 
level is followed as that for continuous outcomes. At the first stage of modelling, 
since we have an ordinal surrogate and an ordinal true outcome as response 
variables, proportional odds models are required. These can again be used to 
calculate treatment effect estimates for each trial.  
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑆𝑖𝑗 ≤ 𝑣)] = 𝜇𝑆𝑉
0 + 𝜇𝑆𝑖 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 + 𝛼𝑖 (𝑍𝑖𝑗 ∗ 𝑡𝑟𝑖𝑎𝑙𝑗 ) 7.11 
𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇𝑖𝑗 ≤ 𝑤)] = 𝜇𝑇𝑊
0 + 𝜇𝑇𝑖 𝑡𝑟𝑖𝑎𝑙𝑖𝑗 + 𝛽𝑖 (𝑍𝑖𝑗 ∗ 𝑡𝑟𝑖𝑎𝑙𝑗 ) 7.12 
Where, 𝑣 = 1, … , 𝑉 − 1 and 𝑤 = 1, … . , 𝑊 − 1. 
here: 𝜇𝑆𝑣
0  and 𝜇𝑇𝑤
0  are assumed fixed intercept cut points relating to the ordinal 
surrogate and true outcome variable; 𝜇𝑆𝑖  and 𝜇𝑇𝑖  are trial specific shifts of the set of 
intercepts (Burzykowski et al., 2004); and ?̂?𝑖 and ?̂?𝑖 are the treatment effect estimates 
on the surrogate and true outcomes respectively.  
At the second stage of modelling, models 3.15 and 3.16 can be fitted and then the 
LRF, using 3.17, can be calculated in a similar way as for the continuous-continuous 
case, using 𝜇𝑆𝑖 , ?̂?𝑖  and ?̂?𝑖. This is exactly the same as in the ordinal-binary setting, 
see section 3.4.2 for more details. 
1.3 Confidence intervals: ordinal-ordinal  
Confidence intervals for trial and individual level surrogacy in the ordinal-ordinal 
setting can be applied in exactly the same manner as the binary-ordinal (and ordinal-
binary) setting. See section 3.5. 
1.4 Separation: ordinal-ordinal 
Separation occurs when there are zero cells in discrete outcome cross tabulations. As 
in the binary-ordinal and ordinal-binary settings the occurrence of separation could 
potentially greatly bias trial level results, see section 3.6. A solution to this is to use 
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the penalized likelihood method of Firth (1993). To see more details of this method 
see section 3.6.3. 
The penalized likelihood method can be applied in the ordinal-ordinal setting in 
much the same manner as in the ordinal-binary setting (section 5.5). As in the 
ordinal-binary setting, the calculation of the intercepts is more complicated than in 
the binary-ordinal setting. A mean intercepts method was adopted in the ordinal-
binary setting, see section 5.5, this was found to work adequately and impose no 
issues of bias. Hence this mean intercept method was used in the ordinal-ordinal 
setting for the penalized likelihood technique. 
1.5 Conclusions: ordinal-ordinal 
I have shown the extension of the information theory approach to the ordinal-ordinal 
scenario at the individual and trial levels and how to apply a penalized likelihood 
technique to deal with issues of separation at the trial level. 
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Chapter 8. Simulation study: for an ordinal 
surrogate and ordinal true outcome 
In the previous chapter I discussed how the information theoretic measures 𝑅ℎ
2 and 
𝑅ℎ𝑡
2  for surrogate evaluation can be extended to the case of an ordinal surrogate and 
ordinal true outcome. I have conducted a simulation study to investigate how these 
measures in the ordinal-ordinal setting behave under various scenarios. 
In this chapter, I outline the setup of the simulation study and various practical 
considerations. I then present the simulation results for both 𝑅ℎ
2 and 𝑅ℎ𝑡
2 . 
As in previous chapters: S denotes a surrogate; T a true outcome; Z treatment; with 
i=1,..,N trials and j=1,..,𝑛𝑖 patients per trial. 
8.1 Simulation study: set up 
The simulation study for the ordinal-ordinal setting was identical to that for the 
ordinal-binary setting. Except that both the surrogate and true outcomes were 
simulated as continuous variables instead of just the surrogate. These were 
categorised as ordinal outcomes in exactly the same manner as the surrogate in the 
ordinal-binary setting. Both ordinal variables were simulated as having seven 
categories. Also, the impact of deviations from the proportional odds assumption 
needed to be tested at both the individual and trial levels since ordinal response 
variables were used for all models. The linear relationship (discussed in section 
6.1.2.3 in the ordinal-binary setting) and proportional odds assumptions both apply at 
the individual level. However, this is essentially the same assumption which was 
tested using the same coding in previous settings, hence for simplicity only the 
proportional odds assumption is referred to from now on. In all other regards the 
simulation followed the setup of the ordinal-binary setting. See section 6.1 for more 
details. 
8.2 Simulation study: results  
In this section the results of the simulation study for individual level and then trial 
level surrogacy are presented. The various issues and biases present in the results 
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were very much in line with those in the binary-ordinal and ordinal-binary settings 
and have been outlined in Table 8.1. 
 Issue Scenarios affected Reason See 
section(s): 





lower than true 
value 
All scenarios Loss of information 































Separation All scenarios Zero cells in trial 
crosstabs 
Resolved through use 





     
Table 8.1: Issues present in results of simulation study 
I have previously discussed the issues of loss of information, underestimation, 
overestimation and separation as highlighted in Table 8.1 for the binary-ordinal 
setting. All issues described in Table 8.1 were present in the results of the ordinal-
ordinal setting and are discussed in the sections indicated.  
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In all the scenarios presented the median 𝑅2 values for the 250 simulations 
performed for each scenario are given. This is to give some idea of the bias in 𝑅2 
estimates. The IQRs of 𝑅2 estimates for the 250 simulations are also given. I present 
the coverage of and the median lower and upper bounds of the confidence intervals, 
for each scenario. Results for selected scenarios are presented in this chapter; 
Appendix C contains full unabridged tables of results for every scenario. 
8.2.1  Results: individual level surrogacy 
In this section the results for the individual level surrogacy where loss of information 
impacts results are presented, see section 4.1.3.3.1 and Table 8.1.  
Here I present the results for the scenarios: 
 where surrogacy was set to be strong at both trial and individual level; 
 where this was weak at both levels; 
 where the strength of surrogacy differed at trial and individual levels; 
 the odds are not proportional. 
 
I also discuss the results of the ceiling investigation for the ordinal-ordinal setting 
and how the results compare to previous settings. 
8.2.1.1 Individual level surrogacy R2h: strong surrogacy 
Surrogacy was set to be strong at both levels, 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90, in the 
underlying continuous setting. Due to loss of information the observed results for the 
ordinal-ordinal setting were expected to be lower than in the underlying continuum. 
Table 8.2 shows that as the number and size of trial increased the value of surrogacy 
in the observed ordinal-ordinal setting converged to around 0.53. The impact of trial 
sizes was greater than that for number of trials, however all values returned were 
close to 0.53. The IQRs of the 𝑅ℎ
2 estimates were much narrower as the number of 
and size of trials increased. The coverage of the confidence intervals was 100% in all 
scenarios and the median confidence intervals were very large and covered nearly the 
whole parameter space where there were ten patients per trial. The precision of these 
  Evaluation of surrogate outcomes 
Simulation: Ordinal-ordinal setting 158 
greatly improved as the size of trials increased, although again the number of trials 
had a much smaller impact.  
Number 




𝟐  IQR 𝑹𝒉





CI upper  
        
5 10 0.562 0.175 100% 0.147 0.893 
5 60 0.536 0.050 100% 0.322 0.724 
5 100 0.536 0.045 100% 0.370 0.687 
5 300 0.538 0.035 100% 0.442 0.629 
       
10 10 0.538 0.101 100% 0.133 0.877 
10 60 0.534 0.037 100% 0.322 0.722 
10 100 0.533 0.033 100% 0.367 0.683 
10 300 0.532 0.022 100% 0.436 0.622 
       
20 10 0.539 0.069 100% 0.143 0.880 
20 60 0.530 0.029 100% 0.318 0.717 
20 100 0.532 0.023 100% 0.366 0.682 
20 300 0.530 0.016 100% 0.433 0.620 
       
30 10 0.549 0.055 100% 0.146 0.881 
30 60 0.530 0.021 100% 0.318 0.718 
30 100 0.528 0.021 100% 0.363 0.679 
30 300 0.529 0.013 100% 0.433 0.619 
       
Table 8.2: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2 =0.64 and 𝑅ℎ𝑡
2  =0.90. 
8.2.1.2 Individual level surrogacy R2h: weak surrogacy 
The findings for strong surrogacy were mirrored in the case of weak surrogacy, 
where 𝑅ℎ
2 =0.30 and 𝑅ℎ𝑡
2 =0.30 in the underlying continuous setting. 
Table 8.3 shows that as the number and sizes of trials increased the value of 
surrogacy in the observed ordinal-ordinal setting converged at around 0.24.  
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𝟐  IQR 𝑹𝒉





CI upper  
        
5 10 0.293 0.154 100% 0.023 0.736 
5 60 0.236 0.051 100% 0.076 0.447 
5 100 0.240 0.048 100% 0.104 0.404 
5 300 0.241 0.027 100% 0.156 0.336 
       
10 10 0.306 0.100 100% 0.037 0.736 
10 60 0.244 0.043 100% 0.080 0.455 
10 100 0.245 0.036 100% 0.109 0.408 
10 300 0.241 0.019 100% 0.156 0.335 
       
20 10 0.302 0.068 100% 0.039 0.732 
20 60 0.243 0.026 100% 0.080 0.453 
20 100 0.239 0.023 100% 0.105 0.403 
20 300 0.238 0.013 100% 0.153 0.331 
       
30 10 0.308 0.057 100% 0.042 0.734 
30 60 0.245 0.022 100% 0.082 0.453 
30 100 0.241 0.019 100% 0.106 0.404 
30 300 0.239 0.012 100% 0.154 0.333 
       
Table 8.3: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2 =0.30 and 𝑅ℎ𝑡
2  =0.30. 
8.2.1.3 Individual level surrogacy R2h: differing strengths of surrogacy 
Table 8.4 shows that 𝑅ℎ
2 estimates for discordant strengths of surrogacy were much 
the same as those for agreement in surrogacy strengths. The width of the IQRs in the 
two scenarios was also much the same. The result for weak individual level and 
strong trial level surrogacy gave comparable results. 
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Number 
of trials  
Trial 
size 






















        
5 10 0.562 0.175 100% 0.537 0.153 100% 
5 60 0.536 0.050 100% 0.534 0.059 100% 
5 100 0.536 0.045 100% 0.535 0.042 100% 
5 300 0.538 0.035 100% 0.534 0.031 100% 
        
10 10 0.538 0.101 100% 0.538 0.102 100% 
10 60 0.534 0.037 100% 0.526 0.038 100% 
10 100 0.533 0.033 100% 0.525 0.033 100% 
10 300 0.532 0.022 100% 0.528 0.025 100% 
        
20 10 0.539 0.069 100% 0.539 0.076 100% 
20 60 0.530 0.029 100% 0.524 0.032 100% 
20 100 0.532 0.023 100% 0.525 0.022 100% 
20 300 0.530 0.016 100% 0.524 0.017 100% 
        
30 10 0.549 0.055 100% 0.543 0.057 100% 
30 60 0.530 0.021 100% 0.526 0.026 100% 
30 100 0.528 0.021 100% 0.523 0.020 100% 
30 300 0.529 0.013 100% 0.524 0.013 100% 
        
Table 8.4: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2 =0.64 and 𝑅ℎ𝑡
2  =0.90 or 0.30. 
8.2.1.4 Individual level surrogacy R2h: proportional odds assumption 
The 𝑅ℎ
2 estimates where the proportional odds assumption was not valid were 
uniformly slightly lower than those where the assumption holds, regardless of 
number or size of trials, see Table 8.5.  
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=0.90            
IQR 𝑅ℎ




=0.90             
IQR 𝑅ℎ
2 % cover 
CIs 
        
5 10 0.562 0.175 100% 0.515 0.155 100% 
5 60 0.536 0.050 100% 0.518 0.067 100% 
5 100 0.536 0.045 100% 0.526 0.042 100% 
5 300 0.538 0.035 100% 0.520 0.032 100% 
        
10 10 0.538 0.101 100% 0.528 0.097 100% 
10 60 0.534 0.037 100% 0.514 0.042 100% 
10 100 0.533 0.033 100% 0.511 0.038 100% 
10 300 0.532 0.022 100% 0.516 0.022 100% 
        
20 10 0.539 0.069 100% 0.535 0.085 100% 
20 60 0.530 0.029 100% 0.514 0.028 100% 
20 100 0.532 0.023 100% 0.512 0.027 100% 
20 300 0.530 0.016 100% 0.510 0.018 100% 
        
30 10 0.549 0.055 100% 0.533 0.057 100% 
30 60 0.530 0.021 100% 0.510 0.025 100% 
30 100 0.528 0.021 100% 0.510 0.020 100% 
30 300 0.529 0.013 100% 0.510 0.013 100% 
        
Table 8.5: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2 =0.64 and 𝑅ℎ𝑡
2  =0.90. Comparing results for 
proportional odds and non-proportional odds scenarios. 
8.2.1.5 Individual level surrogacy R2h: ceiling effect 
The strength of individual level surrogacy in the ordinal-ordinal setting compared the 
underlying continuum was much lower due to loss of information. I investigated 𝑅ℎ
2 
estimated when the strength of surrogacy was ‘perfect’ at the individual level in the 
underlying continuous-continuous setting.  
As can be seen in Table 8.6 the value of surrogacy of the observed ordinal surrogate 
converges to around 0.88 as the number and size of trials increased. This suggests 
that in the case of perfect surrogacy at the underlying continuum the strongest an 
ordinal surrogate for an ordinal true outcome can be is around 0.88.  
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Number 
of  trials 
Trial size 𝑹𝒉
𝟐  IQR 𝑹𝒉







       
5 10 0.879 0.066 100% 0.495 0.982 
5 60 0.888 0.044 100% 0.768 0.946 
5 100 0.902 0.038 96% 0.820 0.944 
5 300 0.903 0.035 91% 0.862 0.930 
       
10 10 0.864 0.062 100% 0.481 0.977 
10 60 0.887 0.036 99% 0.771 0.946 
10 100 0.890 0.035 96% 0.806 0.937 
10 300 0.892 0.033 85% 0.851 0.923 
       
20 10 0.861 0.033 100% 0.472 0.976 
20 60 0.879 0.027 100% 0.761 0.942 
20 100 0.885 0.025 100% 0.802 0.935 
20 300 0.890 0.028 92% 0.847 0.921 
       
30 10 0.856 0.029 100% 0.467 0.975 
30 60 0.878 0.021 100% 0.761 0.942 
30 100 0.884 0.024 100% 0.801 0.934 
30 300 0.888 0.029 93% 0.846 0.920 
       
Table 8.6: Simulation study: Median 𝑅ℎ
2 estimates based on 250 simulations for each 
scenario, where true values set to: 𝑅ℎ
2=1 and 𝑅ℎ𝑡
2 =0.90. 
As in the binary-ordinal setting, the confidence intervals in the case of ‘perfect’ 
surrogacy seems to be behaving slightly differently to other scenarios, see section 
4.2.1.5. As in the binary-ordinal setting. the scenario of ‘perfect’ surrogacy presented 
here is a very particular case of surrogacy that is unlikely to be seen in practice. 
8.2.1.6 Individual level surrogacy R2h: comparison to binary-ordinal and 
ordinal-binary settings 
The ceiling effect for the ordinal-ordinal setting was much higher than for the 
alternative settings when one outcome was binary. In comparison to the underlying 
continuous-continuous setting the ceiling for the ordinal-ordinal setting was 0.88, the 
ordinal-binary was 0.70 and the binary-ordinal was 0.48.  
Clearly dichotomisation causes a large impact on loss of information compared to 
categorisation into seven categories. The ceiling in the ordinal-ordinal setting is very 
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high compared to the other settings where the information in one of the ordinal 
outcomes has been further reduced to create a binary outcome.  
In the context of surrogacy, the amount of information retained in the surrogate was 
most pertinent to the level of the ceiling. The lowest ceiling witnessed occurred when 
the surrogate was binary. However, the ceiling in the ordinal-ordinal setting was 
much higher than the ordinal-binary setting where the true outcome is binary. 
Therefore, retaining information on the true outcome was also very important. 
8.2.1.7 Conclusions individual level surrogacy 
When surrogacy strength agrees at both levels 𝑅ℎ
2 estimates converged to around 0.52 
where this was set to be 0.64 at the underlying continuum and 0.23 where this was 
set to 0.30 at the underlying continuum. Smaller trials gave larger 𝑅ℎ
2 estimates, more 
variability and less precise confidence intervals. The number of trials had limited 
impact on results. Differing strengths of surrogacy at trial and individual levels and 
adherence to the proportional odds assumption had little impact on 𝑅ℎ
2 results.  
The coverage of the confidence intervals was 100% in all scenarios that were 
expected to be seen in practice suggesting these are very conservative. Although, the 
median confidence interval results suggest these were sensible and by no means 
covered the whole parameter space. 
The ceiling effect in the ordinal-ordinal setting was much less pronounced than in 
other settings. This showed that dichotomisation of continuous outcomes leads to a 
much larger loss of information than categorisation to ordinal outcomes. In this 
simulation study the ordinal outcomes had seven categories. However, ordinal 
outcomes with fewer categories are likely to lead to lower ceilings than those 
observed in this study.  
8.2.2  Results: trial level surrogacy 
This section outlines the results for trial level surrogacy using the penalised 
likelihood technique to deal with issues of separation.  
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I will describe the scenario where:  
 surrogacy was strong at both the trial and individual levels;  
 surrogacy was weak at both levels;  
 the strength of surrogacy disagred at the trial and individual levels; 
 non-proportional odds of the ordinal surrogate and true outcome were 
present. 
Finally, I compare the penalised likelihood technique to the technique where trials 
with separation were removed from analysis. 
8.2.2.1 Trial level surrogacy R2ht: strong surrogacy 
I describe the results for trial level surrogacy when this was strong at both levels and 
estimates of 𝑅ℎ𝑡
2  were expected to be in the region of 0.90, see Table 8.7. 
Estimation improved as the size of trials increased. Results showed overestimation 
for five trials but as the number of trials increased estimation improved, especially 
for large trial sizes. The IQRs of 𝑅ℎ𝑡
2  and the coverage of confidence intervals 
improved as the size and number of trials increased. However, the coverage of the 
confidence intervals was poor where there were large numbers of trials and small 
numbers of patients per trial, this is likely because of the relative bias in 𝑅ℎ𝑡
2  results. 
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Number 




𝟐  IQR 𝑹𝒉𝒕





CI upper  
 
       
5 10 0.853 0.228 95% 0.228 0.994 
5 60 0.948 0.085 95% 0.507 0.999 
5 100 0.959 0.077 92% 0.563 0.999 
5 300 0.955 0.079 95% 0.542 0.999 
       
10 10 0.756 0.213 85% 0.274 0.962 
10 60 0.892 0.085 99% 0.534 0.989 
10 100 0.902 0.087 100% 0.559 0.990 
10 300 0.916 0.080 98% 0.597 0.992 
       
20 10 0.682 0.166 48% 0.329 0.897 
20 60 0.877 0.070 98% 0.639 0.972 
20 100 0.887 0.071 99% 0.659 0.974 
20 300 0.899 0.066 99% 0.687 0.978 
       
30 10 0.683 0.114 25% 0.400 0.872 
30 60 0.869 0.073 96% 0.680 0.958 
30 100 0.880 0.058 98% 0.700 0.963 
30 300 0.895 0.047 99% 0.730 0.969 
       
Table 8.7: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, in the ordinal-ordinal setting where true values set to: 𝑅ℎ
2 =0.64 and 
𝑅ℎ𝑡
2  =0.90. 
8.2.2.1.1 Strong surrogacy: comparison to continuous-continuous setting 
In keeping with the results presented in other settings I now compare the ordinal-
ordinal results to those for the underlying continuous variables. Table 8.8 shows that 
the overestimation when the number of trials were small and trial sizes were large 
was present in both settings. In contrast, the ordinal-ordinal setting showed 
underestimation in comparison to the continuous-continuous setting when trial sizes 
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of  trials 
Trial size 𝑅ℎ𝑡
2   IQR 𝑅ℎ𝑡
2  𝑅ℎ𝑡
2   IQR 𝑅ℎ𝑡
2  
      
5 10 0.853 0.228 0.931 0.165 
5 60 0.948 0.085 0.950 0.103 
5 100 0.959 0.077 0.953 0.095 
5 300 0.955 0.079 0.959 0.069 
      
10 10 0.756 0.213 0.840 0.137 




0.902 0.087 0.916 0.072 
10 300 0.916 0.080 0.919 0.068 
      
20 10 0.682 0.166 0.835 0.100 
20 60 0.877 0.070 0.900 0.065 
20 100 0.887 0.071 0.902 0.054 
20 300 0.899 0.066 0.910 0.058 
      
30 10 0.683 0.114 0.826 0.078 
30 60 0.869 0.073 0.895 0.053 
30 100 0.880 0.058 0.900 0.050 
30 300 0.895 0.047 0.902 0.054 
      
Table 8.8: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, in ordinal-ordinal and continuous-continuous setting where true 
values set to:  𝑅ℎ
2 =0.64 and 𝑅ℎ𝑡
2  =0.90. 
8.2.2.1.2 Strong surrogacy: discussion 
As discussed in previous settings the use of a two stage approach at the trial level 
combined with the loss of information present in categorising continuous outcomes 
led to inefficiency, see section 4.2.2.1 for more details. Since the estimates 
converged on the true strength of surrogacy as trial sizes increased this issue was due 
to lack of efficiency in estimation, rather than an inherent bias. 
Further proof of this is provided by the consideration of additional scenarios on top 
of those mentioned in the methods section. Consider Table 8.9, where 3000 patient 
scenarios for each trial size have been presented. These results are very similar to 
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those in the underlying continuum in the 300 patient scenario which indicates that it 
was indeed inefficiency that caused the underestimation. 
 ordinal-ordinal 
Number 




2   IQR 𝑅ℎ𝑡
2   
    
5 3000 0.958 0.097 
10 3000 0.919 0.072 
20 3000 0.910 0.052 
30 3000 0.906 0.044 
    
Table 8.9 Additional simulation scenarios: Median 𝑅ℎ𝑡
2  estimates based on 250 
simulations for each scenario, where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 and trial size was 3000. 
8.2.2.2 Trial level surrogacy R2ht: weak surrogacy 
In this section the case where surrogacy was weak at both levels, 𝑅ℎ
2 = 𝑅ℎ𝑡
2 =0.30, is 
discussed, where I expected the trial level results to be approximately 0.30. 
Considering Table 8.10, we see that as trial size decreased overestimation worsened. 
Where there were five trials and 300 patients’ trial level surrogacy was 0.678 which 
indicates a moderately good surrogate in contrast to the true strength of surrogacy of 
0.30. The variation was larger than for strong surrogacy but still showed 
improvement as the number and size of trials increased. Confidence intervals showed 
improved coverage as the number of trials increased but were insensitive to increases 
in trial size. 
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Number 




𝟐  IQR 𝑹𝒉𝒕





CI upper  
 
       
5 10 0.651 0.431 82% 0.030 0.973 
5 60 0.609 0.435 82% 0.019 0.967 
5 100 0.680 0.442 80% 0.042 0.977 
5 300 0.678 0.451 78% 0.041 0.977 
       
10 10 0.372 0.352 94% 0.009 0.819 
10 60 0.424 0.353 94% 0.019 0.844 
10 100 0.412 0.336 96% 0.016 0.838 
10 300 0.452 0.334 95% 0.026 0.857 
       
20 10 0.287 0.255 95% 0.021 0.647 
20 60 0.346 0.226 97% 0.045 0.695 
20 100 0.340 0.238 96% 0.042 0.691 
20 300 0.348 0.241 95% 0.045 0.697 
       
30 10 0.265 0.192 95% 0.038 0.567 
30 60 0.328 0.186 97% 0.071 0.623 
30 100 0.319 0.186 96% 0.067 0.616 
30 300 0.317 0.209 96% 0.065 0.613 
       
Table 8.10: Simulation study: median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, in the ordinal-ordinal setting where true values set to: 𝑅ℎ
2 =0.30 and 
𝑅ℎ𝑡
2  =0.30. 
8.2.2.2.1 Weak surrogacy: comparison to underlying continuous-continuous 
setting 
Consider Table 8.11, the results for the ordinal-ordinal setting can be compared to 
the underlying continuous-continuous setting. Here we see that the pattern of 
overestimation was consistent at both the observed ordinal-ordinal and underlying 
continuous-continuous settings. Results in the continuous-continuous setting showed 
overestimation in every scenario. However, results for the ordinal-ordinal setting 
were consistently lower than the underlying continuous-continuous setting which, in 
keeping with the patterns seen for strong surrogacy, worsened as trial sizes 
decreased. 
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2  IQR 𝑅ℎ𝑡
2  𝑅ℎ𝑡
2  IQR 𝑅ℎ𝑡
2  
      
5 10 0.651 0.431 0.600 0.453 
5 60 0.609 0.435 0.659 0.399 
5 100 0.680 0.442 0.676 0.539 
5 300 0.678 0.451 0.683 0.440 
      
10 10 0.372 0.352 0.438 0.298 
10 60 0.424 0.353 0.446 0.347 
10 100 0.412 0.336 0.402 0.376 
10 300 0.452 0.334 0.429 0.324 
      
20 10 0.287 0.255 0.349 0.212 
20 60 0.346 0.226 0.353 0.199 
20 100 0.340 0.238 0.327 0.213 
20 300 0.348 0.241 0.355 0.222 
      
30 10 0.265 0.192 0.326 0.172 
30 60 0.328 0.186 0.329 0.179 
30 100 0.319 0.186 0.358 0.210 
30 300 0.317 0.209 0.336 0.204 
      
Table 8.11: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for each scenario, in 
continuous-continuous setting where true values set to: 𝑅ℎ
2 =0.30 and 𝑅ℎ𝑡
2  =0.30. 
8.2.2.2.2 Overestimation: weak trial level surrogacy 
The overestimation witnessed in both the observed ordinal-ordinal and underlying 
continuous-continuous settings occurred because of overfitting of stage two models 
for small trial sizes (as in both the binary-ordinal and ordinal-binary settings, see 
section 4.2.2.2).  
8.2.2.2.3 Underestimation: weak trial level surrogacy 
There was also evidence of underestimation when surrogacy was weak. Notice that 
the results in the ordinal-ordinal setting were consistently lower than in the 
underlying continuous-continuous setting. This occurred because of the inefficiency 
of a two stage approach with discrete outcomes, this was described in more detail in 
section 6.2.2.1.  
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8.2.2.3 Trial level surrogacy R2ht: differing strengths of surrogacy 
Consider Table 8.12, there was very little difference in the results where there was 
strong surrogacy at the trial level but weak surrogacy at the individual level. The 
results were lower for the discordant strengths scenario when there were few patients 
per trial. Confidence intervals coverages were also poorer. Similar discrepant results 
were found when surrogacy was strong at the individual level and weak at the trial 






Surrogacy strong both 
levels 
Surrogacy strong 𝑹𝒉𝒕




2   







2   






        
5 10 0.853 0.228 95% 0.795 0.313 89% 
5 60 0.948 0.085 95% 0.930 0.126 96% 
5 100 0.959 0.077 92% 0.929 0.119 95% 
5 300 0.955 0.079 95% 0.956 0.077 96% 
        
10 10 0.756 0.213 85% 0.634 0.272 63% 
10 60 0.892 0.085 99% 0.871 0.119 98% 
10 100 0.902 0.087 100% 0.894 0.089 98% 
10 300 0.916 0.080 98% 0.906 0.095 99% 
        
20 10 0.682 0.166 48% 0.568 0.218 22% 
20 60 0.877 0.070 98% 0.844 0.078 96% 
20 100 0.887 0.071 99% 0.874 0.075 99% 
20 300 0.899 0.066 99% 0.894 0.069 100% 
        
30 10 0.683 0.114 25% 0.542 0.181 4% 
30 60 0.869 0.073 96% 0.833 0.073 92% 
30 100 0.880 0.058 98% 0.867 0.071 97% 
30 300 0.895 0.047 99% 0.885 0.051 98% 
        
Table 8.12: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, where true values set to: 𝑅ℎ𝑡
2  =0.90 and 𝑅ℎ
2 =0.64 or 0.30 
8.2.2.4 Trial level surrogacy R2ht: non-proportional odds 
There were very little differences due to the divergence from the proportional odds 
assumption on estimates of surrogacy at the trial level, see Table 8.13. 𝑅ℎ𝑡
2  estimates 
  Evaluation of surrogate outcomes 
Simulation: Ordinal-ordinal setting 171 
were marginally lower when the odds were not proportional. The confidence 
intervals generally had similar coverages. 
Number 
of  trials 
Trial 
size 
Proportional Non proportional 
 
  𝑅ℎ𝑡
2   
=0.90            
IQR 𝑅ℎ𝑡
2  % cover 
CIs 
𝑅ℎ𝑡
2   
=0.90              
IQR 𝑅ℎ𝑡
2  % cover 
CIs 
        
5 10 0.853 0.228 95% 0.850 0.268 90% 
5 60 0.948 0.085 95% 0.942 0.127 93% 
5 100 0.959 0.077 92% 0.936 0.128 95% 
5 300 0.955 0.079 95% 0.943 0.099 94% 
        
10 10 0.756 0.213 85% 0.710 0.180 83% 
10 60 0.892 0.085 99% 0.883 0.127 99% 
10 100 0.902 0.087 100% 0.891 0.113 99% 
10 300 0.916 0.080 98% 0.910 0.082 97% 
        
20 10 0.682 0.166 48% 0.681 0.164 48% 
20 60 0.877 0.070 98% 0.860 0.084 98% 
20 100 0.887 0.071 99% 0.875 0.074 98% 
20 300 0.899 0.066 99% 0.895 0.063 100% 
        
30 10 0.683 0.114 25% 0.673 0.134 24% 
30 60 0.869 0.073 96% 0.857 0.060 95% 
30 100 0.880 0.058 98% 0.872 0.064 99% 
30 300 0.895 0.047 99% 0.881 0.054 97% 
        
Table 8.13: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, where true values set to: 𝑅ℎ𝑡
2  =0.90 and 𝑅ℎ
2 =0.64. Comparing results 
for proportional odds and non-proportional odds. 
8.2.2.5 Trial level surrogacy R2ht: dealing with separation 
8.2.2.5.1 Occurrence of separation: trial level 
The percentage of quasi complete separation across scenarios for the ordinal true 
outcomes in the simulation ranged from 0% to 10.4%, complete separation ranged 
from 0 to 5.8%. The average was 0% in both cases. In the ordinal surrogate case 
quasi-complete separation ranged from 0 to 28.8% with an average of 0.5%. 
Complete separation of S ranged from 0% to 44.5% with an average of 0.7%. The 
larger occurrences of separation were for small trial sizes. 
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Trial removal technique 
  𝑅ℎ𝑡
2   
=0.90            
IQR 𝑅ℎ𝑡
2  𝑅ℎ𝑡
2   
=0.90            
IQR 𝑅ℎ𝑡





        
5 10 0.853 0.228 0.880 0.271 36.4% 4 
5 60 0.948 0.085 0.949 0.081 0.0% 5 
5 100 0.959 0.077 0.958 0.066 0.0% 5 
5 300 0.955 0.079 0.959 0.075 0.0% 5 
        
10 10 0.756 0.213 0.746 0.257 0.4% 7 
10 60 0.892 0.085 0.900 0.094 0.0% 10 
10 100 0.902 0.087 0.901 0.084 0.0% 10 
10 300 0.916 0.080 0.916 0.080 0.0% 10 
        
20 10 0.682 0.166 0.671 0.245 0.0% 14 
20 60 0.877 0.070 0.878 0.069 0.0% 20 
20 100 0.887 0.071 0.889 0.064 0.0% 20 
20 300 0.899 0.066 0.904 0.064 0.0% 20 
        
30 10 0.683 0.114 0.651 0.193 0.0% 30 
30 60 0.869 0.073 0.873 0.077 0.0% 30 
30 100 0.880 0.058 0.884 0.058 0.0% 30 
30 300 0.895 0.047 0.902 0.046 0.0% 30 
        
Table 8.14: Simulation study: Median 𝑅ℎ𝑡
2  estimates based on 250 simulations for 
each scenario, where true values set to: 𝑅ℎ𝑡
2  =0.90 and 𝑅ℎ
2 =0.64. Comparing 
penalized likelihood technique against trial removal technique (trial removal 
technique results include the % of time the calculation of 𝑅ℎ𝑡
2  was not possible and 
the median number of trials available for analysis when it was) 
The penalized likelihood technique and the trial removal technique (where trials 
where separation occurred were removed from analysis which led to loss of 
information) were compared as methods of dealing with separation, see section 3.6.  
In Table 8.14 the results for either technique were roughly comparable across 
settings. However, the variance for the penalized likelihood technique was lower for 
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small trial sizes where separation occurred most frequently. This was because under 
the trial removal technique, when separation occurred the trials affected were 
removed from analysis, resulting in loss of information. Indeed in 36.4% of cases, in 
the ten patient and five trials scenario, 𝑅ℎ𝑡
2  could not be calculated at all because 
fewer than three trials were available for analysis under the trial removal technique. 
For the scenarios with only 10 patients generally the mean number of trials available 
for analysis was lower than that set in the simulation. The unavailability of these 
trials for the trial removal approach resulted in a large amount of information loss 
which highlights the advantage of the penalized likelihood approach. 
The estimation of 𝑅ℎ𝑡
2  is slightly better for the trial removal technique when trial 
sizes are large, and separation is likely to be infrequent, with marginally better 
estimation of surrogacy and lower variance. 
8.2.2.6 Trial level surrogacy R2ht: comparison to binary-ordinal and 
ordinal-binary settings 
In comparison to the binary-ordinal and ordinal-binary settings at the trial level the 
results for the ordinal-ordinal setting were similar.  
However, the underestimation observed in the ordinal-ordinal setting compared to 
the others was much less severe. In fact, for larger trial sizes the underestimation in 
the ordinal-ordinal setting was negligible. In the case of 30 trials and 300 patients 
this was 0.895 when 0.90 was expected, the corresponding result for the binary-
ordinal setting was 0.865 and ordinal-binary settings was 0.854. This suggests that a 
much smaller number of patients per trial gives unbiased estimates for the ordinal-
ordinal setting, i.e. estimation in the ordinal-ordinal setting was more efficient.  
8.2.3  Results: conclusions 
In keeping with the results in previous settings, the ordinal-ordinal setting showed 
underestimation which worsened as the number of trials increased and trial sizes 
decreased; there was overestimation especially for weak surrogacy which worsened 
as trial sizes decreased; and little effect where the proportional odds assumptions was 
not valid or surrogacy strength differed at trial and individual levels.  
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Finally, the penalised likelihood technique was more effective at dealing with 
instances of separation compared to a trial removal approach. The results in the 
ordinal-ordinal setting showed much reduced underestimation when compared to the 
binary-ordinal and ordinal-binary settings. This was because both outcomes were 
ordinal and these were more efficient estimators than the binary outcomes of the 
other settings. 
8.3 Simulation study: conclusions 
I ran a simulation to investigate how well the information theory approach in the 
ordinal-ordinal setting estimated surrogacy under a variety of scenarios.  
I found that loss of information impacted estimation of surrogacy in the observed 
ordinal-ordinal setting at the individual level with a ceiling of around 0.88. Loss of 
information was reduced compared to other setting since binary outcomes discarded 
more information than the ordinal outcomes of the ordinal-ordinal setting.  
Confidence intervals at the individual level were conservative with 100% coverage 
for all scenarios which are likely to be seen in practice. 
As in previous settings the two stage trial level surrogacy approach suffered 
modelling issues resulting in: underestimation; overestimation and separation. The 
penalized likelihood technique worked well at avoiding issues related to separation. 
Underestimation was much reduced in the ordinal-ordinal setting compared to 
previous settings since more information is retained in ordinal outcomes. 
These findings suggest that the information theory approach in the ordinal-ordinal 
setting provided a generally effective extension to the surrogacy evaluation 
framework.
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Chapter 9. Case study: All settings 
In this chapter I describe the results of a surrogacy investigation I conducted on the 
stroke clinical trial CLOTS3 (2013) for various forms of discrete true and surrogate 
variables. This case study was conducted to test the methodology extension of the 
binary-ordinal, ordinal-binary and ordinal-ordinal settings and to investigate 
surrogacy in a relevant clinical context. 
In this Chapter I:  
 introduce stroke; 
 introduce the clinical trial CLOTS3 used to investigate surrogacy;  
 introduce the primary outcome of interest and potential surrogates for each 
setting (binary-ordinal, ordinal-binary, and ordinal-ordinal); 
 introduce some practical considerations and the clinical and methodological 
questions of interest; 
 discuss how the clinical and methodology questions of interest were 
addressed following a formal assessment of surrogacy for each setting. 
9.1 Surrogacy in stroke 
Most strokes are caused by a blockage which cuts off the blood supply to the brain - 
known as an ischaemic stroke. It is estimated that around four fifths of strokes are 
ischaemic in white populations (Sandercock et al., 2008). Strokes can also be caused 
by bleeding in the brain known as a haemorrhagic stroke. In either case loss of blood 
flow to the brain leads to cell death meaning parts of the brain may stop functioning 
effectively. This can lead to serious outcomes such as severe disability, permanent 
vegetative state and death. It has been estimated that stroke causes four million 
deaths per year worldwide and is the second most common cause of death in 
developing countries (Murray and Lopez, 1996). 
9.2 CLOTS3 trial introduction 
I have used the clinical trial CLOTS3 to evaluate potential surrogates for primary 
outcomes of interest taken at six months in acute stroke patients. In this section I 
introduce: the terminology; the trial; and its findings.  
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Venous thromboembolism is the collective term for the occurrence of deep vein 
thrombosis (DVT), a blood clot in the deep veins of the legs, and pulmonary 
embolism. Pulmonary embolism (PE) occurs when clots become detached from the 
veins, travel up through the system and cause blockages to the lungs, which can 
seriously threaten a patient’s life. Venous thromboembolism is an important topic in 
health research as it is a serious and avoidable complication that causes over 25,000 
deaths a year in hospital patients in England (Committee, 2004). This is particularly 
true of stroke patients, who remain in hospital, since they are generally bedbound and 
often unable to move one side of their body. After stroke 20-42% of patients suffer a 
venous thromboembolism (CLOTS, 2013). For this reason, it is particularly 
important to reduce the occurrence of DVT in stroke patients. 
Intermittent pneumatic compression (IPC) aids are inflatable sleeves that are applied 
to the legs, and are a means of reducing the occurrence of thromboembolism in 
stroke patients. They compress the legs at fixed time intervals stimulating blood flow 
around the legs. 
CLOTS3 was a 94 centre randomised clinical trial. It was conducted to investigate 
whether IPC applied to the legs of acute stroke patients reduced the occurrence of 
DVT (CLOTS, 2013). PE was a secondary outcome of interest since this is not 
routinely measured and can be difficult to detect. There were 2,876 patients enrolled 
into the trial and randomised to either IPC or standard care. 
CLOTS3 (2013) showed that IPC reduced the odds of DVT by 30 days [OR 0.65 
(95% CI 0.51–0.84; p=0.001) after adjustment for baseline variables] and had a 
positive impact on survival at 6 months, HR 0.86 (0.74–0.99), p=0.042. 
I now introduce both a binary and an ordinal primary outcome of interest in stroke 
clinical trials. 
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9.3 Case study CLOTS3 set up 
In this section I will: 
 discuss true outcomes of interest 
 introduce potential surrogates 
 discuss the clinical surrogacy questions of interest in CLOTS3 for each 
setting;  
 outline the practical considerations required in order to carry out this 
analyses; 
 and discuss two further methodological aspects of information theory in the 
binary-ordinal setting, illustrated using the case study 
9.3.1 Ordinal true outcomes in CLOTS3 
A primary measure of treatment effect in stroke patients is the Oxford Handicap 
Scale (OHS) (Bamford et al., 1989), this is used to assess a patient’s ongoing health 
and survival. The OHS is an ordinal seven point scale of death and disability ranging 
from no disability to severe handicap and death (see Table 9.1). The OHS is used to 
assess how well a patient is recovering from stroke. A patient may expect to 
experience some recovery from their symptoms naturally in the first six months after 
stroke, any amount of further recovery after a year is less likely. Therefore, a 
measurement of the extent of disability at six months is common to investigate the 
likely ongoing disability of a stroke patient. Furthermore, OHS measured at six 
months has been shown to be a useful indicator of long term survival (Slot et al., 
2008).  
Clinicians and researchers would find it useful to know which potential surrogates 
taken at taken early can predict treatment effect on OHS. 
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Oxford Handicap Scale  (OHS)  
  
None 1 90 
Minor symptoms 2 186 
Minor handicap 3 312 
Moderate handicap 4 626 
Moderate to severe handicap 5 366 
Severe handicap 6 564 
Death 7 697 
missing  35 
Table 9.1: Oxford handicap scale: death and disability scale categories 
9.3.2 Binary true outcome in CLOTS3 
Another way that one could investigate recovery after stroke is by investigating a 
binary measure of survival at six months. Clinicians are interested in the causal 
pathway from stroke to death and investigations of surrogates that lie in this pathway 
might shed light on these mechanisms of action. 
9.3.3 Proposed surrogacy investigation in CLOTS3 
As outlined in the previous sections, I wished to investigate potential surrogates for 
the true outcome, the ordinal OHS measured at six months or the binary survival 
measure at six months, in acute stroke patients.  
In the CLOTS3 trial DVT was one such potential surrogate. As discussed, DVT after 
stroke can cause death. In less serious cases it can also be a debilitating ailment that 
may impact a patient’s ability to rehabilitate themselves. Therefore, the occurrence of 
DVT by 30 days as measured in CLOTS3 may serve as some indication of a patient’s 
likely OHS category at six months or their survival.  
This surrogate could be formed as either a binary or ordinal measure.  
  Evaluation of surrogate outcomes 
Case study: All settings 179 
9.3.3.1 Binary surrogate in CLOTS3 
In the CLOTS3 trial there were three potential configurations of the proposed binary 
surrogate DVT in the dataset. These were:  
 The occurrence of any DVT by 30 days. 
This surrogate captured the causal mechanism of action since it directly measures the 
occurrence of the event of interest. This surrogate was used as the primary endpoint 
in CLOTS3 (2013). 
 Any DVT or PE by 30 days (DVTPE) 
PEs were not routinely collected in this trial and are not easily assessed, hence there 
are so few recorded see Table 9.2. Hence, the recording of PE was unlikely to 
provide a great deal of additional information but what was available was still 
potentially worthwhile. 
 Death, any DVT or PE by 30 days (DVTPEDEAD). 
 Occurrence of DVT, PE or 







Table 9.2: Occurrence of DVT, PE or Death by thirty days 
This surrogate incorporated death without the occurrence of DVT or PE by 30 days. 
Therefore, these deaths are not related to the causal mechanism of interest (DVT). 
Therefore, biologically this surrogate was less relevant. However, a measure of death 
is also incorporated in OHS at six months, therefore, DVTPEDEAD was likely to be 
more informative than the other surrogates from a statistical perspective. As can be 
seen in Table 9.2 there are a large number of deaths by thirty days so it seemed likely 
that it would be important to have them recorded. 
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9.3.3.2 Ordinal surrogate in CLOTS3 
It is possible to consider DVT as an ordinal variable as there are various types of 
DVTs that can occur and each have different levels of severity. 
The occurrence of DVT can be either symptomatic or asymptomatic. Symptomatic 
DVTs are more serious as they are large enough to be causing symptoms (i.e. pain, 
swollen limbs etc.). Asymptomatic DVTs can be detected using ultrasound. Two 
compression duplex ultrasound scans were planned for every patient in CLOTS3. The 
first ultrasound was conducted between seven and ten days and the second between 25 
and 30 days after randomisation. Any occurrence of DVT on either scan was recorded 
as a DVT by 30 days in the CLOTS3 dataset. 
Ordinal DVT surrogate (oDVT) Value 
  
No DVT 0 
Asymptomatic distal (calf) DVT 1 
Asymptomatic proximal (Thigh) DVT 2 
Symptomatic DVT 3 
Pulmonary embolism 4 
Death 5 
  
Table 9.3: Ordinal DVT surogate outcome 
DVTs are also considered more serious if they occur in the thigh as opposed to the 
calf, referred to respectively as proximal and distal DVTs. PE is a more serious 
ailment related to DVT that could lead to death. A measure of the severity of these 
outcomes, as agreed with clinical colleagues, is presented in Table 9.3. This is a six-
point ordinal variable of increasing severity of DVT by 30 days (oDVT). 
9.3.4 Binary-ordinal setting 
In the binary-ordinal setting we assess the three binary measures of DVT occurrence 
by 30 days for the ordinal OHS assessed at six months.  
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Ideally a surrogate should encompass both biological and statistical relevancy. Two 
of the proposed binary surrogates gave biological relevancy, DVT and DVTPE since 
they represent the biological mechanism of interest. Whereas, DVTPEDEAD was 
less relevant biologically but perhaps more likely to perform well under formal 
statistical surrogacy evaluation.  
It is hard to know the exact biological workings of stroke recovery. Given this, all 
suggested binary surrogates were investigated in this setting to see if formal 
assessment shed some light on the biological mechanisms of action. 
Therefore, I performed surrogate evaluation on the three potential surrogates, DVT, 
DVTPE and DVTPEDEAD measured by 30 days in the binary-ordinal setting. 
9.3.5 Ordinal-binary setting 
In the ordinal-binary setting an ordinal measure of the severity of DVT, oDVT, by 30 
days is used as a surrogate for survival at six months. Occurrence of DVT may cause 
death therefore in the ordinal-binary setting the surrogate is in the causal pathway to 
the primary outcome of interest death at six months. 
9.3.6 Ordinal-ordinal setting 
In the ordinal-ordinal setting the oDVT surrogate is used as a surrogate for assessing 
OHS at six months. 
9.4 Surrogate evaluations overview 
In the previous settings I have introduced: CLOTs3; the primary outcomes and 
surrogates of interest; and the surrogacy investigations proposed for each setting. 
In all settings: 
 the ordinal OHS or binary survival is the true outcome; 
 acute stroke is the clinical area; 
 compression aids are the treatment class;  
 and a binary or ordinal measure of DVT is the surrogate.  
  Evaluation of surrogate outcomes 
Case study: All settings 182 
In what follows, I have formally evaluated this surrogate using the information 
theory approach in the binary-ordinal, ordinal-binary and ordinal-ordinal settings. 
9.4.1 Practical considerations 
In this section the practicalities of the case study are described. 
9.4.1.1 Regrouping centres 
 
Figure 9.1: Histogram of centre sizes 
Previously, I discussed surrogacy evaluation in relation to multiple trials but it is 
equally valid to consider centres within trials (Abrahantes et al., 2004). Therefore, I 
have based the surrogacy analysis on the centres in the CLOTS3 trial. 
CLOTS3 had 94 centres ranging in size from 1-161, see Figure 9.1. There were 25 
centres that had very small centre sizes of below ten patients. Twelve of these had 
fewer than three patients. Models based on centres of very small sizes failed. 
Furthermore, the smallest trial or centre size considered in the simulation study was 
ten patients, these scenarios showed poor estimation. Since this was the case, the 25 
centres with fewer than ten patients were grouped. They were grouped into four 
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groups of size: 27, 30, 31 and 32. The median centre size without consideration of 
the centres with very small centre sizes was 27. The median size after grouping 
remained 27. Therefore 72 reformatted groups were used in analysis. In what follows 
these reformatted groups will be referred to as trials to provide consistent 
terminology in the thesis. 
9.4.1.2 Case study: in light of simulation study findings 
It was important to make sure that none of the issues of bias reported in the 
simulation study had an impact on the results of the case study in each setting.  
The simulation study showed that underestimation at the trial level increased as the 
number of trials increased. Since there were 72 trials in the case study 
underestimation in results could potentially be substantial. As a sensitivity analysis 
the trials in CLOTS3 were reformatted into 28 groups with a median of 108 patients 
per group. This is similar to the number and size of groups that were studied in the 
simulation. The simulation showed that there is a noticeable but minor amount of 
bias present in this scenario, compared to an unknown amount of bias for a 72 trials 
scenario. 
9.4.1.3 Sensitivity analysis on the causal mechanism of interest 
In the binary-ordinal setting three binary surrogates are proposed with and without 
incorporating death by 30 days, since this is the case we can assess the impact of the 
inclusion of death by 30 days.  
However, in the ordinal-binary and ordinal-ordinal settings the surrogate is a 
composite since it includes deaths by 30 days as a category and this is also reported 
in the true outcome (death by six months or OHS). As with the binary-ordinal 
setting, it is possible that any strength of surrogacy witnessed was driven by the 
deaths that occurred within 30 days rather than being related to the mechanism of 
action of interest (DVT). To test this, sensitivity analyses were performed for the 
ordinal-binary and ordinal-ordinal settings where all patients who died within 30 
days were removed from analysis. The sensitivity analyses were applied to this 
reduced dataset and used to confirm whether DVT severity was the biggest 
determinant of surrogacy strength in these settings. 
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9.4.2 Methodological considerations 
The two stage nature of 𝑅ℎ𝑡
2  raises issues such as separation and the failure of the 
approach to take differences between trials into account, see section 9.4.2.1 and 
9.4.2.2. In this section I use the case study to demonstrate the impact of these issues. 
9.4.2.1 Separation 
In every setting, I was interested in demonstrating why ignoring the occurrence of 
separation in discrete outcomes leads to bias in trial level surrogacy. Therefore, I will 
present the results of trial level surrogacy when the occurrence of separation is 
ignored in the case study, to demonstrate the negative impact it can have. For more 
information on separation see section 3.6. 
9.4.2.2 Weighting 
Given that the 𝑅ℎ𝑡
2  is calculated in two stages the LRF is based only on one 𝐺 
2, see 
section 3.4.4.1. This leads to an issue at the trial level since the two stage approach 
does not adequately take into account the differences between trials. Tibaldi et al. 
(2003a) suggested adjusting the analysis to account for trial size. This does not totally 
solve this issue but it takes account of the fact that smaller trials may not calculate 
treatment effects with enough accuracy. If the treatment effect estimates of smaller 
trials are considered of equal importance to larger trials in second stage models, more 
accurate estimates are considered as reliable as inaccurate results and bias could be 
imposed on results. Weighting allows the estimated treatment effects of larger trials, 
that are likely to be more accurate, to have greater weight in second stage models – 
limiting potential bias. It was not necessary to apply this technique to the simulation 
study as all trial sizes were uniform, however I have done so in the case study as trial 
sizes vary largely. 
In order to adjust for trial size at the second stage of modelling a weighting term can 
be added to the linear models, see 3.4.2, based on the exact trial size, therefore trials 
that are larger contribute more to the model. Weighting can be applied to linear models 
in R using the weight term in the function lm. The weight term tells the model 
to conduct weighted least squares which in this case minimises ∑ 𝑤𝑒𝑖𝑔ℎ𝑡𝑖 ∗ 𝑒
2
𝑖  where 
𝑤𝑒𝑖𝑔ℎ𝑡𝑖 is the set weights for each trial i, R Core Team (2016). If 𝑤𝑒𝑖𝑔ℎ𝑡𝑖 in this case 
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is set to the exact size of the trial i then each trials contribution at the second stage is 
weighted according to the size of the trial with larger trials contributing more to the 
analysis. 
9.5 Case study investigation aims 
The aims of the case study were to:  
1. investigate binary and ordinal measures of DVT as surrogates for OHS or 
survival at six months; 
2. demonstrate the impact of ignoring separation in discrete surrogate and true 
outcomes; 
3. demonstrate the impact of weighting by trial size on surrogacy evaluation at 
the trial level. 
9.5.1 Clinical surrogacy investigation 
First, I present descriptive statistics of the true and surrogate outcomes in relation to 
treatment. I then present the formal evaluation of surrogacy for the proposed 
surrogates using the binary-ordinal, ordinal-binary and ordinal-ordinal information 
theory approach. 
9.5.1.1 Descriptive surrogacy investigation: binary-ordinal 
The outcomes of interest in CLOTS3 that are pertinent to our surrogacy investigation 
are discussed in more detail in the following section. These are the OHS and survival 
at six months, which are the true outcomes, and the binary DVT surrogates, DVT, 
DVTPE and DVTPEDEAD at 30 days and the ordinal oDVT. 
9.5.1.1.1 Descriptive statistics for primary measures 
9.5.1.1.1.1 Treatment by OHS 
In general there appeared to be little difference in the OHS when comparing 
treatment groups as seen in Table 9.4. There was some indication of a slight 
reduction of the number of deaths, recorded by OHS, for IPC patients and an equal 
increase in those with severe disability compared to standard care. The reduction in 
the number of deaths was in keeping with the results of CLOTS3 where a significant 
improvement in survival was found for IPC patients. Since the treatment benefit only 
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affected two categories it was possible that the odds would not be proportional 
(discussed further in section 9.5.1.2).  
The number of patients who had missing OHS data were comparable across 
treatment groups and were removed from analysis, see Table 9.4 and Figure 9.2. 
 Standard care IPC 
 
 N Column % N Column % 
     
None 45 3.2% 45 3.2% 
Minor symptoms 92 6.5% 94 6.6% 
Minor handicap 156 11.0% 156 11.0% 
Moderate handicap 320 22.5% 306 21.5% 
Moderate to severe hand. 185 13.0% 181 12.7% 
Severe handicap 255 18.0% 309 21.7% 
Death 
 
367 25.8% 330 23.2% 
missing 18  17  
     
Table 9.4: Oxford Handicap Scale by treatment 
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Figure 9.2: Ordinal OHS true outcome by treatment 
9.5.1.1.1.2 Treatment by survival at six months 
Considering the binary true outcome, death by six months, there was a small 
decrease in the number of patients who died on IPC, see Table 9.5. 
 Standard care IPC 
 
 N Column % N Column % 
     
No death by 6 months 
 
1078  75.0% 1118  77.7% 
Death by 6 months 360 25.0% 320  22.3% 
     
Table 9.5 Binary true outcome (death by six months) by treatment 
  Evaluation of surrogate outcomes 
Case study: All settings 188 
9.5.1.1.2 Descriptive statistics for surrogate measures 
9.5.1.1.2.1 Treatment by binary DVT 
Here we discuss the three binary DVT measures, DVT, DVTPE and DVTPEDEAD.  
There were 537 patients in total who suffered a DVT within 30 days. Only 16.2% of 
patients on IPC in Table 9.6 suffered a DVT within 30 days as opposed to 21.1% on 
standard care.  
A similar result was seen for DVTPE where 573 patients suffered either a DVT or 
PE within 30 days, 537 DVT and 36 PE sufferers. Here, 15 patients on IPC had a PE 
event as opposed to 21 on standard care, see Table 9.6. These results, in light of 
those for DVT, indicated that IPC reduced the occurrence of DVTPE by 30 days. 
Finally, 882 patients suffered DVT, PE or death by 30 days. This means that 309 
patients died without suffering a DVT or PE by 30 days. In Table 9.6 we see that 
11.5% of standard care patients suffered death by 30 days as opposed to only 9.9% in 
the IPC group which amounts to 23 fewer events. Again, taking these results in light 
of those for PE and DVT, this results suggests that IPC reduced the occurrence of 
DVTPEDEAD by 30 days.  
 Standard care IPC 




     
None 947 65.9%       1047 72.8%         
DVT 304 21.1% 233 16.2%    
PE 21 1.5% 15 1% 
DEAD 166 11.5%            143 9.9% 
     
Table 9.6 No adverse events, DVT, PE and patients who died by 30 days by 
treatment 
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9.5.1.1.2.2 Treatment by oDVT 
Considering the surrogate oDVT in relation to treatment it can be seen that there was 
a reduction in all the oDVT outcomes: DVT; PE; and death by 30 days for IPC 
patients. There was also an increase in the number of patients who suffer no DVT in 
comparison to standard care, see Table 9.7 and Figure 9.3. 
 Standard care IPC 
 
 N Column % N Column % 
     
No DVT 947 65.9% 1047 72.8% 
Asympt. distal DVT 92 6.4% 81 5.6% 
Asympt. proximal DVT 116 8.1% 79 5.5% 
Symptomatic DVT 96 6.7% 73 5.1% 
Pulmonary embolism 21 1.5% 15 1.0% 
Death 166 11.5% 143 9.9% 
     
Table 9.7: Ordinal DVT (oDVT) surrogate by treatment 
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Figure 9.3: oDVT surrogate by treatment 
9.5.1.2 Descriptive statistics conclusions 
All the DVT surrogates both binary and ordinal showed a relationship with 
treatment. This is in contrast to the results for, true outcome of interest, OHS which 
did not appear to show a strong relationship with treatment. There was also only a 
small indication of treatment effect on survival at six months, the other true outcome 
of interest. Ideally, surrogates should show comparable treatment relationships to the 
true outcomes of interest. 
The descriptive statistics suggested the presence of non-proportional odds for two 
categories on the seven point ordinal OHS between the treatment groups, see section 
9.5.1.1.1.1. The occurrence of deviations of the proportional odds assumption for 
only two categories on a seven-point scale was specifically investigated in the 
simulation study. The simulation found that deviations from the proportional odds 
assumption had very little impact on results. Therefore, even if there were non-
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proportional odds in the OHS between treatment groups this should not affect the 
results of the case study. 
9.5.1.3 Formal surrogacy investigation: binary-ordinal 
In the following I discuss the results of the formal surrogacy evaluation conducted on 
the three potential surrogates DVT, DVTPE and DVTPEDEAD for OHS at six 













95% CI (0.001,0.273) 
0.077 
95% CI (0.003,0.231) 
   




   




   
Table 9.8: Binary-ordinal setting: Information theory surrogacy results for binary 
surrogates DVT, DVTPE and DVTPEDEAD 
Table 9.8 gives the formal surrogacy results and Figure 9.4-1.4 shows a graphical 
representation of the second stage models of information theory at the trial level. At 
the individual level 𝑅ℎ
2=0.049 and the trial level 𝑅ℎ𝑡
2 =0.077 for the binary surrogate 
DVT. For even a moderate surrogate we would hope to see results over 0.50. The 
upper limits of the confidence intervals in either case were no higher than 0.30. 
These results indicate that DVT is not a good surrogate for OHS in stroke patients. 
DVTPE had only a few additional surrogate events to those recorded in DVT. As 
such, the results were very similar. There was also no real difference in the 
presentation of treatment effects seen in in Figure 9.5. Again, I concluded that 
DVTPE is not a good surrogate for OHS in stroke clinical trials patients on IPC. 
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For the surrogate DVTPEDEAD individual level surrogacy was 0.173 and trial level 
surrogacy was 0.186. The confidence intervals again showed a good degree of 
precision. 
These surrogate results at the trial and individual level were higher than those for 
both DVT and DVTPE. However, the results were not sufficiently high to suggest 
that DVTPEDEAD was a good surrogate for OHS at six months in stroke patients.  
 
Figure 9.4: Binary-ordinal setting: Graphical display of trial level surrogacy for 
binary surrogate indicating patients with DVT; trial size categorisation based on the 
tertiles of trial size. The regression line represents the regression of the treatment 
effects of the true outcome on those for the surrogate. 
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Figure 9.5: Binary-ordinal setting: Graphical display of trial level surrogacy for 
binary surrogate indicating patients with DVT or PE; trial size categorisation based 
on the terciles of trial size. The regression line represents the regression of the 
treatment effects of the true outcome on those for the surrogate. 
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Figure 9.6: Binary-ordinal setting: Graphical display of trial level surrogacy for 
patients with DVT, PE or who died by 30 days; trial size categorisation based on the 
terciles of trial size. The regression line represents the regression of the treatment 
effects of the true outcome on those for the surrogate. 
9.5.1.4 Formal surrogacy investigation: ordinal-binary 
A formal information theory assessment of oDVT, for survival at six months in the 
ordinal-binary setting, showed that surrogacy was 0.388 at the individual level and 
0.315 at the trial level. This can be seen in Table 9.9 and a graphical display of trial 
level surrogacy in Figure 9.7. Neither result was particularly high. Confidence 
intervals were fairly wide for individual level surrogacy but these are much narrower 
for trial level surrogacy. 
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Figure 9.7 : Ordinal-binary setting: Graphical display of trial level surrogacy for the 
ordinal DVT surrogate (oDVT); trial size categorisation based on the tertiles of trial 
size. The regression line represents the regression of the treatment effects of the true 
outcome on those for the surrogate. 
𝑹𝒉







95% CI (0.101,0.812) 
0.315 
95% CI (0.137,0.511) 
  
Table 9.9: Ordinal-binary setting: Information theory Surrogacy results for oDVT for 
binary survival at six months 
9.5.1.5 Formal surrogacy investigation: ordinal-ordinal 
The information theory approach for an ordinal DVT as a surrogate for the ordinal 
OHS showed that surrogacy was 0.257 at the individual level and 0.227 at the trial 
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level, see Table 9.9 and Figure 9.7. Neither result was particularly high. The 
confidence intervals suggest that the highest individual level and trial level surrogate 
values oDVT could take were still only representative of moderate surrogacy.  
 
Figure 9.8 : Ordinal-ordinal setting: Graphical display of trial level surrogacy for 
ordinal DVT surrogate (oDVT); trial size categorisation based on the tertiles of trial 
size. The regression line represents the regression of the treatment effects of the true 
outcome on those for the surrogate. 
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𝑹𝒉







95% CI (0.062,0.551) 
0.227 
95% CI (0.074,0.420) 
  
Table 9.10: Ordinal-ordinal setting: Information theory Surrogacy results for oDVT 
for OHS 
9.5.1.6 Consideration in relation to simulation study findings: all 
settings 
A sensitivity analysis on a regrouped dataset of 28 groups with a median of 108 
patients was conducted to assess whether the underestimation (driven by large 










Binary-ordinal setting   
DVT 0.077 
95% CI (0.003,0.231) 
0.187 
95% CI(0.008,0.494) 
   




   




   
Ordinal-binary setting 0.399 
95% CI (0.099,0.430) 
0.432 
95% CI (0.135,0.716) 
   
Ordinal-ordinal setting 0.247 
95% CI (0.107,0.414) 
0.327 
95% CI (0.065,0.631) 
   
Table 9.11: Sensitivity regrouping to investigate bias: by setting 
The sensitivity analysis results were very similar to those in the original analyses, see 
Table 9.11 and Table 9.8  Table 9.10. The trial level surrogacy results were higher in 
the sensitivity analysis in all settings, suggesting that there was underestimation in 
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the original analysis. However, the differences were not large enough to change the 
conclusions in any setting that the proposed surrogates are not good surrogates for 
the primary outcomes of interest in stoke clinical trials. 
9.5.1.7 Sensitivity analysis: ordinal-binary, ordinal-ordinal 
A further sensitivity analysis based on concern over the biological relevancy of the 
proposed surrogate in the ordinal-binary and ordinal-ordinal settings was conducted. 
To ascertain if DVT was the driving force behind the surrogacy strengths reported, 
patients that suffered deaths by 30 days were removed from the analysis. See section 
9.4.1.3 for more details. 
As can be seen in Table 9.12 the surrogacy strength under this sensitivity analysis is 
very low indeed in either setting. The highest individual level surrogacy was 0.083 
and trial level was 0.099 both for the ordinal-binary setting. This suggests that the 
results presented for the ordinal-binary and ordinal-ordinal settings were driven by 









   
Ordinal-binary 0.083 
95% CI (0.000,0.133) 
0.099 
95% CI (0.008,0.268) 
   
Ordinal-ordinal 0.061 
95% CI (0.001,0.306) 
0.090 
95% CI (0.005,0.256) 
   
Table 9.12: Sensitivity analysis removing deaths: ordinal-binary and ordinal-ordinal 
settings 
9.5.2 Conclusions on clinical investigation  
9.5.2.1 Conclusions: binary-ordinal setting 
None of DVT, DVTPE or DVTPEDEAD were strong surrogates for OHS. 
DVTPEDEAD was the best surrogate statistically because it incorporates patients 
who died by 30 days and these patients were also a component of the OHS. These 
deaths do not represent the causal mechanism of action DVT. 
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Reflecting on the results of the case study in light of the findings of the simulation 
study did not change the conclusions. 
9.5.2.2 Conclusions: ordinal-binary and ordinal-ordinal setting 
In the ordinal-binary setting it was found that oDVT by 30 days for the true outcome 
death by 6 months was a poor surrogate for stroke patients treated by IPC. In the 
ordinal-ordinal setting, an oDVT surrogate for the true outcome OHS at 6 months 
has poor surrogate potential for stroke patients treated by IPC.  
In both settings sensitivity analyses on regrouped trials showed that the bias that 
impacted results in the simulation study has limited impact the case study. Further 
sensitivity analyses indicated that the moderate strength of surrogacy found in both 
settings was driven by deaths by 30 days which were also present in the true outcome 
rather than due to the occurrence of DVT. As DVT was the causal mechanism of 
interest, this suggests that oDVT is an even poorer surrogate in either case than 
previously concluded. 
9.5.2.3 Overall conclusions 
In each setting measures of DVT were found to be poor surrogates both proposed 
primary outcomes of interest. What little surrogacy potential that was found appeared 
in each setting to be due to the deaths recorded at 30 days that were not part of the 
mechanism of interest. 
Regression diagnostics of trial level surrogacy in second stage models was performed 
for the main analysis of all proposed surrogates. No major issues with the fit of the 
models were identified, see Appendix D, D1-5 for plots and discussion.  
9.5.3 Methodology considerations: CLOTS3 
Below I discuss particular methodological points of interest for trial level surrogacy: 
separation and weighting by trial size. 
In the case of the binary-ordinal setting I use the surrogate results for DVT for 
demonstrative purposes. Hence there is just one surrogate analyses for each setting. 
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9.5.3.1 Separation 
I present surrogacy results where occurrences of separation were dealt with using the 
penalized likelihood technique and the converse case where the bias is not dealt with.  
Consider Table 9.13, the estimates of 𝑅ℎ𝑡
2  - where the penalized likelihood technique 
was applied – were quite different than where it was not applied. In the binary-
ordinal setting the results where the penalised likelihood approach was applied was 
half that of where it was not. In the ordinal-binary and ordinal-ordinal settings the 
results were much larger than where the penalized likelihood approach was not 





𝟐   
Penalized likelihood 
𝑹𝒉𝒕
𝟐   
No Penalized likelihood 
   
Binary-ordinal setting 0.077 
95% CI(0.003,0.231) 
0.145 
95% CI (0.027,0.325) 
   
Ordinal-binary setting 0.315 
95% CI (0.137,0.511) 
0.103 
95% CI (0.010,0.269) 
   
Ordinal-ordinal setting 0.227 
95% CI (0.074,0.420) 
0.105 
95% CI (0.010,0.273) 
   
Table 9.13: Results for trial level surrogacy with and without the application of the 
penalized likelihood technique, by setting 
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Figure 9.9 Binary-ordinal setting: Graphical display of trial level surrogacy for DVT 
where the penalized likelihood technique is not applied; trial size categorisation 
based on the terciles of trial size. The regression line represents the regression of the 
treatment effects of the true outcome on those for the surrogate. 
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Figure 9.10: Ordinal-binary setting: Graphical display of trial level surrogacy for 
ordinal DVT surrogate (oDVT) where the penalized likelihood technique has not 
been applied; trial size categorisation based on the tertiles of trial size. The 
regression line represents the regression of the treatment effects of the true outcome 
on those for the surrogate. 
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Figure 9.11: Ordinal-ordinal setting: Graphical display of trial level surrogacy for 
ordinal DVT surrogate (oDVT) where the penalized likelihood technique has not 
been applied; trial size categorisation based on the tertiles of trial size. The 
regression line represents the regression of the treatment effects of the true outcome 
on those for the surrogate. 
Figure 9.9 -1.9 show the graphical displays of the second stage models of trial level 
surrogacy in each setting, where separation was not dealt with. Separation occurred: 
17 times for the binary surrogate DVT; six times for oDVT; 14 times for the binary 
true outcome survival at six months; and no times for OHS at six months.  
The occurrence of separation at stage one of modelling gives rise to very large, 
biased estimates of treatment effects (see section 3.6.3). If these estimates are used in 
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analysis at the second stage they became influential outliers which impact the fit of 
the model.  
This situation can be demonstrated using the case study. In Figure 9.9-1.9 extreme 
outlying points have clearly influenced the model. The outlying points represent 
trials where separation occurred and overly large treatment effect estimates were 
returned. 𝑅ℎ𝑡
2  estimates based on models of this form are likely to be biased. Hence, 
ignoring separation leads to biased surrogacy investigations at the trial level.  
Regression diagnostic plots for second stage models for each setting show the impact 
of these outlying points on the legitimacy of these regressions, see Appendix D, D6-
D10. 
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Figure 9.12: Binary-ordinal setting – x axis scale to match Figure 9.4: Graphical 
display of trial level surrogacy for DVT where the penalized likelihood technique is 
not applied; trial size categorisation based on the terciles of trial size. The 
regression line represents the regression of the treatment effects of the true outcome 
on those for the surrogate. 
To illustrate a comparison of the regressions under the penalised likelihood approach 
and where separation is ignored we use the DVT surrogacy assessment of the binary-
ordinal setting. See Figure 5.10 - where separation was ignored (and the plot put on 
to the same scale as Figure 5.6)- to Figure 9.4 where the penalized likelihood 
approach was applied, we can see graphically that the regression line for the 
treatment effect on the surrogate against those for the true outcome is much different 
to that in Figure 5.6.The outlying points shown in Figure 9.9 are likely the reason for 
this. 
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9.5.3.2 Weighting  
A further methodological development that can be demonstrated using the case study 
data is the weighting of trial level surrogacy by trial size. As stated in section 3.4.4.1 
and 9.4.2.2 it is important to take account of trial size in the analysis as smaller trials 
will have less ability to estimate treatment effects which are used at the second stage 
of analysis. If the models at the second stage of modelling are unweighted then these 
smaller trial’s treatment estimates will contribute just as much to the model as larger 
trial’s estimates, which are likely to be more precise. Weighting by trial size should 
enable the model to put more emphasis on estimates that are more reliable. 
We can see from Table 9.14 that surrogacy at the trial level for each setting were 
only slightly different after weighting was applied and confidence intervals 
overlapped substantially.  
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𝟐   
Weighting 
𝑹𝒉𝒕
𝟐   
No weighting 
   
Binary-ordinal setting 0.077 
95% CI(0.003,0.231) 
0.106 
95% CI (0.011,0.274) 
   
Ordinal-binary setting 0.315 
95% CI (0.137,0.511) 
0.297 
95% CI (0.123,0.493) 
   
Ordinal-ordinal setting 0.227 
95% CI (0.074,0.420) 
0.215 
95% CI (0.066,0.408) 
   
Table 9.14: Results for trial level surrogacy with and without weighting by trial size, 
by setting 
9.5.3.3 Methodological conclusions 
I have demonstrated that the occurrence of separation has a serious negative impact 
on 𝑅ℎ𝑡
2  estimation. Also, the penalized likelihood approach can effectively deal with 
this issue. 
Weighting by trial size changed the 𝑅ℎ𝑡
2  results slightly. However, the benefit of 
weighting may be clearer in an investigation of a wider range of scenarios than was 
possible in this study. 
9.6 Conclusions: case study CLOTS3 
None of DVT, DVTPE, DVTPEDEAD or oDVT were worthy surrogates for the true 
outcome OHS measured at six months or IPC treated acute stroke patients. oDVT 
was also not a good surrogate for survival at six months.  
Methodological issues of interest were effectively demonstrated using the case study. 
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Chapter 10.  Discussion and conclusions 
Here I will summarise the results and conclusions of this thesis. 
10.1 Motivation 
Surrogate outcomes are biological measurements that can be used to predict the true 
treatment effect on a primary outcome of interest. The use of surrogates can provide 
shortened, smaller and less invasive trials. 
There has been a lot of development in statistical approaches to evaluating 
surrogates. However, there was previously little methodology for evaluating 
surrogates where either the surrogate or true outcome were ordinal. This thesis aimed 
to fill this gap in the literature so that clinical areas such as stroke which routinely 
use ordinal outcomes (for example the Oxford Handicap Scale) could benefit from 
the ability to evaluate surrogates. 
10.2 Aims 
The work of this thesis focused on extending, investigating and refining the current 
surrogate methodology to the case where outcomes are ordinal in nature. The main 
aims were as follows: 
1. Conduct a systematic review of all the relevant surrogate evaluation 
methodological literature. This was conducted to determine the best statistical 
approach to enable evaluation of ordinal outcomes. 
2. Extend the selected methodology to situations where either the surrogate, true 
outcome or both are ordinal. 
3. Apply a simulation to assess the resultant surrogate evaluation measures for 
ordinal outcomes. 
4. Illustrate the methodological advancements using a case study in stroke 
clinical trials data with ordinal outcomes. 
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10.3 Systematic review conclusions 
Through my assessment of the surrogacy literature, and after consideration of the 
subsequent surrogacy investigations, I conclude, that a good surrogate evaluation 
approach should: 
1. Be practically viable. 
2. Be able to inform on the causal nature of treatment effect relationships 
between the surrogate and true outcome. 
3. Identify the surrogate paradox. 
The surrogate paradox occurs when there are positive treatment 
effects on the surrogate, and a positive relationship between the 
surrogate and true outcome, but a negative treatment effect on the true 
outcome, (i.e. the surrogate will validate harmful treatments) see 
section 2.3.1.3. 
4. Inform on the surrogate’s transportability or predictive ability. 
Transportable surrogates evaluated in one trial should be able to 
inform on the treatment effect on the true outcome in a new trial. A 
surrogate that is unable to do this is useless. 
The systematic review identified two main schools of thought in surrogate evaluation 
methodology. Pragmatic multi-trial approaches (the meta-analytical and information 
theory approaches) and causality driven approaches (principal stratification and 
direct and indirect effects approaches). 
Baker and Kramer (2003) stated that where outcomes, in the surrogate context, work 
through multiple pathways (as is often the case) surrogacy assessment is difficult. 
The drive to identify causal relations between the surrogate and true outcome is 
therefore a commendable one. 
The two main schools of thought deviate in that: causal approaches aim to identify 
all the causal treatment relationships, and validate surrogates whose causal treatment 
effects fully agree with the causal treatment effects on the true outcome. At the trial 
level, the pragmatic multi-trial approaches aim to make sure that the surrogate is able 
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to predict the treatment effect on the true outcome in a new trial based on the 
treatment effect on the surrogate. This is regardless of whether the surrogate 
outcomes fully agree with those of the true outcome. Individual level surrogacy 
under the multi-trial approach requires agreement in treatment outcomes, though not 
on a causal basis. Here we see that the causal approaches hold surrogate evaluation 
up to a much higher standard than the multi-trial approaches. Unfortunately, in 
practice these higher standards are hard to fulfil. 
The current foremost causal approach, principal stratification (PS), requires the 
calculation of counterfactuals which leads to issues of identifiability. Attempts to 
resolve the issue of identifiability through the use of strict assumptions can lead to 
bias. In some very particular circumstances and under strong assumptions this 
approach is practically viable but this is not true in general. There are also conceptual 
difficulties with PS. Further checks are needed in addition to original proposals to 
determine whether surrogates fulfil the requirements of transportability and avoid the 
surrogate paradox. Practical application of these checks has not been thoroughly 
investigated and will add more complexity to an already practically difficult 
approach. Therefore, the causal based approaches only fulfil criterion 2, to a good 
standard, of the main aims I identified as important for surrogate evaluation 
approaches. 
The multi-trial approaches have a causal interpretation at the trial but not the 
individual level. This lack of causal rigour is a matter of some concern to authors 
(Frangakis and Rubin, 2004) and (Joffe and Greene, 2009). However, it could be 
argued that trial level surrogacy is more likely to be useful to trialists and therefore 
the lack of causal interpretation at the individual level is not a difficulty (Tibaldi et 
al., 2003a). Furthermore, the multi-trial approaches are well-established, provide 
intuitive, informative and practically sound approaches to surrogate evaluation. They 
can inform on the surrogate paradox unlike the other main approaches 
(VanderWeele, 2013). Finally, and most crucially, they inform of the transportability 
of the surrogate which is a vital aim of surrogacy (Joffe, 2011). Therefore the multi-
trial approaches fulfil, to a good standard, all of the main criteria I identified as 
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important for surrogate assessment approaches, unlike the causality based 
approaches.  
Of the two multi-trial approaches the information theory approach is superior to the 
meta-analytical approach since it provides a consistent interpretation across settings 
(for example the continuous, binary or ordinal settings). Therefore, this approach is 
the most worthy candidate for application and for extension to ordinal outcomes. 
10.4 Meta-analytical approach: discussion 
I will first briefly describe the predecessor to the information theory approach, the 
meta-analytical approach, which will be useful for context. 
The meta-analytical approach was based on a joint mixed model of the surrogate and 
true outcome regressed on a fixed treatment and a random treatment*trial effect. The 
joint individual level error variance covariance matrix informed individual level 
surrogacy and the joint random effects variance covariance matrix informed trial 
level surrogacy. See section 2.2.1 for models and more information. 
There are two issues with this approach:  
 First, individual level surrogacy based on this approach was inconsistent across 
different settings. This issue was the motivation for the development of the 
information theory approach.  
 Second, the joint mixed model came with extreme computational difficulties, 
which lead to the proposal of a two stage approach. Individual level surrogacy 
can be calculated at the first stage of this approach but trial level surrogacy can 
only be assessed at the second stage. This was also the case in the information 
theory approach which is an analogous approach at the trial level. The reliance 
on the two stage approach at the trial level in discrete outcomes settings leads to 
several issues. These issues will be fully discussed in reference to the 
information theory approach for ordinal outcomes in section 10.6. 
The meta-analytical and information theory approaches are intertwined as the latter 
was set up to approximate the former and the methods are analogous in many 
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respects. Therefore, a lot of publications for the meta-analytical approach are 
relevant to the information theory approach. 
10.5 Information theory methodology development: 
discussion 
Alonso and Molenberghs (2007) introduced the information theory approach. This 
uses concepts of information theory to calculate the amount of information gained 
about the (treatment effects on the) true outcome after adjustment for the (treatment 
effects on the) surrogate at the (trial) individual level. Under this approach two 
measures, 𝑅ℎ
2  and 𝑅ℎ𝑡
2 , estimate surrogacy at the individual and trial levels 
respectively. These measures fall in the unit interval and ideally both should be close 
to one to validate surrogacy. Alonso and Molenberghs (2007) took a multi-trial or 
multi-centre approach and the information theory measures can be calculated via the 
likelihood reduction factor (LRF) for continuous outcomes. The use of multiple trials 
or centres within trials would be equally valid for surrogacy evaluation (Abrahantes 
et al., 2004). In the following, I will refer to trials to represent either case. 
10.5.1 Extension of the information theory approach: 
ordinal outcomes 
This methodology has been extended at the individual and trial level to the binary-
ordinal, ordinal-binary and ordinal-ordinal settings. This was possible through 
changing the models from which the LRF is derived in the continuous context to 
accommodate discrete outcomes.  
10.5.1.1 Advancements compared to previous research 
The extension of the information theory approach to ordinal outcomes was a novel 
and useful development of the methodology.  
There have previously been two papers on information theory for discrete outcomes 
one for the binary-continuous (Tilahun et al., 2008b) and the other for the binary-
binary setting (Pryseley et al., 2007). This current work has additional advantages to 
these previous publications as outlined below. 
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10.5.1.1.1 Individual level 
In contrast to the individual level measures of the information theory approach for 
discrete outcomes in previous research (Tilahun et al., 2008b) and (Pryseley et al., 
2007) individual level surrogacy was based on a multi-trial method. This avoided the 
assumption that the “association between both variables was constant over trials” 
(Alonso et al., 2004) which may not hold in practice.  
10.5.1.1.2 Trial level  
If separation occurs in the cross tab of surrogate/true outcome*treatment for a 
particular trial this can have a serious impact on the calculation of 𝑅ℎ𝑡
2 . In the 
presence of separation the treatment effect parameters for the S and T have no unique 
maximum likelihoods which leads to difficulties in estimation for available software. 
These programs return extremely large estimates and standard errors. These 
treatment effect estimates are crucial to the calculation of 𝑅ℎ𝑡
2  as they are used at the 
second stage of modelling as response and explanatory variables. If separation 
occurs, there are influential outlying points in these second stage models and biased 
𝑅ℎ𝑡
2  estimates are returned. 
After careful consideration of the options I adopted the penalised likelihood 
technique of Firth (1993) to deal with this issue. Under this technique maximum 
likelihood estimates of treatment effect estimates are possible and the potential for 
bias in second stage models is removed. Therefore, trials where separation occurred 
are able to be retained in analysis and unbiased estimation is possible. This issue was 
not addressed in previous information theory publications with discrete outcomes 
(Tilahun et al., 2008b) and (Pryseley et al., 2007). 
10.6 Simulation studies: discussion 
Simulation studies were conducted for the binary-ordinal, ordinal-binary and ordinal-
ordinal settings. This determined how well the approaches might be expected to 
behave in practice under a range of scenarios. These scenarios:  
 varied by the size of trial and the number of trials; 
 assessed strong or weak strengths of surrogacy;  
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 assessed the case of (non) proportional odds  
 assessed the case of a (non) linear relationship;  
 and represented the case where surrogacy strengths agree or disagree between 
individual and trial levels. 
A thorough investigation was conducted into the best means of setting up the 
simulation study. One, primarily based on Burzykowski et al. (2005) was adopted 
based on the joint mixed models of the meta-analysis approach where the surrogate 
and true outcome were regressed on treatment. The parameters of the model were set 
to enable simulation and infer certain surrogacy strengths. Continuous surrogates and 
true outcomes were first simulated under this method which were then dichotomised 
or categorised to create ordinal or binary outcomes.  
10.6.1 Individual level results: discussion 
In general, individual level surrogacy performed well in all settings. The size of trial 
had a bigger impact on results than the number of trials. The IQRs in 𝑅ℎ
2 results were 
generally narrow indicating good precision in estimation.  
There seemed to be little impact on 𝑅ℎ
2 results where the proportional hazards or 
linear relationship assumptions were invalid. The same was true where surrogacy 
strengths disagreed across the individual and trial levels. 
10.6.1.1 Coverage: individual level 
The median confidence intervals showed that the confidence intervals generally had 
sensible bounds and by no means covered the whole parameter space. However, the 
coverage of the intervals was 100% in nearly every scenario, that were likely to 
occur in practice, suggesting that the intervals were conservative.  
10.6.1.2 Loss of information: individual level 
Under the simulation strategy employed, the individual level results were impacted 
by loss of information due to the categorisation or dichotomisation of simulated 
‘underlying’ continuous outcomes to ‘observed’ ordinal or binary surrogate and true 
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outcomes. This situation was true to life since binary and ordinal outcomes often 
stand in for an underlying unobservable continuum.  
Binary or ordinal surrogates have lower surrogacy potential than their underlying 
counterparts since they provide less information. It is not possible to calculate the 
true strength of surrogacy at the individual level for the observed discrete outcomes 
settings. I added an additional scenario to the simulation in order to investigate the 
ceilings on the strength of surrogacy possible in the settings involving ordinal and 
binary outcomes.  
I found that discreting continuous variables leads to a great reduction in surrogacy 
potential. For example, in the worst case of the binary-ordinal setting, surrogacy 
strength was just less than half as strong as that set at the underlying continuum. A 
comparison of the impact of loss of information across settings will be given in 
section 10.6.3.1. 
10.6.2 Trial level results: discussion 
In general trial level surrogacy estimation performed well. As loss of information 
does not theoretically affect trial level surrogacy, in discrete settings it should be able 
to estimate the strength of surrogacy set at the underlying continuum. 
10.6.2.1 General results 
In general, estimation improved as the size of trials increased. There was little bias 
imposed by scenarios which deviated from the proportional odds assumption (the 
linear relationship assumption was not relevant at the trial level). The same was true 
for scenarios where surrogacy strength differed at the trial and individual levels. 
There were three sources of bias found at the trial level. The first of these, separation, 
has been dealt with by the application of a penalised likelihood approach. The 
simulation study also identified that both underestimation and overestimation 
occurred across scenarios. All three of these issues were a result of the two stage 
estimation of trial level surrogacy and are discussed below. 
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10.6.2.1.1 Underestimation 
Underestimation was worse for small trial sizes and large trial numbers and where 
surrogacy was strong. Even for large trial sizes of 300 patients the bias was as much 
as -0.05 for 30 trials.  
This underestimation was because of the two stage approach. First, recall that the 
ability to estimate treatment effects for the true and surrogate outcomes for each trial 
was crucial in the calculation of trial level surrogacy. Any inefficiency in calculating 
these treatment effect estimates leads to bias. 
The two stage approach of trial level surrogacy can be thought of as splitting up a 
difficult computational problem into separate parts, solving each part and combining 
the results. This has been shown to lead to inefficiency in estimation which was 
worse if the number of partitions was large compared to the size of the partitions 
(Molenberghs et al., 2011). Partitions in this multi-trial context were trials. The 
worsening of underestimation with decreases in trial size and increases in number of 
trials therefore fits with this theory. 
Furthermore, the discrete nature of the outcomes in this context compounds this issue 
as discrete outcomes were shown to be much more inefficient at estimation 
compared to continuous outcomes (Taylor et al., 2006) and (Taylor and Yu, 2002).  
When large sample sizes (3000 patients) for each number of trials scenario were 
simulated unbiased estimates were returned supporting the theory of inefficiency. 
Therefore, a combination of the two stage approach and loss of information in 
discrete outcomes leads to inefficiency which in turn causes underestimation. 
10.6.2.1.2 Overestimation 
Overestimation was also present and was worse for low strengths of surrogacy and 
small numbers of trials. In the case of five trials surrogacy can be seriously 
overestimated which might lead to a false positive validation of a surrogate. This 
issue was present in results for the continuous-continuous setting also and was 
therefore not due to the discrete nature of the outcomes investigated. 
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Second stage models were based on the treatment effect estimates for each trial. 
Overestimation for small trial numbers was found to be due to models at the second 
stage suffering overfitting. Instead of modelling the true relationship, the model fits 
too closely to the data (in this case because there were too few data points). The 
models appeared to predict the response variable well and return a high 𝑅ℎ𝑡
2  even 
though the true strength of surrogacy was low. 
10.6.2.1.3 Separation 
The simulation study showed that the occurrence of separation was high in all 
settings. However, even the occurrence of one instance of separation could seriously 
bias results if not identified. Therefore, resolving this issue was extremely important. 
A penalised likelihood technique was adopted to deal with separation as it allows for 
unbiased estimation in the presence of separation. It was compared to a trial removal 
technique and found to be greatly superior: it provided less biased estimation and 
avoided the large loss of information present in the alternative.  
10.6.3 Comparison across settings: discussion 
The results as discussed above were applicable to all settings investigated in this 
thesis. However, there were particular differences in the results of the binary-ordinal, 
ordinal-binary, and the ordinal-ordinal settings.   
10.6.3.1 Differences across settings: individual level 
At the individual level the main difference between settings was in the ceiling effect. 
The ceiling for the ordinal-ordinal setting was around 0.88, the ordinal-binary was 
around 0.70 and the binary-ordinal was around 0.48 when surrogacy is set to be 
perfect, 𝑅ℎ
2=1, in the underlying continuum. 
Cox (1957) shows that the maximum amount of information retained when a 
dichotomisation occurs was 63.7%. The retention of information increased for 
categorical outcomes as the number of categorises increased. The reported largest 
amount of information retained was 94.2% for six categories: our ordinal variable 
has seven categories. These findings agree with my results as more information was 
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retained for the ordinal-ordinal setting where both outcomes were ordinal. The 
ceiling in the ordinal-ordinal setting is around 0.88 which shows a good amount of 
retention of information. 
In comparison the binary-ordinal and ordinal-binary setting have much lower 
individual level surrogacy ceilings. We see that the amount of information retained in 
the surrogate was most pertinent to the height of the ceiling. The lowest ceiling 
witnessed occurred when the surrogate was binary in the binary-ordinal setting. This 
is around 0.48 which demonstrates a very large decrease in surrogacy potential for 
the binary surrogate. Which suggests that at the individual level binary surrogates 
cannot provide enough information to act as good surrogates.  
Retaining information on the true outcome was also very important as the ceiling in 
the ordinal-ordinal setting was much higher than where the true outcome is binary in 
the ordinal-binary setting.  
In summary, loss of information in the surrogate or true outcome has a negative 
impact on surrogacy strength at the individual level. Ordinal outcomes on a seven 
point scale were vastly preferable to binary outcomes which do not provide very 
good information on surrogacy at the individual level. 
10.6.3.2 Differences across settings: trial level 
At the trial level results generally differed only in terms of underestimation and 
separation. Results for overestimation were much the same.  
10.6.3.2.1 Differences: underestimation 
Underestimation was not as severe for the ordinal-ordinal setting.  
As previously mentioned, underestimation was partially driven by inefficiency due to 
the loss of information in the discrete outcomes compared to the underlying 
continuum.  
Where regression variables were categorised inefficiency occurs, this was much 
worse for binary outcomes compared to ordinal outcomes since they suffer greater 
loss of information (Taylor et al., 2006) and (Taylor and Yu, 2002). Since, ordinal 
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outcomes were not as inefficient at estimation the underestimation was not as bad for 
the ordinal-ordinal setting. 
10.6.3.2.2 Differences: separation 
Separation occurred less frequently for the ordinal outcomes in the simulation. 
Hence, instances of separation were less in the ordinal-ordinal setting where both 
outcomes were ordinal. 
10.6.4 Comparison of simulation to previous research: 
discussion 
The simulation studies of this thesis incorporated a more thorough investigation of 
scenarios than previous simulation studies for information theory approaches. In 
addition to scenarios investigated by previous authors, I included scenarios for: weak 
strengths of surrogacy; assessment of differing strengths of surrogacy at the trial and 
individual levels; the investigation of ceiling values for individual level surrogacy; 
and extremely large trial sizes to investigate inefficiency. 
10.6.4.1 Previous research: individual level 
In this research a multi-trial surrogate evaluation method at the individual level was 
adopted. This was not used in previous discrete surrogate research for the binary-
binary or binary-continuous settings (Tilahun et al., 2008a), (Pryseley et al., 2007) 
respectively, see section 4.2.1.6.  
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Table 10.1: Median 𝑅ℎ
2 results for 30 trials and 300 patients where the true strength 
of surrogacy was 𝑅ℎ
2=0.64. Decimal places were to three dp except for binary-
continuous case where this was not provided. 
In Table 10.1 we see the information loss for strong surrogacy across previous 
studies and in my research for the intuitive best scenario of 30 patients and 300 
patients. The settings in this table was ordered, from left to right, according to the 
increasing amounts of information expected to be retained in each (expectations were 
driven by the results of my work where retention of information in S as opposed to T 
had the bigger impact). 
Results at the individual level show much more loss of information in the binary-
continuous setting, 𝑅ℎ𝑡
2 =0.16 (Pryseley et al., 2007), than any of the settings I 
investigated. This was lower than expected as the continuous true outcome does not 
suffer loss of information therefore the results of this setting should, at least, be 
higher than the binary-binary and binary-ordinal settings. Results for the binary-
binary setting (Tilahun et al., 2008a) were much lower than the results in all the 
settings I have investigated. However, this might be explained by the fact that more 
information was retained in the outcomes I investigated compared to the two binary 
outcomes of the binary-binary setting.  
However, the evidence of more impact of loss of information in the binary-binary 
and binary-continuous settings compared to those of this thesis may be explained, at 
least in part, by the fact that they have not adopted a multi-trial method. A multi-trial 
surrogate evaluation method avoids the strong assumption of constant association 
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across trials and is more in keeping with the ethos of the information theory multi -
trial approach.  
10.6.4.2 Comparison to previous research: trial level 
10.6.4.2.1 Previous research: underestimation 
Underestimation was witnessed in previous research however it was not possible to 
compare this to my research since the vast majority of this was likely to be due to 
unresolved occurrences of separation.  The impact of separation will be discussed in 
section 10.6.4.2.3. 
10.6.4.2.2 Overestimation 
In the meta-analytical approach, Burzykowski et al. (2005) investigated moderate 
surrogacy strength 𝑅ℎ𝑡
2 =0.50 for continuous outcomes. Overestimation of around 
0.04 was witnessed for the 25 trials and 50 patient scenario under simulation. This 
was a similar amount of overestimation as seen in my results for similar scenarios. At 
the trial level I would expect patterns of behaviour to be very similar between the 
meta-analytical and information theory approaches. These results therefore 
corroborate my findings to some extent. 
10.6.4.2.3 Separation 
In the case of surrogacy evaluation for discrete outcomes neither the binary-binary or 
binary-continuous settings (Tilahun et al., 2008a) and (Pryseley et al., 2007) 
respectively, dealt with the issue of separation. As such the results at the trial level 
suffered extreme underestimation in comparison to the ordinal settings I investigated.  
In the case of 30 trials and 300 patients per trial for high strengths of surrogacy a 
median 𝑅ℎ𝑡
2  of 0.764 was given in the binary-binary and 0.75 in the binary-
continuous setting when 0.90 was expected (Tilahun et al., 2008a) and (Pryseley et 
al., 2007) respectively. This was in comparison to 0.865 in the binary-ordinal, 0.854 
in the ordinal-binary and 0.895 in the ordinal-ordinal setting results for the same 
scenarios in my work.  
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These previous publications, therefore, demonstrate the serious negative impact of 
ignoring the presence of separation in evaluating surrogacy.  
10.7 Simulation study: conclusions 
The simulation study provided a more thorough examination of a more 
comprehensive range of scenarios than previous research based on the information 
theory approach. 
In general, trial and individual level surrogacy evaluation performed well using the 
information theory methodology for ordinal outcomes developed in Chapter 3, 
Chapter 5 and Chapter 7. 
Loss of information meant that individual level surrogacy for the observed discrete 
outcome setting was negatively impacted. Ordinal outcomes were less impacted than 
binary outcomes especially in regard to the surrogate outcome. Potentially a multi-
trial approach led to improved results compared to previous literature (Tilahun et al., 
2008a) and (Pryseley et al., 2007) although this may be due to other factors. 
Confidence intervals for individual level surrogacy where found to be conservative. 
The two stage nature of trial level surrogacy led to three issues: overestimation; 
underestimation; and separation. Overestimation was due to overfitting in second 
stage models. Underestimation and separation were due to issues in estimation in 
stage one models.  
Of these three issues, separation had the potential to cause the most serious bias. If 
separation occurred even once within a trial and went unnoticed the 𝑅ℎ𝑡
2  results were 
likely to be unsound. A penalised likelihood approach was applied to address these 
issues which removed bias and avoided the serious issues of loss of information. In 
comparison to ignoring the problem as was done in previous literature (Tilahun et al., 
2008a) and (Pryseley et al., 2007) bias was reduced. This was a highly beneficial 
development for surrogacy evaluation in discrete settings. 
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10.8 Case study: discussion 
I used the CLOTS3 (2013) trial to investigate ordinal surrogates and true outcomes 
using the information theory methodology under all the theoretical settings 
investigated in this thesis.  
DVT is a serious event which causes pain and discomfort and may lead to life 
threatening events. A routine measurement of outcome for stoke patients is the 
Oxford Handicap Scale (OHS) typically measured at six months. The OHS is a 
measure of death and disability and records the severity of ongoing amounts of 
disability of patients who suffered a stroke. I was interested in whether some 
measurement of DVT may be a surrogate for death at six months or OHS. 
 
CLOTS3 (2013) investigated whether intermittent pneumatic compression aids (IPC) 
applied to the legs reduced the occurrence of DVT by thirty days. I used this trial to 
investigate whether: 
 a binary indicator of occurrence of DVT by 30 days was a surrogate for OHS 
at six months 
o using the information theory approach for the binary-ordinal setting 
 an ordinal measure of DVT by 30 days was a good surrogate for death at six 
months 
o using the information theory approach for the ordinal-binary setting 
 an ordinal measure of DVT by 30 days was a good surrogate for OHS at six 
months 
o using the information theory approach for the ordinal-ordinal setting. 
10.8.1 Clinical findings: discussion 
I found that none of the proposed surrogates were good surrogates for OHS at six 
months for stroke patients. What little surrogacy potential was available was mostly 
driven by deaths within 30 days that were recorded as part of the DVT surrogate 
measures, rather than driven by the mechanism of interest DVT. Therefore, DVT was 
not a good surrogate in its own right for either death or OHS at six months in stroke 
clinical trials patients on IPC.  
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10.8.2 Methodological findings: discussion 
10.8.2.1 Separation 
The case study was used to demonstrate the benefits of the penalized likelihood 
approach to deal with instances of separation. The graphical displays of trial level 
surrogacy where separation was not dealt with showed the extreme impact on 
surrogacy evaluation imposed by this issue.  
10.8.2.2 Weighting 
Tibaldi et al. (2003b) suggested using a weighting technique, based on trial size, at 
the second stage of trial level surrogacy to partially account for differences between 
trials. I provided results with and without weighting and found limited impact on 
surrogacy estimation.  
10.9 Case study: conclusions 
I found that both binary and ordinal measures of DVT were not good surrogates for 
death or OHS at six months in stroke clinical trials patients on IPC.  
The case study showed that separation frequently occurred in real life scenarios. The 
results also told a cautionary tale of the dangers of ignoring instances of separation 
when evaluating surrogacy for discrete outcomes. It also showed how effectively the 
penalized likelihood removed the instances of bias associated with separation. 
The usefulness of weighting by trial size to partially account for differences between 
trials was not strongly demonstrated in this work. 
10.10 Future work 
This thesis has provided a useful extension of surrogate evaluation using the 
information theory approach and a thorough examination of the various ways in 
which this works in practice. It has identified areas where: investigation to give 
further insight into the mechanics of this approach are needed; and development of 
the methodology to overcome issues raised in this work is required. 
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10.10.1 Confidence intervals: individual level 
The confidence intervals at the individual level were found to be conservative. 
Bootstrap intervals were suggested by Tilahun et.al. (2008a) to give improved 
precision in confidence intervals for the information theory approach in the binary-
binary setting. Therefore, the development of bootstrap intervals in the ordinal 
settings covered in this thesis may resolve the issue of the conservative confidence 
intervals seen in my work. 
10.10.2 Number of ordinal categories 
In the simulation study, I showed that the use of seven point ordinal outcomes gives 
superior results to binary outcomes in a number of different ways: first, loss of 
information was not as severe at the individual level; second, underestimation was 
not as bad at the trial level; and finally, separation does not occur as frequently. 
However, a seven point ordinal outcome retains a lot of information compared to 
ordinal outcomes with less categories. A full investigation of ordinal outcomes with a 
range of numbers of categories would better demonstrate how evaluation of ordinal 
surrogates and true outcomes would behave in real life scenarios. 
10.10.3 Trial level 
I have demonstrated that the two stage approach at the trial level has led to three 
issues with trial level surrogacy: separation; underestimation and overestimation. 
Previous research used random effects models at stage one or a weighting method at 
stage two to partially deal with potential issues in the two stage approach (Tibaldi et 
al., 2003b). Another alternative, not previously proposed, is to consider a Bayesian 
analysis. These three potential solutions are now considered in turn. 
10.10.3.1 Trial level: weighting 
Tibaldi et al. (2003b) suggested using a weighting technique based on trial size, see 
section 10.8.2.2, to partially account for differences between trials in the calculation 
of 𝑅ℎ𝑡
2 . 
  Evaluation of surrogate outcomes 
Conclusion 227 
The simulations used in this thesis adopted the approach of previous research and 
used trials of equal sizes in each scenario. Therefore, it was unnecessary to apply a 
weighting technique based on trial size. 
In the case studies I have applied the weighting technique so that differences in trials 
were partially accounted for. The benefit of this approach was not strongly 
demonstrated. However, these applications were only under the conditions of one 
specific scenario where surrogacy was generally weak and the true strength of 
surrogacy was unknown. Therefore, in order to determine the true benefit of the 
weighting technique it might be useful to conduct a simulation study for various 
scenarios where the size of trial varies within each simulated set of trials and the true 
value of surrogacy is known. 
10.10.3.2 Trial level: random effects 
Previous approaches have used mixed models at the first stage of the two stage 
approach to potentially provide better estimation of treatment effects, suggested in 
Tibaldi et al. (2003b). These were applied for discrete outcomes in the information 
theory approach in Pryseley et al.(2007) and Tilahun et al. (2008b). Such an 
approach might limit the underestimation witnessed in my results if a random effects 
approach is more efficient at estimation. 
We could hypothetically have adopted a random effects approach for our ordinal 
outcome settings. I have done some preliminary investigation into the feasibility of 
this. Where there were ordinal outcomes, under current statistical software, it was 
possible to model random effects for proportional odds models. However, it was only 
possible to get an overall random treatment effects estimate for trial*treatment. 
Unfortunately, the information theory approach requires treatment effect estimates 
for each trial. In the frequentist context it is difficult to integrate over random effects 
for discrete responses (McCulloch and Searle, 2001). Approximations of the 
estimates needed are possible for binary outcomes but the present available software 
would suggest this is not the case for ordinal outcomes. Therefore, these estimates 
cannot be provided. There were packages available that provided these results using 
a Bayesian approach but initial investigation returned nonsensical results for 
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uninformative priors. In order to make a random effects approach possible for ordinal 
outcomes more investigation of the Bayesian option is needed. 
A Bayesian approach could be a big undertaking for potentially little reward (i.e. if a 
random effects approach has little additional benefit in estimation compared to the 
fixed effects approach). 
10.10.3.3 Trial level: Bayesian joint mixed model 
The main difficulties of discrete outcome surrogacy evaluation at the trial level were 
due to the two stage nature of the information theory approach. The two stage 
approach was necessary because the original joint modelling approach of the meta-
analytical approach was too computationally burdensome. In the original proposal 
trial level surrogacy was based on the variance covariance matrix of a frequentist 
joint mixed model, see section 10.4. Therefore, only a one stage approach was 
needed. If it had been computationally effective this original proposal would have 
been the ideal means of evaluating surrogacy at the trial level. Under this approach 
the issues encountered at stage two of the approach I used would not occur. 
Potentially, a Bayesian one stage meta-analytical approach could resolve the 
computational issues of the frequentist approach as Bayesian analysis is more 
flexible than frequentist methods. Developing and testing a Bayesian method would 
potentially be a large undertaking and may also have a high computational burden. 
10.11 Conclusions 
In conclusion, this work provides an important investigation of the methodological 
approaches for evaluation of surrogacy which carefully examined the advantages and 
disadvantages of the main approaches. It also provides an essential extension of the 
means of evaluating surrogacy for ordinal outcomes.  
The information theory approach, for ordinal outcomes, has been extremely well 
investigated via simulation and case study. The simulation studies were much more 
thorough than any previous publications in information theory in terms of the 
scenarios investigated and the attention given to understanding patterns in results (the 
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latter point proved by the oversight of previous authors (Tilahun et al., 2008b) and 
(Pryseley et al., 2007) to identify the presence of separation or highlight the bias in 
results). 
These investigations have identified the probable ceiling strengths of binary and 
ordinal surrogates at the individual level and three previously unknown issues 
relating to the calculation of trial level surrogacy. These issues are: separation and 
underestimation which were particular to discrete outcome settings; and 
overestimation which was a serious issue present in all settings. Of the three the most 
extreme bias was imposed by separation; the occurrence of which can have an 
extremely detrimental impact on results. The separation issue has been resolved 
through the application of a penalized likelihood approach, which performed 
extremely well in the simulation and case studies. The other issues of overestimation 
and underestimation were not so easily remedied. Random effects and weighting 
approaches may provide partial improvement for the underestimation but a joint 
mixed model Bayesian approach may be the best solution for both these issues. 
To summarise: the methodological work of this thesis has: filled a gap in the 
literature to provide clinicians, trialists and researchers with the means of evaluating 
surrogates in the case of ordinal outcomes; been shown to work well in practice; and 
provided a solution to the serious issue of separation. The simulation study 
investigations will help researchers to better understand the behaviour of the 
information theory approach under a wide range of scenarios. It has also identified 
issues in estimation that require resolution. Finally, the case studies conducted ruled 
out DVT as a potential surrogate for death or OHS at six months in stroke patients 
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Appendix A: Binary-ordinal 
Tables presented here are for a binary surrogate and ordinal true outcome, for each 
scenario covered in the simulation for the binary-ordinal setting. The results given 
are the median 𝑅 
2 values at the trial and individual level for each scenario, the IQR, 
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5 10 0.347 0.154 100% 0.046 0.757 
5 20 0.318 0.127 100% 0.062 0.650 
5 40 0.307 0.093 100% 0.103 0.562 
5 60 0.305 0.086 100% 0.126 0.519 
5 100 0.300 0.063 99% 0.155 0.465 
5 150 0.311 0.058 99% 0.185 0.446 
5 200 0.307 0.062 98% 0.198 0.426 
5 300 0.304 0.058 96% 0.213 0.401 
       
10 10 0.337 0.107 100% 0.046 0.742 
10 20 0.310 0.071 100% 0.066 0.641 
10 40 0.298 0.069 100% 0.096 0.547 
10 60 0.293 0.063 100% 0.121 0.499 
10 100 0.302 0.056 100% 0.156 0.467 
10 150 0.298 0.051 100% 0.178 0.433 
10 200 0.300 0.045 99% 0.194 0.417 
10 300 0.294 0.040 99% 0.207 0.389 
       
20 10 0.342 0.072 100% 0.046 0.743 
20 20 0.301 0.060 100% 0.064 0.629 
20 40 0.302 0.044 100% 0.098 0.547 
20 60 0.297 0.039 100% 0.121 0.501 
20 100 0.293 0.036 100% 0.151 0.455 
20 150 0.294 0.034 100% 0.173 0.427 
20 200 0.295 0.031 100% 0.188 0.411 
20 300 0.292 0.031 100% 0.205 0.386 
       
30 10 0.340 0.071 100% 0.047 0.739 
30 20 0.307 0.044 100% 0.064 0.628 
30 40 0.301 0.040 100% 0.100 0.545 
30 60 0.295 0.033 100% 0.121 0.500 
30 100 0.294 0.027 100% 0.151 0.454 
30 150 0.297 0.024 100% 0.176 0.429 
30 200 0.293 0.023 100% 0.187 0.408 
30 300 0.293 0.025 100% 0.206 0.387 
Table A.1: Simulation binary-ordinal: 𝑅ℎ
2 results. Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 and 
the odds are proportional 
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5 10 0.781 0.367 82% 0.120 0.988 
5 20 0.850 0.207 90% 0.222 0.994 
5 40 0.908 0.184 88% 0.359 0.997 
5 60 0.923 0.146 93% 0.408 0.998 
5 100 0.924 0.135 92% 0.411 0.998 
5 150 0.947 0.114 91% 0.502 0.999 
5 200 0.939 0.115 93% 0.468 0.998 
5 300 0.949 0.111 93% 0.513 0.999 
       
10 10 0.616 0.304 68% 0.121 0.922 
10 20 0.737 0.239 72% 0.249 0.957 
10 40 0.805 0.175 76% 0.352 0.973 
10 60 0.838 0.153 84% 0.412 0.979 
10 100 0.862 0.132 91% 0.462 0.984 
10 150 0.869 0.127 94% 0.479 0.985 
10 200 0.885 0.119 93% 0.516 0.987 
10 300 0.900 0.090 95% 0.553 0.990 
       
20 10 0.571 0.203 45% 0.207 0.843 
20 20 0.681 0.175 47% 0.328 0.897 
20 40 0.792 0.125 70% 0.485 0.943 
20 60 0.803 0.120 76% 0.503 0.947 
20 100 0.831 0.098 86% 0.552 0.957 
20 150 0.840 0.104 86% 0.568 0.960 
20 200 0.861 0.083 92% 0.606 0.966 
20 300 0.870 0.082 95% 0.625 0.969 
       
30 10 0.549 0.169 21% 0.249 0.791 
30 20 0.671 0.126 30% 0.384 0.864 
30 40 0.766 0.116 53% 0.512 0.913 
30 60 0.798 0.100 69% 0.560 0.928 
30 100 0.829 0.092 83% 0.611 0.942 
30 150 0.846 0.078 85% 0.640 0.949 
30 200 0.849 0.069 85% 0.645 0.950 
30 300 0.865 0.065 94% 0.672 0.957 
Table A.2: Simulation binary-ordinal: 𝑅ℎ𝑡
2 results, Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 and 
the odds are proportional 
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5 10 0.336 0.172 100% 0.042 0.745 
5 20 0.315 0.130 100% 0.063 0.643 
5 40 0.301 0.096 100% 0.100 0.553 
5 60 0.302 0.078 100% 0.120 0.516 
5 100 0.304 0.064 99% 0.158 0.471 
5 150 0.302 0.060 99% 0.177 0.440 
5 200 0.297 0.065 98% 0.188 0.415 
5 300 0.301 0.056 97% 0.211 0.396 
       
10 10 0.330 0.106 100% 0.043 0.742 
10 20 0.301 0.079 100% 0.060 0.635 
10 40 0.299 0.060 100% 0.096 0.547 
10 60 0.300 0.058 100% 0.121 0.507 
10 100 0.294 0.052 100% 0.152 0.457 
10 150 0.294 0.047 100% 0.173 0.428 
10 200 0.294 0.039 100% 0.187 0.411 
10 300 0.298 0.046 99% 0.209 0.394 
       
20 10 0.327 0.082 100% 0.046 0.736 
20 20 0.303 0.059 100% 0.065 0.629 
20 40 0.298 0.041 100% 0.097 0.545 
20 60 0.292 0.033 100% 0.119 0.497 
20 100 0.291 0.039 100% 0.148 0.452 
20 150 0.295 0.033 100% 0.174 0.428 
20 200 0.292 0.027 100% 0.187 0.406 
20 300 0.291 0.033 100% 0.203 0.384 
       
30 10 0.327 0.073 100% 0.045 0.730 
30 20 0.304 0.046 100% 0.062 0.628 
30 40 0.293 0.038 100% 0.094 0.539 
30 60 0.290 0.031 100% 0.118 0.495 
30 100 0.290 0.031 100% 0.147 0.451 
30 150 0.291 0.027 100% 0.172 0.425 
30 200 0.290 0.025 100% 0.185 0.405 
30 300 0.288 0.025 100% 0.202 0.381 
Table A.3: Simulation binary-ordinal: 𝑅ℎ
2 results. Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.30 and 
the odds are proportional 
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5 10 0.672 0.485 70% 0.039 0.976 
5 20 0.670 0.446 74% 0.037 0.976 
5 40 0.673 0.476 72% 0.039 0.976 
5 60 0.637 0.490 72% 0.026 0.971 
5 100 0.680 0.437 80% 0.042 0.977 
5 150 0.617 0.482 80% 0.021 0.968 
5 200 0.644 0.471 77% 0.028 0.972 
5 300 0.612 0.471 80% 0.020 0.967 
       
10 10 0.363 0.390 79% 0.008 0.811 
10 20 0.386 0.308 87% 0.011 0.824 
10 40 0.378 0.335 94% 0.010 0.820 
10 60 0.414 0.358 93% 0.016 0.839 
10 100 0.428 0.344 93% 0.020 0.846 
10 150 0.404 0.329 93% 0.014 0.834 
10 200 0.446 0.300 94% 0.025 0.854 
10 300 0.374 0.353 97% 0.009 0.818 
       
20 10 0.296 0.229 92% 0.024 0.656 
20 20 0.326 0.194 99% 0.036 0.679 
20 40 0.319 0.219 95% 0.033 0.674 
20 60 0.339 0.246 98% 0.042 0.690 
20 100 0.331 0.208 96% 0.038 0.683 
20 150 0.329 0.219 95% 0.037 0.681 
20 200 0.347 0.267 97% 0.045 0.696 
20 300 0.343 0.247 96% 0.043 0.693 
       
30 10 0.261 0.187 98% 0.036 0.564 
30 20 0.306 0.181 95% 0.059 0.606 
30 40 0.324 0.188 93% 0.069 0.620 
30 60 0.315 0.182 91% 0.064 0.612 
30 100 0.331 0.213 92% 0.073 0.628 
30 150 0.349 0.220 92% 0.085 0.642 
30 200 0.277 0.195 94% 0.044 0.577 
30 300 0.340 0.202 95% 0.079 0.634 
Table A.4: Simulation binary-ordinal: 𝑅ℎ𝑡
2  results. Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.30 
and the odds are proportional 
  Evaluation of surrogate outcomes 

















5 10 0.213 0.125 100% 0.012 0.655 
5 20 0.174 0.104 100% 0.015 0.499 
5 40 0.149 0.055 100% 0.022 0.387 
5 60 0.147 0.056 100% 0.029 0.339 
5 100 0.146 0.044 100% 0.044 0.293 
5 150 0.137 0.043 100% 0.052 0.254 
5 200 0.138 0.033 100% 0.061 0.238 
5 300 0.140 0.028 99% 0.074 0.223 
       
10 10 0.214 0.093 100% 0.016 0.651 
10 20 0.161 0.060 100% 0.014 0.486 
10 40 0.146 0.040 100% 0.022 0.376 
10 60 0.140 0.040 100% 0.028 0.328 
10 100 0.141 0.028 100% 0.042 0.286 
10 150 0.137 0.027 100% 0.052 0.253 
10 200 0.134 0.025 100% 0.059 0.233 
10 300 0.134 0.022 100% 0.071 0.215 
       
20 10 0.215 0.068 100% 0.019 0.647 
20 20 0.165 0.040 100% 0.016 0.489 
20 40 0.144 0.029 100% 0.023 0.372 
20 60 0.142 0.030 100% 0.031 0.329 
20 100 0.138 0.023 100% 0.042 0.282 
20 150 0.136 0.017 100% 0.052 0.252 
20 200 0.133 0.015 100% 0.059 0.232 
20 300 0.133 0.017 100% 0.070 0.214 
       
30 10 0.208 0.050 100% 0.018 0.646 
30 20 0.165 0.032 100% 0.019 0.488 
30 40 0.147 0.028 100% 0.023 0.378 
30 60 0.143 0.022 100% 0.031 0.330 
30 100 0.136 0.018 100% 0.041 0.279 
30 150 0.134 0.018 100% 0.051 0.250 
30 200 0.132 0.013 100% 0.058 0.230 
30 300 0.133 0.013 100% 0.070 0.212 
Table A.5: Simulation binary-ordinal: 𝑅ℎ
2 results. Where 𝑅ℎ
2=0.30 and 𝑅ℎ𝑡
2 =0.90 and 
the odds are proportional 
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5 10 0.753 0.325 85% 0.091 0.986 
5 20 0.821 0.232 90% 0.173 0.992 
5 40 0.866 0.222 86% 0.254 0.995 
5 60 0.902 0.174 88% 0.341 0.997 
5 100 0.913 0.154 93% 0.376 0.997 
5 150 0.935 0.131 92% 0.453 0.998 
5 200 0.937 0.099 94% 0.462 0.998 
5 300 0.947 0.101 92% 0.504 0.999 
       
10 10 0.531 0.320 74% 0.061 0.891 
10 20 0.681 0.244 71% 0.183 0.943 
10 40 0.785 0.190 81% 0.319 0.969 
10 60 0.826 0.159 88% 0.389 0.977 
10 100 0.852 0.148 85% 0.442 0.982 
10 150 0.881 0.129 90% 0.506 0.987 
10 200 0.885 0.115 93% 0.515 0.987 
10 300 0.896 0.085 96% 0.543 0.989 
       
20 10 0.451 0.226 38% 0.106 0.770 
20 20 0.632 0.192 29% 0.271 0.874 
20 40 0.726 0.139 56% 0.386 0.916 
20 60 0.774 0.136 71% 0.457 0.936 
20 100 0.817 0.104 83% 0.527 0.952 
20 150 0.834 0.105 86% 0.557 0.958 
20 200 0.849 0.106 92% 0.584 0.963 
20 300 0.861 0.081 94% 0.607 0.966 
       
30 10 0.447 0.194 17% 0.156 0.720 
30 20 0.601 0.162 16% 0.303 0.823 
30 40 0.714 0.126 34% 0.439 0.887 
30 60 0.757 0.103 55% 0.499 0.909 
30 100 0.798 0.088 79% 0.561 0.928 
30 150 0.829 0.080 88% 0.611 0.942 
30 200 0.838 0.089 85% 0.626 0.946 
30 300 0.857 0.066 92% 0.658 0.953 
Table A.6: Simulation binary-ordinal: 𝑅ℎ𝑡
2  results. Where 𝑅ℎ
2=0.30 and 𝑅ℎ𝑡
2 =0.90 
and the odds are proportional  
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5 10 0.216 0.142 100% 0.013 0.659 
5 20 0.166 0.089 100% 0.014 0.493 
5 40 0.154 0.064 100% 0.021 0.385 
5 60 0.147 0.056 100% 0.030 0.336 
5 100 0.135 0.043 100% 0.038 0.282 
5 150 0.138 0.040 100% 0.052 0.256 
5 200 0.137 0.039 99% 0.061 0.238 
5 300 0.135 0.033 99% 0.070 0.216 
       
10 10 0.211 0.101 100% 0.018 0.648 
10 20 0.166 0.057 100% 0.015 0.493 
10 40 0.151 0.048 100% 0.023 0.384 
10 60 0.141 0.037 100% 0.029 0.327 
10 100 0.136 0.032 100% 0.041 0.281 
10 150 0.135 0.027 100% 0.051 0.250 
10 200 0.131 0.025 100% 0.057 0.229 
10 300 0.134 0.023 100% 0.070 0.214 
       
20 10 0.212 0.070 100% 0.018 0.645 
20 20 0.164 0.045 100% 0.017 0.489 
20 40 0.145 0.032 100% 0.023 0.377 
20 60 0.139 0.029 100% 0.030 0.325 
20 100 0.136 0.021 100% 0.041 0.279 
20 150 0.133 0.016 100% 0.051 0.248 
20 200 0.134 0.018 100% 0.059 0.232 
20 300 0.131 0.017 100% 0.068 0.210 
       
30 10 0.209 0.050 100% 0.018 0.645 
30 20 0.163 0.041 100% 0.016 0.488 
30 40 0.145 0.027 100% 0.023 0.375 
30 60 0.140 0.022 100% 0.030 0.328 
30 100 0.136 0.019 100% 0.040 0.279 
30 150 0.134 0.016 100% 0.051 0.249 
30 200 0.132 0.015 100% 0.058 0.229 
30 300 0.131 0.011 100% 0.068 0.210 
Table A.7: Simulation binary-ordinal: 𝑅ℎ
2 results: Where 𝑅ℎ
2=0.30 and 𝑅ℎ𝑡
2 =0.30 and 
the odds are proportional 
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5 10 0.561 0.539 74% 0.011 0.959 
5 20 0.647 0.438 72% 0.029 0.973 
5 40 0.653 0.402 79% 0.031 0.973 
5 60 0.596 0.485 76% 0.016 0.965 
5 100 0.670 0.491 71% 0.038 0.976 
5 150 0.687 0.415 76% 0.046 0.978 
5 200 0.638 0.426 80% 0.026 0.971 
5 300 0.658 0.473 79% 0.033 0.974 
       
10 10 0.327 0.326 76% 0.005 0.790 
10 20 0.389 0.300 92% 0.012 0.826 
10 40 0.400 0.381 96% 0.013 0.831 
10 60 0.440 0.366 91% 0.023 0.852 
10 100 0.431 0.360 95% 0.020 0.847 
10 150 0.448 0.373 95% 0.025 0.855 
10 200 0.415 0.385 94% 0.016 0.839 
10 300 0.401 0.385 95% 0.014 0.832 
       
20 10 0.238 0.227 92% 0.009 0.602 
20 20 0.276 0.230 98% 0.017 0.637 
20 40 0.327 0.239 98% 0.036 0.680 
20 60 0.324 0.299 95% 0.035 0.678 
20 100 0.329 0.202 97% 0.037 0.682 
20 150 0.295 0.261 97% 0.024 0.654 
20 200 0.332 0.228 96% 0.038 0.684 
20 300 0.333 0.224 96% 0.039 0.685 
       
30 10 0.211 0.171 97% 0.017 0.510 
30 20 0.249 0.179 93% 0.031 0.550 
30 40 0.281 0.192 82% 0.046 0.581 
30 60 0.283 0.176 88% 0.047 0.583 
30 100 0.303 0.154 92% 0.057 0.601 
30 150 0.312 0.200 91% 0.062 0.610 
30 200 0.302 0.208 95% 0.057 0.600 
30 300 0.313 0.164 94% 0.063 0.610 
Table A.8 : Simulation binary-ordinal: 𝑅ℎ𝑡
2  results: Where 𝑅ℎ
2=0.30 and 𝑅ℎ𝑡
2 =0.30 
and the odds are proportional 
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5 10 0.344 0.160 100% 0.040 0.754 
5 20 0.318 0.115 100% 0.067 0.651 
5 40 0.304 0.083 100% 0.096 0.555 
5 60 0.310 0.087 99% 0.125 0.522 
5 100 0.308 0.063 100% 0.160 0.474 
5 150 0.304 0.064 98% 0.180 0.440 
5 200 0.300 0.051 99% 0.193 0.419 
5 300 0.302 0.058 95% 0.212 0.398 
       
10 10 0.322 0.114 100% 0.044 0.731 
10 20 0.311 0.084 100% 0.067 0.639 
10 40 0.299 0.059 100% 0.097 0.548 
10 60 0.295 0.051 100% 0.120 0.500 
10 100 0.296 0.051 100% 0.152 0.459 
10 150 0.296 0.049 100% 0.174 0.430 
10 200 0.297 0.040 100% 0.189 0.414 
10 300 0.288 0.050 100% 0.202 0.384 
       
20 10 0.333 0.078 100% 0.047 0.738 
20 20 0.304 0.056 100% 0.063 0.629 
20 40 0.294 0.052 100% 0.096 0.542 
20 60 0.294 0.038 100% 0.119 0.499 
20 100 0.294 0.033 100% 0.150 0.454 
20 150 0.293 0.032 100% 0.172 0.426 
20 200 0.292 0.034 100% 0.186 0.408 
20 300 0.292 0.031 100% 0.203 0.386 
       
30 10 0.330 0.066 100% 0.047 0.739 
30 20 0.297 0.051 100% 0.062 0.625 
30 40 0.293 0.036 100% 0.095 0.539 
30 60 0.292 0.036 100% 0.119 0.496 
30 100 0.290 0.030 100% 0.150 0.451 
30 150 0.292 0.030 100% 0.172 0.425 
30 200 0.292 0.026 100% 0.187 0.408 
30 300 0.288 0.021 100% 0.201 0.381 
Table A.9: Simulation binary-ordinal: 𝑅ℎ
2 results: Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 and 
the odds are non-proportional 
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5 10 0.791 0.311 86% 0.132 0.989 
5 20 0.856 0.275 90% 0.233 0.994 
5 40 0.906 0.154 92% 0.354 0.997 
5 60 0.916 0.152 88% 0.386 0.998 
5 100 0.920 0.124 91% 0.399 0.998 
5 150 0.936 0.124 93% 0.457 0.998 
5 200 0.927 0.147 92% 0.423 0.998 
5 300 0.945 0.114 93% 0.494 0.999 
       
10 10 0.595 0.304 72% 0.103 0.915 
10 20 0.748 0.226 69% 0.264 0.960 
10 40 0.803 0.137 81% 0.349 0.972 
10 60 0.837 0.133 86% 0.410 0.979 
10 100 0.858 0.129 89% 0.453 0.983 
10 150 0.881 0.113 92% 0.504 0.987 
10 200 0.886 0.114 90% 0.517 0.987 
10 300 0.881 0.123 93% 0.506 0.987 
       
20 10 0.533 0.221 41% 0.171 0.821 
20 20 0.683 0.161 41% 0.330 0.898 
20 40 0.771 0.134 60% 0.452 0.935 
20 60 0.808 0.120 79% 0.511 0.949 
20 100 0.827 0.101 79% 0.544 0.955 
20 150 0.844 0.093 89% 0.574 0.961 
20 200 0.852 0.085 93% 0.590 0.964 
20 300 0.858 0.080 94% 0.602 0.966 
       
30 10 0.525 0.164 21% 0.224 0.777 
30 20 0.668 0.138 30% 0.381 0.862 
30 40 0.757 0.125 53% 0.499 0.909 
30 60 0.788 0.098 64% 0.545 0.924 
30 100 0.833 0.077 81% 0.617 0.943 
30 150 0.829 0.078 87% 0.611 0.942 
30 200 0.833 0.081 87% 0.618 0.944 
30 300 0.858 0.080 94% 0.661 0.954 
Table A.10: Simulation binary-ordinal: 𝑅ℎ𝑡
2  results: Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 
and the odds are non-proportional   
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5 10 0.521 0.174 100% 0.109 0.856 
5 20 0.521 0.163 98% 0.196 0.796 
5 40 0.530 0.146 95% 0.291 0.746 
5 60 0.531 0.155 93% 0.332 0.714 
5 100 0.516 0.156 86% 0.368 0.648 
5 150 0.530 0.136 81% 0.405 0.656 
5 200 0.536 0.151 71% 0.426 0.642 
5 300 0.490 0.155 53% 0.413 0.566 
       
10 10 0.500 0.113 100% 0.108 0.840 
10 20 0.505 0.109 100% 0.193 0.777 
10 40 0.501 0.097 98% 0.277 0.706 
10 60 0.502 0.098 99% 0.315 0.672 
10 100 0.504 0.097 93% 0.358 0.634 
10 150 0.499 0.099 88% 0.384 0.608 
10 200 0.494 0.084 87% 0.394 0.590 
10 300 0.488 0.106 70% 0.410 0.566 
       
20 10 0.493 0.086 100% 0.107 0.836 
20 20 0.501 0.074 100% 0.195 0.771 
20 40 0.494 0.066 100% 0.274 0.694 
20 60 0.501 0.068 100% 0.312 0.669 
20 100 0.491 0.066 98% 0.351 0.624 
20 150 0.495 0.071 98% 0.380 0.604 
20 200 0.495 0.068 94% 0.396 0.590 
20 300 0.489 0.066 88% 0.409 0.568 
       
30 10 0.484 0.071 100% 0.105 0.823 
30 20 0.496 0.061 100% 0.195 0.765 
30 40 0.491 0.060 100% 0.270 0.692 
30 60 0.493 0.055 100% 0.310 0.664 
30 100 0.491 0.056 100% 0.351 0.621 
30 150 0.487 0.054 98% 0.373 0.596 
30 200 0.485 0.051 98% 0.388 0.579 
30 300 0.479 0.051 96% 0.401 0.554 
Table A.11: Ceiling: Simulation binary-ordinal: 𝑅ℎ
2 results. Where 𝑅ℎ
2=1 and 
𝑅ℎ𝑡
2 =0.90 and the odds are proportional
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Appendix B: Ordinal-binary 
Tables presented here are for an ordinal surrogate and a binary true outcome, for 
each scenario covered in the simulation for the ordinal-binary setting. The results 
given are the median 𝑅 
2 values at the trial and individual level for each scenario, the 
IQR, the coverage of the confidence intervals and the median 95% confidence 
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5 10 0.452 0.177 100% 0.051 0.999 
5 20 0.446 0.145 100% 0.092 0.880 
5 40 0.423 0.114 100% 0.137 0.757 
5 60 0.410 0.106 100% 0.168 0.687 
5 100 0.414 0.096 100% 0.214 0.631 
5 150 0.396 0.081 100% 0.233 0.573 
5 200 0.412 0.069 99% 0.264 0.567 
5 300 0.405 0.068 98% 0.287 0.531 
       
10 10 0.446 0.140 100% 0.054 0.989 
10 20 0.430 0.117 100% 0.091 0.863 
10 40 0.413 0.072 100% 0.135 0.742 
10 60 0.399 0.076 100% 0.164 0.674 
10 100 0.395 0.058 100% 0.204 0.610 
10 150 0.401 0.063 100% 0.238 0.576 
10 200 0.389 0.051 100% 0.248 0.542 
10 300 0.397 0.054 100% 0.279 0.522 
       
20 10 0.420 0.104 100% 0.049 0.964 
20 20 0.423 0.078 100% 0.089 0.850 
20 40 0.405 0.051 100% 0.135 0.730 
20 60 0.396 0.058 100% 0.165 0.667 
20 100 0.393 0.045 100% 0.205 0.607 
20 150 0.393 0.041 100% 0.233 0.567 
20 200 0.395 0.039 100% 0.255 0.547 
20 300 0.393 0.037 100% 0.277 0.517 
       
30 10 0.424 0.074 100% 0.051 0.964 
30 20 0.422 0.062 100% 0.092 0.849 
30 40 0.406 0.050 100% 0.135 0.732 
30 60 0.397 0.040 100% 0.163 0.669 
30 100 0.393 0.033 100% 0.203 0.605 
30 150 0.389 0.032 100% 0.231 0.564 
30 200 0.391 0.034 100% 0.252 0.542 
30 300 0.389 0.033 100% 0.273 0.513 




and the odds are proportional 
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5 10 0.760 0.376 92% 0.097 0.986 
5 20 0.873 0.253 93% 0.269 0.995 
5 40 0.876 0.282 91% 0.275 0.995 
5 60 0.907 0.165 95% 0.358 0.997 
5 100 0.923 0.172 94% 0.408 0.998 
5 150 0.928 0.137 94% 0.427 0.998 
5 200 0.937 0.109 94% 0.461 0.998 
5 300 0.944 0.116 93% 0.489 0.999 
       
10 10 0.588 0.324 55% 0.097 0.913 
10 20 0.689 0.295 71% 0.192 0.945 
10 40 0.796 0.199 88% 0.338 0.971 
10 60 0.823 0.188 92% 0.385 0.976 
10 100 0.860 0.143 93% 0.457 0.983 
10 150 0.872 0.119 98% 0.485 0.985 
10 200 0.883 0.109 97% 0.510 0.987 
10 300 0.888 0.104 98% 0.523 0.988 
       
20 10 0.487 0.204 14% 0.133 0.793 
20 20 0.640 0.207 37% 0.279 0.877 
20 40 0.724 0.156 63% 0.384 0.916 
20 60 0.771 0.142 75% 0.452 0.935 
20 100 0.820 0.111 89% 0.531 0.953 
20 150 0.842 0.106 94% 0.571 0.960 
20 200 0.848 0.102 94% 0.583 0.962 
20 300 0.862 0.077 97% 0.610 0.967 
       
30 10 0.480 0.197 3% 0.184 0.744 
30 20 0.614 0.152 10% 0.317 0.831 
30 40 0.718 0.127 38% 0.445 0.889 
30 60 0.760 0.103 61% 0.503 0.910 
30 100 0.798 0.081 80% 0.560 0.928 
30 150 0.825 0.080 88% 0.604 0.940 
30 200 0.834 0.088 90% 0.619 0.944 
30 300 0.854 0.071 96% 0.653 0.952 
Table B. 2: Simulation ordinal-binary: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 
and the odds are proportional 
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5 10 0.443 0.206 100% 0.046 0.993 
5 20 0.426 0.132 100% 0.086 0.853 
5 40 0.411 0.098 100% 0.137 0.746 
5 60 0.415 0.088 100% 0.173 0.692 
5 100 0.409 0.089 100% 0.213 0.626 
5 150 0.407 0.082 100% 0.242 0.585 
5 200 0.405 0.086 98% 0.261 0.559 
5 300 0.403 0.073 96% 0.284 0.529 
       
10 10 0.433 0.138 100% 0.052 0.978 
10 20 0.423 0.106 100% 0.087 0.854 
10 40 0.406 0.083 100% 0.136 0.737 
10 60 0.405 0.072 100% 0.167 0.677 
10 100 0.397 0.056 100% 0.203 0.615 
10 150 0.395 0.056 100% 0.234 0.569 
10 200 0.394 0.050 100% 0.255 0.547 
10 300 0.388 0.055 100% 0.272 0.512 
       
20 10 0.429 0.087 100% 0.049 0.970 
20 20 0.423 0.075 100% 0.089 0.851 
20 40 0.401 0.060 100% 0.130 0.727 
20 60 0.400 0.044 100% 0.166 0.673 
20 100 0.389 0.047 100% 0.200 0.602 
20 150 0.389 0.038 100% 0.230 0.564 
20 200 0.390 0.042 100% 0.250 0.542 
20 300 0.389 0.038 100% 0.273 0.512 
       
30 10 0.425 0.079 100% 0.048 0.963 
30 20 0.419 0.059 100% 0.090 0.845 
30 40 0.395 0.042 100% 0.129 0.718 
30 60 0.395 0.042 100% 0.162 0.666 
30 100 0.393 0.034 100% 0.203 0.605 
30 150 0.389 0.034 100% 0.231 0.565 
30 200 0.390 0.032 100% 0.250 0.542 
30 300 0.384 0.031 100% 0.270 0.507 




and the odds are proportional 
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5 10 0.548 0.506 84% 0.010 0.956 
5 20 0.645 0.487 77% 0.029 0.972 
5 40 0.652 0.445 80% 0.031 0.973 
5 60 0.639 0.457 78% 0.026 0.971 
5 100 0.643 0.434 85% 0.028 0.972 
5 150 0.677 0.465 80% 0.041 0.977 
5 200 0.658 0.489 77% 0.033 0.974 
5 300 0.668 0.429 80% 0.037 0.976 
       
10 10 0.324 0.406 97% 0.005 0.788 
10 20 0.409 0.342 95% 0.015 0.836 
10 40 0.367 0.363 95% 0.009 0.814 
10 60 0.416 0.338 97% 0.017 0.840 
10 100 0.421 0.357 94% 0.018 0.842 
10 150 0.396 0.363 95% 0.013 0.830 
10 200 0.385 0.291 93% 0.011 0.823 
10 300 0.418 0.376 94% 0.017 0.841 
       
20 10 0.285 0.266 96% 0.020 0.645 
20 20 0.298 0.278 95% 0.025 0.656 
20 40 0.336 0.249 96% 0.040 0.688 
20 60 0.321 0.248 95% 0.034 0.676 
20 100 0.330 0.222 95% 0.037 0.682 
20 150 0.337 0.235 96% 0.040 0.688 
20 200 0.352 0.220 97% 0.048 0.700 
20 300 0.344 0.241 96% 0.044 0.694 
       
30 10 0.229 0.199 92% 0.023 0.530 
30 20 0.279 0.180 96% 0.045 0.579 
30 40 0.289 0.216 94% 0.050 0.588 
30 60 0.324 0.202 96% 0.069 0.620 
30 100 0.303 0.180 94% 0.057 0.601 
30 150 0.324 0.190 97% 0.069 0.620 
30 200 0.317 0.216 97% 0.065 0.614 
30 300 0.323 0.199 96% 0.068 0.619 
Table B. 4: Simulation ordinal-binary: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.30 
and the odds are proportional 
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5 10 0.274 0.173 100% 0.018 0.856 
5 20 0.218 0.127 100% 0.017 0.648 
5 40 0.204 0.079 100% 0.031 0.512 
5 60 0.190 0.071 100% 0.038 0.443 
5 100 0.181 0.063 100% 0.054 0.373 
5 150 0.185 0.050 100% 0.071 0.338 
5 200 0.176 0.052 100% 0.078 0.309 
5 300 0.181 0.042 100% 0.096 0.288 
       
10 10 0.294 0.135 100% 0.021 0.871 
10 20 0.221 0.084 100% 0.020 0.644 
10 40 0.199 0.057 100% 0.030 0.506 
10 60 0.187 0.050 100% 0.039 0.431 
10 100 0.185 0.039 100% 0.056 0.372 
10 150 0.182 0.035 100% 0.070 0.333 
10 200 0.178 0.034 100% 0.078 0.309 
10 300 0.175 0.029 100% 0.092 0.280 
       
20 10 0.272 0.088 100% 0.022 0.848 
20 20 0.222 0.059 100% 0.023 0.648 
20 40 0.196 0.043 100% 0.031 0.501 
20 60 0.186 0.036 100% 0.040 0.430 
20 100 0.178 0.028 100% 0.054 0.367 
20 150 0.175 0.021 100% 0.067 0.326 
20 200 0.175 0.023 100% 0.077 0.304 
20 300 0.176 0.021 100% 0.092 0.280 
       
30 10 0.275 0.074 100% 0.021 0.854 
30 20 0.223 0.047 100% 0.024 0.650 
30 40 0.199 0.033 100% 0.032 0.502 
30 60 0.187 0.032 100% 0.040 0.432 
30 100 0.182 0.022 100% 0.056 0.369 
30 150 0.177 0.019 100% 0.068 0.328 
30 200 0.176 0.019 100% 0.078 0.306 
30 300 0.174 0.018 100% 0.091 0.278 




and the odds are proportional 
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5 10 0.703 0.335 89% 0.054 0.980 
5 20 0.814 0.295 92% 0.163 0.991 
5 40 0.847 0.250 92% 0.216 0.994 
5 60 0.895 0.187 94% 0.323 0.997 
5 100 0.920 0.171 98% 0.400 0.998 
5 150 0.922 0.122 95% 0.404 0.998 
5 200 0.927 0.135 91% 0.422 0.998 
5 300 0.947 0.112 95% 0.503 0.999 
       
10 10 0.504 0.367 44% 0.047 0.881 
10 20 0.619 0.304 61% 0.123 0.923 
10 40 0.771 0.211 85% 0.297 0.965 
10 60 0.789 0.195 86% 0.325 0.969 
10 100 0.837 0.154 94% 0.411 0.979 
10 150 0.854 0.133 95% 0.446 0.982 
10 200 0.861 0.119 97% 0.459 0.983 
10 300 0.881 0.101 98% 0.506 0.987 
       
20 10 0.436 0.235 4% 0.094 0.761 
20 20 0.566 0.218 20% 0.202 0.839 
20 40 0.695 0.158 52% 0.345 0.903 
20 60 0.746 0.129 71% 0.415 0.925 
20 100 0.790 0.126 85% 0.483 0.942 
20 150 0.816 0.119 89% 0.525 0.951 
20 200 0.838 0.108 92% 0.563 0.959 
20 300 0.864 0.084 95% 0.613 0.967 
       
30 10 0.388 0.221 1% 0.111 0.675 
30 20 0.552 0.187 3% 0.252 0.793 
30 40 0.675 0.126 22% 0.390 0.866 
30 60 0.725 0.118 46% 0.454 0.893 
30 100 0.790 0.102 72% 0.548 0.924 
30 150 0.810 0.101 82% 0.580 0.934 
30 200 0.826 0.079 87% 0.605 0.941 
30 300 0.851 0.079 92% 0.648 0.951 
Table B. 6: Simulation ordinal-binary: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.30 and 𝑅ℎ𝑡
2 =0.90 
and the odds are proportional  
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5 10 0.296 0.184 100% 0.017 0.868 
5 20 0.228 0.107 100% 0.017 0.662 
5 40 0.195 0.095 100% 0.026 0.507 
5 60 0.195 0.069 100% 0.040 0.445 
5 100 0.182 0.055 100% 0.054 0.375 
5 150 0.180 0.050 100% 0.068 0.333 
5 200 0.180 0.045 100% 0.080 0.312 
5 300 0.181 0.038 100% 0.095 0.287 
       
10 10 0.266 0.115 100% 0.019 0.851 
10 20 0.228 0.091 100% 0.022 0.658 
10 40 0.196 0.056 100% 0.030 0.501 
10 60 0.187 0.048 100% 0.038 0.434 
10 100 0.180 0.039 100% 0.054 0.368 
10 150 0.179 0.030 100% 0.069 0.332 
10 200 0.178 0.032 100% 0.079 0.307 
10 300 0.173 0.030 100% 0.090 0.278 
       
20 10 0.279 0.081 100% 0.023 0.855 
20 20 0.223 0.061 100% 0.024 0.650 
20 40 0.193 0.040 100% 0.031 0.498 
20 60 0.182 0.030 100% 0.038 0.429 
20 100 0.177 0.033 100% 0.053 0.362 
20 150 0.175 0.026 100% 0.067 0.325 
20 200 0.173 0.021 100% 0.077 0.302 
20 300 0.175 0.019 100% 0.092 0.280 
       
30 10 0.280 0.067 100% 0.022 0.854 
30 20 0.221 0.045 100% 0.024 0.644 
30 40 0.193 0.034 100% 0.031 0.495 
30 60 0.184 0.026 100% 0.039 0.428 
30 100 0.179 0.024 100% 0.054 0.366 
30 150 0.175 0.021 100% 0.067 0.325 
30 200 0.176 0.016 100% 0.078 0.305 
30 300 0.172 0.017 100% 0.089 0.275 




and the odds are proportional 
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5 10 0.619 0.431 84% 0.021 0.968 
5 20 0.676 0.463 80% 0.040 0.977 
5 40 0.590 0.471 84% 0.015 0.964 
5 60 0.596 0.503 80% 0.016 0.965 
5 100 0.672 0.506 83% 0.038 0.976 
5 150 0.613 0.439 85% 0.020 0.967 
5 200 0.665 0.451 80% 0.036 0.975 
5 300 0.666 0.391 80% 0.036 0.975 
       
10 10 0.285 0.350 96% 0.000 0.763 
10 20 0.350 0.284 96% 0.007 0.804 
10 40 0.383 0.373 97% 0.011 0.823 
10 60 0.385 0.353 98% 0.011 0.823 
10 100 0.399 0.357 95% 0.013 0.831 
10 150 0.454 0.356 93% 0.027 0.858 
10 200 0.372 0.351 96% 0.009 0.816 
10 300 0.424 0.326 97% 0.019 0.844 
       
20 10 0.225 0.232 94% 0.007 0.589 
20 20 0.274 0.207 97% 0.017 0.635 
20 40 0.301 0.228 96% 0.026 0.659 
20 60 0.314 0.198 96% 0.030 0.669 
20 100 0.324 0.271 98% 0.035 0.678 
20 150 0.337 0.242 97% 0.041 0.688 
20 200 0.342 0.248 97% 0.043 0.692 
20 300 0.284 0.249 96% 0.020 0.644 
       
30 10 0.196 0.155 90% 0.012 0.495 
30 20 0.235 0.175 92% 0.025 0.535 
30 40 0.302 0.214 94% 0.057 0.601 
30 60 0.285 0.173 95% 0.048 0.584 
30 100 0.297 0.199 98% 0.054 0.596 
30 150 0.321 0.216 95% 0.068 0.618 
30 200 0.307 0.190 96% 0.060 0.605 
30 300 0.321 0.190 96% 0.068 0.618 
Table B. 8: Simulation ordinal-binary: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.30 and 𝑅ℎ𝑡
2 =0.30 
and the odds are proportional 
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5 10 0.449 0.204 100% 0.051 0.996 
5 20 0.435 0.149 100% 0.087 0.862 
5 40 0.412 0.128 100% 0.133 0.744 
5 60 0.416 0.097 100% 0.172 0.695 
5 100 0.406 0.081 100% 0.210 0.622 
5 150 0.402 0.088 99% 0.240 0.581 
5 200 0.402 0.076 100% 0.259 0.558 
5 300 0.399 0.070 97% 0.281 0.526 
       
10 10 0.437 0.158 100% 0.054 0.982 
10 20 0.416 0.106 100% 0.086 0.849 
10 40 0.403 0.083 100% 0.130 0.728 
10 60 0.398 0.067 100% 0.163 0.672 
10 100 0.403 0.060 100% 0.210 0.615 
10 150 0.393 0.059 100% 0.233 0.569 
10 200 0.387 0.045 100% 0.248 0.541 
10 300 0.391 0.048 100% 0.275 0.516 
       
20 10 0.414 0.102 100% 0.049 0.953 
20 20 0.414 0.074 100% 0.088 0.842 
20 40 0.400 0.053 100% 0.131 0.728 
20 60 0.392 0.052 100% 0.160 0.665 
20 100 0.390 0.044 100% 0.200 0.603 
20 150 0.388 0.040 100% 0.228 0.563 
20 200 0.387 0.038 100% 0.248 0.538 
20 300 0.383 0.043 100% 0.268 0.506 
       
30 10 0.423 0.076 100% 0.051 0.963 
30 20 0.417 0.056 100% 0.091 0.844 
30 40 0.398 0.043 100% 0.130 0.721 
30 60 0.393 0.038 100% 0.162 0.665 
30 100 0.386 0.036 100% 0.197 0.599 
30 150 0.387 0.034 100% 0.228 0.561 
30 200 0.386 0.032 100% 0.247 0.538 
30 300 0.382 0.028 100% 0.267 0.505 




and the odds are non-proportional 
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5 10 0.758 0.401 85% 0.096 0.986 
5 20 0.871 0.260 90% 0.264 0.995 
5 40 0.880 0.206 94% 0.285 0.996 
5 60 0.905 0.185 94% 0.350 0.997 
5 100 0.925 0.149 96% 0.416 0.998 
5 150 0.930 0.141 95% 0.432 0.998 
5 200 0.933 0.128 95% 0.447 0.998 
5 300 0.931 0.111 96% 0.436 0.998 
       
10 10 0.562 0.299 52% 0.080 0.908 
10 20 0.693 0.267 74% 0.196 0.946 
10 40 0.770 0.214 86% 0.296 0.965 
10 60 0.808 0.202 90% 0.358 0.973 
10 100 0.828 0.150 94% 0.394 0.977 
10 150 0.860 0.133 94% 0.458 0.983 
10 200 0.879 0.118 98% 0.501 0.986 
10 300 0.885 0.099 99% 0.515 0.987 
       
20 10 0.505 0.196 11% 0.146 0.805 
20 20 0.616 0.213 33% 0.252 0.866 
20 40 0.717 0.155 59% 0.374 0.913 
20 60 0.756 0.156 70% 0.430 0.929 
20 100 0.805 0.131 83% 0.507 0.948 
20 150 0.830 0.116 88% 0.550 0.956 
20 200 0.839 0.114 93% 0.566 0.959 
20 300 0.859 0.088 96% 0.603 0.966 
       
30 10 0.495 0.195 2% 0.195 0.754 
30 20 0.615 0.148 10% 0.318 0.831 
30 40 0.697 0.138 36% 0.418 0.878 
30 60 0.756 0.112 56% 0.498 0.908 
30 100 0.797 0.097 76% 0.560 0.928 
30 150 0.819 0.089 85% 0.594 0.937 
30 200 0.834 0.083 90% 0.618 0.944 
30 300 0.852 0.074 91% 0.649 0.951 
Table B. 10: Simulation ordinal-binary: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 
and the odds are non-proportional  
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5 10 0.620 0.220 100% 0.107 1.000 
5 20 0.709 0.177 100% 0.277 1.000 
5 40 0.719 0.161 99% 0.392 0.998 
5 60 0.733 0.140 97% 0.461 0.969 
5 100 0.726 0.136 96% 0.516 0.916 
5 150 0.740 0.136 91% 0.568 0.895 
5 200 0.753 0.124 88% 0.604 0.889 
5 300 0.733 0.135 75% 0.611 0.847 
       
10 10 0.615 0.133 100% 0.113 1.000 
10 20 0.689 0.123 100% 0.255 1.000 
10 40 0.710 0.091 100% 0.391 0.984 
10 60 0.723 0.098 100% 0.460 0.955 
10 100 0.718 0.088 99% 0.510 0.904 
10 150 0.717 0.091 98% 0.549 0.872 
10 200 0.714 0.084 96% 0.569 0.848 
10 300 0.717 0.096 90% 0.596 0.828 
       
20 10 0.603 0.093 100% 0.108 1.000 
20 20 0.669 0.077 100% 0.252 1.000 
20 40 0.693 0.084 100% 0.380 0.969 
20 60 0.704 0.066 100% 0.441 0.937 
20 100 0.707 0.071 100% 0.502 0.891 
20 150 0.711 0.069 100% 0.542 0.865 
20 200 0.710 0.065 100% 0.563 0.846 
20 300 0.707 0.071 100% 0.586 0.819 
       
30 10 0.595 0.078 100% 0.107 1.000 
30 20 0.666 0.077 100% 0.247 1.000 
30 40 0.697 0.057 100% 0.379 0.971 
30 60 0.697 0.053 100% 0.436 0.932 
30 100 0.701 0.049 100% 0.496 0.887 
30 150 0.698 0.062 100% 0.532 0.855 
30 200 0.707 0.052 100% 0.562 0.842 
30 300 0.704 0.054 100% 0.587 0.816 




2 =0.90 and the odds are proportional
  Evaluation of surrogate outcomes 
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Appendix C: Ordinal-ordinal 
Tables presented here are for an ordinal surrogate and an ordinal true outcome, for 
each scenario covered in the simulation for the ordinal-ordinal setting. The results 
given are the median 𝑅 
2 values at the trial and individual level for each scenario, the 
IQR, the coverage of the confidence intervals and the median 95% confidence 
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5 10 0.562 0.175 100% 0.147 0.893 
5 20 0.535 0.095 100% 0.190 0.819 
5 40 0.538 0.072 100% 0.280 0.760 
5 60 0.536 0.050 100% 0.322 0.724 
5 100 0.536 0.045 100% 0.370 0.687 
5 150 0.533 0.038 100% 0.397 0.659 
5 200 0.539 0.034 100% 0.421 0.648 
5 300 0.538 0.035 100% 0.442 0.629 
       
10 10 0.538 0.101 100% 0.133 0.877 
10 20 0.532 0.066 100% 0.198 0.818 
10 40 0.527 0.050 100% 0.272 0.751 
10 60 0.534 0.037 100% 0.322 0.722 
10 100 0.533 0.033 100% 0.367 0.683 
10 150 0.534 0.025 100% 0.399 0.659 
10 200 0.533 0.027 100% 0.416 0.643 
10 300 0.532 0.022 100% 0.436 0.622 
       
20 10 0.539 0.069 100% 0.143 0.880 
20 20 0.528 0.054 100% 0.194 0.814 
20 40 0.531 0.036 100% 0.277 0.752 
20 60 0.530 0.029 100% 0.318 0.717 
20 100 0.532 0.023 100% 0.366 0.682 
20 150 0.529 0.019 100% 0.393 0.654 
20 200 0.531 0.017 100% 0.413 0.640 
20 300 0.530 0.016 100% 0.433 0.620 
       
30 10 0.549 0.055 100% 0.146 0.881 
30 20 0.526 0.040 100% 0.194 0.812 
30 40 0.529 0.028 100% 0.274 0.750 
30 60 0.530 0.021 100% 0.318 0.718 
30 100 0.528 0.021 100% 0.363 0.679 
30 150 0.528 0.015 100% 0.393 0.654 
30 200 0.529 0.015 100% 0.411 0.638 
30 300 0.529 0.013 100% 0.433 0.619 




and the odds are proportional 
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5 10 0.853 0.228 95% 0.228 0.994 
5 20 0.921 0.154 97% 0.403 0.998 
5 40 0.943 0.116 95% 0.485 0.999 
5 60 0.948 0.085 95% 0.507 0.999 
5 100 0.959 0.077 92% 0.563 0.999 
5 150 0.960 0.092 94% 0.571 0.999 
5 200 0.955 0.080 94% 0.540 0.999 
5 300 0.955 0.079 95% 0.542 0.999 
       
10 10 0.756 0.213 85% 0.274 0.962 
10 20 0.824 0.160 95% 0.386 0.977 
10 40 0.875 0.118 99% 0.491 0.986 
10 60 0.892 0.085 99% 0.534 0.989 
10 100 0.902 0.087 100% 0.559 0.990 
10 150 0.912 0.101 98% 0.585 0.991 
10 200 0.918 0.089 98% 0.604 0.992 
10 300 0.916 0.080 98% 0.597 0.992 
       
20 10 0.682 0.166 48% 0.329 0.897 
20 20 0.793 0.099 86% 0.487 0.943 
20 40 0.857 0.083 97% 0.600 0.965 
20 60 0.877 0.070 98% 0.639 0.972 
20 100 0.887 0.071 99% 0.659 0.974 
20 150 0.894 0.078 99% 0.676 0.977 
20 200 0.895 0.072 98% 0.676 0.977 
20 300 0.899 0.066 99% 0.687 0.978 
       
30 10 0.683 0.114 25% 0.400 0.872 
30 20 0.792 0.086 77% 0.549 0.926 
30 40 0.847 0.078 92% 0.641 0.950 
30 60 0.869 0.073 96% 0.680 0.958 
30 100 0.880 0.058 98% 0.700 0.963 
30 150 0.884 0.062 96% 0.709 0.964 
30 200 0.891 0.053 98% 0.721 0.967 
30 300 0.895 0.047 99% 0.730 0.969 
Table C. 2 Simulation ordinal-ordinal: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 
and the odds are proportional 
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5 10 0.537 0.153 100% 0.131 0.886 
5 20 0.520 0.105 100% 0.186 0.814 
5 40 0.527 0.071 100% 0.272 0.750 
5 60 0.534 0.059 100% 0.320 0.723 
5 100 0.535 0.042 100% 0.367 0.685 
5 150 0.533 0.037 100% 0.396 0.659 
5 200 0.533 0.035 100% 0.415 0.642 
5 300 0.534 0.031 100% 0.437 0.625 
       
10 10 0.538 0.102 100% 0.135 0.878 
10 20 0.533 0.075 100% 0.194 0.816 
10 40 0.527 0.048 100% 0.270 0.750 
10 60 0.526 0.038 100% 0.315 0.715 
10 100 0.525 0.033 100% 0.359 0.676 
10 150 0.527 0.026 100% 0.391 0.654 
10 200 0.527 0.026 100% 0.409 0.637 
10 300 0.528 0.025 100% 0.432 0.618 
       
20 10 0.539 0.076 100% 0.143 0.874 
20 20 0.525 0.047 100% 0.195 0.810 
20 40 0.526 0.036 100% 0.271 0.747 
20 60 0.524 0.032 100% 0.313 0.713 
20 100 0.525 0.022 100% 0.359 0.676 
20 150 0.526 0.021 100% 0.391 0.651 
20 200 0.526 0.019 100% 0.409 0.636 
20 300 0.524 0.017 100% 0.428 0.615 
       
30 10 0.543 0.057 100% 0.143 0.879 
30 20 0.523 0.039 100% 0.193 0.811 
30 40 0.526 0.030 100% 0.272 0.748 
30 60 0.526 0.026 100% 0.314 0.714 
30 100 0.523 0.020 100% 0.358 0.674 
30 150 0.525 0.016 100% 0.389 0.651 
30 200 0.526 0.015 100% 0.408 0.635 
30 300 0.524 0.013 100% 0.427 0.614 
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5 10 0.699 0.394 78% 0.052 0.980 
5 20 0.680 0.425 77% 0.042 0.977 
5 40 0.673 0.431 80% 0.039 0.976 
5 60 0.645 0.502 82% 0.028 0.972 
5 100 0.629 0.471 81% 0.024 0.970 
5 150 0.660 0.430 80% 0.034 0.974 
5 200 0.706 0.415 78% 0.056 0.980 
5 300 0.689 0.404 81% 0.046 0.978 
       
10 10 0.443 0.380 93% 0.024 0.853 
10 20 0.428 0.389 95% 0.020 0.846 
10 40 0.449 0.329 94% 0.026 0.856 
10 60 0.448 0.324 95% 0.025 0.855 
10 100 0.434 0.324 93% 0.021 0.849 
10 150 0.446 0.345 95% 0.025 0.855 
10 200 0.425 0.313 96% 0.019 0.844 
10 300 0.425 0.350 91% 0.019 0.844 
       
20 10 0.345 0.279 96% 0.042 0.697 
20 20 0.343 0.256 95% 0.043 0.693 
20 40 0.368 0.235 95% 0.056 0.712 
20 60 0.348 0.238 97% 0.046 0.697 
20 100 0.357 0.213 96% 0.050 0.704 
20 150 0.340 0.247 98% 0.042 0.690 
20 200 0.370 0.228 97% 0.057 0.713 
20 300 0.372 0.240 98% 0.058 0.715 
       
30 10 0.371 0.188 95% 0.099 0.661 
30 20 0.344 0.199 93% 0.082 0.638 
30 40 0.347 0.198 96% 0.083 0.640 
30 60 0.354 0.182 95% 0.088 0.646 
30 100 0.348 0.193 96% 0.084 0.641 
30 150 0.319 0.185 98% 0.066 0.616 
30 200 0.341 0.195 97% 0.079 0.634 
30 300 0.340 0.199 96% 0.079 0.634 
Table C.4: Simulation ordinal-ordinal: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.30 
and the odds are proportional 
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5 10 0.301 0.142 100% 0.029 0.738 
5 20 0.264 0.112 100% 0.040 0.604 
5 40 0.256 0.075 100% 0.064 0.513 
5 60 0.251 0.065 100% 0.083 0.462 
5 100 0.248 0.048 100% 0.110 0.413 
5 150 0.244 0.039 100% 0.128 0.379 
5 200 0.243 0.030 100% 0.141 0.360 
5 300 0.245 0.028 100% 0.160 0.339 
       
10 10 0.308 0.102 100% 0.037 0.732 
10 20 0.257 0.085 100% 0.039 0.597 
10 40 0.246 0.050 100% 0.062 0.501 
10 60 0.246 0.044 100% 0.083 0.456 
10 100 0.247 0.036 100% 0.110 0.412 
10 150 0.242 0.026 100% 0.127 0.376 
10 200 0.242 0.021 100% 0.139 0.356 
10 300 0.240 0.019 100% 0.155 0.334 
       
20 10 0.306 0.080 100% 0.040 0.734 
20 20 0.266 0.047 100% 0.045 0.603 
20 40 0.253 0.034 100% 0.065 0.506 
20 60 0.247 0.029 100% 0.083 0.456 
20 100 0.244 0.023 100% 0.108 0.407 
20 150 0.241 0.020 100% 0.126 0.375 
20 200 0.241 0.017 100% 0.140 0.356 
20 300 0.239 0.014 100% 0.155 0.334 
       
30 10 0.307 0.065 100% 0.042 0.734 
30 20 0.269 0.040 100% 0.046 0.606 
30 40 0.248 0.030 100% 0.062 0.503 
30 60 0.244 0.024 100% 0.081 0.453 
30 100 0.241 0.018 100% 0.106 0.404 
30 150 0.240 0.015 100% 0.126 0.374 
30 200 0.241 0.014 100% 0.139 0.356 
30 300 0.240 0.011 100% 0.155 0.334 
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5 10 0.795 0.313 89% 0.137 0.990 
5 20 0.880 0.243 94% 0.286 0.996 
5 40 0.923 0.155 96% 0.410 0.998 
5 60 0.930 0.126 96% 0.433 0.998 
5 100 0.929 0.119 95% 0.429 0.998 
5 150 0.949 0.097 94% 0.515 0.999 
5 200 0.951 0.091 96% 0.522 0.999 
5 300 0.956 0.077 96% 0.546 0.999 
       
10 10 0.634 0.272 63% 0.136 0.928 
10 20 0.737 0.198 86% 0.249 0.957 
10 40 0.850 0.162 94% 0.436 0.981 
10 60 0.871 0.119 98% 0.482 0.985 
10 100 0.894 0.089 98% 0.538 0.989 
10 150 0.896 0.091 98% 0.542 0.989 
10 200 0.911 0.092 99% 0.585 0.991 
10 300 0.906 0.095 99% 0.570 0.991 
       
20 10 0.568 0.218 22% 0.205 0.842 
20 20 0.713 0.151 60% 0.367 0.911 
20 40 0.805 0.109 88% 0.505 0.948 
20 60 0.844 0.078 96% 0.575 0.961 
20 100 0.874 0.075 99% 0.632 0.970 
20 150 0.885 0.076 97% 0.655 0.974 
20 200 0.885 0.075 97% 0.656 0.974 
20 300 0.894 0.069 100% 0.676 0.977 
       
30 10 0.542 0.181 4% 0.242 0.788 
30 20 0.706 0.127 34% 0.427 0.883 
30 40 0.801 0.100 75% 0.566 0.930 
30 60 0.833 0.073 92% 0.618 0.944 
30 100 0.867 0.071 97% 0.677 0.958 
30 150 0.872 0.062 96% 0.686 0.960 
30 200 0.877 0.053 96% 0.694 0.961 
30 300 0.885 0.051 98% 0.711 0.965 
Table C.6: Simulation ordinal-ordinal: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.30 and 𝑅ℎ𝑡
2 =0.90 
and the odds are proportional  
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5 10 0.293 0.154 100% 0.023 0.736 
5 20 0.267 0.110 100% 0.040 0.613 
5 40 0.249 0.076 100% 0.062 0.504 
5 60 0.236 0.051 100% 0.076 0.447 
5 100 0.240 0.048 100% 0.104 0.404 
5 150 0.243 0.040 100% 0.128 0.376 
5 200 0.242 0.034 100% 0.139 0.359 
5 300 0.241 0.027 100% 0.156 0.336 
       
10 10 0.306 0.100 100% 0.037 0.736 
10 20 0.272 0.085 100% 0.045 0.613 
10 40 0.246 0.054 100% 0.062 0.499 
10 60 0.244 0.043 100% 0.080 0.455 
10 100 0.245 0.036 100% 0.109 0.408 
10 150 0.241 0.033 100% 0.126 0.375 
10 200 0.240 0.023 100% 0.138 0.355 
10 300 0.241 0.019 100% 0.156 0.335 
       
20 10 0.302 0.068 100% 0.039 0.732 
20 20 0.268 0.042 100% 0.042 0.604 
20 40 0.249 0.033 100% 0.064 0.501 
20 60 0.243 0.026 100% 0.080 0.453 
20 100 0.239 0.023 100% 0.105 0.403 
20 150 0.238 0.018 100% 0.125 0.371 
20 200 0.237 0.016 100% 0.137 0.352 
20 300 0.238 0.013 100% 0.153 0.331 
       
30 10 0.308 0.057 100% 0.042 0.734 
30 20 0.264 0.042 100% 0.043 0.606 
30 40 0.250 0.027 100% 0.064 0.503 
30 60 0.245 0.022 100% 0.082 0.453 
30 100 0.241 0.019 100% 0.106 0.404 
30 150 0.241 0.016 100% 0.126 0.374 
30 200 0.239 0.013 100% 0.138 0.354 
30 300 0.239 0.012 100% 0.154 0.333 
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5 10 0.651 0.431 82% 0.030 0.973 
5 20 0.650 0.450 82% 0.030 0.973 
5 40 0.672 0.469 81% 0.038 0.976 
5 60 0.609 0.435 82% 0.019 0.967 
5 100 0.680 0.442 80% 0.042 0.977 
5 150 0.694 0.483 74% 0.049 0.979 
5 200 0.678 0.423 80% 0.041 0.977 
5 300 0.678 0.451 78% 0.041 0.977 
       
10 10 0.372 0.352 94% 0.009 0.819 
10 20 0.371 0.397 95% 0.009 0.816 
10 40 0.398 0.349 96% 0.013 0.831 
10 60 0.424 0.353 94% 0.019 0.844 
10 100 0.412 0.336 96% 0.016 0.838 
10 150 0.427 0.320 94% 0.019 0.845 
10 200 0.408 0.333 96% 0.015 0.836 
10 300 0.452 0.334 95% 0.026 0.857 
       
20 10 0.287 0.255 95% 0.021 0.647 
20 20 0.345 0.248 98% 0.044 0.694 
20 40 0.374 0.218 94% 0.059 0.716 
20 60 0.346 0.226 97% 0.045 0.695 
20 100 0.340 0.238 96% 0.042 0.691 
20 150 0.324 0.232 96% 0.035 0.677 
20 200 0.351 0.252 93% 0.047 0.699 
20 300 0.348 0.241 95% 0.045 0.697 
       
30 10 0.265 0.192 95% 0.038 0.567 
30 20 0.293 0.216 95% 0.052 0.592 
30 40 0.306 0.187 97% 0.059 0.604 
30 60 0.328 0.186 97% 0.071 0.623 
30 100 0.319 0.186 96% 0.067 0.616 
30 150 0.329 0.170 99% 0.072 0.624 
30 200 0.342 0.179 97% 0.080 0.635 
30 300 0.317 0.209 96% 0.065 0.613 
Table C.8: Simulation ordinal-ordinal: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.30 and 𝑅ℎ𝑡
2 =0.30 
and the odds are proportional 
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5 10 0.515 0.155 100% 0.128 0.873 
5 20 0.517 0.112 100% 0.181 0.811 
5 40 0.530 0.080 100% 0.274 0.753 
5 60 0.518 0.067 100% 0.304 0.710 
5 100 0.526 0.042 100% 0.359 0.678 
5 150 0.524 0.037 100% 0.387 0.650 
5 200 0.521 0.039 100% 0.402 0.631 
5 300 0.520 0.032 100% 0.422 0.611 
       
10 10 0.528 0.097 100% 0.131 0.873 
10 20 0.521 0.069 100% 0.190 0.810 
10 40 0.515 0.055 100% 0.260 0.741 
10 60 0.514 0.042 100% 0.301 0.706 
10 100 0.511 0.038 100% 0.344 0.665 
10 150 0.516 0.029 100% 0.380 0.642 
10 200 0.513 0.027 100% 0.394 0.625 
10 300 0.516 0.022 100% 0.420 0.607 
       
20 10 0.535 0.085 100% 0.136 0.877 
20 20 0.517 0.051 100% 0.187 0.806 
20 40 0.513 0.037 100% 0.259 0.738 
20 60 0.514 0.028 100% 0.303 0.705 
20 100 0.512 0.027 100% 0.347 0.664 
20 150 0.512 0.021 100% 0.376 0.638 
20 200 0.511 0.022 100% 0.393 0.622 
20 300 0.510 0.018 100% 0.414 0.601 
       
30 10 0.533 0.057 100% 0.141 0.874 
30 20 0.511 0.036 100% 0.183 0.800 
30 40 0.512 0.029 100% 0.259 0.738 
30 60 0.510 0.025 100% 0.300 0.701 
30 100 0.510 0.020 100% 0.345 0.663 
30 150 0.510 0.020 100% 0.374 0.636 
30 200 0.510 0.018 100% 0.392 0.621 
30 300 0.510 0.013 100% 0.414 0.602 




and the odds are non-proportional 
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5 10 0.850 0.268 90% 0.223 0.994 
5 20 0.917 0.146 95% 0.388 0.998 
5 40 0.931 0.121 94% 0.437 0.998 
5 60 0.942 0.127 93% 0.483 0.999 
5 100 0.936 0.128 95% 0.458 0.998 
5 150 0.948 0.105 94% 0.510 0.999 
5 200 0.949 0.093 95% 0.514 0.999 
5 300 0.943 0.099 94% 0.487 0.999 
       
10 10 0.710 0.180 83% 0.216 0.950 
10 20 0.790 0.173 92% 0.327 0.970 
10 40 0.862 0.126 97% 0.462 0.984 
10 60 0.883 0.127 99% 0.512 0.987 
10 100 0.891 0.113 99% 0.529 0.988 
10 150 0.892 0.098 98% 0.532 0.988 
10 200 0.907 0.088 100% 0.572 0.991 
10 300 0.910 0.082 97% 0.579 0.991 
       
20 10 0.681 0.164 48% 0.327 0.897 
20 20 0.785 0.127 82% 0.474 0.941 
20 40 0.842 0.084 95% 0.571 0.960 
20 60 0.860 0.084 98% 0.606 0.966 
20 100 0.875 0.074 98% 0.636 0.971 
20 150 0.885 0.077 98% 0.656 0.974 
20 200 0.888 0.063 98% 0.662 0.975 
20 300 0.895 0.063 100% 0.676 0.977 
       
30 10 0.673 0.134 24% 0.387 0.866 
30 20 0.771 0.105 66% 0.519 0.915 
30 40 0.828 0.074 92% 0.610 0.942 
30 60 0.857 0.060 95% 0.658 0.953 
30 100 0.872 0.064 99% 0.685 0.960 
30 150 0.871 0.062 96% 0.683 0.959 
30 200 0.876 0.055 95% 0.693 0.961 
30 300 0.881 0.054 97% 0.703 0.963 
Table C.10: Simulation ordinal-ordinal: Results 𝑅ℎ𝑡
2 . Where 𝑅ℎ
2=0.64 and 𝑅ℎ𝑡
2 =0.90 
and the odds are non-proportional  
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5 10 0.879 0.066 100% 0.495 0.982 
5 20 0.903 0.044 100% 0.673 0.974 
5 40 0.902 0.039 99% 0.751 0.959 
5 60 0.888 0.044 100% 0.768 0.946 
5 100 0.902 0.038 96% 0.820 0.944 
5 150 0.895 0.037 92% 0.830 0.933 
5 200 0.901 0.033 94% 0.844 0.932 
5 300 0.903 0.035 91% 0.862 0.930 
       
10 10 0.864 0.062 100% 0.481 0.977 
10 20 0.883 0.041 100% 0.642 0.967 
10 40 0.892 0.032 100% 0.743 0.956 
10 60 0.887 0.036 99% 0.771 0.946 
10 100 0.890 0.035 96% 0.806 0.937 
10 150 0.888 0.033 94% 0.824 0.930 
10 200 0.892 0.037 88% 0.839 0.928 
10 300 0.892 0.033 85% 0.851 0.923 
       
20 10 0.861 0.033 100% 0.472 0.976 
20 20 0.882 0.028 100% 0.640 0.966 
20 40 0.883 0.025 100% 0.734 0.952 
20 60 0.879 0.027 100% 0.761 0.942 
20 100 0.885 0.025 100% 0.802 0.935 
20 150 0.879 0.027 98% 0.813 0.924 
20 200 0.879 0.034 94% 0.824 0.920 
20 300 0.890 0.028 92% 0.847 0.921 
       
30 10 0.856 0.029 100% 0.467 0.975 
30 20 0.881 0.024 100% 0.642 0.965 
30 40 0.881 0.021 100% 0.729 0.951 
30 60 0.878 0.021 100% 0.761 0.942 
30 100 0.884 0.024 100% 0.801 0.934 
30 150 0.879 0.022 99% 0.814 0.925 
30 200 0.872 0.028 98% 0.816 0.915 
30 300 0.888 0.029 93% 0.846 0.920 




2 =0.90 and the odds are proportional
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Appendix D: Case study  
 
This appendix gives model diagnostic plots for second stage models of trial level 
surrogacy produced in the case study. In each case the diagnostic plots given are a: 
residual vs fitted values plot; QQ plot; standardized residual vs fitted values plot; and 
a Cook’s distance plot. These diagnostic plots are given for second stage models for: 
the clinical results of CLOTs3; and the methodological setting where separation was 
ignored. The diagnostics plots are given for each surrogate in each setting 
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D.1. Diagnostics for clinical surrogacy assessment 
 
D. 1: Binary-ordinal setting: Diagnostic plots for the second stage models of the 
surrogate evaluation of DVT by 30 days for OHS at six months. 
There was an indication that trial seven was an outlier but there appeared to be no 
particular reason for this and removal of the trial did not change the results. Hence 
this trial was retained in the analysis. 
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D. 2: Binary-ordinal setting: Diagnostic plots for the second stage models of the 
surrogate evaluation of DVT and PE by 30 days for OHS at six months. 
There was an indication that trial seven was an outlier but there appeared to be no 
particular reason for this and removal of the trial did not change the results. Hence 
this trial was retained in the analysis. 
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D. 3: Binary-ordinal setting: Diagnostic plots for the second stage models of the 
surrogate evaluation of DVT, PE and Death by 30 days for OHS at six months. 
There was an indication that trial seven was an outlier but there appeared to be no 
particular reason for this and removal of the trial did not change the results. Hence 
this trial was retained in the analysis. 
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D. 4: Ordinal-binary setting: Diagnostic plots for the second stage models of the 
surrogate evaluation oDVT by 30 days for binary survival at six months.  
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D. 5: Ordinal-ordinal setting: Diagnostic plots for the second stage models of the 
surrogate evaluation oDVT by 30 days for OHS at six months.  
There was an indication that trial seven was an outlier but there appeared to be no 
particular reason for this and removal of the trial did not change the results. Hence 
this trial was retained in the analysis. 
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D.2. Diagnostics for regression where separation 
ignored 
 
D. 6: Binary-ordinal setting: Diagnostic plots for the second stage models of the 
surrogate evaluation of DVT by 30 days for OHS at six months where separation was 
ignored.  
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D. 7: Binary-ordinal setting: Diagnostic plots for the second stage models of the 
surrogate evaluation of DVT and PE by 30 days for OHS at six months where 
separation was ignored. 
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D. 8: Binary-ordinal setting: Diagnostic plots for the second stage models of the 
surrogate evaluation of DVT, PE and Death by 30 days for OHS at six months where 
separation was ignored. 
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D. 9: Ordinal-binary setting: Diagnostic plots for the second stage models of the 
surrogate evaluation of oDVT by 30 days for survival at six months where separation 
was ignored. 
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D. 10: Ordinal-ordinal setting: Diagnostic plots for the second stage models of the 
surrogate evaluation of oDVT by 30 days for OHS at six months where separation 
was ignored. 
 
 
 
 
 
 
